Redaktion Gestaltung: Medizinische Klinik Poliklinik · Publikationen der Medizinischen Klinik und...

Publikationen der

Medizinischen Klinik und Poliklinik

für Allgemeine Innere Medizin

unter der Leitung von

Prof. Dr. Tilman Sauerbruch

1992 bis 2012

2

Zusammenstellung, Redaktion und Gestaltung:

Ursula Moser, Medizinische Klinik und Poliklinik

3

Übersicht

Jahr Seitenzahl

1992 4 ‐ 9

1993 10 ‐ 17

1994 18 ‐ 24

1995 25 ‐ 29

1996 30 ‐ 35

1997 36 ‐ 46

1998 47 ‐ 53

1999 54 ‐ 63

2000 64 ‐ 74

2001 75 ‐ 82

2002 83 ‐ 92

2003 93 ‐ 102

2004 103 ‐ 116

2005 117 ‐ 132

2006 133 ‐ 148

2007 149 ‐ 161

2008 162 ‐ 172

2009 173 ‐ 181

2010 182 – 191

2011 192 – 206

2012 207 – 208

4

1992

1: Bayerdörffer E, Lehn N, Hatz R, Mannes GA, Oertel H, Sauerbruch T, Stolte M.

Difference in expression of Helicobacter pylori gastritis in antrum and body.

Gastroenterology. 1992 May;102(5):1575‐82.

2: Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, Weinzierl M, Pape

GR, Sauerbruch T, Paumgartner G.

Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo‐controlled

trial.

Hepatology. 1992 Sep;16(3):707‐14.

3: Beuers U, Spengler U, Sackmann M, Paumgartner G, Sauerbruch T.

Deterioration of cholestasis after endoscopic retrograde cholangiography in advanced pri‐

mary sclerosing cholangitis.

J Hepatol. 1992 May;15(1‐2):140‐3.

4: Beuers U, Spengler U, Zwiebel FM, Pauletzki J, Fischer S, Paumgartner G.

Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health

and in chronic cholestatic liver disease.

Hepatology. 1992 Apr;15(4):603‐8.

5: de Franchis R, Pascal JP, Ancona E, Burroughs AK, Henderson M, Fleig W, Groszmann R,

Bosch J, Sauerbruch T, Soederlund C, et al.

Definitions, methodology and therapeutic strategies in portal hypertension. A Consensus De‐

velopment Workshop, Baveno, Lake Maggiore, Italy, April 5 and 6, 1990.

J Hepatol. 1992 May;15(1‐2):256‐61.

6: Dengler TJ, Robertz‐Vaupel GM, Dengler HJ.

Albumin binding in uraemia: quantitative assessment of inhibition by endogenous ligands and

carbamylation of albumin.

Eur J Clin Pharmacol. 1992;43(5):491‐9.

7: Ewig S, Steudel A, Vogel J, Niese D.

[Pulmonary Kaposi sarcoma in patients with AIDS].

Pneumologie. 1992 Feb;46(2):52‐7.

5

8: Franke F, Sackmann M, Holl J, Pauletzki J, Neubrand M, Paumgartner G, Sauerbruch T.

Does computed tomography improve patients selection for extracorporeal shock wave lith‐

otripsy (ESWL) of radiolucent gallbladder stones?

Z Gastroenterol. 1992 Mar;30(3):180‐2.

9: Fürst H, Storck M, Jauch KW, Scheurlen C, Kaltenecker A, Wiebecke B.

[Crohn disease in advanced age].

Chirurg. 1992 Jan;63(1):26‐30.

10: Haller M, Schönfelder R, Briegel J, Pratschke E, Spengler U, Pfeiffer M, Forst H, Finsterer

U.

Renal function in the postoperative period after orthotopic liver transplantation.

Transplant Proc. 1992 Dec;24(6):2704‐6.

11: Hasan I, Wickenhöfer R, Görich J, Hartlapp JH, Reiser M.

[The palliative treatment of primary hepatocellular carcinoma by chemoembolization].

Dtsch Med Wochenschr. 1992 Apr 10;117(15):576‐80.

12: Kleber G, Sauerbruch T.

Pathophysiology and Management of Esophageal‐Varices.

Current Opinion in Gastroenterology. 1992, 8(4):583‐90.

13: Kleber G, Ansari H, Sauerbruch T.

Prophylaxis of first variceal bleeding.

Baillieres Clin Gastroenterol. 1992 Sep;6(3):563‐80.

14: Musch E, Malek M, Peter‐Katalinic J, Egge H, Rink H, Lathan B, Riedel, E

Cellular kinetics of Prenimustine versus Chlorambucil Prednisolone in vitro.

Cancer Chemotherapy Pharmacology. 1992 29 (4):297‐304

15: Paar WD, Frankus P, Dengler HJ.

The metabolism of tramadol by human liver microsomes.

Clin Investig. 1992 Aug;70(8):708‐10.

16: Paar WD, von Bergmann, K.

Pharmakokinetik und Toxikologie von Wismut.

Verdauungskrankheiten. 1992, 10:140‐3.

17: Raedsch R, Sauerbruch T.

[Use of ERCP in suspected bile duct and pancreatic cancer].

Z Gastroenterol. 1992 Oct;30(10):765‐9.

18: Robertz‐Vaupel GM, Glasmacher AG, Brilla H, Dengler HJ

6

Laborchemische Parameter bei Patienten mit Lebermetastasen.

Verdauungskrankheiten. 1992, 10: 197‐201.

19: Robertz‐Vaupel GM, Lindecken KD, Edeki T, Funke C, Belwon S, Dengler HJ.

Disposition of antipyrine in patients with extensive metastatic liver disease.


20: Rockstroh JK, Schmieder RE, Schächinger H, Messerli FH.

Stress response pattern in obesity and systemic hypertension.

Am J Cardiol. 1992 Oct 15;70(11):1035‐9.

21: Rockstroh JK, Schmieder RE.

Diagnostik der linksventrikulären Hypertrophie.

Münchener Medizinische Wochenschrift. 1992;134(13):220‐22.

22: Rockstroh JK, Schmieder RE.

Durch LVH beeinträchtigte systolische und diastolische Funktion.

Münchener Medizinische Wochenschrift. 1992;134(13):234‐236.

23: Sackmann M, Pauletzki J, Delius M, Holl J, Neubrand M, Sauerbruch T, Paumgartner G.

Noninvasive therapy of gallbladder calculi with a radiopaque rim.

Gastroenterology. 1992 Mar;102(3):988‐93.

24: Sauerbruch T, Holl J, Sackmann M, Paumgartner G.

Extracorporeal lithotripsy of pancreatic stones in patients with chronic pancreatitis and pain:

a prospective follow up study.

Gut. 1992 Jul;33(7):969‐72.

25: Sauerbruch T, Holl J, Sackmann M, Paumgartner G.

Fragmentation of bile duct stones by extracorporeal shock‐wave lithotripsy: a five‐year ex‐

perience.

Hepatology. 1992 Feb;15(2):208‐14.

26: Sauerbruch T, Kleber G.

Upper gastrointestinal endoscopy in patients with portal hypertension.

Endoscopy. 1992 Jan‐Feb;24(1‐2):45‐51.

27: Sauerbruch T.

Non‐surgical management of bile duct stones refractory to routine endoscopic measures.

Baillieres Clin Gastroenterol. 1992 Nov;6(4):799‐817.

28: Sauerbruch T.

Endoscopic management of bile duct stones.

7

J Gastroenterol Hepatol. 1992 May‐Jun;7(3):328‐34.

29: Sauerbruch T.

[Portal hypertension: beta‐receptor blockers for the prevention of upper intestinal leeding].

Dtsch Med Wochenschr. 1992 Mar 27;117(13):520‐1.

30: Sauerbruch T.

[Therapy of pancreatic duct calculi: cosmetic or causal therapy?].

Bildgebung. 1992 Mar;59 Suppl 1:18‐9.

31: Sauerbruch T.

Nichtoperative Behandlung von Gallenblasensteinen.

Chir Gastroenterol 1992;8 (Suppl. 3):27‐29.

32: Sauerbruch T, Neubrand M.

Nonsurgical management of gallstones.

Prog Liver Dis. 1992;10:193‐218.

33: Sauter G, Ruckdeschel G, Sauerbruch T.

Antibiotic prevention and therapy of infectious complications in ERCP].

Leber Magen Darm. 1992 Sep;22(5):173‐6.

34: Sauter G, Ruckdeschel G, Sauerbruch T.

Antibiotische Prophylaxe und Therapie infektiöser Komplikationen.

Z Gastroenterol. 1992; 30(9):705‐08.

35: Scheurlen C, Neubrand M, Fischer G, Soehnchen R, Kröner G, Sauerbruch T.

[Muscle pain, scleroderma‐like skin changes and eosinophilia following administration of a

psychotropic drug].

Internist (Berl). 1992 Apr;33(4):269‐73.

36: Scheurlen C, Kruis W.

5‐Aminosalicyclic acid preparation in the therapy of chronic inflammatory bowel diseases.

Innere Medizin. 1992; 19 (3):88‐93.

37. Scheurlen C.

Diät und Ω‐3‐Fettsäuren bei chronisch entzündlichen Darmerkrankungen.

Heilkunst. 1992; 105: 124‐130.

38. Scheurlen C.

Natürlicher Verlauf und Komplikationen beim Morbus Crohn.

Bauchredner. 1992; 30: 9‐16

8

39: Scheurlen C, Wedel S, Kruis W, Zwiebel FM, Allgayer H, Scholz R.

Olsalazine‐related diarrhoea: does rat intestine adapt in vivo?

Scand J Gastroenterol. 1992 Apr;27(4):311‐6.

40: Schmidt EK, von Unruh GE, Paar WD, Dengler HJ.

A gas chromatographic/mass spectrometric assay for prenylamine suitable for pharmacoki‐

netic studies of the racemate and the enantiomers.

Biol Mass Spectrom. 1992 Feb;21(2):103‐8.

41: Schmieder RE, Rüddel H, Schlebusch H, Rockstroh J, Schächinger H, Schulte W.

Impact of antihypertensive therapy with isradipine and metoprolol on early markers of hyper‐

tensive nephropathy.

Am J Hypertens. 1992 May;5(5 Pt 1):318‐21.

42: Spengler U, Möller A, Jung MC, Messer G, Zachoval R, Hoffmann RM, Eisenburg

J, Paumgartner G, Riethmüller G, Weiss EH, et al.

T lymphocytes from patients with primary biliary cirrhosis produce reduced amounts of lym‐

photoxin, tumor necrosis factor and interferon‐gamma upon mitogen stimulation.

J Hepatol. 1992 May;15(1‐2):129‐35.

43: Stiehl A, Sauerbruch T.

Guidelines for endoscopic studies of infectious cholangitis].


44: Stiehl A, Sauerbruch T.

[Guidelines for endoscopic studies in primary sclerosing cholangitis].

Z Gastroenterol. 1992 Apr;30(4):313‐4.

45: Zwiebel FM, Sauerbruch T.

Quality assurance by computerized endoscopy record systems.

Endoscopy. 1992 Jul;24 Suppl 2:527‐31.

9

1993

1: Bode G, Mauch F, Ditschuneit H, Malfertheiner P.

Identification of structures containing polyphosphate in Helicobacter pylori.

J Gen Microbiol. 1993 Dec;139(12):3029‐33.

2: Bode G, Mauch F, Malfertheiner P.

The coccoid forms of Helicobacter pylori. Criteria for their viability.

Epidemiol Infect. 1993 Dec;111(3):483‐90.

3: Böhler J, Becker A, Reetze‐Bonorden P, Woitas R, Keller E, Schollmeyer P.

Effect of antihypertensive drugs on glomerular hyperfiltration and renal haemodynamics.

Comparison of captopril with nifedipine, metoprolol and celiprolol.

Eur J Clin Pharmacol. 1993;44 Suppl 1:S57‐61.

4: Brensing KA, Smyczek B, Waibel‐Treber S, Wildt L, Leyendecker G.

Luteinizing hormone (LH) pulsatility during the oestradiol‐ and oestradiol/progesterone‐

induced LH surge in the human female.

Hum Reprod. 1993 Nov;8 Suppl 2:72‐6.

5: Büchler M, Malfertheiner P, Uhl W, Schölmerich J, Stöckmann F, Adler G, Gaus W, Rolle K,

Beger HG.

Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group.

Gastroenterology. 1993 Apr;104(4):1165‐70.

6: Domínguez‐Muñoz JE, Malfertheiner P.

[Diagnosis and staging of chronic pancreatitis (I). The role of imaging methods].

Rev Esp Enferm Dig. 1993 May;83(5):367‐72.


[Diagnosis and staging of chronicpancreatitis (II). The role of functional tests].

Rev Esp Enferm Dig. 1993 Jun;83(6):453‐7.


Management of severe acute pancreatitis.

Gastroenterologist. 1993 Dec;1(4):248‐56.

10

9: Domínguez‐Muñoz JE, Pieramico O, Büchler M, Malfertheiner P.

Clinical utility of the serum pancreolauryl test in diagnosis and staging of chronic pancreatitis.

Am J Gastroenterol. 1993 Aug;88(8):1237‐41.

10: Domínguez‐Muñoz JE, Pieramico O, Büchler M, Malfertheiner P.

Ratios of different serum pancreatic enzymes in the diagnosis and staging of chronic pan‐

creatitis.

Digestion. 1993;54(4):231‐6.

11: Domínguez‐Muñoz JE, Manes G, Büchler M, Malfertheiner P.

Assessment of the fibrogenetic activity in chronic pancreatitis. The role of circulating levels of

extracellular matrix components.

Int J Pancreatol. 1993 Dec;14(3):253‐9.

12: Dumoulin FL, Daniel WG, Lichtlen P, Schmidt RE.

[Pulmonary thromboembolism in antiphospholipid syndrome].

Dtsch Med Wochenschr. 1993 Jun 18;118(24):903‐6.

13: Ewig S, Rockstroh JK, Christ F.

Pneumocystis carinii pneumonia presenting as an upper lobe cavity after aerosolized pen‐

tamidine prophylaxis in an HIV‐infected patient.

Scand J Infect Dis. 1993;25(3):379‐83.

14: Ewig S, Rockstroh JK, Seitz HM, Marklein G, Christ F, Lüchters G, Brackmann HH, Lüderitz

B.

Pneumocystis carinii infections in HIV‐infected hemophiliacs during aerosolized pentamidine

prophylaxis.

Respiration. 1993;60(3):186‐92.

15: Ewig S, Schaal KP, Steudel A, Nikorowitsch R, von Kempis J, Staib P, Vaupel HA.

[42‐year‐old patient with fever and a palpable abdominal tumor].

Internist. (Berl). 1993 Jan;34(1):59‐62. German.

16: Fischer S, Neubrand M, Paumgartner G.

Biotransformation of orally administered ursodeoxycholic acid in man as observed in gall‐

bladder bile, serum and urine.

Eur J Clin Invest. 1993 Jan;23(1):28‐36.

11

17: Gertsch P, Fischer G, Kleber G, Wheatley AM, Geigenberger G, Sauerbruch T.

Manometry of esophageal varices: comparison of an endoscopic balloon technique with nee‐

dle puncture.

Gastroenterology. 1993 Oct;105(4):1159‐66.

18: Glasbrenner B, Malfertheiner P, Pieramico O, Klatt S, Riepl R, Friess H, Ditschuneit H.

Gallbladder dynamics in chronic pancreatitis. Relationship to exocrine pancreatic function,

CCK, and PP release.

Dig Dis Sci. 1993 Mar;38(3):482‐9.

19: Glasbrenner B, Pieramico O, Brecht‐Krauss D, Baur M, Malfertheiner P.

Gastric emptying of solids and liquids in obesity.

Clin Investig. 1993 Jul;71(7):542‐6.

20: Isenmann R, Büchler M, Uhl W, Malfertheiner P, Martini M, Beger HG.

Pancreatic necrosis: an early finding in severe acute pancreatitis.

Pancreas. 1993 May;8(3):358‐61.

21: Issing WJ, Wustrow TP, Oeckler R, Mezger J, Nerlich A.

An association of the RB gene with osteosarcoma: molecular genetic evaluation of a case of

hereditary retinoblastoma.

Eur Arch Otorhinolaryngol. 1993;250(5):277‐80.

22: Jacobs U, Klehr HU.

Predictive value of immunological parameters in the early diagnosis of cytomegalovirus infec‐

tion in renal transplantation.

Transplant Proc. 1993 Aug;25(4):2670.

23: Jung MC, Schraut W, Santantonio T, Spengler U, Eichenlaub D, Eisenburg J, Zachoval R,

Hoffmann R, Paumgartner G, Pastore G, et al.

Increased frequency of CD8+ CD45R0+ memory T lymphocytes in acute hepatitis B virus infec‐

tion.

J Hepatol. 1993 Jul;18(3):295‐300.

24: Kasper P, Kaiser R, Kleim JP, Oldenburg J, Brackmann HH, Rockstroh J,

Schneweis KE.

Diversification of HIV‐1 strains after infection from a unique source.

AIDS Res Hum Retroviruses. 1993 Feb;9(2):153‐7.

12

25: Klueppelberg UG, Zachoval R, Tutsch‐Bauer E, Josephi E, Babic R, Sauerbruch T.

[A 33‐year‐old male patient with jaundice and right‐sided epigastric pain].

Internist (Berl). 1993 Mar;34(3):268‐73.

26: Lange V, Meyer G, Neubrand M, Klüppelberg U, Schildberg FW.

[Laparoscopic cholecystectomy of large gallbladder calculi].

Chirurg. 1993 Dec;64(12):1008‐11.

27: Lobentanzer H, Neubrand M, Hermeking H, Sauerbruch T.

In vitro study to elucidate the physical laws concerning the fragmentation of both solitary

and multiple artificial stones.

Clin Investig. 1993 Nov;71(11):882‐7.

28: Maintz C, Hartlapp JH.

Excessive dosage of Carboplatin in the treatment of a patient with metastatic teratoma

Tumordiagnostik & Therapie. 1993, 14 (5): 204‐207.

29: Malfertheiner P.

Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment.

Scand J Gastroenterol Suppl. 1993;196:34‐7.

30: Malfertheiner P, Bode, G.

Helicobacter‐pylori and the pathogenesis of duodenal‐ulcer disease.

European Journal of Gastroenterology & Hepatology 1993; 5 Suppl 1: S1‐S8.

31: Malfertheiner P, Domínguez‐Muñoz JE.

Effect of exogenous pancreatic enzymes on gastrointestinal and pancreatic hormone release

and gastrointestinal motility.

Digestion. 1993;54 Suppl 2:15‐20.


Rationale for eradication of Helicobacter pylori infection in duodenal ulcer disease.

Clin Ther. 1993;15 Suppl B:37‐48.


Follow‐up strategies in helicobacter pylori infection.

European Journal of Gastroenterology & Hepatology 1993; 5 Suppl 2: S85‐S88.


Prognostic factors in acute pancreatitis.

Int J Pancreatol. 1993 Aug;14(1):1‐8.

35: Malfertheiner P, Glasbrenner B.

13

Konservative Therapie der akuten Pankreatitis.

Krankenhaus‐Arzt 1993; 66(3): 80‐84.

36: Malfertheiner P, Glasbrenner B.

Konservative Therapie der akuten Pankreatitis.

Therapiewoche 1993; 43(15): 825‐829.

37: Malfertheiner P, Nelson DK, Kemmer TP, Glasbrenner B, Schneider A, Ditschuneit H.

Exocrine pancreatic secretion in man following one week of M1‐muscarinic receptor block‐

ade.

Aliment Pharmacol Ther. 1993 Aug;7(4):423‐8.

38: Malfertheiner P, Nilius M.

Serologischer Nachweis von Helicobacter pylori.

Der Allgemeinarzt 1993; 16: 1035‐36.

39: Mauch F, Bode G, Ditschuneit H, Malfertheiner P.

Demonstration of a phospholipid‐rich zone in the human gastric epithelium damaged by

Helicobacter pylori.

Gastroenterology. 1993 Dec;105(6):1698‐704.

40: Mauch F, Bode G, Malfertheiner P.

Identification and characterization of an ATPase system of Helicobacter pylori and the effect

of proton pump inhibitors.

Am J Gastroenterol. 1993 Oct;88(10):1801‐2.

41: Mezger J.

Malignomverdacht ‐ mehr Treffsicherheit in der Ergußdiagnostik ‐ Nachweis tumorassiziierter

Antigene in Aszites und Pleuraerguß.

Fortschritte der Medizin. 1993. 111: 200‐201.

42: Mezger J, Sandor P, Diem H.

[Low platelet count without manifest disease].


43: Mezger J, Stötzer O, Lamerz R.

The diagnostic‐value of cea levels in ascitic and pleural effusions ‐ a prospektive‐study in 724

patients

Tumordiagnostik & Therapie 1993; 14: 152‐157.

14

44: Nilius M, Ströhle A, Bode G, Malfertheiner P.

Coccoid like forms (CLF) of Helicobacter pylori. Enzyme activity and antigenicity.

Zentralbl Bakteriol. 1993 Sep;280(1‐2):259‐72.

45: Oehler R, Sauerbruch T.

[Guidelines for patient monitoring in endoscopic examinations in gastroenterology. The Ger‐

man Society of Digestive and Metabolic Diseases].

Z Gastroenterol. 1993 Feb;31(2):165‐7.

46: Paar WD, Look M, Robertz‐Vaupel GM, Wöhrle N, Sauerbruch T.

[25‐year‐old patient with febrile infection, thrombopenia and hemolysis].

Internist (Berl).1993 Nov;34(11):1049‐52.

47: Paar WD, Wieres FJ, Bösche D, Glasmacher A, Dengler HJ.

[Pharmacokinetics of colloidal bismuth subcitrate. Solution versus tablet].

Arzneimittelforschung.1993 Nov;43(11):1189‐92.

48: Pauletzki J, Cicala M, Holl J, Sauerbruch T, Schafmayer A, Paumgartner G.

Correlation between gall bladder fasting volume and postprandial emptying in patients with

gall stones and healthy controls.

Gut. 1993 Oct;34(10):1443‐7.

49: Pieramico O, Ditschuneit H, Malfertheiner P.

Gastrointestinal motility in patients with non‐ulcer dyspepsia: a role for Helicobacter pylori

infection?

Am J Gastroenterol. 1993 Mar;88(3):364‐8.

50: Robertz‐Vaupel GM, Sauerbruch T.

[Use of sclerotherapy in patients with esophageal varices. Guidelines of the German Society

of Digestive and Metabolic Diseases].


51: Rockstroh JK, Schächinger H, Schmieder RE.

Effects of antihypertensive drugs on stress‐induced blood pressure response.

Primary Cardiology, 1993, 19: 76‐84.

52: Rockstroh JK, Schmieder RE, Gatzka CD, Messerli FH.

Relation of circadian blood‐pressure changes to left‐ventricular hypertrophy in essential‐

hypertension.

Nieren‐ und Hochdruckkrankheiten, 1993; 22:330‐334.

15

53: Rockstroh JK, Spengler U, Sauerbruch T.

[The prevention of Pneumocystis carinii pneumonia in HIV infection].

Dtsch Med Wochenschr. 1993 Nov 19;118(46):1694‐7.

54: Sackmann M, Eder H, Spengler U, Pauletzki J, Holl J, Paumgartner G, Sauerbruch T.

Gallbladder emptying is an important factor in fragment disappearance after shock wave lith‐

otripsy.

J Hepatol. 1993 Jan;17(1):62‐6.


[Gallbladder saving therapy in symptomatic cholecystolithiasis].

Chirurg. 1993 Dec;64(12):1000‐7.

56: Sauerbruch T.

Langzeitergebnisse der Sklerosierungstherapie bei Patienten mit portaler Hypertension.

Acta chirurgica Austriaca. 1993; 25(3): 159‐62.

57: Scheurlen C, Allgayer H, Kruis W, Erdmann E, Sauerbruch T.

Effect of olsalazine and mesalazine on human ileal and colonic (Na+ + K+)‐ATPase. A possible

diarrhogenic factor?

Clin Investig. 1993 Apr;71(4):286‐9.

58: Schmieder RE, Rockstroh JK.

Antihypertensive therapy and blood pressure response to mental stress.

Hypertension Index Reviews 1993; 3: 12‐17.

59: Stolte M, Malfertheiner P, Borchard F.

[Order in the chaos of classifications of erosions of the gastric mucosa].

Leber Magen Darm. 1993 Mar;23(2):59‐62, 65‐6.

60: Stoschus B, Allescher HD.

Drug‐induced dysphagia.

Dysphagia. 1993;8(2):154‐9.

61: Utku N, von Kempis J, Rockstroh JK, Sauerbruch T.

[Immunoglobulin therapy for systemic lupus erythematosus].

Immun Infekt. 1993 Apr;21 Suppl 1:26‐7.

62: Weitkamp JH, Pérez‐Pérez GI, Bode G, Malfertheiner P, Blaser MJ.

Identification and characterization of Helicobacter pylori phospholipase C activity.

Zentralbl Bakteriol. 1993 Sep;280(1‐2):11‐27.

16

63: Witte T, Dumoulin FL, Gessner JE, Schubert J, Götze O, Neumann C, Todd RF 3rd, Deicher

H, Schmidt RE.

Defect of a complement receptor 3 epitope in a patient with systemic lupus erythematosus.

J Clin Invest. 1993 Sep;92(3):1181‐7.

17

1994 1: Berr F, Mayer M, Sackmann MF, Sauerbruch T, Holl J, Paumgartner G.

Pathogenic factors in early recurrence of cholesterol gallstones.

Gastroenterology. 1994 Jan;106(1):215‐24.

2: Binder M, Uhl W, Friess H, Malfertheiner P, Büchler MW.

Octreotide in the treatment of acute pancreatitis: results of a unicenter prospective trial with

three different octreotide dosages.


3: Breuer T, Malfertheiner P.

Epidemiologie und Pathogenese der Helicobacter pylori Infektion.

Gastro Liga Report 1994;3/4:1‐5.

4: Büchler MW, Binder M, Friess H, Malfertheiner P.

Potential role of somatostatin and octreotide in the management of acute pancreatitis. Di‐

gestion. 1994;55 Suppl 1:16‐9.

5: Caspari R, Friedl W, Mandl M, Möslein G, Kadmon M, Knapp M, Jacobasch KH, Ecker KW,

Kreissler‐Haag D, Timmermanns G, et al.

Familial adenomatous polyposis: mutation at codon 1309 and early onset of colon cancer.

Lancet. 1994 Mar 12;343(8898):629‐32. Erratum in: Lancet 1994 Apr 2;343(8901):863.

6: Dumoulin FL, Klein P, Fischer HP, Spengler U, Sauerbruch T.

[Chronic hepatitis C in type‐II cryoglobulinemia and cutaneous vasculitis].

Dtsch Med Wochenschr. 1994 Sep 16;119(37):1239‐42.

7: Ewig S, Fehske W, Omran H, Rockstroh JK, Lüderitz B.

[Cardiac manifestations in advanced HIV infection].

Dtsch Med Wochenschr. 1994 May 13;119(19):683‐9.

8: Friedl W, Caspari R, Propping P.

[Diagnosis of familial adenomatosis polyposis].

Dtsch Med Wochenschr. 1994 Jan 7;119(1‐2):27‐30.

9: Friedrich JM, Leibing U, Pfeifer T, Schnarkowski P, Büchler M, Malfertheiner P, Beger HG.

[The early recognition of infected fluid collections in acute pancreatitis in computed tomo‐

graphy].

Röfo. 1994 Sep;161(3):208‐13.

18

10: Friess H, Bordihn K, Ebert M, Malfertheiner P, Kemmer T, Dennler HJ, Büchler MW.

Inhibition of pancreatic secretion under long‐term octreotide treatment in humans.


11: Glasbrenner B, Domínguez‐Muñoz JE, Nelson DK, Pieramico O, Holzwarth C, Riepl RL, Mal‐

fertheiner P.

Postprandial release of cholecystokinin and pancreatic polypeptide in health and in gallstone

disease: relationships with gallbladder contraction.

Am J Gastroenterol. 1994 Mar;89(3):404‐10.

12: Glasbrenner B, Dominguez‐Muñoz JE, Nelson DK, Riepl RL, Büchler M, Malfertheiner P.

Relationship between postprandial release of CCK and PP in health and in chronic pancreati‐

tis.

Regul Pept. 1994 Feb 3;50(1):45‐52.

13: Hamm S, von Unruh GE, Paar WD, Dengler HJ.

Isotope Effects during Metabolism of (+/‐)‐Tramodol Isotomers by Human Liver‐Microsomes.

Isotopenpraxis 1994, 30(2‐3.

14: Heinemann T, Metzger S, Fisher EA, Breslow JL, Huang LS.

Alternative polyadenylation of apolipoprotein B RNA is a major cause of B‐48 protein forma‐

tion in rat hepatoma cell lines transfected with human apoB‐100 minigenes.

J Lipid Res. 1994 Dec;35(12):2200‐11.

15: Jacobs U, Brensing KA, Klehr HU.

Chronic allograft destruction vs chronic allograft rejection.


16: Janowitz P, Wechsler JG, Malfertheiner P, Blanco J, Kern P.

[Yersinia enterocolitica infection with extraintestinal manifestations: case report and over‐

view].


17: Jung W, Neubrand M, Lüderitz B.

[Use of high‐frequency current in endoscopy in patients with cardiac pacemakers].

Z Gastroenterol. 1994 Aug;32(8):479‐82.

18: Kaminski M, Hirner A, Low A, Rockstroh J, Vogel J.

[Abdominal emergencies in patients with AIDS].

Chirurg. 1994 May;65(5):469‐72.

19

19: Kemmer TP, Duntas L, Munz W, Malfertheiner P.

[Effect of thyrotropin releasing hormone and histidyl‐proline diketopiperazine on enzyme

section of isolated pancreatic acinar cells of the rat].

Leber Magen Darm. 1994 Jul;24(4):156‐60, 163.

20: Kemmer TP, Dominguez‐Munoz JE, Klingel H, Zemmler T, Kuhn K, Malfertheiner P.

The association between non‐ulcer‐dyspepsia and Helicobacter pylory infection.

Eur J Gastroenterol Hepatol. 1994, 6:571‐7.

21: Lange V, Meyer G, Schardey HM, Neubrand M, Klüppelberg U.

Extracorporeal shock‐wave lithotripsy prior to laparoscopic cholecystectomy. Does it make

sense?

Surg Endosc. 1994 Nov;8(11):1297‐300.

22: Look MP, Musch E.

Lipid peroxides in the polychemotherapy of cancer patients.

Chemotherapy. 1994 Jan‐Feb;40(1):8‐15.

23: Malfertheiner P, Sarr MG, Nelson DK, DiMagno EP.

Role of the duodenum in postprandial release of pancreatic and gastrointestinal hormones.

Pancreas. 1994 Jan;9(1):13‐9.

24: Malfertheiner P, Deltenre M.

Helicobacter pylori eradication: the rational treatment for peptic ulcer disease‐‐chairmen's

conclusion.

Scand J Gastroenterol Suppl. 1994;205:59‐60.

25: Malfertheiner P, Domínguez‐Muñoz JE, Büchler MW.

Chronic pancreatitis: management of pain.


26: Mandl M, Kadmon M, Sengteller M, Caspari R, Propping P, Friedl W.

A somatic mutation in the adenomatous polyposis coli (APC) gene in peripheral blood cells‐‐

implications for predictive diagnosis.

Hum Mol Genet. 1994 Jun;3(6):1009‐11.

27: Mandl M, Paffenholz R, Friedl W, Caspari R, Sengteller M, Propping P.

Frequency of common and novel inactivating APC mutations in 202 families with familial ade‐

nomatous polyposis.

Hum Mol Genet. 1994 Jan;3(1):181‐4.

20

28: Manes G, Büchler M, Pieramico O, Di Sebastiano P, Malfertheiner P.

Is increased pancreatic pressure related to pain in chronic pancreatitis?

Int J Pancreatol. 1994 Apr;15(2):113‐7.

29: Mann K, Rendl J, Busley R, Saller B, Seybold S, Hoermann R, Sauerbruch T, Börner W.

Systemic iodine absorption during endoscopic application of radiographic contrast agents for

endoscopic retrograde cholangiopancreaticography.

Eur J Endocrinol. 1994 May;130(5):498‐501.

30: Mezger J, Calavrezos A, Drings P, Gatzemeier U, Kaukel E, Konietzko N, Koschel G,

Lamerz R, von Pawel J, Römer W.

Value of serum and effusion fluid CEA levels for distinguishing between diffuse malignant

mesothelioma and carcinomatous pleural metastases.

Lung. 1994;172(3):183‐4.

31: Mezger J.

[Adjuvant therapy in colorectal carcinomas].

Dtsch Med Wochenschr. 1994 Dec 2;119(48):1663‐8.

32: Morioka T, Woitas R, Fujigaki Y, Batsford SR, Vogt A.

Histone mediates glomerular deposition of small size DNA anti‐DNA complex.

Kidney Int. 1994 Apr;45(4):991‐7.

33: Nelson DK, Pieramico O, Malfertheiner P.

Gastrointestinal motility and hormones in obesity.

Am J Gastroenterol. 1994 Jul;89(7):1120‐1.

34: Neubrand M, Holl J, Sackmann M, Klüppelberg U, Pauletzki J, Paumgartner G, Sauer‐

bruch T.

Combination of extracorporeal shock‐wave lithotripsy and dissolution of gallbladder stones

with methyl tert‐butyl ether: a randomized study.

Hepatology. 1994 Jan;19(1):133‐7.

35: Neubrand M, Sauerbruch T.

Gallenblasensteinbehandlung durch ESWL.

Verdauungskrankheiten. 1994;12:24‐26.

36: Nilius M, Bode G, Büchler M, Malfertheiner P.

Adhesion of Helicobacter pylori and Escherichia coli to human and bovine surface mucus cells

in vitro.

Eur J Clin Invest. 1994 Jul;24(7):454‐9.

21

37: Paffenholz R, Mandl M, Caspari R, Sengteller M, Propping P, Friedl W.

Eleven novel germline mutations in the adenomatous polyposis coli (APC) gene.

Hum Mol Genet. 1994 Sep;3(9):1703‐4.

38: Pauletzki J, Sailer C, Klüppelberg U, von Ritter C, Neubrand M, Holl J, Sauerbruch T,

Sackmann M, Paumgartner G.

Gallbladder emptying determines early gallstone clearance after shock‐wave lithotripsy.

Gastroenterology. 1994 Nov;107(5):1496‐502.

39: Pieramico O, Nelson DK, Glasbrenner B, Malfertheiner P.

Impaired interdigestive pancreatic polypeptide release. Early hormonal disorder in chronic

pancreatitis?

Dig Dis Sci. 1994 Jan;39(1):69‐74.

40: Reichel C, Fehske W, Fischer HP, Hartlapp JH.

Undifferentiated (embryonal) sarcoma of the liver in an adult patient with metastasis of the

heart and brain.

Clin Investig. 1994 Feb;72(3):209‐12.

41: Reichel C, von Falkenhausen M, Brockmeier D, Dengler HJ.

Characterization of cyclosporine A uptake in human erythrocytes.


42: Rosanowski F, Walther EK, Rockstroh J, Hück P, Oldenburg J.

[HIV‐associated parotid cysts].

Laryngorhinootologie. 1994 Apr;73(4):215‐8.

43: Sackmann M, Niller H, Klueppelberg U, von Ritter C, Pauletzki J, Holl J, Berr F, Neubrand

M, Sauerbruch T, Paumgartner G.

Gallstone recurrence after shock‐wave therapy.

Gastroenterology. 1994 Jan;106(1):225‐30.

44: Sauerbruch T.

[Current therapeutic possibilities in esophageal varices].

Praxis (Bern 1994). 1994 Nov 15;83(46):1275‐6.

45: Sauerbruch T.

Prophylaxis of first variceal bleeding: where does the truth lie.

Endoscopy. 1994 Nov;26(9):748‐9.

22


Lithotripsy of gallbladder stones.

Eur J Clin Invest. 1994 Jan;24(1):20‐1.

47: Sauerbruch T, Feussner H, Frimberger E, Hasegawa H, Ihse I, Riemann JF, Yasuda H.

Treatment of common bile duct stones. A consensus report.

Hepatogastroenterology. 1994 Dec;41(6):513‐5.

48: Sauerbruch T, Brensing KA.

[Esophageal varices: injection, banding, TIPS, drugs].

Bildgebung. 1994 Apr;61 Suppl 1:32‐7.

49: Scheurlen C, Neubrand M, Brensing KA, Sauerbruch T.

Dastellung einer neuen, nicht‐invasiven Technik zur Varizendruckmessung.

Verdauungskrankheiten 1994;12:238.

50: Scheurlen C, Spannbrucker N, Spengler U, Zachoval R, Schulte‐Witte H, Brensing KA,

Sauerbruch T.

Amanita phalloides intoxications in a family of russian immigrants. Case reports and review of

the literature with a focus on orthotopic liver transplantation.

Z Gastroenterol. 1994 Jul;32(7):399‐404.

51: Scheurlen C, Wöbke G, Terjung B, Sauerbruch T, Elmadfa I.

Status endogener Antioxidantien bei Patienten mit Morbus Crohn in Remission und intestina‐

len Stenosen oder Fisteln.

Infusionstherapie 1994;35:255.

52: Scheurlen CH, Sauerbruch T

[Applications of endoscopy in esophageal diseases. German Society of Digestive and Meta‐

bolic Diseases].

Z Gastroenterol. 1994 Dec;32(12):707‐12.


Obesity and hypertension.

Curr Opin Nephrol Hypertens. 1994 Sep;3(5):546‐9.


Efficacy and tolerance of low‐dose loop diuretics in hypertension.

Cardiology. 1994;84 Suppl 2:36‐42.

23

55: Schomburg A, Stoschus B, Reinhold U, Hartl C, Malfertheiner P, Biersack HJ.

Die Differentialdiagnose von Motilitätsstörungen mittels Ösophagus‐Transit‐Szintigraphie.

Endoskopie heute 1994;2:157‐62.

56: Schulte‐Witte H, Schäfer PK, Malfertheiner P.

Epidemiologische Aspekte des Magenkarzinoms unter Berücksichtigung von BRD West und

Ost.

Verdauungskrankheiten 1994;5:192‐196.

57: Spengler U, Rockstroh JK, Sauerbruch T.

[HIV‐associated cholangiopathy].

Dtsch Med Wochenschr. 1994 Jul 15;119(28‐29):1004‐5.

58: Tian DA, Malfertheiner P.

[Synthesis of glycoproteins by mucosa of gastric antrum in chronic gastritis B].

J Tongji Med Univ. 1994;14(2):71‐6.

59: Wehler M, Grote J, Klehr HU.

Hemoglobin oxygen affinity and acid‐base status in blood of chronic hemodialysis patients.

Adv Exp Med Biol. 1994;345:139‐44.

60: Willis S, Allescher HD, Stoschus B, Schusdziarra V, Classen M, Schumpelick V.

Double blind placebo controlled study on the effect of the nitric oxide donor molsidomin and

the 5‐HT3 antagonist ondansetron on human esophageal motility.

Z Gastroenterol. 1994 Nov;32(11):632‐6.

61: Zachoval R, Günther C, Scheurlen C, Klüppelberg UG, Zilker T, Pape GR.

[A 27‐year old patient with watery diarrhea, nausea and vomiting 10 hours after eating a

mushroom dish. Interdisciplinary liver transplantation team of the Grosshadern Clinic].


24

1995

1: Allescher HD, Stoschus B, Wünsch E, Schusdziarra V, Classen M.

Effect of human gastrin‐17 with and without acid suppression on human esophageal motility.


2: Bauer T, Ewig S, Hasper E, Rockstroh JK, Lüderitz B.

Predicting in‐hospital outcome in HIV‐associated Pneumocystis carinii pneumonia.

Infection. 1995 Sep‐Oct;23(5):272‐7.

3: Bierhoff E, Fischer HP, Pfeifer U, Rockstroh J, Spengler U.

[Hepatitis and posthepatic cirrhosis in AIDS].

Verh Dtsch Ges Pathol. 1995;79:249‐53.

4: Caspari R, Olschwang S, Friedl W, Mandl M, Boisson C, Böker T, Augustin A, Kadmon M,

Möslein G, Thomas G, et al.

Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE)

associated with APC mutations beyond codon 1444.

Hum Mol Genet. 1995 Mar;4(3):337‐40.

5: Domínguez‐Muñoz JE, Hieronymus C, Sauerbruch T, Malfertheiner P.

Fecal elastase test: evaluation of a new noninvasive pancreatic function test.


6: Ewig S, Moter A, Nachtsheim KH, Seuffert HM, Marklein G, Schumacher R, Eis G, Leutner

C, Bauer T, Reichel C, et al.

[Diagnostic value of protected bronchoalveolar lavage in HIV‐associated pneumonia].

Pneumologie. 1995 Oct;49(10):546‐55. German.

7: Flieger D, Gruber R, Schlimok G, Reiter C, Pantel K, Riethmüller G.

A novel non‐radioactive cellular cytotoxicity test based on the differential assessment of liv‐

ing and killed target and effector cells.

J Immunol Methods. 1995 Mar 13;180(1):1‐13.

8: Görich J, Brensing KA, Müller‐Miny H, Basche S, Sauerbruch T, Brambs HJ.

[CT follow‐up after transjugular intrahepatic portosystemic stent shunt (TIPSS)].

Rontgenpraxis. 1995 Mar;48(3):72‐5.

25

9: Görich J, Brensing KA, Kunze V, Sokiranski R, Rilinger N, Müller‐Miny H, Brambs HJ.

[Percutaneous drainage of refractory necrotizing tumors: experience in 9 patients].

Röfo. 1995 Dec;163(6):527‐31.

10: Görich J, Hasan I, Kunze V, Sittek H, Brensing KA, Reiser M, Layer G, Rilinger N, Sokiranski

R, Steudel A.

[Intra‐arterial treatment of therapy‐resistant residual tumors of the pelvis].

Strahlenther Onkol. 1995 Dec;171(12):671‐8.

11: Gorschlüter M, Bohlen H, Hasenclever D, Diehl V, Tesch H.

Serum cytokine levels correlate with clinical parameters in Hodgkin's disease.

Ann Oncol. 1995 May;6(5):477‐82.

12: Guo HB, Stoffel‐Wagner B, Bierwirth T, Mezger J, Klingmüller D.

Clinical significance of serum S100 in metastatic malignant melanoma.

Eur J Cancer. 1995 Jun;31A(6):924‐8.

13: Heimbach D, Miersch WD, Buszello H, Schoeneich G, Klehr HU.

Is the transplant‐preserving management of renal allograft rupture justified?

Br J Urol. 1995 Jun;75(6):729‐32.

14: Jacobs U, Ferber J, Heimbach D, Klehr HU.

Manifestation of metabolic risk factors after renal transplantation: III. Impact on cerebrocar‐

diovascular complications.

Transplant Proc. 1995 Jun;27(3):2052‐3.


Manifestation of metabolic risk factors after renal transplantation: II. Impact of maintenance

therapy.



Manifestation of metabolic risk factors after renal transplantation: I: Association with long‐

term allograft function.


17: kein Artikel

26

18: Jacobs U, Klein B, Niese D.

Transplantantat‐Abstossung.

Der Kassenarzt. 1995;35(49):44‐46.

19: Jung MC, Diepolder HM, Spengler U, Wierenga EA, Zachoval R, Hoffmann RM, Eichenlaub

D, Frösner G, Will H, Pape GR.

Activation of a heterogeneous hepatitis B (HB) core and e antigen‐specific CD4+ T‐cell popu‐

lation during seroconversion to anti‐HBe and anti‐HBs in hepatitis B virus infection.

J Virol. 1995 Jun;69(6):3358‐68.

20: Klehr HU, Jacobs U, Klein B, Molitor D, Miersch WD, Buszello H.

Organ sharing or local transplantation? Results of the kidney transplantation program in

Bonn.


21: Kruis W, Judmaier G, Kayasseh L, Stolte M, Theuer D, Scheurlen C, Hentschel E, Kratochvil

P.

Double‐blind dose‐finding study of olsalazine versus sulphasalazine as maintenance therapy

for ulcerative colitis.

Eur J Gastroenterol Hepatol. 1995 May;7(5):391‐6.

22: Look MP, Chrissafidou A.

[Whole blood selenium level and lipid peroxides in tumor patients treated with chemother‐

apy. DNA effects of oxygen free radicals exemplified by the NF kappa B transcription factor

and the p53 tumor suppressor gene].

Med Klin (Munich). 1995 Jan 15;90 Suppl 1:18‐22.

23: Mezger J, Glasmacher A, Sauerbruch T.

[Aftercare in patients with colorectal carcinomas].


24: Molitor E, Glasmacher A.

Diagnostik und Prophylaxe invasiver Aspergillus‐Infektionen – welche Möglichkeiten beste‐

hen heute?

Hyg Med. 1995;20:561‐2.

25: Paar WD.

[Immunoglobulins‐‐merely expensive or also useful?].

Ther Umsch. 1995 Oct;52(10):639‐44.

27

26: Paar WD, Look MP, Robertz Vaupel GM, Kreft B, Hirner A, Sauerbruch T.

Non‐operative management in a case of spontaneous splenic rupture in infectious mononu‐

cleosis.

Z Gastroenterol. 1995 Jan;33(1):13‐4.

27: Pauletzki J, Cicala M, Spengler U, Sauerbruch T, Paumgartner G.

Gallbladder emptying during high‐dose cholecystokinin infusions. Effect in patients with gall‐

stone disease and healthy controls.

Scand J Gastroenterol. 1995 Feb;30(2):128‐32.

28: Pauletzki J, Holl J, Sackmann M, Neubrand M, Klueppelberg U, Sauerbruch T, Paumgart‐

ner G.

Gallstone recurrence after direct contact dissolution with methyl tert‐butyl ether.

Dig Dis Sci. 1995 Aug;40(8):1775‐81.

29: Reichel C, Sauerbruch T.

Serum bile acids: physiology and clinical relevance.

Eur J Gastroenterol Hepatol. 1995 Oct;7(10):951‐3.

30: Reichel C, Wienkoop G, Nacke A, Sudhop T, Spengler U, Sauerbruch T.

Which lidocaine dose should be used for the MEGX liver function test?

J Hepatol. 1995 May;22(5):600.

31: Reichel C, Wienkoop G, Nacke A, Spengler U.

[Monoethylglycinexylidide (MEGX)‐test. A test for the assessment of prognosis before and

after liver transplantation].

Dtsch Med Wochenschr. 1995 Feb 10;120(6):179‐83.

32: Risse F, Glasmacher A, Gorschlüter M, Mezger J.

Invasive Aspergillus‐Infektionen in der hämatologischen Onkologie.

Hyg Med. 1995; 20:543‐8.

33: Rockstroh JK, Ewig S, Bauer T, Lüchters G, Oldenburg J, Bailly E, Kaiser R, Schneweis KE,

Brackmann HH, Dengler HJ, et al.

Male‐to‐female transmission of HIV in a cohort of hemophiliacs‐‐frequency, risk factors and

effect of sexual counseling.

Infection. 1995 Jan‐Feb;23(1):29‐32.

34: Rockstroh JK, Spengler U, Sauerbruch T.

[The therapy of viral hepatitis in HIV‐infected patients].


28

35: Sauerbruch T, Brensing KA.

[Treatment of portal hypertension].

Med Klin (Munich). 1995 Sep 15;90(9):532‐40.

36: Sauerbruch T.

[Endoscopic therapy of esophageal varices. An evaluation of the current status].

Chirurg. 1995 Jun;66(6):549‐54.

37: Sauerbruch T, Heller J.

[Gallbladder and bile duct diseases in the elderly].

Internist (Berl). 1995 Jul;36(7):677‐84.

38: Sauter G, Sackmann M, Holl J, Pauletzki J, Sauerbruch T, Paumgartner G.

Dormia baskets impacted in the bile duct: release by extracorporeal shock‐wave lithotripsy.

Endoscopy. 1995 Jun;27(5):384‐7.

39: Scheurlen C, Sauerbruch T.

Einsatz der Endoskopie bei Ösophaguserkrankungen.

Endopraxis. 1995;11:12‐20.

40: Schmieder RE, Rockstroh JK, Aepfelbacher F, Schulze B, Messerli FH.

Gender‐specific cardiovascular adaptation due to circadian blood pressure variations in essen‐

tial hypertension.

Am J Hypertens. 1995 Dec;8(12 Pt 1):1160‐6.

41: Spengler U.

[Interferons as therapy in viral hepatitis: are promises kept?].

Ther Umsch. 1995 Oct;52(10):645‐51.

42: Theisen A, Reichel C, Rüsch‐Gerdes S, Haas WH, Rockstroh JK, Spengler U,

Sauerbruch T.

Mixed‐strain infection with a drug‐sensitive and multidrug‐resistant strain of Mycobacterium

tuberculosis.

Lancet. 1995 Jun 10;345(8963):1512.

43: von Unruh GE, Hamm S, Paar WD, Dengler HJ.

Isotope Effects during Metabolism of (+)‐ and (−)‐ Trans Tramadol Isotopomers by Human

Liver Microsomes

Isotopes in Environmental and Health Studies. 1995; 31(3‐4):247‐53.

29

44: Wilhelm K, Schild H, Textor J, Mildenberger P, Strunk H, Terjung B, Lorenz J.

[Stent implantation for the palliative therapy of upper inflow obstruction in bronchial carci‐

noma].

Dtsch Med Wochenschr. 1995 Oct 20;120(42):1419‐25.

45: Wilhelm K, Schild H, Bruch E, Mildenberger P, Strunk H, Textor J, Terjung B, Lorenz J.

[Stent implantation as a palliative therapeutic measure in tumor‐induced stenoses of the

large veins of the body].

Röfo. 1995 Jun;162(6):514‐20.

46: Woitas RP, Sippel M, Ackermann T, Sauerbruch T, Spengler U.

T‐Cell response to hepatitis C proteins in chronic hepatitis C.

Immunbiol 1995;194(1‐3):326‐7.

30

1996

1: Bartz C, Ziske C, Wiedenmann B, Moelling K.

p53 tumour suppressor gene expression in pancreatic neuroendocrine tumour cells.

Gut. 1996 Mar;38(3):403‐9.

2: Bierhoff E, Weiss A, Wolf HK, Ewig S, Rockstroh J, Pfeifer U.

Autopsy findings in patients with human immunodeficiency virus infection with emphasis on

the risk factor of hemophilia.

Gen Diagn Pathol. 1996 May;141(5‐6):295‐304.

3: Breuer T,, Sudhop T, Hoch J, Sauerbruch T, Malfertheiner P.

Prevalence of and risk factors for Helicobacter pylori infection in the western part of Ger‐

many.

Eur J Gastroenterol Hepatol. 1996 Jan;8(1):47‐52.

4: Ewig S, Schäfer H, Rockstroh JK, Pickenhain A, Lüderitz B.

Effect of long‐term primary aerosolized pentamidine prophylaxis on breakthrough Pneumo‐

cystis carinii pneumonia.

Eur Respir J. 1996 May;9(5):1006‐12.

5: Ewig S, Schäfer H, Rockstroh JK, Lüderitz B.

[Improved prognosis of first episode HIV associated Pneumocystis carinii pneumonia without

preventive treatment: etiology and sequelae].

Pneumologie. 1996 Jul;50(7):455‐61.

6: Ewig S, Rockstroh JK, Schäfer H, Leutner C, Pickenhain A, Lüderitz B.

[HIV‐associated Pneumocystis carinii pneumonia, primary pentamidine inhalation prophylaxis

notwithstanding. Are there differences with Pneumocystis carinii pneumonia without proo‐

phylaxis?].

Dtsch Med Wochenschr. 1996 Jan 26;121(4):83‐9.

7: Friedl W, Meuschel S, Caspari R, Lamberti C, Krieger S, Sengteller M, Propping P.

Attenuated familial adenomatous polyposis due to a mutation in the 3' part of the APC gene.

A clue for understanding the function of the APC protein.

Hum Genet. 1996 May;97(5):579‐84.

31

8: Glasmacher A, Molitor E, Mezger J, Marklein G.

Antifungal prophylaxis with itraconazole in neutropenic patients: pharmacological, microbi‐

ological and clinical aspects.

Mycoses. 1996 Jul‐Aug;39(7‐8):249‐58.

9: Hagendorff A, Hertfelder HJ, Fehske W, Kirchhoff PG, Malfertheiner P.

[Recurrent arterial thromboembolism in hereditary hypoplasminogenaemia].


10: Heller J, Musiolik J, Homrighausen A, Sauerbruch T, Spengler U.

[Occurrence and significance of autoantibodies in the course of interferon therapy of chronic

hepatitis C].


11: Jacobs U, Niese D, Klein B, Paar D, Miersch WD, Klehr HU.

Cold ischemia, histocompatibility, donor and recipient age: impact on early lymphocyte sub‐

sets and transplant outcome.


12: Jacobs U, Niese D, Brensing KA, Eis‐Hübinger A, Buszello H, Klehr HU.

Immunologic disorders in posttransplant lymphoma: therapeutic implications.


13: Jacobs U, Paar D, Buszello H, Klehr HU.

Tumors after transplantation: are there associated factors?

Transplant Proc. 1996 Dec;28(6):3248.

14: Jacobs U, Niese D, Brensing KA, Klein B, Buszello H, Klehr HU.

Clinical and immunologic characteristics of transplant recipients with recurrent acute

rejection episodes.


15: Jacobs U, Klein B, Miersch WD, Molitor D, Klehr HU.

Dilemma: maintenance therapy enhances sclerogenic risk profile.


16: Jacobs U, Niese D, Miersch WD, Klehr HU.

Acute rejection relapsesposttransplant: definition of risk group and evaluation of potent

therapeutic regimens.

Transpl Int. 1996;9 Suppl 1:S34‐7.

32

17: John M, Meyerhof W, Richter D, Waser B, Schaer JC, Scherübl H, Boese‐Landgraf J, Neu‐

haus P, Ziske C, Mölling K, Riecken EO, Reubi JC, Wiedenmann B.

Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin

receptor subtype 2.

Gut. 1996 Jan;38(1):33‐9.

18: Klehr HU, Jacobs U, Miersch WD, Molitor D.

[Comparison of kidney transplantation with and without regard to HLA typing].


19: Kreuzer KA, Rockstroh JK, Sauerbruch T, Spengler U.

A comparative study of different enzyme immunosorbent assays for human tumor necrosis

factor‐alpha.

J Immunol Methods. 1996 Sep 9;195(1‐2):49‐54.

20: Kruse R, Lamberti C, Wang Y, Ruelfs C, Bruns A, Esche C, Lehmann P, Ruzicka T, Rütten A,

Friedl W, Propping P.

Is the mismatch repair deficient type of Muir‐Torre syndrome confined to mutations in the

hMSH2 gene?

Hum Genet. 1996 Dec;98(6):747‐50.

21: Lechmann M, Ihlenfeldt HG, Braunschweiger I, Giers G, Jung G, Matz B, Kaiser R, Sauer‐

bruch T, Spengler U.

T‐ and B‐cell responses to different hepatitis C virus antigens in patients with chronic hepatitis

C infection and in healthy anti‐hepatitis C virus‐‐positive blood donors without viremia.

Hepatology. 1996 Oct;24(4):790‐5.

22: Lorenz‐Meyer H, Bauer P, Nicolay C, Schulz B, Purrmann J, Fleig WE, Scheurlen C, Koop I,

Pudel V, Carr L.

Omega‐3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn's dis‐

ease. A randomized controlled multicenter trial. Study Group Members (German Crohn's Dis‐

ease Study Group).

Scand J Gastroenterol. 1996 Aug;31(8):778‐85.

23: Malfertheiner P, Enrique Domínguez‐Muñoz J, Heckenmüller H, Neubrand M, Fischer HP,

Sauerbruch T.

Modified rapid urease test for detection of Helicobacter pylori infection.


33

24: Mandl M, Caspari R, Jauch A, Böker T, Raschke H, Sengteller M, Propping P, Friedl W.

Familial adenomatous polyposis: a submicroscopic deletion at the APC locus in a family with

mentally normal patients.

Hum Genet. 1996 Feb;97(2):204‐8.

25: Mezger J, Malfertheiner P, Glasmacher A, Breuer TH, Fischer HP, Meybehm M, Kipnowski

HJ, Sauerbruch T.

[Libyan patient with chronic diarrhea].


26: Morioka T, Fujigaki Y, Batsford SR, Woitas R, Oite T, Shimizu F, Vogt A.

Anti‐DNA antibody derived from a systemic lupus erythematosus (SLE) patient forms histone‐

DNA‐anti‐DNA complexes that bind to rat glomeruli in vivo.

Clin Exp Immunol. 1996 Apr;104(1):92‐6.

27: Paar WD, Frankus P, Dengler HJ.

High‐performance liquid chromatographic assay for the simultaneous determination of

tramadol and its metabolites in microsomal fractions of human liver.

J Chromatogr B Biomed Appl. 1996 Nov 15;686(2):221‐7.

28: Paar WD, Spengler U, Müller A, Hirner A, Sauerbruch T.

[Diagnosis of acute liver failure].


29: Paar WD, Spengler U, Sauerbruch T.

[Conservative therapy of acute liver failure].


30: Pavlovic J, Nawrath M, Tu R, Heinicke T, Moelling K.

Anti‐tumor immunity is involved in the thymidine kinase‐mediated killing of tumors induced

by activated Ki‐ras(G12V).

Gene Ther. 1996 Jul;3(7):635‐43.

31: Reichel C, Theisen A, Rockstroh JK, Müller‐Miny H, Spengler U, Sauerbruch T.

Splenic abscesses and abdominal tuberculosis in patients with AIDS.


34

32: Rockstroh JK, Spengler U, Sudhop T, Ewig S, Theisen A, Hammerstein U, Bierhoff E, Fi‐

scher HP, Oldenburg J, Brackmann HH, Sauerbruch T.

Immunosuppression may lead to progression of hepatitis C virus‐associated liver disease in

hemophiliacs coinfected with HIV.

Am J Gastroenterol. 1996 Dec;91(12):2563‐8.

33: Rommel C, Radziwill G, Lovrić J, Noeldeke J, Heinicke T, Jones D, Aitken A, Moelling K.

Activated Ras displaces 14‐3‐3 protein from the amino terminus of c‐Raf‐1.

Oncogene. 1996 Feb 1;12(3):609‐19.

34: Sauerbruch T, Decker D, Hirner A.

[Endoscopic treatment of gallstones].

Internist (Berl). 1996 Aug;37(8):793‐9.

35: Schepke M, Brensing KA, Sauerbruch T.

Interventionelle Therapie bei portalem Hypertonus

Z Gastroenterol. 1996 34(Suppl.5):15‐7.

36: Scheurlen C.

[Lambliasis‐‐a treatment responsive complication of Crohn disease].

Fortschr Med. 1996 Feb 20;114(5):53‐4.

37: Scheurlen C, Sauerbruch T.

Interventionelle Techniken am Gallenwegssystem.

Chir Gastroenterol. 1996;12:32‐6

38: Schomburg A, Bender H, Reichel C, Sommer T, Ruhlmann J, Kozak B, Biersack HJ.

Standardized uptake values of fluorine‐18 fluorodeoxyglucose: the value of different normali‐

zation procedures.

Eur J Nucl Med. 1996 May;23(5):571‐4.

39: Spengler U, Zachoval R, Gallati H, Jung MC, Hoffmann R, Riethmüller G, Pape G.

Serum levels and in situ expression of TNF‐alpha and TNF‐alpha binding proteins in inflamma‐

tory liver diseases.

Cytokine. 1996 Nov;8(11):864‐72.

40: Spengler U, Lechmann M, Irrgang B, Dumoulin FL, Sauerbruch T.

Immune responses in hepatitis C virus infection.

J Hepatol. 1996;24(2 Suppl):20‐5.

35

41: Spengler U, Scheurlen CH, Sauerbruch T.

Vom Symptom zur Diagnose ‐ Stufendiagnostik in der Gastroenterologie und Hepatologie.

Internist 1996;37:121‐31.

42: Stoschus B, Domínguez‐Muñoz JE, Kalhori N, Sauerbruch T, Malfertheiner P.

Effect of omeprazole on Helicobacter pylori urease activity in vivo.

Eur J Gastroenterol Hepatol. 1996 Aug;8(8):811‐3.

43: Textor HJ, Strunk H, Brensing KA, Wilhelm K, Schild HH.

[Percutaneous removal of displaced metal stents in TIPS].

Röfo. 1996 Sep;165(3):288‐92.

44: Wichers M, Kaiser R, Rockstroh J, Matz B, Schneweis KE.

Biological testing versus sequence analysis for determination of drug resistance of human

immunodeficiency virus.

Zentralbl Bakteriol. 1996 Jul;284(2‐3):457‐65.

45: Woitas RP, Morioka T.

Influence of isoelectric point on glomerular deposition of antibodies and immune complexes.

Nephron. 1996;74(4):713‐9.

36

1997

1: Adomeit A, Mezger J, Fischer HP, Sauerbruch T.

Perkutane Ethanol‐Injektion bei hepatozellulärem Karzinom.

Tumordiag Ther. 1997;18:61‐64.

2: Alt M, Renz R, Hofschneider PH, Caselmann WH.

Core specific antisense phosphorothioate oligodeoxynucleotides as potent and specific in‐

hibitors of hepatitis C viral translation.

Arch Virol. 1997;142(3):589‐99.

3: Azizeh BY, Ahn JM, Caspari R, Shenderovich MD, Trivedi D, Hruby VJ.

The role of phenylalanine at position 6 in glucagon's mechanism of biological action: multiple

replacement analogues of glucagon.

J Med Chem. 1997 Aug 1;40(16):2555‐62.

4: Berns EM, De Witte HH, Klijn JG, Willman K, Look MP, Meijer‐Van Gelder ME, Benraad TJ,

Foekens JA.

Prognostic value of TP53 protein accumulation in human primary breast cancer: an analysis by

luminometric immunoassay on 1491 tumor cytosols.

Anticancer Res. 1997 Jul‐Aug;17(4B):3003‐6.

5: Bierhoff E, Fischer HP, Willsch E, Rockstroh J, Spengler U, Brackmann HH, Oldenburg J.

Liver histopathology in patients with concurrent chronic hepatitis C and HIV infection.

Virchows Arch. 1997 Apr;430(4):271‐7.

6: Blaufuss A, Lohn T, Paar WD, Sauerbruch T.

Orale antibiotische Therapie bei stationären Patienten ‐ Ergebnisse einer prospektiven Unter‐

suchung.

Immun Infekt. 1997;4:151‐6.

7: Block W, Reichel C, Träber F, Skodra T, Lamerichs R, Kreft B, Spengler U, Sauerbruch T,

Schild HH.

Effect of cytochrome P450 induction on phosphorus metabolites and proton relaxation times

measured by in vivo 31P‐magnetic resonance spectroscopy and 1H‐magnetic resonance re‐

laxometry in human liver.

Hepatology. 1997 Dec;26(6):1587‐91.

37

8: Brennemann W, Stoffel‐Wagner B, Helmers A, Mezger J, Jäger N, Klingmüller D.

Gonadal function of patients treated with cisplatin based chemotherapy for germ cell cancer.

J Urol. 1997 Sep;158(3 Pt 1):844‐50.

9: Brensing KA, Textor J, Strunk H, Klehr HU, Schild H, Sauerbruch T.

Transjugular intrahepatic portosystemic stent‐shunt for hepatorenal syndrome.

Lancet. 1997 Mar 8;349(9053):697‐8.

10: Bultmann T, Heller J, Scheurlen C, Grünwald F, Sauerbruch T, Biersack HJ.

[Determination of the count rate for quality control of combined lung ventilation and perfu‐

sion scintigraphy: case report].

Nuklearmedizin. 1997 Sep;36(6):213‐7.

11: Burger W, Kneissl GD, Hartmann A, Bauersachs R, Döring V, Spengler U, Neumann G, Ro‐

the KW.

Successful thrombolysis after prosthetic pulmonary valve obstruction under aspirin mono‐

therapy.

Ann Thorac Surg. 1997 Jul;64(1):255‐7; discussion 257‐8.

12: Caselmann WH, Spengler U, Fischer HP, Sauerbruch T.

[Liver cirrhosis as precancerous conditions].

Internist (Berl). 1997 Oct;38(10):928‐36.

13: Caselmann WH, Renner M, Schlüter V, Hofschneider PH, Koshy R, Meyer M.

The hepatitis B virus MHBst167 protein is a pleiotropic transactivator mediating its effect via

ubiquitous cellular transcription factors.

J Gen Virol. 1997 Jun;78 ( Pt 6):1487‐95.

14: Caselmann WH, Eisenhardt S, Alt M.

Synthetic antisense oligodeoxynucleotides as potential drugs against hepatitis C.

Intervirology. 1997;40(5‐6):394‐9.

15: Delsmann BM, Caselmann WH.

Images in hepatology. Manifestation of hepatocellular carcinoma as osteolytic acrometasta‐

sis.

J Hepatol. 1997 May;26(5):1154.

16: Dengler HJ.

The role of pharmacodynamics in drug research and therapeutics.

J Clin Pharmacol. 1997 Jan;37(1 Suppl):2S‐3S.

17: Dombrowski F, Eis‐Hübinger AM, Ackermann T, Blümel J, Spengler U, Pfeifer U.

38

Adenovirus‐induced liver necrosis in a case of AIDS.

Virchows Arch. 1997 Dec;431(6):469‐72.

18: Domínguez‐Muñoz JE, Leodolter A, Sauerbruch T, Malfertheiner P.

A citric acid solution is an optimal test drink in the 13C‐urea breath test for the diagnosis of

Helicobacter pylori infection.

Gut. 1997 Apr;40(4):459‐62.

19: Domínguez‐Muñoz JE, Birckelbach U, Glasbrenner B, Sauerbruch T, Malfertheiner P.

Effect of oral pancreatic enzyme administration on digestive function in healthy subjects:

comparison between two enzyme preparations.

Aliment Pharmacol Ther. 1997 Apr;11(2):403‐8.

20: Dose U, Klehr HU, MüllerMiny H, Brensing KA, Paar D, Raab P, Ackermann T, Sauerbruch

T.

Bone densitometry by quantitative computed tomography as noninvasive Diagnostic for re‐

nal osteopathy in hemodialysis patients.

Nieren‐ und Hochdruckkrankheiten. 1997;26: 482‐3.

21: Dumoulin FL, Terjung B, Neubrand M, Scheurlen C, Fischer HP, Sauerbruch T.

Treatment of Barrett's esophagus by endoscopic argon plasma coagulation.

Endoscopy. 1997 Oct;29(8):751‐3.

22: Dumoulin FL, Spengler U, Sauerbruch T.

Hepatitis C virus‐associated mixed cryoglobulinaemia.

Eur J Gastroenterol Hepatol. 1997 Nov;9(11):1063‐5.

23: Dumoulin FL, Sauerbruch T.

[Adverse contrast medium‐induced effects in ERCP].

Internist (Berl). 1997 Nov;38(11):1108.

24: Dumoulin FL, Bach A, Leifeld L, El‐Bakri M, Fischer HP, Sauerbruch T, Spengler U.

Semiquantitative analysis of intrahepatic cytokine mRNAs in chronic hepatitis C.

J Infect Dis. 1997 Mar;175(3):681‐5.

25: Dumoulin FL, Reichel C, Sauerbruch T, Spengler U.

Semiquantitation of intrahepatic MDR3 mRNA levels by reverse transcription/competitive

polymerase chain reaction.

J Hepatol. 1997 Apr;26(4):852‐6.

26: Ebert O, Finke S, Salahi A, Herrmann M, Trojaneck B, Lefterova P, Wagner E, Kircheis R,

Huhn D, Schriever F, Schmidt‐Wolf IG.

39

Lymphocyte apoptosis: induction by gene transfer techniques.

Gene Ther. 1997 Apr;4(4):296‐302.

27: Engelhart S, Hanfland J, Gilges S, Krizek L, Glasmacher A, Exner M.

Untersuchungen zur Exposition hämaonkologischer Patienten gegenüber Aspergillus‐

Konidien.

Hyg Med. 1997; 22(S 1), 5‐10.

28: Esche C, Kruse R, Lamberti C, Friedl W, Propping P, Lehmann P, Ruzicka T.

Muir‐Torre syndrome: clinical features and molecular genetic analysis.

Br J Dermatol. 1997 Jun;136(6):913‐7.

29: Ewig S, Schäfer H, Rockstroh JK.

[Intensive therapy of acute respiratory insufficiency in HIV infected patients. Current decision

guidelines and therapy options].

Pneumologie. 1997 Aug;51(8):815‐21.

30: Fätkenheuer G, Theisen A, Rockstroh JK, Garbow T, Wicke C, Becker K, Wieland U, Pfister

M, Hegener P, Franzen C, Schwenk A, Salzberger B.

Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV‐

infected patients.

AIDS. 1997; 11(14):F113‐F116.

31: Finke S, Trojaneck B, Möller P, Schadendorf D, Neubauer A, Huhn D, Schmidt‐Wolf IG.

Increase of cytotoxic sensitivity of primary human melanoma cells transfected with the inter‐

leukin‐7 gene to autologous and allogeneic immunologic effector cells.

Cancer Gene Ther. 1997 Jul‐Aug;4(4):260‐8.

32: Franzen C, Altfeld M, Hegener P, Hartmann P, Arendt G, Jablonowski H, Rockstroh J,

Diehl V, Salzberger B, Fätkenheuer G.

Limited value of PCR for detection of Toxoplasma gondii in blood from human immunodefi‐

ciency virus‐infected patients.

J Clin Microbiol. 1997 Oct;35(10):2639‐41.

33: Gieseler F, Glasmacher A, Kämpfe D, Zernak C, Valsamas S, Kunze J, Clark M.

Topoisomerase activities in undifferentiated acute myeloblastic leukemias and monocytic

differentiated leukemias.

Recent Results Cancer Res. 1997;143:321‐7.

34: Glasmacher A, Haferlach T, Gorschlüter M, Mezger J, Maintz C, Clemens MR, Ko Y, Hahn

C, Ubelacker R, Kleinschmidt R, Gieseler F.

Oral idarubicin, dexamethasone and vincristine (VID) in the treatment of multiple myeloma.

40

Leukemia. 1997 Dec;11 Suppl 5:S22‐6.

35: Glasmacher A, Kleinschmidt R, Unkrig C, Mezger J, Scharf RE.

Coagulation disorders induced by L‐asparaginase: Correction with and without fresh‐frozen

plasma.

Infusionsther Transfusionsmed. 1997;24(3):138‐43.

36: Glasmacher A, Mezger J, Exner M.

Prophylaxe der invasien Aspergillus‐Infektion in der hämatologischen Onkologie.

Krankenhausgygiene und Infektionsverhütung. 1997;19:114‐9.

37: Glasmacher A, Molitor E, Leutner C, Ewig S.

Diagnostik und Therapie systemischer Mykosen bei neutropenischen Patienten.

Der Onkologe. 1997;3(S1),S49‐S54.

38: Glasmacher A.

Die Bedeutung von Itraconazol in der Hämatologie und Onkologie.

Spektrum der Onkologie.1997;1:17‐21.

39: Glasmacher A, Molitor E.

Invasive Aspergillusinfektionen.

Hyg Med.1997.22(S1):3‐4.

40: Glasmacher A, Hahn C, Molitor E.

Medikamentöse Prophylaxe invasiver Mykosen bei neutropenischen Patienten mit hämatolo‐

gischen Systemerkrankungen.

Hyg Med. 1997;22(S1);20‐6.

41: Gorschlüter M, Glasmacher A, Risse F, Klein B, Klehr HU, Mezger J.

Successful induction and consolidation therapy of acute myeloid leukaemia in a renal allograft

recipient.

Nephrol Dial Transplant. 1997 Mar;12(3):593‐5.

42: Inchauspe G, Vitvitski L, Major ME, Jung G, Spengler U, Maisonnas M, Trepo C.

Plasmid DNA expressing a secreted or a nonsecreted form of hepatitis C virus nucleocapsid:

comparative studies of antibody and T‐helper responses following genetic immunization.

DNA Cell Biol. 1997 Feb;16(2):185‐95.

43: Jacobs U, Blaufuss A, Klehr HU.

Clinical and immunological characteristics of transplant recipients with recurrent acute rejec‐

tion episodes.

Transplant Proc. 1997 Feb‐Mar;29(1‐2):181‐3.

41

44: Klehr HU, Vennemann S, Blaufuss A, Brensing KA, Jacobs U, Klein B, Paar D, Raab P, Höl‐

ler T, Heimbach D.

Results of donor kidney pairs after local versus HLA‐dependent allocation.

Transplant Proc. 1997 Nov;29(7):3101‐5.

45: Kreuzer KA, Rockstroh JK.

Pathogenesis and pathophysiology of anemia in HIV infection.

Ann Hematol. 1997 Nov‐Dec;75(5‐6):179‐87.

46: Kreuzer KA, Dayer JM, Rockstroh JK, Sauerbruch T, Spengler U.

The IL‐1 system in HIV infection: peripheral concentrations of IL‐1beta, IL‐1 receptor antagonist

and soluble IL‐1 receptor type II.

Clin Exp Immunol. 1997 Jul;109(1):54‐8.

47: Kreuzer KA, Rockstroh JK, Jelkmann W, Theisen A, Spengler U, Sauerbruch T.

Inadequate erythropoietin response to anaemia in HIV patients: relationship to serum levels

of tumour necrosis factor‐alpha, interleukin‐6 and their soluble receptors.

Br J Haematol. 1997 Feb;96(2):235‐9.

48: Lefterova P, Schmidt‐Wolf IG.

Coexpression of lymphoid and myeloid markers on cell surfaces.

Leuk Lymphoma. 1997 Jun;26(1‐2):27‐33.

49: Leutner C, Strunk H, Müller‐Miny H, Ewig S, Glasmacher A, Losem C, Molitor E, Schild HH.

[The typical radiological findings and course of invasive pulmonary aspergillosis in the immu‐

nosuppressed patient].

Röfo. 1997 Jul;167(7):24‐31.

50: Look MP, Rockstroh JK, Rao GS, Kreuzer KA, Spengler U, Sauerbruch T.

Serum selenium versus lymphocyte subsets and markers of disease progression and inflam‐

matory response in human immunodeficiency virus‐1 infection.

Biol Trace Elem Res. 1997 Jan;56(1):31‐41.

42

51: Look MP, Rockstroh JK, Rao GS, Kreuzer KA, Barton S, Lemoch H, Sudhop T, Hoch J, Sto‐

ckinger K, Spengler U, Sauerbruch T.

Serum selenium, plasma glutathione (GSH) and erythrocyte glutathione peroxidase (GSH‐Px)‐

levels in asymptomatic versus symptomatic human immunodeficiency virus‐1 (HIV‐1)‐infection.

Eur J Clin Nutr. 1997 Apr;51(4):266‐72.

52: Maintz D, Fiedler K, Koopmann J, Rollbrocker B, Nechev S, Lenartz D, Stangl AP, Louis

DN, Schramm J, Wiestler OD, von Deimling A.

Molecular genetic evidence for subtypes of oligoastrocytomas.

J Neuropathol Exp Neurol. 1997 Oct;56(10):1098‐104.

53: Mezger J, Löcherbach U, Hagenhoff B, Funken O, Gallkowski U, Hahn C, Pfeifer U, Sauer‐

bruch T.

[Symptoms, tumor stage and primary treatment in patients with colorectal carcinoma].

Dtsch Med Wochenschr. 1997 May 30;122(22):703‐8. German.

54: Molitor E, Glasmacher A, Klucmy C, Marklein G.

Molekularbiologische Verfahren zur Diagnostik invasiver Mykosen.

Hyg Med. 1997;22(S1):11‐5.

55: Neubrand M, Greinwald I, Lobentanzer H, Paumgartner G, Hermeking H, Sauerbruch T.

Physical laws of cholesterol gallstone fragmentation.

Eur J Clin Invest. 1997 Mar;27(3):234‐41.

56: Neubrand M, Schepke M, Sauerbruch T.

Dysphagie.

Internist. 1997;38:391‐403.

57: Nooter K, Brutel de la Riviere G, Look MP, van Wingerden KE, Henzen‐Logmans SC, Sche‐

per RJ, Flens MJ, Klijn JG, Stoter G, Foekens JA.

The prognostic significance of expression of the multidrug resistance‐associated protein

(MRP) in primary breast cancer.

Br J Cancer. 1997;76(4):486‐93.

58: Paar WD.

Klinisch‐pharmakologische Aspekte der Therapy mit Amphotericin B.

Hyg Med. 1997;22(S1):27‐32.

59: Paar D, Terjung B, Sauerbruch T.

Life‐threatening interaction between clarithromycin and disopyramide.

Lancet. 1997 Feb 1;349(9048):326‐7.

60: Paar WD, Poche S, Gerloff J, Dengler HJ.

43

Polymorphic CYP2D6 mediates O‐demethylation of the opioid analgesic tramadol.

Eur J Clin Pharmacol. 1997;53(3‐4):235‐9.

61: Potyka U, Paar WD, Sauerbruch T, Von Unruh GE.

Labelling studies for structure elucidation of a new hydroxymetabolite of tramadol. Isotopes

Environ Health Stud. 1997 Jul;33(1‐2):119‐25.

62: Reichel C, Block W, Skodra T, Träber F, Schiedermaier P, Spengler U, Nuber R, Schild HH,

Sauerbruch T.

Relationship between cytochrome P‐450 induction by rifampicin, hepatic volume and portal

blood flow in man.


63: Reichel C, Meier‐Abt PJ.

[Cholestatic liver diseases].

Ther Umsch. 1997 Nov;54(11):639‐44.

64: Reichel C, Nacke A, Sudhop T, Wienkoop G, Lüers C, Hahn C, Pohl C, Spengler U, Sauer‐

bruch T.

The low‐dose monoethylglycinexylidide test: assessment of liver function with fewer side

effects.

Hepatology. 1997 Jun;25(6):1323‐7.

65: Rockstroh JK, Schmieder RE, Schlaich MP, Messerli FH.

Renal and systemic hemodynamics in black and white hypertensive patients.

Am J Hypertens. 1997 Sep;10(9 Pt 1):971‐8.

66: Rockstroh JK, Schobel HP, Vogt‐Ladner G, Hauser I, Neumayer HH, Schmieder RE.

Blood pressure independent effects of nitrendipine on cardiac structure in patients after re‐

nal transplantation.

Nephrol Dial Transplant. 1997 Jul;12(7):1441‐7.

67: Rockstroh JK, Woitas RP, Glasmacher A.

Invasive Aspergillusinfektionen bei Patienten mit AIDS.

Hyg Med. 1997;22(S1): 16‐9.

68: Sauerbruch T, Schepke M.

Sclerotherapy is out‐‐nearly.

Endoscopy. 1997 May;29(4):281‐2.

69: Rockstroh JK, Spengler U.

Pilzinfektionen im Verlauf der HIV‐Infektion.

44

Arzneimitteltherapie. 1997;15:112‐23.

70: Sauerbruch T, Stoschus B, Willkomm P, Neubrand M.

[The diagnosis of dyskinesias of Oddi's sphincter].


71: Sauerbruch T.

Extracorporeal shock wave lithotripsy.


72: Schepke M, Unkrig C, Sauerbruch T.

[Endoscopy in patients at risk for bleeding].


73: Schiedermaier P, Neubrand M, Hansen S, Sauerbruch T.

Variability of gallbladder emptying after oral stimulation.

Scand J Gastroenterol. 1997 Jul;32(7):719‐24.

74: Schild HH, Sauerbruch T.

Images in hepatology. Herniation of the liver.

J Hepatol. 1997 Dec;27(6):1117.

75: Schliefer K, Rockstroh JK, Spengler U, Sauerbruch T.

Nephrogenic diabetes insipidus in a patient taking cidofovir.

Lancet. 1997 Aug 9;350(9075):413‐4. Erratum in: Lancet 1997 Nov 22;350(9090):1558.

76: Schmidt‐Wolf GD, Negrin RS, Schmidt‐Wolf IG.

Activated T cells and cytokine‐induced CD3+CD56+ killer cells.

Ann Hematol. 1997 Feb;74(2):51‐6.

77: Schmieder RE, Rockstroh JK, Gatzka CD, Rüddel H, Schächinger H.

Discontinuation of antihypertensive therapy: prevalence of relapses and predictors of suc‐

cessful withdrawal in a hypertensive community.

Cardiology. 1997 May‐Jun;88(3):277‐84.

78: Schmieder RE, Rockstroh JK, Lüchters G, Hammerstein U, Messerli FH.

Comparison of early target organ damage between blacks and whites with mild systemic ar‐

terial hypertension.

Am J Cardiol. 1997 Jun 15;79(12):1695‐8.

79: Schriever F, Korinth D, Salahi A, Lefterova P, Schmidt‐Wolf IG, Behr SI.

Human T lymphocytes bind to germinal centers of human tonsils via integrin alpha4/VCAM‐1

and LFA‐1/ICAM‐1 and ‐2.

45

Eur J Immunol. 1997 Jan;27(1):35‐9.

80: Spengler U.

[When does hepatitis C infection become chronic?].

Fortschr Med. 1997 Jan 30;115(3):33‐4.

81: Spengler U, Leifeld L, Braunschweiger I, Dumoulin FL, Lechmann M, Sauerbruch T.

Anomalous expression of costimulatory molecules B7‐1, B7‐2 and CD28 in primary

biliary cirrhosis.

J Hepatol. 1997 Jan;26(1):31‐6.

82: Spengler U, Reichel C, Terjung B, Sauerbruch T.

Biochemical diagnosis of cholestatic liver disease.

Hepytologia Polska. 1997(4):109‐113.

83 : Stoschus B, Meybehm M, Spengler U, Scheurlen C, Sauerbruch T.

Cholestasis associated with mesalazine therapy in a patient with Crohn's disease.

J Hepatol. 1997 Feb;26(2):425‐8.

84: Strunk H, Textor J, Leifeld L.

[Hepatic pseudolesion caused by puncture].

Aktuelle Radiol. 1997 Sep;7(5):249‐52.

85: Strunk HM, Textor J, Brensing KA, Schild HH.

Acute Budd‐Chiari syndrome: treatment with transjugular intrahepatic portosystemic shunt.

Cardiovasc Intervent Radiol. 1997 Jul‐Aug;20(4):311‐3.

86: Terjung B, Paar WD, Schepke M, Klehr HU, Hufnagel A, Sauerbruch T.

[The Churg‐Strauss syndrome with cerebral seizures and terminal kidney failure].

Dtsch Med Wochenschr. 1997 Jul 4;122(27):853‐8.

46

87: Wang Y, Friedl W, Lamberti C, Ruelfs C, Kruse R, Propping P.

Hereditary nonpolyposis colorectal cancer: causative role of a germline missense mutation in

the hMLH1 gene confirmed by the independent occurrence of the same somatic mutation in

tumour tissue.

Hum Genet. 1997 Sep;100(3‐4):362‐4.

88: Wehner M, Buschhausen L, Lamberti C, Kruse R, Caspari R, Propping P, Friedl W.

Hereditary nonpolyposis colorectal cancer (HNPCC): eight novel germline mutations in

hMSH2 or hMLH1 genes.

Hum Mutat. 1997;10(3):241‐4.

89: Wilhelm K, Textor J, Strunk H, Brensing KA, Schüller H, Schild H.

[Carbon dioxide (CO2) as contrast medium for the new installation and follow‐up of a TIPS].

Röfo. 1997 Mar;166(3):238‐42.

90: Winter P, Schoeneich G, Miersch WD, Klehr HU.

Tumour induction as a consequence of immunosuppression after renal transplantation.

Int Urol Nephrol. 1997;29(6):701‐9.

912: Woitas KR, Sauerbruch T, Spengler H.

Bystander T‐cell clones in chronic hepatitis C.

Gastroenterology. 1997 Sep;113(3):1050‐1.

92: Woitas RP, Heller J, Stoffel‐Wagner B, Spengler U, Sauerbruch T.

Renal functional reserve and nitric oxide in patients with compensated liver cirrhosis.

Hepatology. 1997 Oct;26(4):858‐64.

93: Woitas RP, Lechmann M, Jung G, Kaiser R, Sauerbruch T, Spengler U.

CD30 induction and cytokine profiles in hepatitis C virus core‐specific peripheral blood T lym‐

phocytes.

J Immunol. 1997 Jul 15;159(2):1012‐8.

47

1998

1: Altfeld M, Rockstroh JK, Addo M, Kupfer B, Pult I, Will H, Spengler U.

Reactivation of hepatitis B in a long‐term anti‐HBs‐positive patient with AIDS following lami‐

vudine withdrawal.

J Hepatol. 1998 Aug;29(2):306‐9.

2: Brensing KA.

Transjugular intrahepatic portosystemic stent shunt for acute variceal bleeding: an option?

Digestion. 1998 Jul;59 Suppl 2:37‐40.

3: Brensing KA, Neubrand M, Textor J, Raab P, Müller‐Miny H, Scheurlen C, Görich J, Schild

H, Sauerbruch T.

Endoscopic manometry of esophageal varices: evaluation of a balloon technique compared

with direct portal pressure measurement.

J Hepatol. 1998 Jul;29(1):94‐102.

4: Bungard S, Flieger D, Schweitzer S, Sauerbruch T, Spengler U.

The combination of interleukin‐2 and interferon alpha effectively augments the antibody‐

dependent cellular cytotoxicity of monoclonal antibodies 17‐1A and BR55‐2 against the colo‐

rectal carcinoma cell line HT29.

Cancer Immunol Immunother. 1998 Jun;46(4):213‐20.

5: Caselmann WH.

Pathogenesis of hepatocellular carcinoma.

Digestion. 1998 Jul;59 Suppl 2:60‐3.

6: Davis GL, Esteban‐Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S,

Craxi A, Ling MH, Albrecht J.

Interferon alfa‐2b alone or in combination with ribavirin for the treatment of relapse of

chronic hepatitis C. International Hepatitis Interventional Therapy Group.

N Engl J Med. 1998 Nov 19;339(21):1493‐9.

7: Delsmann BM, Lienemann A, Nerlich A, Hoffmann E, Caselmann WH, Refior HJ.

[Primary manifestation of hepatocellular carcinoma as osteolytic hand metastasis‐‐a case re‐

port].

Z Orthop Ihre Grenzgeb. 1998 Nov‐Dec;136(6):571‐3.

48

8: Domínguez‐Muñoz JE, Bregulla M, Nelson DK, Glasbrenner B, Sauerbruch T, Malfertheiner

P.

Independent cycles of exocrine pancreatic secretion, hormones and gastroduodenal motility

in healthy fasting humans: reassessment of a complex partnership.

Neurogastroenterol Motil. 1998 Feb;10(1):27‐34.

9: Ewig S, Paar WD, Pakos E, Schäfer H, Tasci S, Marklein G, Lüderitz B.

[Nosocomial ventilator‐associated pneumonias caused by Aspergillus fumigatus in non‐

immunosuppressed, non‐neutropenic patients].

Pneumologie. 1998 Feb;52(2):85‐90.

10: Ewig S, Glasmacher A, Ulrich B, Wilhelm K, Schäfer H, Nachtsheim KH.

Pulmonary infiltrates in neutropenic patients with acute leukemia during chemotherapy: out‐

come and prognostic factors.

Chest. 1998 Aug;114(2):444‐51.

11: Finke S, Trojaneck B, Lefterova P, Csipai M, Wagner E, Kircheis R, Neubauer A, Huhn D,

Wittig B, Schmidt‐Wolf IG.

Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human

CD3+ CD56+ immunologic effector cells by receptor‐mediated transfection with the inter‐

leukin‐7 gene.

Gene Ther. 1998 Jan;5(1):31‐9.

12: Fätkenheuer G, Rockstroh J, Salzberger B.

Reply: Virological treatment failure of protease inhibitor therapy in an unselected cohort of

HIV‐infected patients.

AIDS. 1998 Jul 30;12(11):1402‐3.

13: Glasmacher A, Molitor E, Hahn C, Bomba K, Ewig S, Leutner C, Wardelmann E, Schmidt‐

Wolf IG, Mezger J, Marklein G, Sauerbruch T.

Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. Leu‐

kemia. 1998 Sep;12(9):1338‐43.

14: Glasmacher A.

[Etiology and diagnosis of fever of unknown origin].

Krankenpfl J. 1998 Jul‐Aug;36(7‐8):270‐4.

15: Glasmacher A, Marklein G, Just‐Nübling G, Leutner C, Ewig S.

[Diagnosis of invasive mycoses in neutropenic patients with systemic hematologic diseases].


16: Glasmacher A, Just‐Nübling G, Molitor E.

49

[Therapy of invasive mycoses in neutropenic patients with hematologic system diseases].


17: Glasmacher AG, Brennemann W, Hahn C, Marko C, Wehnert S, Löhr U, Kutschkow R.

Evaluation of five devices for self‐monitoring of blood glucose in the normoglycaemic range.

Exp Clin Endocrinol Diabetes. 1998;106(5):360‐4.

18: Harbrecht U, Oldenburg J, Klein P, Weber D, Rockstroh J, Hanfland P.

Increased sensitivity of factor IX to phenprocoumon as a cause of bleeding in a patient with

antiphospholipid antibody associated thrombosis.

J Intern Med. 1998 Jan;243(1):73‐7.

19 Hellstern A, Leuschner U, Benjaminov A, Ackermann H, Heine T, Festi D, Orsini M, Roda E,

Northfield TC, Jazrawi R, Kurtz W, Schmeck‐Lindenau HJ, Stumpf J, Eidsvoll BE, Aadland E,

Lux G, Boehnke E, Wurbs D, Delhaye M, Cremer M, Sinn I, Höring E, v Gaisberg U, Neubrand

M, Paul F, et al.

Dissolution of gallbladder stones with methyl tert‐butyl ether and stone recurrence: a Euro‐

pean survey.

Dig Dis Sci. 1998 May;43(5):911‐20. Erratum in: Dig Dis Sci 1998 Nov;43(11):2572.

20: Kupfer B, Kaiser R, Rockstroh JK, Matz B, Schneweis KE.

Role of HIV‐1 phenotype in viral pathogenesis and its relation to viral load and CD4+ T‐cell

count.

J Med Virol. 1998 Nov;56(3):259‐63.

21: Look MP, Rockstroh JK, Rao GS, Barton S, Lemoch H, Kaiser R, Kupfer B, Sudhop T,

Spengler U, Sauerbruch T.

Sodium selenite and N‐acetylcysteine in antiretroviral‐naive HIV‐1‐infected patients: a random‐

ized, controlled pilot study.

Eur J Clin Invest. 1998 May;28(5):389‐97.

22: Mann B, Gratchev A, Riede E, Schmidt‐Wolf I, Trojanek B, Moyer P, Hanski C, Buhr HJ.

[beta‐catenin overexpression in metastasized colorectal carcinoma‐‐an important mechanism

in progression of the disease?].

Langenbecks Arch Chir Suppl Kongressbd. 1998;115(Suppl I):303‐

23: Mezger J, Sauerbruch T, Ko Y, Wolter H, Funk C, Glasmacher A.

Phase II study with gemcitabine in gallbladder and biliary tract carcinomas.

Onkologie. 1998;21(3):232‐4.

24: Morakkabati N, Dumont‐Dos‐Santoz D, Glasmacher A, Kreft B.

[Primary non‐Hodgkin lymphoma of the ovary].

50

Aktuelle Radiol. 1998 May;8(3):145‐7.

25: Musch E, Högemann B, Gerritzen A, Fischer HP, Wiese M, Kruis W, Malek M, Gugler R,

Schmidt G, Huchzermeyer H, Gerlach U, Dengler HJ, Sauerbruch T.

Phase II clinical trial of combined natural interferon‐beta plus recombinant interferon‐gamma

treatment of chronic hepatitis B.

Hepatogastroenterology. 1998 Nov‐Dec;45(24):2282‐94.

26: Müller M, Scheffold C, Lefterova P, Huhn D, Neubauer A, Schmidt‐Wolf IG.

Potential of autologous immunologic effector cells for prediction of progression of disease in

patients with chronic myelogenous leukemia.

Leuk Lymphoma. 1998 Oct;31(3‐4):335‐41.

27: Neubrand M, Sauerbruch T.

Erythromycin, a motilin agonist, increases postprandial gallbladder emptying during therapy

with ursodeoxycholic acid.

Z Gastroenterol. 1998 Apr;36(4):267‐71.

28: Paar WD, Müller A, Spengler U, Fischer HP, Hertfelder HJ, Hirner A, Sauerbruch T.

[Progress of acute liver failure and indications for liver transplantation].


29: Potyka U, Paar WD, Sauerbruch T, von Unruh GE.

Labelling studies for structure elucidation of a new hydroxymetabolite of tramadol.

Isotopes Environ Health Stud. 1998;33(1‐2):119‐25.

30: Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J,

Zeuzem S, Trepo C, Albrecht J.

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus in‐

terferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis

C virus. International Hepatitis Interventional Therapy Group (IHIT).

Lancet. 1998 Oct 31;352(9138):1426‐32.

31: Reichel C, Skodra T, Nacke A, Spengler U, Sauerbruch T.

The lignocaine metabolite (MEGX) liver function test and P‐450 induction in humans.

Br J Clin Pharmacol. 1998 Dec;46(6):535‐9.

51

32: Reiter‐Owona I, Bialek R, Rockstroh JK, Seitz HM.

The probability of acquiring primary Toxoplasma infection in HIV‐infected patients: results of

an 8‐year retrospective study.

Infection. 1998 Jan‐Feb;26(1):20‐5.

33: Rockstroh J.

Present status of the treatment of HIV infections .

Medizinische Welt. 1998;49(10A):40‐3.

34: Rockstroh JK, Reichel C, Hille H, Oldenburg J, Brackmann HH.

Pharmacokinetics of azidothymidine and its major metabolite glucuronylazidothymidine in

hemophiliacs coinfected with human immunodeficiency virus and chronic hepatitis C.

Am J Ther. 1998 Nov;5(6):387‐91.

35: Rockstroh JK, Kreuzer KA, Sauerbruch T, Spengler U.

Protein levels of interleukin‐12 p70 holomer, its p40 chain and interferon‐gamma during ad‐

vancing HIV infection.

J Infect. 1998 Nov;37(3):282‐6.

36: Rockstroh JK, Theisen A, Kaiser R, Sauerbruch T, Spengler U.

Antiretroviral triple therapy decreases HIV viral load but does not alter hepatitis C virus (HCV)

serum levels in HIV‐HCV‐co‐infected haemophiliacs.

AIDS. 1998 May 7;12(7):829‐30.

37: Rockstroh JK, Woitas RP, Brackmann HH, Kupfer B, Kaiser R, Schneweis KE, Sudhop T,

Spengler U.

In vitro cytopathogenicity of the human immunodeficiency virus (HIV)‐1 predicts survival in

HIV‐infected hemophiliacs independent from CD4 cell count.

Eur J Med Res. 1998 May 12;3(5):223‐30.

38: Rockstroh JK, Woitas RP, Spengler U.

Human immunodeficiency virus and hepatitis C virus coinfection.

Eur J Med Res. 1998 Jun 17;3(6):269‐77.

39: Rust C, Pratschke E, Hartl W, Kessler M, Weibecke B, Sauerbruch T, Paumgartner G, Beu‐

ers U.

Fibrotic entrapment of the small bowel in congenital intestinal lymphangiectasia.


52

40: Sauerbruch T.

[Paths of clinical research].

Dtsch Med Wochenschr. 1998 Nov13;123(46):1365‐6.

41: Sauerbruch T, Schiedermaier P.

[Medical treatment of intestinal hemorrhage in portal hypertension].


42: Scheurlen C, Allgayer H, Hardt M, Kruis W.

Effect of short‐term topical corticosteroid treatment on mucosal enzyme systems in patients

with distal inflammatory bowel disease.

Hepatogastroenterology. 1998 Sep‐Oct;45(23):1539‐45.

43: Scheurlen C, Roleff A, Neubrand M, Sauerbruch T.

Noninvasive endoscopic determination of intravariceal pressure in patients with portal hyper‐

tension: clinical experience with a new balloon technique.

Endoscopy. 1998 May;30(4):326‐32.

44: Schiemann R, Glasmacher A, Bailly E, Horré R, Molitor E, Leutner C, Smith MT, Klein‐

schmidt R, Marklein G, Sauerbruch T.

Geotrichum capitatum septicaemia in neutropenic patients: case report and review of the

literature.

Mycoses. 1998 Mar‐Apr;41(3‐4):113‐6.

45: Schimpf R, Hagendorff A, Dettmers C, Jung W, Omran H, Rockstroh J, Lüderitz B.

[37‐year‐old patient with myalgia, arthralgia, pseudovasculitis and palpitations].

Internist (Berl). 1998 Sep;39(9):974‐7.

46: Schmitz V, Klehr HU, Delfs M, Leifeld L, Meybehm M, Sauerbruch T.

[56‐year‐old man with acrocyanosis, livedo reticularis, renal failure and arterial hypertension.

Cholesterol embolism syndrome (CES)].

Internist (Berl). 1998 Jan;39(1):87‐90.

47: Spengler U, Rockstroh JK.

Hepatitis C in the patient with human immunodeficiency virus infection.

J Hepatol. 1998 Dec;29(6):1023‐30. Review.

48: Stoschus B, Hamscher G, Ikonomou S, Partoulas G, Eberle C, Sauerbruch T, Feurle GE.

Effect of omeprazole treatment on plasma concentrations of the gastric peptides, xenin, gas‐

trin and somatostatin, and of pepsinogen.

J Pept Res. 1998 Jul;52(1):27‐33.

53

49: Terjung B, Herzog V, Worman HJ, Gestmann I, Bauer C, Sauerbruch T, Spengler U.

Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic in‐

flammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina pro‐

teins.

Hepatology. 1998 Aug;28(2):332‐40.

50: Textor HJ, Brensing KA, Wilhelm K, Strunk H, Block W, Raab P, Hofer U, Müller‐Miny H,

Layer G, Schiedermeier P, Schüller H, Sauerbruch T, Schild HH.

[TIPSS: technical and clinical results after 4 years].

Röfo. 1998 Apr;168(4):361‐8.

51: Varaklioti A, Georgopoulou U, Kakkanas A, Psaridi L, Serwe M, Caselmann WH, Mavro‐

mara P.

Mutational analysis of two unstructured domains of the 5' untranslated region of HCV RNA.

Biochem Biophys Res Commun. 1998 Dec 30;253(3):678‐85.

52: von Unruh GE, Langer MA, Paar DW, Hesse A.

Mass spectrometric‐selected ion monitoring assay for an oxalate absorption test applying

[13C2]oxalate.

J Chromatogr B Biomed Sci Appl. 1998 Sep 25;716(1‐2):343‐9.

55: Wedemeyer H, Caselmann WH, Manns MP.

Combination therapy of chronic hepatitis C: an important step but not the final goal!

J Hepatol. 1998 Dec;29(6):1010‐4.

56: Woitas RP, Rockstroh JK, Theisen A, Leutner C, Sauerbruch T, Spengler U.

Changing role of invasive aspergillosis in AIDS‐‐a case control study.

J Infect. 1998 Sep;37(2):116‐22.

57: Woitas RP, Wilhelm K, Hortling N, Becher H, Grünwald F.

[Diagnosis of acute pulmonary embolism].


58: Zoll B, Lefterova P, Csipai M, Finke S, Trojaneck B, Ebert O, Micka B, Roigk K, Fehlinger

M, Schmidt‐Wolf GD, Huhn D, Schmidt‐Wolf IG.

Generation of cytokine‐induced killer cells using exogenous interleukin‐2, ‐7 or ‐12.

Cancer Immunol Immunother. 1998 Dec;47(4):221‐6.

54

1999

1: Alt M, Eisenhardt S, Serwe M, Renz R, Engels JW, Caselmann WH.

Comparative inhibitory potential of differently modified antisense oligodeoxynucleotides on

hepatitis C virus translation.

Eur J Clin Invest. 1999 Oct;29(10):868‐76.

2: Berthold HK, Parhofer KG, Ritter MM, Addo M, Wasmuth JC, Schliefer K, Spengler U,

Rockstroh JK.

Influence of protease inhibitor therapy on lipoprotein metabolism.

J Intern Med. 1999 Dec;246(6):567‐75.

3: Biecker E, Brensing KA, Perz J, Woitas R, Sauerbruch T.

[The therapy of the hepatorenal syndrome in liver cirrhosis].


4: Böhme A, Karthaus M, Einsele H, Ruhnke M, Südhoff T, Buchheidt D, Enzensberger R, Sze‐

lényi H, Glasmacher A, Just‐Nübling G, Gümbel H.

[Diagnosis of systemic fungal infections in hematology. Standard recommendations of the

Working Group for Infections in Hematology and Oncology of the German Association for

Hematology and Oncology].

Dtsch Med Wochenschr. 1999 Apr 9;124 Suppl 1:S24‐30.

5: Brensing KA, Sauerbruch T.

Pathophysiologie der portalen Hypertonie und des hyperdynamen Kreislaufsyndroms.


6: Brockmeyer NH, Willers CP, Anders S, Mertins L, Rockstroh JK, Stürzl M.

Cytokine profile of HIV‐positive Kaposi's sarcoma derived cells in vitro.

Eur J Med Res. 1999 Mar 26;4(3):95‐100.

7: Caselmann WH, Blum HE, Fleig WE, Huppert PE, Ramadori G, Schirmacher P, Sauerbruch

T.

[Guidelines of the German Society of Digestive and Metabolic Diseases for diagnosis and

therapy of hepatocellular carcinoma. German Society of Digestive and Metabolic Diseases].

Z Gastroenterol. 1999 May;37(5):353‐65.

55

8: Diepolder HM, Ries G, Jung MC, Schlicht HJ, Gerlach JT, Grüner N, Caselmann WH, Pape

GR.

Differential antigen‐processing pathways of the hepatitis B virus e and core proteins.


9: Dumoulin FL, von dem Bussche A, Söhne J, Sauerbruch T, Spengler U.

Hepatitis C virus core protein does not inhibit apoptosis in human hepatoma cells.

Eur J Clin Invest. 1999 Nov;29(11):940‐6.

10: Dumoulin FL, Leifeld L, Honecker U, Sauerbruch T, Spengler U.

Intrahepatic expression of interleukin‐1beta and tumor necrosis factor‐alpha in chronic hepa‐

titis C.

J Infect Dis. 1999 Nov;180(5):1704‐8.

11: Dumoulin FL, Leifeld L, Sauerbruch T, Spengler U.

Autoimmunity induced by interferon‐alpha therapy for chronic viral hepatitis.

Biomed Pharmacother. 1999 Jun;53(5‐6):242‐54.

12: Dumoulin FL, Altfeld M, Rockstroh JK, Leifeld L, Sauerbruch T, Spengler U.

Semiquantitation of human chemokine mRNA levels with a newly constructed multispecific

competitor fragment.

J Immunol Methods. 1999 Apr 22;224(1‐2):61‐7.

13: Fätkenheuer G, Hoetelmans RMW, Hunn N, Schwenk A, Franzen C, Reiser M, Jütte A,

Rockstroh JK, Diehl V, Salzberger B.

Salvage therapy with regimens containing ritonavir and saquinavir in extensively pretreated

HIV‐infected patients.

Aids. 1999;13(12):1485‐99.

14: Flieger D, Spengler U, Beier I, Kleinschmidt R, Hoff A, Varvenne M, Sauerbruch T,

Schmidt‐Wolf I.

Enhancement of antibody dependent cellular cytotoxicity (ADCC) by combination of cyto‐

kines.

Hybridoma. 1999 Feb;18(1):63‐8.

15: Friedl W, Kruse R, Uhlhaas S, Stolte M, Schartmann B, Keller KM, Jungck M, Stern M, Loff

S, Back W, Propping P, Jenne DE.

Frequent 4‐bp deletion in exon 9 of the SMAD4/MADH4 gene in familial juvenile polyposis

patients.

Genes Chromosomes Cancer. 1999 Aug;25(4):403‐6.

56

16: Gadano A, Moreau R, Heller J, Chagneau C, Vachiéry F, Trombino C, Elman A, Dié C, Valla

D, Lebrec D.

Relationship between serverity of liver disease and renal oxygen consumption in patients

with cirrhosis.

Gut. 1999; 45(1):117‐21.

17: Gadano A, Sogni P, Heller J, Moreau J, Bories PN, Lebrec D.

Vascular nitric oxide production during the development of two experimental models of por‐

tal hypertension.

J Hepatol. 1999;30(5):896‐903.

18: Glasmacher A, Hahn C, Molitor E, Marklein G, Sauerbruch T, Schmidt‐Wolf IG.

Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regi‐

mens using hydroxypropyl‐beta‐cyclodextrin oral solution or coated‐pellet capsules.

Mycoses. 1999;42(11‐12):591‐600.

19: Glasmacher A, Hahn C, Leutner C, Molitor E, Wardelmann E, Losem C, Sauerbruch T,

Marklein G, Schmidt‐Wolf IG.

Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itra‐

conazole.

Mycoses. 1999;42(7‐8):443‐51.

20: Glasmacher A, Hahn C, Molitor E, Sauerbruch T, Schmidt‐Wolf IG, Marklein G.

Fungal surveillance cultures during antifungal prophylaxis with itraconazole in neutropenic

patients with acute leukaemia.

Mycoses. 1999;42(5‐6):395‐402.

21: Goebel FD, Mannhalter JW, Belshe RB, Eibl MM, Grob PJ, de Gruttola V, Griffiths PD, Erfle

V, Kunschak M, Engl W and the European Multinational IMMUNO AIDS Vaccine Study Group.

Recombinant gp 160 as a therapeutic vaccine for HIV‐infection results of a large randomized

controlled trial.

AIDS. 1999;13(12):1461‐8.

22: Heller J, Kristeleit H, Brensing KA, Woitas RP, Spengler U, Sauerbruch T.

Nitrite and nitrate levels in patients with cirrhosis of the liver: influence of kidney function and

fasting state.

Scand J Gastroenterol. 1999 Mar;34(3):297‐302.

57

23: Heller J, Schepke M, Gehnen N, Molderings GJ, Müller A, Erhard J, Spengler U, Sauer‐

bruch T.

Altered adrenergic responsiveness of endothelium‐denuded hepatic arteries and portal veins

in patients with cirrhosis.

Gastroenterology. 1999 Feb;116(2):387‐93.

24: Heller J, Sogni P, Tazi KA, Chagneau C, Poirel O, Moreau R, Lebrec D.

Abnormale regulation of NOS2 und NOS3 activity and expression in portal vein‐stenosed rat

aortae after lipopolysaccharide administration.

Hepatology. 1999 Sep;30(3):698‐704.

25: Hesse A, Schneeberger W, Engfeld S, Von Unruh GE, Sauerbruch T.

Intestinal hyperabsorption of oxalate in calcium oxalate stone formers: application of a new

test with [13C2]oxalate.

J Am Soc Nephrol. 1999 Nov;10 Suppl 14:S329‐33.

26: Hoffmann RM, Berg T, Teuber G, Prümmer O, Leifeld L, Jung MC, Spengler U, Zeuzem S,

Hopf U, Pape GR.

Interferon‐antibodies and the breakthrough phenomenon during ribavirin/interferon‐alpha

combination therapy and interferon‐alpha monotherapy of patients with chronic hepatitis C.


27: Jungck M, Friedl W, Propping P.

[Hereditary gastrointestinal tumors].

Internist (Berl). 1999 May;40(5):502‐12.

28: Kruse R, Uhlhaas S, Lamberti C, Keller KM, Jackisch C, Steinhard J, Knöpfle G, Loff S, Back

W, Stolte M, Jungck M, Propping P, Friedl W, Jenne DE.

Peutz‐Jeghers syndrome: four novel inactivating germline mutations in the STK11 gene. Muta‐

tions in brief no. 227. Online.

Hum Mutat. 1999;13(3):257‐8.

29: Kupfer B, Kaiser R, Brackmann HH, Effenberger W, Rockstroh JK, Matz B, Schneweis KE.

Protection against parenteral HIV‐1 infection by homozygous deletion in the C‐C chemokine

receptor 5 gene.

AIDS. 1999 Jun 18;13(9):1025‐8.

58

30: Lamberti C, Kruse R, Ruelfs C, Caspari R, Wang Y, Jungck M, Mathiak M, Malayeri HR,

Friedl W, Sauerbruch T, Propping P.

Microsatellite instability‐a useful diagnostic tool to select patients at high risk for hereditary

non‐polyposis colorectal cancer: a study in different groups of patients with colorectal can‐

cer.

Gut. 1999 Jun;44(6):839‐43.

31: Lechmann M, Woitas RP, Langhans B, Kaiser R, Ihlenfeldt HG, Jung G, Sauerbruch T,

Spengler U.

Decreased frequency of HCV core‐specific peripheral blood mononuclear cells with type 1

cytokine secretion in chronic hepatitis C.

J Hepatol. 1999 Dec;31(6):971‐8.

32: Lechmann M, Schneider EM, Giers G, Kaiser R, Dumoulin FL, Sauerbruch T, Spengler U.

Increased frequency of the HLA‐DR15 (B1*15011) allele in German patients with self‐limited

hepatitis C virus infection.

Eur J Clin Invest. 1999 Apr;29(4):337‐43.

33: Leifeld L, Trautwein C, Dumoulin FL, Manns MP, Sauerbruch T, Spengler U.

Enhanced expression of CD80 (B7‐1), CD86 (B7‐2), and CD40 and their ligands CD28 and CD154

in fulminant hepatic failure.

Am J Pathol. 1999 Jun;154(6):1711‐20.

34: Leifeld L, Ramakers J, Dumoulin FL, Spengler U, Trautwein C, Manns MP, Sauerbruch T.

Enhanced expression of CD 80 (B7‐1), CD 86 (B7‐2), and CD40 and their ligands CD 28 and CD

154 in fulminat hepatic failure.

Am J Pathol. 1999;154:1711‐1720

35: Leutner C, Gieseke J, Lutterbey G, Kuhl CK, Flacke S, Glasmacher A, Theisen A, Wardel‐

mann E, Grohe C, Schild HH.

[MRT versus CT in the diagnosis of pneumonias: an evaluation of a T2‐weighted ultrafast

turbo‐spin‐echo sequence (UTSE)].

Röfo. 1999 May;170(5):449‐56.

36: Look MP, Gerard A, Rao GS, Sudhop T, Fischer HP, Sauerbruch T, Spengler U.

Interferon/antioxidant combination therapy for chronic hepatitis C‐‐a controlled pilot trial.

Antiviral Res. 1999 Sep;43(2):113‐22.

59

37: Look MP, Reichel C, von Falkenhausen M, Hahn C, Stockinger K, von Bergmann K, Rao GS,


Vitamin E status in patients with liver cirrhosis: normal or deficient?

Metabolism. 1999 Jan;48(1):86‐91.

38: Luers C, Sudhop T, Spengler U, Berthold HK.

Improvement of sarcoidosis under therapy with interferon‐alpha 2b for chronic hepatitis B

virus infection.

J Hepatol. 1999 Feb;30(2):347.

39: Mann B, Gratchev A, Riede E, Schmidt‐Wolf I, Trojaneck B, Moyer MP, Hanski C, Buhr HJ.

FasL is more frequently expressed in liver metabolism than in paired primary colorectal can‐

cer.

Brit J Cancer. 1999;79(718):1262‐9.

40: Müller M, Wolff, M, Spengler U.

Portale Hypertension und Lebertransplantation.

Leber Magen Darm. 1999;17:159‐169.

41: Neef M, Sauerbruch T.

[Can hemorrhoids facilitate the transit of allergens from feces into the blood circulation?].

Dtsch Med Wochenschr. 1999 Jun 4;124(22):711.

42: Pateron D, Oberti F, Lefiliatre P, Veal N, Tazi K, Sogni P, Poirel O, Heller J, Moreau R, Ca‐

les P, Lebrec D.

Relationship between in vitro vascular reactivity and blood‐flows in rats with cirrhosis.

Clinical Science. 1999;97:313‐8.

43: Rabe C, Scheurlen C, Caselmann WH.

[Management of Amanita phalloides poisoning].


44: Reichel C, Gao B , Van Montfoort J, Cattori V, Rahner C, Hagenbuach B, Stieger B, Kami‐

sako T, Meier PJ.

Localization and funktion of the organic anion‐transporting polypeptide Oatp2 in rat liver.

Gastroenterology. 1999; 117(3);688‐95.

45: Reimann G, Barthel B, Rockstroh JK, Spatz D, Brockmeyer NH.

Effect of fusidic acid on the hepatic cytochrome P450 enzyme system.

Int J Clin Pharmacol Ther. 1999 Nov;37(11):562‐6.

46: Rockstroh JK.

60

Aktuelle therapeutische Strategien und Wirksamkeit neuer antiretroviraler Medikamente zur

Behandlung der HIV‐Infektion unter Berücksichtigung geschlechtsspezifischer Nebenwir‐

kungsprofile.

Zentralblatt Gynäkologie. 1999; 121:545‐9.

47: Rockstroh JK.

[Epidemiology and transmission of HIV infection].

Pharm Unserer Zeit. 1999 Mar;28(2):95‐101.

48: Rockstroh JK, Altfeld M, Kupfer B, Kaiser R, Fätkenheuer G, Salzberger B, Schneweis KE,

Spengler U.

Failure of double protease inhibitor therapy as a salvage therapy for HIV‐infected patients

resistant to conventional triple therapy.

Eur J Med Res. 1999 Jul 28;4(7):271‐4.

49: Salzberger B, Rockstroh JK, Wieland U, Franzen C, Schwenk A, Jütte A, Hegener P, Cor‐

nely O, Mörchen C, Gaensicke T, Diehl V, Fätkenheuer G.

Clinical efficacy of protease inhibitor based antiretroviral combination therapy ‐ a prospektive

cohort study.

Eur J Med Res. 1999;4:449‐55.

50: Sauerbruch T.

[Serologic diagnosis of liver fibrosis].

Dtsch Med Wochenschr. 1999 Oct 15;124(41):1191.

51: Sauerbruch T, Caselmann WH, Spengler U.

Hepatic disease.


52: Schepke M, Scheurlen C.

Abschätzung des Blutungsrisikos zur Prophylaxe der primären Blutung bei Patienten mit Le‐

berzirrhose und Ösophagusvarizen.


53: Schepke M, Raab P, Hoppe A, Brensing K, Paar D, Potyka U, Sauerbruch T.

Propranolol stereoisomer plasma concentrations and portal haemodynamic response in pa‐

tients with liver cirrhosis.

Aliment Pharmacol Ther. 1999 Nov;13(11):1451‐8.

61

54: Schiedermaier P, Brensing KA, Göke B, Schätzle T, Sauerbruch T.

Effects of different octreotide dosages on splanchnic hemodynamics and glucagon in healthy

volunteers.

Digestion. 1999 Mar‐Apr;60(2):132‐40.

55: Schiedermaier P, Scheurlen C, Müller‐Miny H.

Diagnostik der Portalen Hypertension.

Verdauungskrankheiten. 1999;17:113‐7

56: Schiedermaier P, Strunk H, Spätz G, Scheurlen C.

Therapie der akuten Varizenblutung.

Verdauungskrankheiten. 1999; 118‐25.

57: Schliefer K, Gümbel HO, Rockstroh JK, Spengler U.

Management of progressive outer retinal necrosis with cidofovir in a human immunodefi‐

ciency virus‐infected patient.

Clin Infect Dis. 1999 Sep;29(3):684‐5.

58: Schmidt‐Wolf, IGH, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft HG,

Prange G, Korte M, Takeya M, Dorbic T, Neubauer A, Wittig B, Huhn D.

Phase I clinical study applying autologous immunologic effector cells transfected with the

interleukin‐2 gene in patients with metastic renal cancer, colorectal cancer and lymphoma.

Brit J Cancer. 1999;81(6):1009‐16.

59: Spengler U, Addo M, Block W, Reichel C.

Diagnostik und Therapie der hepatischen Enzephalopathie bei portaler Hypertension.

Leber Magen Darm. 1999;17:148‐58.

60: Steinmetz HT, Schulz A, Staib P, Scheid C, Glasmacher A, Neufang A, Franklin J, Tesch H,

Diehl V, Dias Wickramanayake P.

Phase‐II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida‐FLAG) for

treatment of refractory, relapsed, and secondary AML.

Ann Hematol. 1999 Sep;78(9):418‐25.

61: Stoehr A, Arasteh K, Staszewski S, Brockmeyer N, Albrecht H, Mertenskötter T,

Jablonowski H, Emminger C, Rockstroh JK, Baumgarten R, Bogner J, Loch T, Plettenberg A.

Pneumocystis carinii pneumonia in the Federal Republic of Germany in the era of changing

antiretroviral therapy ‐ IDKF 13 ‐. German AIDS Study Group (GASG/IdKF).

Eur J Med Res. 1999 Apr 27;4(4):131‐4.

62

62: Stoschus B, Fernandez I, Heller J, Neubrand M, Sauerbruch T.

Prediction of the lower esophageal sphincter pressure after oral molsidomine by sydnonimine

plasma concentrations.

Hepatogastroenterology. 1999 Mar‐Apr;46(26):933‐7.

63: Terjung B, Spengler U, Sauerbruch T.

[Antineutrophil cytoplasmatic antibodies and their diagnostic significance as serum markers].


64: Uhl W, Büchler MW, Malfertheiner P, Berger HG, Adler G, Gaus W and the German Pan‐

creatitis Study Group (member).

A randomised, double blind, multicentre trial of octreotide in moderate to severe acute pan‐

creatitis.

Gut.1999.45(1);97‐104.

65: Vidalin O, Tanaka E, Spengler U, Trépo C, Inchauspé G.

Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance

induction of immune responses to DNA vaccination.

DNA Cell Biol. 1999 Aug;18(8):611‐21.

66: Wasmuth JC, Wasmuth‐Pietzuch A, Spengler U, Rockstroh JK.

[Progressive multifocal leukoencephalopathy].

Med Klin (Munich). 1999 May 15;94(5):264‐73.

67: Woitas RP, Petersen U, Moshage D, Brackmann H, Sauerbruch T, Spengler U.

Hepatitis C‐spezifische Monikinantwort bei Patienten mit chronischer und selbstlimitierter

Hepatitis C Infektion.

Z Gastroenterol.1999; 37:907.

68: Woitas RP, Rockstroh JK, Beier I, Jung G, Kochan B, Matz B, Brackmann HH, Sauerbruch

T, Spengler U.

Antigen‐specific cytokine response to hepatitis C virus core epitopes in HIV/hepatitis C virus‐

coinfected patients.

AIDS. 1999 Jul 30;13(11):1313‐22.

69: Wolff M, Brensing KA, Scheurlen C, Textor J.

Verhinderung der Rezidivblutung.

Verdauungskrankheiten. 1999; 17:125‐36.

63

70: Wolff M, Scheurlen C, Ulrich A, Hirner A.

Portale Hypertension und Varizenblutung‐Shunt bei zusätzlichen oder alleinigem prähepati‐

schen Block.

Verdauungskrankheiten. 1999; 17:137‐42.

64

2000

1: Altfeld M, Addo MM, Kreuzer KA, Rockstroh JK, Dumoulin FL, Schliefer K, Leifeld L, Sauer‐


T(H)1 to T(H)2 shift of cytokines in peripheral blood of HIV‐infected patients is detectable by

reverse transcriptase polymerase chain reaction but not by enzyme‐linked immunosorbent

assay under nonstimulated conditions.

J Acquir Immune Defic Syndr. 2000 Apr 1;23(4):287‐94.

2: Barriere E, Tazi KA, Rona JP, Pessione F, Heller J, Lebrec D, Moreau R.

Evidence for an endothelium‐derived hyperpolarizing factor in the superior mesenteric artery

from rats with cirrhosis.

Hepatology. 2000 Nov;32(5):935‐41.

3: Berg T, Hoffmann RM, Teuber G, Leifeld L, Lafrenz M, Baumgarten R, Spengler U, Zeuzem

S, Pape GR, Hopf U.

Efficacy of a short‐term ribavirin plus interferon alpha combination therapy followed by inter‐

feron alpha alone in previously untreated patients with chronic hepatitis C: a randomized

multicenter trial.

Liver. 2000 Dec;20(6):427‐36.

4: Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, Klehr HU, Kramer HJ,

Spengler U, Schild H, Sauerbruch T.

Long term outcome after transjugular intrahepatic portosystemic stent‐shunt in non‐

transplant cirrhotics with hepatorenal syndrome: a phase II study.

Gut. 2000 Aug;47(2):288‐95.

5: Buttgereit P, Weineck S, Röpke G, Märten A, Brand K, Heinicke T, Caselmann WH, Huhn D,

Schmidt‐Wolf IG.

Efficient gene transfer into lymphoma cells using adenoviral vectors combined with lipofec‐

tion.

Cancer Gene Ther. 2000 Aug;7(8):1145‐55.

6: Caselmann WH, Serwe M, Lehmann T, Ludwig J, Sproat BS, Engels JW.

Design, delivery and efficacy testing of therapeutic nucleic acidsused to inhibit hepatitis C

virus gene expression in vitro and in vivo.

World J Gastroenterol. 2000 Oct;6(5):626‐629.

65

7: Caspari R, Uhlhaas S, Friedl W, Knapp M, Propping P.

Mapping of a gene for nonspecific X‐linked mental retardation (MRX 75) to Xq24‐q26.

Am J Med Genet. 2000 Aug 14;93(4):290‐3.

8: Caspari R, Jungck M, Lamberti C, Schmidt‐Wolf IG, Friedl W, Propping P.

[The diagnosis of hereditary colorectal carcinomas].


9: Chagneau C, Tazi KA, Heller J, Sogni P, Poirel O, Moreau R, Lebrec D.

The role of nitric oxide in the reduction of protein kinase C‐induced contractile response in

aortae from rats with portal hypertension.

J Hepatol. 2000 Jul;33(1):26‐32.

10: Düesberg U, Sauerbruch T, Spengler U.

Which is the hen and which is the egg?

Gastroenterology. 2000 Apr;118(4):807.

11: Dumoulin FL, Nischalke HD, Leifeld L, von dem Bussche A, Rockstroh JK, Sauerbruch T,

Spengler U.

Semi‐quantification of human C‐C chemokine mRNAs with reverse transcription/real‐time PCR

using multi‐specific standards.

J Immunol Methods. 2000 Jul 31;241(1‐2):109‐19.

12: Dumoulin FL, Rockstroh JK.

Behandlungsempfehlungen bei Verdacht auf intestinalen Drogentransport.

Deutsche Medizinische Wochenschrift. 2000;125:S24‐5

13: Dürr R, Caselmann WH.

Carcinogenesis of primary liver malignancies.

Langenbecks Arch Surg. 2000 Apr;385(3):154‐61.

14: Flieger D, Kufer P, Beier I, Sauerbruch T, Schmidt‐Wolf IG.

A bispecific single‐chain antibody directed against EpCAM/CD3 in combination with the cyto‐

kines interferon alpha and interleukin‐2 efficiently retargets T and CD3+CD56+ natural‐killer‐

like T lymphocytes to EpCAM‐expressing tumor cells.

Cancer Immunol Immunother. 2000 Oct;49(8):441‐8.

15: Flieger D, Spengler U, Beier I, Sauerbruch T, Schmidt‐Wolf IG.

Prestimulation of monocytes by the cytokines GM‐CSF or IL‐2 enhances the antibody depend‐

ent cellular cytotoxicity of monoclonal antibody 17‐1A.


66

16: Flieger D, Spengler U, Beier I, Sauerbruch T, Schmidt‐Wolf I.

Combinations of the cytokines IL‐12, IL‐2 and IFN‐alpha significantly augment whereas the

cytokine IL‐4 suppresses the cytokine‐induced antibody‐dependent cellular cytotoxicity of

monoclonal antibodies 17‐1A and BR55‐2.

Cytokine. 2000 Jun;12(6):756‐61.

17: Flieger D, Spengler U, Beier I, Kleinschmidt R, Sauerbruch T, Schmidt‐Wolf IG.

Augmentation of 17‐1A‐induced antibody‐dependent cellular cytotoxicity by the triple cyto‐

kine combination of interferon‐alpha, interleukin‐2, and interleukin‐12.

J Immunother. 2000 Jul‐Aug;23(4):480‐6.

18: Flieger D, Renoth S, Beier I, Sauerbruch T, Schmidt‐Wolf I.

Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC‐

C2B8 in CD20‐expressing lymphoma cell lines.

Cell Immunol. 2000 Aug 25;204(1):55‐63.

19: Heinicke T, Radziwill G, Nawrath M, Rommel C, Pavlovic J, Moelling K.

Retroviral gene transfer of dominant negative raf‐1 mutants suppresses ha‐ras‐induced trans‐

formation and delays tumor formation.

Cancer Gene Ther. 2000 May;7(5):697‐706.

20: Heller J, Sogni P, Barrière E, Tazi KA, Chauvelot‐Moachon L, Guimont MC, Bories PN,

Poirel O, Moreau R, Lebrec D.

Effects of lipopolysaccharide on TNF‐alpha production, hepatic NOS2 activity, and hepatic

toxicity in rats with cirrhosis.

J Hepatol. 2000 Sep;33(3):376‐81.

21: Hentrich M, Rockstroh J, Sandner R, Brack N, Hartenstein R.

Acute myelogenous leukaemia and myelomonocytic blast crisis following polycythemia vera

in HIV positive patients: report of cases and review of the literature.

Ann Oncol. 2000 Feb;11(2):195‐200

22: Jacobi J, Rockstroh J, John S, Schreiber M, Schlaich MP, Neumayer HH, Schmieder RE.

Prospective analysis of the value of 24‐hour ambulatory blood pressure on renal function af‐

ter kidney transplantation.

Transplantation. 2000 Sep 15;70(5):819‐27.

23: Jungck M.

[Hereditary carcinoma: pathogenesis and diagnosis].

Zentralbl Chir. 2000;125 Suppl 1:8‐11.

67

24: Koopmann J, Dombrowski F, Rockstroh JK, Pfeifer U, Sauerbruch T, Spengler U.

Fatal pneumonia in an AIDS patient coinfected with adenovirus and Pneumocystis carinii.

Infection. 2000 Sep;28(5):323‐5.

25: Kreuzer KA, Rockstroh JK, Kupfer B, Spengler U.

Endogenous levels of C‐C chemokines MIP‐1alpha, MIP‐1beta, and RANTES do not reflect the

disease course in HIV‐seropositive individuals.

Int J Clin Lab Res. 2000;30(4):163‐8.

26: Lamberti C, Jungck M, Caspari R, Schmidt‐Wolf I, Sauerbruch T.

[Therapy and after‐care of familial adenomatous polyposis and hereditary colorectal carci‐

noma without polyposis].


27: Langhans B, Lechmann M, Ihlenfeldt H, Jung G, Giers G, Schweitzer S, El Bakri M, Sauer‐


A hepatitis C virus (HCV) core protein derived peptide inhibits HCV specific lymphocyte prolif‐

eration.

Eur J Med Res. 2000 Mar 27;5(3):115‐20.

28: Layer G, Sander W, Träber F, Block W, Ko Y, Ziske CG, König R, Vahlensieck M, Schild HH.

[The diagnostic problems in magnetic resonance tomography of the bone marrow in patients

with malignomas under G‐CSF therapy].

Radiologe. 2000 Aug;40(8):710‐5.

29: Lefterova P, Schakowski F, Buttgereit P, Scheffold C, Huhn D, Schmidt‐Wolf IG.

Expansion of CD3+CD56+ cytotoxic cells from patients with chronic lymphocytic leukemia: in

vitro efficacy.

Haematologica. 2000 Oct;85(10):1108‐9.

30: Lefterova P, Märten A, Buttgereit P, Schakowski F, Micka B, Scheffold C, Schmidt‐Wolf

IG.

Induction of apoptosis in B lymphoma cells by activation with CD40L.

Acta Haematol. 2000;103(3):168‐71.

31: Lefterova P, Märten A, Buttgereit P, Weineck S, Scheffold C, Huhn D, Schmidt‐Wolf IG.

Targeting of natural killer‐like T immunologic effector cells against leukemia and lymphoma

cells by reverse antibody‐dependent cellular cytotoxicity.

J Immunother. 2000 May‐Jun;23(3):304‐10.

68

32: Leifeld L, Rockstroh J, Skaide S, Wasmuth JC, Altfeld M, Paar WD, Sauerbruch T, Spengler

U.

Indication, outcome and follow up of intensive care in patients with HIV‐infection.

Eur J Med Res. 2000 May 23;5(5):199‐202.

33: Leifeld L, Spengler U, Sauerbruch T.

[Clinical aspects and diagnosis of hepatitis C].


34: Leutner CC, Gieseke J, Lutterbey G, Kuhl CK, Glasmacher A, Wardelmann E, Theisen A,

Schild HH.

MR imaging of pneumonia in immunocompromised patients: comparison with helical CT.

AJR Am J Roentgenol. 2000 Aug;175(2):391‐7.

35: Look MP, Altfeld M, Kreuzer KA, Riezler R, Stabler SP, Allen RH, Sauerbruch T, Rockstroh

JK.

Parallel decrease in neurotoxin quinolinic acid and soluble tumor necrosis factor receptor p75

in serum during highly active antiretroviral therapy of HIV type 1 disease.

AIDS Res Hum Retroviruses. 2000 Sep 1;16(13):1215‐21.

36: Look MP, Riezler R, Reichel C, Brensing KA, Rockstroh JK, Stabler SP, Spengler U, Ber‐

thold HK, Sauerbruch T.

Is the increase in serum cystathionine levels in patients with liver cirrhosis a consequence of

impaired homocysteine transsulfuration at the level of gamma‐cystathionase?


37: Lucht MJ, Kleinschmidt R, Maier W, Rietschel M.

Agranulocytosis during treatment with mianserin and venlafaxine.

J Clin Psychopharmacol. 2000 Aug;20(4):490‐1.

38: Märten A, Ziske C, Schöttker B, Renoth S, Weineck S, Buttgereit P, Schakowski F, Kling‐

müller D, Scheffold C, von Rücker A, Sauerbruch T, Schmidt‐Wolf IG.

Increase in the immunostimulatory effect of dendritic cells by pulsing with serum derived

from pancreatic and colorectal cancer patients.

Int J Colorectal Dis. 2000 Aug;15(4):197‐205.

39: Märten A, Schöttker B, Ziske C, Weineck S, Buttgereit P, Huhn D, Sauerbruch T, Schmidt‐

Wolf IG.

Increase of the immunostimulatory effect of dendritic cells by pulsing with CA 19‐9 protein.

J Immunother. 2000 Jul‐Aug;23(4):464‐72

69

40: Mey U, Kleinschmidt R, Sauerbruch T.

[Therapy‐refractory thrombocytopenia in chronic hepatitis C].


41: Micka B, Trojaneck B, Niemitz S, Lefterova P, Kruopis S, Huhn D, Wittig B, Schadendorf D,

Schmidt‐Wolf IG.

Comparison of non‐viral transfection methods in melanoma cell primary cultures.

Cytokine. 2000 Jun;12(6):828‐33.

42: Morakkabati N, Paar WD, Schild HH, Sauerbruch T.

[52‐year‐old patient with pleural effusion after a stay in Cameroon].

Internist (Berl). 2000 Nov;41(11):1243‐4, 1245‐6.

43: Neubrand M, Sackmann M, Caspary WF, Feussner H, Schild H, Lauchart W, Schildberg

FW, Reiser M, Classen M, Paumgartner G, Sauerbruch T.

[Guidelines by the German Society of Digestive and Metabolic Diseases for treatment of gall‐

stones. German Society of Digestive and Metabolic Diseases].

Z Gastroenterol. 2000 Jun;38(6):449‐68.

44: Pateron D, Tazi KA, Sogni P, Heller J, Chagneau C, Poirel O, Philippe M, Moreau R, Lebrec

D.

Role of aortic nitric oxide synthase 3 (eNOS) in the systemic vasodilation of portal hyperten‐

sion.

Gastroenterology. 2000 Jul;119(1):196‐200.

45: Pels H, Deckert‐Schlüter M, Glasmacher A, Kleinschmidt R, Oehring R, Fischer HP, Bode

U, Schlegel U.

Primary central nervous system lymphoma: a clinicopathological study of 28 cases.

Hematol Oncol. 2000 Mar;18(1):21‐32.

46: Qian C, Drozdzik M, Caselmann WH, Prieto J.

The potential of gene therapy in the treatment of hepatocellular carcinoma.

J Hepatol. 2000 Feb;32(2):344‐51.

47: Rabe C, Caselmann WH.

Interaction of Hepatitis B virus with cellular processes in liver carcinogenesis.

Crit Rev Clin Lab Sci. 2000 Oct;37(5):407‐29.

70

48: Reichel C, Sudhop T, Braun B, Kreuzer KA, Hahn C, Look MP, von Bergmann K, Sauer‐


Elevated soluble tumour necrosis factor receptor serum concentrations and short‐term mor‐

tality in liver cirrhosis without acute infections.

Digestion. 2000;62(1):44‐51.

49: Reiter‐Owona I, Seitz H, Gross U, Sahm M, Rockstroh JK, Seitz HM.

Is stage conversion the initiating event for reactivation of Toxoplasma gondii in brain tissue of

AIDS patients?

J Parasitol. 2000 Jun;86(3):531‐6.

50: Risse JH, Grünwald F, Kersjes W, Strunk H, Caselmann WH, Palmedo H, Bender H, Bier‐

sack HJ.

Intraarterial HCC therapy with I‐131‐Lipiodol.

Cancer Biother Radiopharm. 2000 Feb;15(1):65‐70.

51: Rockstroh JK.

[Antiretroviral therapy of HIV‐infections].

Pharm Unserer Zeit. 2000 Sep;29(5):284‐96.

52: Rockstroh JK, Bergmann F, Wiesel W, Rieke A, Thiesen A, Fätkenheuer G, Oette M, Carls

H, Fenske S, Nadler M, Knechten H.

Efficacy and safety of twice daily first‐line ritonavir/indinavir plus double nucleoside combina‐

tion therapy in HIV‐infected individuals. German Ritonavir/Indinavir Study Group.

AIDS. 2000 Jun 16;14(9):1181‐5.

53: Rockstroh JK.

Abacavir ‐ ein neuer nukleodischer Reverse Transkriptase‐Inhibitor zur Behandlung der HIV‐

Infektion.

Arzneimitteltherapie. 2000;18:133‐7.

54: Roda E, Festl D, Lezoche E, Leuschner U, Paumgartner G, Sauerbruch T.

Strategies in the treatment of biliary stones.

Gastroenterology International.2000; 7‐15.

55: Röpke G, Ebert O, Märten A, Lefterova P, Micka B, Buttgereit P, Niemitz S, Trojaneck B,

Schmidt‐Wolf G, Rücker AV, Huhn D, Wittig B, Schmidt‐Wolf IG.

Increase in proliferation rate and normalization of TNF‐alpha secretion by blockage of gene

transfer‐induced apoptosis in lymphocytes using low‐dose cyclosporine A.

Cancer Gene Ther. 2000 Nov;7(11):1411‐3.

71

56: Sauerbruch T.

[DMW special topic issue: Gastroenterology].

Dtsch Med Wochenschr. 2000 Sep 8;125(36):1029.

57: Scheffold C, Schöttker B, Lefterova P, Csipai M, Glasmacher A, Huhn D, Neubauer A,

Schmidt‐Wolf IG.

Increased sensitivity of myeloid leukemia cell lines: potential of lovastatin as bone‐marrow‐

purging agent.

Acta Haematol. 2000;104(2‐3):72‐9.

58: Schepke M, Raab P, Hoppe A, Schiedermaier P, Brensing KA, Sauerbruch T.

Comparison of portal vein velocity and the hepatic venous pressure gradient in assessing the

acute portal hemodynamic response to propranolol in patients with cirrhosis.


59: Scheurlen C, Neubrand M, Kaminski M, Sauerbruch T.

[Fecal incontinence].

Internist (Berl). 2000 Nov;41(11):1213‐8, 1220‐2, 1224‐34.

60: Schiedermaier P, Hansen S, Asdonk D, Brensing K, Sauerbruch T.

Effects of ursodeoxycholic acid on splanchnic and systemic hemodynamics. A double‐blind,

cross‐over, placebo‐controlled study in healthy volunteers.

Digestion. 2000;61(2):107‐12.

61: Schleiermacher D, Rockstroh JK, Wilhelm K, Spengler U.

[Mycobacterium avium infection presenting as a mass in the right lung].

Med Klin (Munich). 2000 Feb 15;95(2):93‐5.

62: Schliefer K, Paar WD, Aydemir G, Wolff M, Rockstroh JK, Spengler U, Sauerbruch T.

[Orthotopic liver transplantation in a 33‐year‐old patient with fulminant hepatitis B and HIV

infection].


63: Schlegel U, Schmidt‐Wolf IG, Deckert M.

Primary CNS lymphoma: clinical presentation, pathological classification, molecular patho‐

genesis and treatment.

J Neurol Sci. 2000 Dec 1;181(1‐2):1‐12.

72

64: Schmiegel W, Adler G, Frühmorgen P, Fölsch U, Graeven U, Layer P, Petrasch S, Porschen

R, Pox C, Sauerbruch T, Schmoll HJ, Zeitz M.

[Colorectal carcinoma: prevention and early detection in an asymptomatic population‐‐

prevention in patients at risk‐‐endoscopic diagnosis, therapy and after‐care of polyps and car‐

cinomas. German Society of Digestive and Metabolic Diseases/Study Group for Gastrointesti‐

nal Oncology].


65: Schmiegel W, Adler G, Fölsch U, Layer P, Pox C, Sauerbruch T.

Prävention und Früherkennung in der asymptomatischen Bevölkerung ‐ Vorsorge bei Risiko‐

gruppen.

Deutsches Ärzteblatt. 2000; 97:2234‐2240.

66: Schroers R, Biecker E, Keller E, Sauerbruch T.

[59‐year‐old patient with chronic joint symptoms and generalized weakness].


67: Schroers R, Sinha I, Segall H, Schmidt‐Wolf IG, Rooney CM, Brenner MK, Sutton RE, Chen

SY.

Transduction of human PBMC‐derived dendritic cells and macrophages by an HIV‐1‐based len‐

tiviral vector system.

Mol Ther. 2000 Feb;1(2):171‐9.

68: Schweitzer S, Schneiders AM, Langhans B, Kraas W, Jung G, Vidalin O, Inchauspe G, Sau‐

erbruch T, Spengler U.

Flow cytometric analysis of peptide binding to major histocampatibility complex class I for

hepatitis C virus core T‐cell epitopes.

Cytometry. 2000 Dec 1;41(4):271‐8.

69: Spengler U.

[Anaphylaxis due to contrast media].

Internist (Berl). 2000 Aug;41(8):765. R.

70: Spreer J, Dietz M, Raab P, Arnold S, Klisch J, Lanfermann H.

Functional MRI of language‐related activation in left frontal schizencephaly.

J Comput Assist Tomogr. 2000 Sep‐Oct;24(5):732‐4.

73

71: Spreer J, Yahya H, Raab P.

Missing hemodynamic response in retained neuronal function: pitfall of functional MRT in

patients with stenosing vascular processes].

Röfo. 2000 Apr;172(4):398‐400.

72: Streetz K, Leifeld L, Grundmann D, Ramakers J, Eckert K, Spengler U, Brenner D, Manns

M, Trautwein C.

Tumor necrosis factor alpha in the pathogenesis of human and murine fulminant hepatic fail‐

ure.

Gastroenterology. 2000 Aug;119(2):446‐60.

73: Tazi KA, Moreau R, Heller J, Poirel O, Lebrec D.

Changes in protein kinase C isoforms in association with vascular hyporeactivity in cirrhotic

rat aortas.


74: Terjung B, Spengler U, Sauerbruch T, Worman HJ.

"Atypical p‐ANCA" in IBD and hepatobiliary disorders react with a 50‐kilodalton nuclear enve‐

lope protein of neutrophils and myeloid cell lines.


75: Terjung B, Spengler U, Sauerbruch T.

[Antineutrophil cytoplasmatic antibodies and their diagnostic significance as serum markers].

Dtsch Med Wochenschr. 1999Nov 5;124(44):1314‐20.

76: Teuber G, Berg T, Hoffmann RM, Leifeld L, Lafrenz M, Spengler U, Pape GR, Hopf U, Zeu‐

zem S.

Retreatment with interferon‐alpha and ribavirin in primary interferon‐alpha non‐responders

with chronic hepatitis C.

Digestion. 2000;61(2):90‐7.

77: Trojaneck B, Niemitz S, Micka B, Lefterova P, Blasczyk R, Scheffold C, Huhn D, Schmidt‐

Wolf IG.

Establishment and characterization of colon carcinoma and renal cell carcinoma primary cul‐

tures.

Cancer Biother Radiopharm. 2000 Apr;15(2):169‐74.

78: Von Ruecker A, Schmidt‐Wolf IG.

Strategies to evaluate metabolic stress and catabolism by means of immunological variables.

Clin Nutr. 2000 Jun;19(3):147‐56.

74

79: von Unruh GE, Voss S, Hesse A.

Experience with the [13C2]oxalate absorption test.

Isotopes Environ Health Stud. 2000;36(1):11‐20.

80: Wasmuth JC, Klein KH, Hackbarth F, Rockstroh JK, Sauerbruch T, Spengler U.

Prediction of imminent complications in HIV‐1‐infected patients by markers of lymphocyte

apoptosis.

J Acquir Immune Defic Syndr. 2000 Jan 1;23(1):44‐51.

81: Weiner OH, Alt M, Dürr R, Noegel AA, Caselmann WH.

Rapid and reproducible quantification of hepatitis C virus cDNA by fluorescence correlation

spectroscopy.

Digestion. 2000;61(2):84‐9.

82: Willkomm P, Schomburg A, Brensing KA, Reichmann K, Bangard M, Overbeck B, Sauer‐

bruch T, Biersack HJ.

Liver perfusion scintigraphy prior to and after transjugular intrahepatic portosystemic shunts

(TIPS) in patients with portal hypertension.

Nuklearmedizin. 2000 Aug;39(5):139‐41.

83: Woitas RP, Stoffel‐Wagner B, Flommersfeld S, Poege U, Schiedermaier P, Klehr HU,

Spengler U, Bidlingmaier F, Sauerbruch T.

Correlation of serum concentrations of cystatin C and creatinine to inulin clearance in liver

cirrhosis.

Clin Chem. 2000 May;46(5):712‐5.

84: Zoll B, Lefterova P, Ebert O, Huhn D, Von Ruecker A, Schmidt‐Wolf IG.

Modulation of cell surface markers on NK‐like T lymphocytes by using IL‐2, IL‐7 or IL‐12 in vitro

stimulation.

Cytokine. 2000 Sep;12(9):1385‐90.

75

2001

1: Antoniv TT, De Val S, Wells D, Denton CP, Rabe C, de Crombrugghe B, Ramirez F,Bou‐

Gharios G.

Characterization of an evolutionarily conserved far‐upstream

enhancer in the human alpha 2(I) collagen (COL1A2) gene.

J Biol Chem. 2001 Jun 15;276(24):21754‐64.

2: Arendt BM, Boetzer AM, Lemoch H, Winkler P, Rockstroh JK, Berthold HK,Spengler U,

Goerlich R.

Plasma antioxidant capacity of HIV‐seropositive and healthy subjects during long‐term inges‐

tion of fruit juices or a fruit‐vegetable‐concentrate containing antioxidant polyphenols.

Eur J Clin Nutr. 2001 Sep;55(9):786‐92.

3: Biecker E, Schwarze C, Ko YD, Sauerbruch T.

[Renal failure, thrombocytopenia and hemolytic anemia in a 36‐year‐old patient].

Internist (Berl). 2001 Jul;42(7):1031‐4.

4: Buttgereit P, Schakowski F, Märten A, Brand K, Renoth S, Ziske C, Schöttker B,Ebert O,

Schroers R, Schmidt‐Wolf IG.

Effects of adenoviral wild‐type p53 gene transfer in p53‐mutated lymphoma cells.

Cancer Gene Ther. 2001 Jun;8(6):430‐9.

5: Cichon S, Schmidt‐Wolf G, Schumacher J, Müller DJ, Hürter M, Schulze TG,Albus M,

Borrmann‐Hassenbach M, Franzek E, Lanczik M, Fritze J, Kreiner R, Weigelt B, Minges J,

Lichtermann D, Lerer B, Kanyas K, Strauch K, Windemuth C, Baur MP, Wienker TF, Maier W,

Rietschel M, Propping P, Nöthen MM.

A possible susceptibility locus for bipolar affective disorder in chromosomal region 10q25‐‐

q26.

Mol Psychiatry. 2001 May;6(3):342‐9.

6: Cichon S, Schumacher J, Müller DJ, Hürter M, Windemuth C, Strauch K, Hemmer S,

Schulze TG, Schmidt‐Wolf G, Albus M, Borrmann‐Hassenbach M, Franzek E, Lanczik M, Fritze

J, Kreiner R, Reuner U, Weigelt B, Minges J, Lichtermann D, Lerer B, Kanyas K, Baur MP,

Wienker TF, Maier W, Rietschel M, Propping P, Nöthen MM.

A genome screen for genes predisposing to bipolar affective disorder detects a new suscep‐

tibility locus on 8q.

Hum Mol Genet. 2001 Dec 1;10(25):2933‐44. Erratum in: Hum Mol Genet. 2002 Jul 1;11(14):1685.

76

7: Colle I, Moreau R, Pessione F, Rassiat E, Heller J, Chagneau C, Pateron D, Barrière E, Con‐

dat B, Sogni P, Valla D, Lebrec D.

Relationships between haemodynamic alterations and the development of ascites or refrac‐

tory ascites in patients with cirrhosis.

Eur J Gastroenterol Hepatol. 2001 Mar;13(3):251‐6.

8: Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, Cremer F, Alsina M,

Glasmacher A.

Bisphosphonates in multiple myeloma.

Cochrane Database Syst Rev. 2001;(4):CD003188. Review. Update in: Cochrane Database Syst

Rev.2002;(3):CD003188.

9 : Dumoulin FL, Wennrich U, Nischalke HD, Leifeld L, Fischer HP, Sauerbruch T, Spengler U.

Intrahepatic mRNA levels of interferon gamma and tumor necrosis factor alpha and response

to antiviral treatment of chronic hepatitis C.

J Hum Virol. 2001 Jul‐Aug;4(4):195‐9.

10: Düesberg U, Schneiders AM, Flieger D, Inchauspé G, Sauerbruch T, Spengler U.

Natural cytotoxicity and antibody‐dependent cellular cytotoxicity (ADCC) is not impaired in

patients suffering from chronic hepatitis C.

J Hepatol. 2001 Nov;35(5):650‐7.

11: Düesberg U, Geulen O, Schneiders AM, Kaiser R, Brackmann HH, Matz B, Sauerbruch T,

Spengler U.

Transient loss of T‐cell reactivity in a patient with hepatitis C virus reinfection.

Digestion. 2001;64(1):66‐70.

12: Engelhart S, Glasmacher A, Kaufmann F, Exner M.

Protecting vulnerable groups in the home: the interface between institutions and the domes‐

tic setting.

J Infect. 2001 Jul;43(1):57‐9; discussion 59‐60.

13: Flieger D, Hoff AS, Sauerbruch T, Schmidt‐Wolf IG.

Influence of cytokines,monoclonal antibodies and chemotherapeutic drugs on epithelial cell

adhesion molecule (EpCAM) and LewisY antigen expression.

Clin Exp Immunol. 2001 Jan;123(1):9‐14.

14: Friedl W, Mangold E, Caspari R, Lamberti C, Propping P.

Ileorectal anastomosis is appropriate for a subset of patients with familial adenomatous

polyposis.


77

15: Friedl W, Caspari R, Sengteller M, Uhlhaas S, Lamberti C, Jungck M, Kadmon M, Wolf M,

Fahnenstich J, Gebert J, Möslein G, Mangold E, Propping P.

Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous poly‐

posis? Experience from 680 FAP families.

Gut. 2001 Apr;48(4):515‐21.

16: Gorschlüter M, Glasmacher A, Hahn C, Schakowski F, Ziske C, Molitor E, Marklein G, Sau‐

erbruch T, Schmidt‐Wolf IG.

Clostridium difficile infection in patients with neutropenia.

Clin Infect Dis. 2001 Sep 15;33(6):786‐91.

17: Gorschlüter M, Ziske C, Glasmacher A, Schmidt‐Wolf IG.

Current clinical and laboratory strategies to augment the efficacy of immunotherapy in multi‐

ple myeloma.

Clin Cancer Res. 2001 Aug;7(8):2195‐204.

18: Gorschlüter M, Glasmacher A, Hahn C, Leutner C, Marklein G, Remig J, Schmidt‐Wolf IG,

Sauerbruch T.

Severe abdominal infections in neutropenic patients.

Cancer Invest. 2001;19(7):669‐77.

19: Holinski‐Feder E, Müller‐Koch Y, Friedl W, Moeslein G, Keller G, Plaschke J, Ballhausen W,

Gross M, Baldwin‐Jedele K, Jungck M, Mangold E, Vogelsang H, Schackert HK, Lohsea P,

Murken J, Meitinger T.

DHPLC mutation analysis of the hereditary nonpolyposis colon cancer (HNPCC) genes hMLH1

and hMSH2.

J Biochem Biophys Methods. 2001 Jan 30;47(1‐2):21‐32.

20: Korfel A, Finke J, Schmidt‐Wolf I, Thiel E.

5. Report on workshop: Primary CNS lymphoma.

Ann Hematol. 2001;80 Suppl 3:B20‐3.

21: Langhans B, Braunschweiger I, Schweitzer S, Jung G, Inchauspé G, Sauerbruch T, Speng‐

ler U.

Lipidation of T helper sequences from hepatitis C virus core significantly enhances T‐cell activ‐

ity in vitro.

Immunology. 2001 Apr;102(4):460‐5.

22: Lauschke H, Caspari R, Friedl W, Schwarz B, Mathiak M, Propping P, Hirner A.

Detection of APC and k‐ras mutations in the serum of patients with colorectal cancer.

Cancer Detect Prev. 2001;25(1):55‐61.

23: Lehmann TJ, Serwe M, Caselmann WH, Engels JW.

78

Design and properties of hepatitis C virus antisense oligonucleotides for liver specific drug

targeting.

Nucleosides Nucleotides Nucleic Acids. 2001 Apr‐Jul;20(4‐7):1343‐6.

24: Leifeld L, Ramakers J, Schneiders AM, Dumoulin FL, Sterneck M, Müller A, Sauerbruch T,

Spengler U.

Intrahepatic MxA expression is correlated with interferon‐alpha expression in chronic and

fulminant hepatitis.

J Pathol. 2001 Aug;194(4):478‐83.

25: Look MP, Riezler R, Berthold HK, Stabler SP, Schliefer K, Allen RH, Sauerbruch T, Rock‐

stroh JK.

Decrease of elevated N,N‐dimethylglycine and N‐methylglycine in human immunodeficiency

virus infection during short‐term highly active antiretroviral therapy.

Metabolism. 2001 Nov;50(11):1275‐81.

26: Märten A, Greten T, Ziske C, Renoth S, Schöttker B, Buttgereit P, Schakowski F, von Rü‐

cker A, Sauerbruch T, Schmidt‐Wolf IH.

Generation of activated and antigen‐specific T cells with cytotoxic activity after co‐culture

with dendritic cells.

Cancer Immunol Immunother. 2002 Mar;51(1):25‐32.

27: Märten A, Renoth S, von Lilienfeld‐Toal M, Buttgereit P, Schakowski F, Glasmacher A,

Sauerbruch T, Schmidt‐Wolf IG.

Enhanced lytic activity of cytokine‐induced killer cells against multiple myeloma cells after co‐

culture with idiotype‐pulsed dendritic cells.

Haematologica. 2001 Oct;86(10):1029‐37.

28: Märten A, Ziske C, Schöttker B, Renoth S, Weineck S, Buttgereit P, Schakowski F, von

Rücker A, Sauerbruch T, Schmidt‐Wolf IG.

Interactions between dendritic cells and cytokine‐induced killer cells lead to an activation of

both populations.

J Immunother. 2001 Nov‐Dec;24(6):502‐10.

29: Märten A, Ziske C, Schöttker B, Weineck S, Renoth S, Buttgereit P, Schakowski F, König

S, von Rücker A, Allera A, Schroers R, Sauerbruch T, Wittig B, Schmidt‐Wolf IG.

Transfection of dendritic cells (DCs) with the CIITA gene: increase in immunostimulatory activ‐

ity of DCs.

Cancer Gene Ther. 2001 Mar;8(3):211‐9.

30: Märten A, Ziske C, Weineck S, Buttgereit P, Lefterova P, Klingmüller D. von Rücker A,

Scheffold C, Sauerbruch T, Schmidt‐Wolf IGH.

79

Priming of NK‐like t lymphocytes by addition of dendritic cells pulsed with CEA protein and

patient serum containing CEA.

Cancer Research, Therapy and Control. 2001 11:157‐166

31: Moreau R, Chagneau C, Heller J, Chevenne D, Langlet P, Deltenre P, Hillaire S, Lefilliatre

P, Pateron D, Sogni P, Valla D, Lebrec D.

Hemodynamic, metabolic and hormonal responses to oral glibenclamide in patients with cir‐

rhosis receiving glucose.


32: Niketeghad F, Decker HJ, Caselmann WH, Lund P, Geissler F, Dienes HP,

Schirmacher P.

Frequent genomic imbalances suggest commonly altered tumour genes in human hepatocar‐

cinogenesis.

Br J Cancer. 2001 Sep 1;85(5):697‐704.

33: Palmedo H, Rockstroh JK, Bangard M, Schliefer K, Risse J, Menzel C, Biersack HJ.

Painful multifocal arthritis: therapy with rhenium 186 hydroxyethylidenediphosphonate

((186)Re HEDP) after failed treatment with medication‐‐initial results of a prospective study.

Radiology. 2001 Oct;221(1):256‐60.

34: Rabe C, Heller J, Sauerbruch T, Caselmann WH.

[Liver cirrhosis‐‐1:Pathogenesis and diagnosis].

Dtsch Med Wochenschr. 2001 Sep 7;126(36):975‐7; quiz 982‐3.

35: Rabe C, Pilz T, Klostermann C, Berna M, Schild HH, Sauerbruch T, Caselmann WH.

Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma.

World J Gastroenterol. 2001 Apr;7(2):208‐15.

36: Rabe C, Cheng B, Caselmann WH.

Molecular mechanisms of hepatitis B virus‐associated liver cancer.

Dig Dis. 2001;19(4):279‐87.

37: Risse F, Dombrowski F, Ruf T, Dienes HP, Sauerbruch T, Spengler U.

Virus‐like particles in a case of acute hepatitis with human GB virus‐C viraemia.

Eur J Gastroenterol Hepatol. 2001 Feb;13(2):195‐8.

80

38: Rockstroh JK

Hepatitis C und HIV‐Koinfektion.

Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2001, 44: 586‐92

39: Rockstroh JK

Aktuelle Aspekte zu Verlauf und Therapie der Hepatitis C bei HIV‐Doppelinfektion.

Retrovirus Bull. 2001; 4:3‐6

40: Sauerbruch T.

[Pain therapy instead of antibiotics].

MMW Fortschr Med. 2001 May 31;143(22):40.

41: Schaible R, Textor J, Kreft B, Neubrand M, Schild H.

[Value of selective MIP reconstructions in respiratory triggered 3D TSE MR‐cholangiography

on a workstation in comparison with MIP standard projections and single‐shot MRCP].

Röfo. 2001 May;173(5):416‐23.

42: Schakowski F, Gorschlüter M, Junghans C, Schroff M, Buttgereit P, Ziske C, Schöttker B,

König‐Merediz SA, Sauerbruch T, Wittig B, Schmidt‐Wolf IG.

A novel minimal‐size vector (MIDGE) improves transgene expression in colon carcinoma

cells and avoids transfection of undesired DNA.

Mol Ther. 2001 May;3(5 Pt 1):793‐800.

43: Schepke M, Reichel C, Ziske C, Spengler U, Caselmann WH, Sauerbruch T.

[Liver cirrhosis‐‐2: Complications and treatment].

Dtsch Med Wochenschr. 2001 Sep 7;126(36):978‐81; quiz 982‐4.

44: Schepke M, Sauerbruch T.

[Liver cirrhosis‐‐case report].

Dtsch Med Wochenschr. 2001 Sep 7;126(36); quiz 982.

45: Schepke M, Heller J, Paschke S, Thomas J, Wolff M, Neef M, Malago M, Molderings GJ,


Contractile hyporesponsiveness of hepatic arteries in humans with cirrhosis: evidence for a

receptor‐specific mechanism.

Hepatology. 2001 Nov;34(5):884‐8.

81

46: Schepke M, Werner E, Biecker E, Schiedermaier P, Heller J, Neef M, Stoffel‐Wagner B,

Hofer U, Caselmann WH, Sauerbruch T.

Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with

cirrhosis and portal hypertension.



Transjugular portosystemic stent shunt in treatment of liver diseases.

World J Gastroenterol. 2001 Apr;7(2):170‐4.

48: Schiedermaier P, Göke B, Sauerbruch T.

Effects of different octreotide dosages on splanchnic hemodynamics and glucagon in pa‐

tients with TIPS.

Am J Gastroenterol. 2001 Jul;96(7):2218‐24.

49: Schlegel U, Pels H, Glasmacher A, Kleinschmidt R, Schmidt‐Wolf I, Helmstaedter C, Fli‐

essbach K, Deckert M, Van Roost D, Fimmers R, Bode U, Klockgether T.

Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot

study.

J Neurol Neurosurg Psychiatry. 2001 Jul;71(1):118‐22.

50: Schlüter V, Rabe C, Meyer M, Koshy R, Caselmann WH.

Intracellular accumulation of middle hepatitis B surface protein activates gene transcription.

Dig Dis. 2001;19(4):352‐63.

51: Spengler U.

Unravelling complexity‐‐the scientific basis of genetic predisposition in autoimmune liver dis‐

ease.

J Hepatol. 2001 Jul;35(1):127‐9.

52: Terjung B, Worman HJ.

Anti‐neutrophil antibodies in primary sclerosing cholangitis.

Best Pract Res Clin Gastroenterol. 2001 Aug;15(4):629‐42.

53: Terjung B, Worman HJ, Herzog V, Sauerbruch T, Spengler U.

Differentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune

liver diseases from antineutrophil cytoplasmic antibodies (p‐ANCA) using immunofluores‐

cence microscopy.

Clin Exp Immunol. 2001 Oct;126(1):37‐46.

54: van Nunen AB, Baumann M, Manns MP, Reichen J, Spengler U, Marschner JP, de Man RA;

International Study Group.

82

Efficacy and safety of an intravenous monoclonal anti‐HBs in chronic hepatitis B patients.

Liver. 2001 Jun;21(3):207‐12.

55: von Lilienfeld‐Toal M, Ebert O, Theuerkauf I, Glasmacher A, Schmidt‐Wolf IG.

Small bowel obstruction in acute myelogenous leukemia: stenosis or paralysis?

Ann Hematol. 2001 Oct;80(10):611‐3.

56: Wittig B, Märten A, Dorbic T, Weineck S, Min H, Niemitz S, Trojaneck B, Flieger D, Kru‐

opis S, Albers A, Löffel J, Neubauer A, Albers P, Müller S, Sauerbruch T, Bieber T, Huhn D,

Schmidt‐Wolf IG.

Therapeutic vaccination against metastatic carcinoma by expression‐modulated and immu‐

nomodified autologous tumor cells: a first clinical phase I/II trial.

Hum Gene Ther. 2001 Feb 10;12(3):267‐78.

57: Woitas RP, Stoffel‐Wagner B, Poege U, Schiedermaier P, Spengler U, Sauerbruch T.

Low‐molecular weight proteins as markers for glomerular filtration rate.

Clin Chem. 2001 Dec;47(12):2179‐80.

58: Ziske C, Meybehm M, Sauerbruch T, Schmidt‐Wolf IG.

Littoral cell angioma as a rare cause of splenomegaly.

Ann Hematol. 2001 Jan;80(1):45‐8.

59: Ziske C, Märten A, Schöttker B, Buttgereit P, Schakowski F, Gorschlüter M, von Rücker A,

Scheffold C, Chao N, Sauerbruch T, Schmidt‐Wolf IG.

Resistance of pancreatic carcinoma cells is reversed by coculturing NK‐like T cells with den‐

dritic cells pulsed with tumor‐derived RNA and CA 19‐9.

Mol Ther. 2001 Jan;3(1):54‐60.

83

2002

1: Brensing KA, Raab P, Frotscher U.

Diabetic nephropathy.

N Engl J Med. 2002 Sep 19;347(12):947‐8; author reply 947‐8.

2: Brensing KA, Hörsch M, Textor J, Schiedermaier P, Raab P, Schepke M, Strunk H, Schild H,

Sauerbruch T.

Hemodynamic effects of propranolol and nitrates in cirrhotics with transjugular intrahepatic

portosystemic stent‐shunt.

Scand J Gastroenterol. 2002 Sep;37(9):1070‐6.

3: Brensing KA, Raab P, Textor J, Görich J, Schiedermaier P, Strunk H, Paar D, Schepke M,

Sudhop T, Spengler U, Schild H, Sauerbruch T.

Prospective evaluation of a clinical score for 60‐day mortality after transjugular intrahepatic

portosystemic stent‐shunt: Bonn TIPSS early mortality analysis.

Eur J Gastroenterol Hepatol. 2002 Jul;14(7):723‐31.

4: Buttgereit P, Schmidt‐Wolf IG.

Gene therapy of lymphoma.

J Hematother Stem Cell Res. 2002 Jun;11(3):457‐67.

5: Cheng B, Jüngst C, Lin J, Caselmann WH.

[Potential role of human DNA‐repair enzymes hMTH1, hOGG1 and hMYHalpha in the hepato‐

carcinogenesis].

J Huazhong Univ Sci Technolog Med Sci. 2002;22(3):206‐11, 215.

6: Colle I, Langlet P, Barrière E, Heller J, Rassiat E, Condat B, Carayon A, Valla D, Moreau R,

Lebrec D.

Evolution of hypoxemia in patients with severe cirrhosis.

J Gastroenterol Hepatol. 2002 Oct;17(10):1106‐9.

7: Djulbegovic B, Wheatley K, Ross J, Clark O, Bos G, Goldschmidt H, Cremer F, Alsina M,

Glasmacher A.

Bisphosphonates in multiple myeloma.

Cochrane Database Syst Rev. 2002;(3):CD003188.

84

8: Düesberg U, von dem Bussche A, Kirschning C, Miyake K, Sauerbruch T, Spengler U.

Cell activation by synthetic lipopeptides of the hepatitis C virus (HCV)—core protein is medi‐

ated by toll like receptors (TLRs) 2 and 4.

Immunol Lett. 2002 Nov 1;84(2):89‐95.

9: Engelhart S, Krizek L, Glasmacher A, Fischnaller E, Marklein G, Exner M.

Pseudomonas aeruginosa outbreak in a haematology‐oncology unit associated with contami‐

nated surface cleaning equipment.

J Hosp Infect. 2002 Oct;52(2):93‐8.

10: Engelhart S, Glasmacher A, Exner M, Kramer MH.

Surveillance for nosocomial infections and fever of unknown origin among adult hematology‐

oncology patients.

Infect Control Hosp Epidemiol. 2002 May;23(5):244‐8.

11: Gerhardt T, Mey U, Sauerbruch T, Dumoulin FL.

[Palliative therapy of inoperable cholangiocarcinoma].


12: Gillich MS, Heimbach D, Schoeneich G, Müller SC, Klehr HU.

Comparison of blood group versus HLA‐dependent transplantation and its influence on donor

kidney survival.

Nephrol Dial Transplant. 2002 May;17(5):884‐6.

13: Gorschlüter M, Marklein G, Höfling K, Clarenbach R, Baumgartner S, Hahn C, Ziske C, Mey

U, Heller R, Eis‐Hübinger AM, Sauerbruch T, Schmidt‐Wolf IG, Glasmacher A.

Abdominal infections in patients with acute leukaemia: a prospective study applying ultra‐

sonography and microbiology.

Br J Haematol. 2002 May;117(2):351‐8.

14: Gorschlüter M, Hahn C, Ziske C, Mey U, Schöttker B, Molitor E, Becker S, Marklein G, Sau‐

erbruch T, Schmidt‐Wolf IG, Glasmacher A.

Low frequency of enteric infections by Salmonella, Shigella, Yersinia and Campylobacter in

patients with acute leukemia.

Infection. 2002 Jan;30(1):22‐5.

85

15: Gülberg V, Schepke M, Geigenberger G, Holl J, Brensing KA, Waggershauser T, Reiser M,

Schild HH, Sauerbruch T, Gerbes AL.

Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band

ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled

trial.


16: Hanke P, Rabe C, Serwe M, Böhm S, Pagenstecher C, Sauerbruch T, Caselmann WH.

Cirrhotic patients with or without hepatocellular carcinoma harbour AFP‐specific T‐

lymphocytes that can be activated in vitro by human alpha‐fetoprotein.


17: Hanke P, Serwe M, Dombrowski F, Sauerbruch T, Caselmann WH.

DNA vaccination with AFP‐encoding plasmid DNA prevents growth of subcutaneous AFP‐

expressing tumors and does not interfere with liver regeneration in mice.

Cancer Gene Ther. 2002 Apr;9(4):346‐55.

18: Heller J, Schepke M, Neef M, Woitas R, Rabe C, Sauerbruch T.

Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension.

J Hepatol. 2002 Dec;37(6):767‐72.

19: Jungck M, Sauerbruch T.

[Cost‐effectiveness of screening in familial adenomatous polyposis].


20: Kaiser R, Geulen O, Matz B, Brackmann HH, Spengler U, Kramer MH, Exner M, Net‐

tekoven W, Ko YD, Zeitler H, Vetter H.

Risk of hepatitis C after immunoadsorption.

Infect Control Hosp Epidemiol. 2002 Jun;23(6):342‐3

21: Kaufmann F, Engelhart S, Glasmacher A, Exner M.

[Risk of infection and preventative strategies in the domestic environment of immunosup‐

pressed hematologic oncology patients].

Med Klin (Munich). 2002 Jan 15;97(1):22‐9.

22: Lamberti C, Jungck M, Laarmann M, Knapp M, Caspari R, Friedl W, Sauerbruch T, Prop‐

ping P, Kruse R.

Arylamine N‐acetyltransferase type 2 and glutathione S‐transferases M1 and T1 polymor‐

phisms in familial adenomatous polyposis.

Pharmacogenetics. 2002 Jan;12(1):49‐54.

86

23: Leifeld L, Cheng S, Ramakers J, Dumoulin FL, Trautwein C, Sauerbruch T, Spengler U.

Imbalanced intrahepatic expression of interleukin 12, interferon gamma, and interleukin 10 in

fulminant hepatitis B.

Hepatology. 2002 Oct;36(4 Pt 1):1001‐8.

24: Leifeld L, Fielenbach M, Dumoulin FL, Speidel N, Sauerbruch T, Spengler U.

Inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) expres‐

sion in fulminant hepatic failure.

J Hepatol. 2002 Nov;37(5):613‐9.

25: Lichterfeld M, Leifeld L, Nischalke HD, Rockstroh JK, Hess L, Sauerbruch T, Spengler U.

Reduced CC chemokine receptor (CCR) 1 and CCR5 surface expression on peripheral blood T

lymphocytes from patients with chronic hepatitis C infection.

J Infect Dis. 2002 Jun 15;185(12):1803‐7.

26: Lichterfeld M, Nischalke HD, Bergmann F, Wiesel W, Rieke A, Theisen A, Fätkenheuer G,

Oette M, Carls H, Fenske S, Nadler M, Knechten H, Wasmuth JC, Rockstroh JK.

Long‐term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination

with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy.

HIV Med. 2002 Jan;3(1):37‐43.

27: Lichterfeld M, Lorenz C, Nischalke HD, Scheurlen C, Sauerbruch T, Rockstroh.JK.

Decreased prevalence of Helicobacter pylori infection in HIV patients with AIDS defining dis‐

eases.


28: Lindenthal B, Sudhop T, Schiedermaier P, Agnan M, Sauerbruch T, von Bergmann K.

Serum plant sterols and biliary cholesterol secretion in humans: studies with ursodeoxycholic

acid.

J Lipid Res. 2002 Jul;43(7):1072‐7.

29: Märten A, Renoth S, Schmidt‐Wolf IG.

Increase of the stimulatory effect of dendritic cells by pulsing with apoptotic bodies trans‐

fected with the MHC class II gene.

Mol Immunol. 2002 Nov;39(7‐8):395‐8.

30: Märten A, Greten T, Ziske C, Renoth S, Schöttker B, Buttgereit P, Schakowski F, von Rü‐

cker A, Sauerbruch T, Schmidt‐Wolf IH.

Generation of activated and antigen‐specific T cells with cytotoxic activity after co‐culture

with dendritic cells.

Cancer Immunol Immunother. 2002 Mar;51(1):25‐32.

87

31: Märten A, Flieger D, Renoth S, Weineck S, Albers P, Compes M, Schöttker B,Ziske C, En‐

gelhart S, Hanfland P, Krizek L, Faber C, von Ruecker A, Müller S, Sauerbruch T, Schmidt‐

Wolf IG.

Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells:

preclinical results and outcome of a first clinical phase I/II trial.

Cancer Immunol Immunother. 2002 Dec;51(11‐12):637‐44.

32: Maschmeyer G, Glasmacher A

Caspofungin ‐ ein neues Antimykotikum zur Behandlung invasiver Mykosen.

Arzneimitteltherapie 2002; 20: 282‐288.

33: Neubrand M, Scheurlen C, Schepke M, Sauerbruch T.

Long‐term results and prognostic factors in the treatment of achalasia with botulinum toxin.

Endoscopy. 2002 Jul;34(7):519‐23.

34: Platen E, Dumoulin FL, Fischer HP, Sauerbruch T.

[Endemic celiac sprue and Hodgkin's disease in a 72‐year‐old patient].


35: Rabe C, Caselmann WH.

[Is MRI reliable for screening for hepatocellular carcinoma?].


36: Rabe C, Pilz T, Allgaier HP, Halm U, Strasser C, Wettstein M, Sauerbruch T, Caselmann

WH.

[Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with oc‐

treotide].


37: Rabe C, Gramann T, Sons X, Berna M, González‐Carmona MA, Klehr HU, Sauerbruch T,

Caselmann WH.

Keeping central venous lines open: a prospective comparison of heparin, vitamin C and so‐

dium chloride sealing solutions in medical patients.

Intensive Care Med. 2002 Aug;28(8):1172‐6.

38: Reinhard G, Märten A, Kiske SM, Feil F, Bieber T, Schmidt‐Wolf IG.

Generation of dendritic cell‐based vaccines for cancer therapy.

Br J Cancer. 2002 May 20;86(10):1529‐33.

88

39: Rockstroh JK, Mudar M, Lichterfeld M, Nischalke HD, Klausen G, Gölz J, Dupke S, Notheis

G, Stein L, Mauss S; German Clinical AIDS Working group (KAAD).

Pilot study of interferon alpha high‐dose induction therapy in combination with ribavirin for

chronic hepatitis C in HIV‐co‐infected patients.

AIDS. 2002 Oct 18;16(15):2083‐5.

40: Rockstroh JK.

[Hepatitis C and HIV coinfection. Current aspects of therapy].

MMW Fortschr Med. 2002 Apr 9;144 Suppl 1:30‐2.

41: Rockstroh JK.

HIV‐ und Hepatitis‐Koinfektion.

Sexualmedizin für den Arzt 2002, 2: 27‐32.

42: Rockstroh JK.

HIV und Hepatitis B‐Koinfektion.

Lebenszeichen 2002: 1: 21‐22.

43: Rockstroh JK.

HIV and hepatitis C coinfection.

Infection 2002; 30 (Suppl 2):16.

44: Rockstroh JK.

HIV‐Infektion. Aktuelle Therapieverfahren.

Der Kassenarzt 2002; 40/41: 32‐36.

45: Rockstroh JK

Charakteristik und Studienergebnisse der pegylierten Interferone Alpha‐2a und ‐2b.

Suchttherapie. Supplement 2002; 3: S45‐S48

46: Sauerbruch T.

[Guidelines of the German Society of Gastroenterology for the treatment of gallstones].

Z Ärztl Fortbild Qualitatssich. 2002 May;96(4):222‐6.

47: Sauerbruch T.

[DCVG Congress in Bonn, September 11‐l4, 2002. President's report: account and addenda].

Z Gastroenterol. 2002 Dec;40(12):I‐V.

48: Sauerbruch T.

[Gallstones: pathogenesis and therapy].

Z Gastroenterol. 2002 Dec;40 Suppl 2:27‐8.

49: Schaible R, Textor J, Schepke M, Wolff M, Schild H, Kreft B.

89

[MRI in cavernous transformation of the portal vein: secondary biliary abnormalities and por‐

toportal collaterals].

Röfo. 2002 Nov;174(11):1408‐14.

50: Schiedermaier P, Layer G, Sauerbruch T.

Impact of the continuous infusion of Levovist on color Doppler sonography in portal hyper‐

tension.

AJR Am J Roentgenol.2002 Jan;178(1):61‐5.

51: Schiedermaier P, Harrison P, Arthur M, Grandt D, Sutton R, Drewe J, Larsen F, Sieber C;

European Lanreotide Study Group.

Effect of the somatostatin analogue lanreotide on meal‐stimulated portal blood flow in pa‐

tients with liver cirrhosis.

Digestion. 2002;65(1):56‐60.

52: Schmidt‐Wolf GD, Schmidt‐Wolf IG.

Immunomodulatory gene therapy for haematological malignancies.

Br J Haematol. 2002 Apr;117(1):23‐32.

53: Schmidt‐Wolf IG, Rockstroh JK, Schlegel U, Pels H, Weiss R, Huhn D.

New aspects in the treatment of AIDS‐related lymphoma.

Eur J Med Res. 2002 Jul 24;7(7):295‐303.

54: Schwarze C, Schmitz V, Fischer HP, Sauerbruch T, Spengler U.

Vanishing bile duct syndrome associated with elevated pancreatic enzymes after short‐term

administration of amoxicillin.


55: Soriano V, Sulkowski M, Bergin C, Hatzakis A, Cacoub P, Katlama C, Cargnel A, Mauss S,

Dieterich D, Moreno S, Ferrari C, Poynard T, Rockstroh J.

Care of patients with chronic hepatitis C and HIV co‐infection: recommendations from the

HIV‐HCV International Panel.

AIDS. 2002 Apr 12;16(6):813‐28.

56: Spengler U, Lichterfeld M, Rockstroh JK.

Antiretroviral drug toxicity – a challenge for the hepatologist?

J Hepatol. 2002 Feb;36(2):283‐94.

90

57: Tazi KA, Barrière E, Moreau R, Heller J, Sogni P, Pateron D, Poirel O, Lebrec D.

Role of shear stress in aortic eNOS up‐regulation in rats with biliary cirrhosis.

Gastroenterology. 2002 Jun;122(7):1869‐77.

58: Textor HJ, Flacke S, Pauleit D, Keller E, Neubrand M, Terjung B, Gieseke J, Scheurlen C,

Sauerbruch T, Schild HH.

Three‐dimensional magnetic resonance cholangiopancreatography with respiratory trigger‐

ing in the diagnosis of primary sclerosing cholangitis: comparison with endoscopic retrograde

cholangiography.

Endoscopy. 2002 Dec;34(12):984‐90.

59: Voigt E, Wickesberg A, Wasmuth JC, Gute P, Locher L, Salzberger B, Wöhrmann A, Adam

A, Weitner L, Rockstroh JK.

First‐line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase in‐

hibitors in a German multicentre study: 48‐week results.

HIV Med. 2002 Oct;3(4):277‐82.

60: Wang Y, Friedl W, Sengteller M, Jungck M, Filges I, Propping P, Mangold E.

A modified multiplex PCR assay for detection of large deletions in MSH2 and MLH1.

Hum Mutat. 2002 Mar;19(3):279‐86.

61: Wasmuth JC, Herhaus C, Römer K, Salzberger B, Kaiser R, Schliefer K, Voigt E, Rockstroh

JK.

Efficacy and safety of abacavir plus efavirenz as a salvage regimen in HIV‐infected individuals

after 48 weeks.

AIDS. 2002 May 3;16(7):1077‐8.

62: Wasmuth JC, Oliver y Miñarro D, Homrighausen A, Leifeld L, Rockstroh JK, Sauerbruch T,

Spengler U.

Phospholipid autoantibodies and the antiphospholipid antibody syndrome: diagnostic accu‐

racy of 23 methods studied by variation in ROC curves with number of clinical manifestations.

Clin Chem. 2002 Jul;48(7):1004‐10.

63: Wasmuth JC, Schliefer K, Scheurlen C, Sudhop T, Rockstroh JK, Sauerbruch T, Spengler

U.

Enteric dysfunction in patients with asymptomatic HIV‐infection versus patients with hypo‐

proteinemia/hypalbuminemia and advanced HIV‐infection.

Eur J Med Res. 2002 Dec 17;7(12):536‐42.

91

64: Wheatley K, Djulbegovic B, Glasmacher A.

Priority‐setting decisions for new cancer drugs.

Lancet. 2002 Apr 27;359(9316):1525.

65: Woitas RP, Sippel M, Althausen EM, Brackmann HH, Kochan B, Matz B, Rockstroh JK,

Sauerbruch T, Spengler U.

Differential expansion of T‐cell receptor variable beta subsets after antigenic stimulation in

patients with different outcomes of hepatitis C infection.

Immunology. 2002 Jul;106(3):419‐27

66: Woitas RP, Ahlenstiel G, Iwan A, Rockstroh JK, Brackmann HH, Kupfer B, Matz B, Offer‐

geld R, Sauerbruch T, Spengler U.

[Do polymorphisms of the SDF1 and CCR2b genes modify the course of hepatitis C or HIV/HCV

co‐infection?].


67: Woitas RP, Flommersfeld S, Stoffel‐Wagner B, Schiedermaier P, Brensing KA, Spengler

U, Sauerbruch T.

Renal functional reserve is well maintained in patients with advanced liver cirrhosis and as‐

cites.

Scand J Gastroenterol. 2002 Nov;37(11):1321‐7.

68: Woitas RP, Stoffel‐Wagner B, Poege U, Sauerbruch T.

Increased homocysteine in liver cirrhosis: a result of renal impairment?

Clin Chem. 2002 May;48(5):796‐7; author reply 797‐8.

69: Woitas RP, Ahlenstiel G, Iwan A, Rockstroh JK, Brackmann HH, Kupfer B, Matz B, Offer‐

geld R, Sauerbruch T, Spengler U.

Frequency of the HIV‐protective CC chemokine receptor 5‐Delta32/Delta32 genotype is in‐

creased in hepatitis C.


70: Woitas RP, Petersen U, Moshage D, Brackmann HH, Matz B, Sauerbruch T, Spengler U.

HCV‐specific cytokine induction in monocytes of patients with different outcomes of hepatitis

C.

World J Gastroenterol. 2002 Jun;8(3):562‐6.

92

71: Woitas RP, Sippel M, Althausen EM, Brackmann HH, Kochan B, Matz B, Rockstroh JK,

Sauerbruch T, Spengler U.

Differential expansion of T‐cell receptor variable beta subsets after antigenic stimulation in

patients with different outcomes of hepatitis C infection.

Immunology. 2002 Jul;106(3):419‐27.

72: Ziske C, Gorschlüter M, Mey U, Offergeld R, Glasmacher A, Schmidt‐Wolf IG.

Sequential high‐dose chemotherapy with autologous stem cell support in patients with lim‐

ited‐stage small cell lung cancer.

Anticancer Res. 2002 Nov‐Dec;22(6B):3723‐6.

73: Ziske C, Sauerbruch T.

[Is total body hyperthermia plus chemotherapy useful in pancreas carcinoma?].

Dtsch Med Wochenschr. 2002 Aug 2;127(31‐32):1660.

74: Ziske CG, Schöttker B, Gorschlüter M, Mey U, Kleinschmidt R, Schlegel U, Sauerbruch T,

Schmidt‐Wolf IG.

Acute transient encephalopathy after paclitaxel infusion: report of three cases.

Ann Oncol. 2002 Apr;13(4):629‐31.

93

2003

1: Aarnoutse RE, Wasmuth JC, Fätkenheuer G, Schneider K, Schmitz K, de Boo TM, Reiss P,

Hekster YA, Burger DM, Rockstroh JK.

Administration of indinavir and low‐dose ritonavir (800/100 mg twice daily) with food reduces

nephrotoxic peak plasma levels of indinavir.

Antivir Ther. 2003 Aug;8(4):309‐14.

2: Abken H, Hombach A, Reinhard G, Märten A, Schlimper C, Glasmacher A, Bieber T,

Schmidt‐Wolf IG.

Cellular immunotherapy after autologous hematopoietic stem cell transplantation: experi‐

mental strategies and clinical experiences.

Leuk Lymphoma. 2003 Apr;44(4):583‐92.

3: Ahlenstiel G, Berg T, Woitas RP, Grünhage F, Iwan A, Hess L, Brackmann HH, Kupfer B,

Schernick A, Sauerbruch T, Spengler U.

Effects of the CCR5‐Delta32 mutation on antiviral treatment in chronic hepatitis C.

J Hepatol. 2003 Aug;39(2):245‐52.

4: Altfeld M, Addo MM, Rosenberg ES, Hecht FM, Lee PK, Vogel M, Yu XG, Draenert R, Johns‐

ton MN, Strick D, Allen TM, Feeney ME, Kahn JO, Sekaly RP, Levy JA, Rockstroh JK, Goulder

PJ, Walker BD.

Influence of HLA‐B57 on clinical presentation and viral control during acute HIV‐1 infection.

AIDS. 2003 Dec 5;17(18):2581‐91.

5: Amberg S, Tamke A, Caselmann WH, Engels JW.

Specific inhibition of hepatitis C viral gene expression by non‐polar (phenylalkyl) phospho‐

nates.

Nucleosides Nucleotides Nucleic Acids. 2003 May‐Aug;22(5‐8):1631‐4.

6: Berg T, Kronenberger B, Hinrichsen H, Gerlach T, Buggisch P, Herrmann E, Spengler U,

Goeser T, Nasser S, Wursthorn K, Pape GR, Hopf U, Zeuzem S.

Triple therapy with amantadine in treatment‐naive patients with chronic hepatitis C: a pla‐

cebo‐controlled trial.

Hepatology. 2003 Jun;37(6):1359‐67.

7: Biecker E, Fischer HP, Strunk H, Sauerbruch T.

Benign hepatic tumours.


94

8: Biecker E, Zimmermann A, Dufour JF.

Spontaneous regression of an inflammatory pseudotumor of the liver.


9: Biecker E, Zeidler D, Klingmüller D, Layer P, Sauerbruch T.

[Muscle weakness, skin manifestations and para‐hilar space‐occupying lesions in a 59‐year‐old

patient. Cushing disease and pulmonary lymph node tuberculosis].

Internist (Berl). 2003 Feb;44(2):209‐14.

10: Cornely OA, Böhme A, Buchheidt D, Glasmacher A, Kahl C, Karthaus M, Kern W, Krüger

W, Maschmeyer G, Ritter J, Salwender HJ, Sandherr M, Schiel X, Schüttrumpf S, Sieniawski

M, Silling G, Ullmann AJ, Wolf HH; Infectious Diseases Working Party (AGIHO) of the Ger‐

man Society of Hematology and Oncology (DGHO).

Prophylaxis of invasive fungal infections in patients with haematological malignancies and

solid tumors‐‐guidelines of the Infectious Diseases Working Party (AGIHO) of the German So‐

ciety of Hematology and Oncology (DGHO).

Ann Hematol. 2003 Oct;82 Suppl 2:S186‐200.

11: Dumoulin FL, Gerhardt T, Fuchs S, Scheurlen C, Neubrand M, Layer G, Sauerbruch T.

Phase II study of photodynamic therapy and metal stent as palliative treatment for nonre‐

sectable hilar cholangiocarcinoma.

Gastrointest Endosc. 2003 Jun;57(7):860‐7.

12: Dumoulin FL, Sauerbruch T.

[Differential diagnosis of isolated increased SGOT level].

Dtsch Med Wochenschr. 2003 Feb 14;128(7):342.

13: Dumoulin FL, von dem Bussche A, Li J, Khamzina L, Wands JR, Sauerbruch T, Spengler U.

Hepatitis C virus NS2 protein inhibits gene expression from different cellular and viral pro‐

moters in hepatic and nonhepatic cell lines.

Virology. 2003 Jan 20;305(2):260‐6.

14: Engelhart S, Hanfland J, Glasmacher A, Krizek L, Schmidt‐Wolf IG, Exner M.

Impact of portable air filtration units on exposure of haematology‐oncology patients to air‐

borne Aspergillus fumigatus spores under field conditions.

J Hosp Infect. 2003 Aug;54(4):300‐4.

95

15: Fliessbach K, Urbach H, Helmstaedter C, Pels H, Glasmacher A, Kraus JA, Klockgether T,

Schmidt‐Wolf I, Schlegel U.

Cognitive performance and magnetic resonance imaging findings after high‐dose systemic

and intraventricular chemotherapy for primary central nervous system lymphoma.

Arch Neurol. 2003 Apr;60(4):563‐8.

16: Friedrichs N, Eis‐Hubinger AM, Heim A, Platen E, Zhou H, Buettner R.

Acute adenoviral infection of a graft by serotype 35 following renal transplantation.

Pathol Res Pract. 2003;199(8):565‐70.

17: Glasmacher A, Prentice A, Gorschlüter M, Engelhart S, Hahn C, Djulbegovic B, Schmidt‐

Wolf IG.

Itraconazole prevents invasive fungal infections in neutropenic patients treated for hema‐

tologic malignancies: evidence from a meta‐analysis of 3,597 patients.

J Clin Oncol. 2003 Dec 15;21(24):4615‐26.

18: Glasmacher A.

High dose therapy may have no survival benefit over CHOEP primary chemotherapy for peo‐

ple with aggressive non‐Hodgkin's lymphoma.

Cancer Treat Rev. 2003 Apr;29(2):139‐42.

19: Goldschmidt H, Sonneveld P, Cremer FW, van der Holt B, Westveer P, Breitkreutz I, Ben‐

ner A, Glasmacher A, Schmidt‐Wolf IG, Martin H, Hoelzer D, Ho AD, Lokhorst HM.

Joint HOVON; GMMG. Joint HOVON‐50/GMMG‐HD3 randomized trial on the effect of tha‐

lidomide as part of a high‐dose therapy regimen and as maintenance treatment for newly

diagnosed myeloma patients.

Ann Hematol. 2003 Oct;82(10):654‐9.

20: Gorschlüter M, Hahn C, Fixson A, Mey U, Ziske C, Molitor E, Horré R, Sauerbruch T, Mark‐

lein G, Schmidt‐Wolf IG, Glasmacher A.

Piperacillin‐tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutro‐

penic patients with hematological malignancies: a randomized comparison.

Support Care Cancer. 2003 Jun;11(6):362‐70.

21: Groll AH, Gea‐Banacloche JC, Glasmacher A, Just‐Nuebling G, Maschmeyer G,

Walsh TJ.

Clinical pharmacology of antifungal compounds.

Infect Dis Clin North Am. 2003 Mar;17(1):159‐91, ix.

96

22: Gross C, Schmidt‐Wolf IG, Nagaraj S, Gastpar R, Ellwart J, Kunz‐Schughart LA, Multhoff G.

Heat shock protein 70‐reactivity is associated with increased cell surface density of

CD94/CD56 on primary natural killer cells.

Cell Stress Chaperones. 2003 Winter;8(4):348‐60.

23: Grünhage F, Fischer HP, Sauerbruch T, Reichel C.

[Drug‐ and toxin‐induced hepatotoxicity].


24: He Y, Wheatley K, Clark O, Glasmacher A, Ross H, Djulbegovic B.

Early versus deferred treatment for early stage multiple myeloma.

Cochrane Database Syst Rev. 2003;(1):CD004023.

25: Heller J, Shiozawa T, Trebicka J, Hennenberg M, Schepke M, Neef M, Sauerbruch T.

Acute haemodynamic effects of losartan in anaesthetized cirrhotic rats.

Eur J Clin Invest. 2003 Nov;33(11):1006‐12.

26: Hempfling W, Grünhage F, Dilger K, Reichel C, Beuers U, Sauerbruch T.

Pharmacokinetics and pharmacodynamic action of budesonide in early‐ and late‐stage pri‐

mary biliary cirrhosis.

Hepatology. 2003 Jul;38(1):196‐202.

27: Hoffmann P., Quasdorff M., Gonzales‐Carmona MA, Caselmann WH.

Recent Patents on Experimental Therapy for Hepatitis C Virus Infection (1999‐2000).

Expert Opin Ther Patents 2003, 13 (11), S. 1707‐1723.

28: Holub M, Zakeri SM, Lichtenberger C, Pammer J, Paolini P, Leifeld L, Rockenschaub S,

Wolschek MF, Steger G, Willheim M, Gangl A, Reinisch W.

Heterogeneous expression and regulation of CD40 in human hepatocellular carcinoma.


29: Hoppe B, Leumann E, von Unruh G, Laube N, Hesse A.

Diagnostic and therapeutic approaches in patients with secondary hyperoxaluria.

Front Biosci. 2003 Sep 1;8:e437‐43.

30: Igel‐Korcagova A, Raab P, Brensing KA, Pöge U, Klehr HU, Igel M, von Bergmann K, Sud‐

hop T.

Cholesterol metabolism in patients with chronic renal failure on hemodialysis.

J Nephrol. 2003 Nov‐Dec;16(6):850‐4.

97

31: la Porte CJ, Wasmuth JC, Schneider K, Rockstroh JK, Burger DM.

Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and effi‐

cacy.

AIDS. 2003 Jul 25;17(11):1700‐2.

32: Laurent N, Lafont D, Dumoulin F, Boullanger P, Mackenzie G, Kouwer PH, Goodby JW.

Synthesis of amphiphilic phenylazophenyl glycosides and a study of their liquid crystal prop‐

erties.

J Am Chem Soc. 2003 Dec 17;125(50):15499‐506.

33: Leifeld L, Dumoulin FL, Purr I, Janberg K, Trautwein C, Wolff M, Manns MP, Sauerbruch T,

Spengler U.

Early up‐regulation of chemokine expression in fulminant hepatic failure.

J Pathol. 2003 Mar;199(3):335‐44.

34: Lichterfeld M, Fischer HP, Spengler U, Rockstroh JK.

[Fatty liver and increased serum lactate in a woman with HIV].


35: Lichterfeld M, Wöhrmann A, Schmeisser N, Fätkenheuer G, Salzberger B, Wyen C,

Schmitz K, Sauerbruch T, Rockstroh JK.

Superior virological efficacy of ritonavir‐boosted protease inhibitor regimens compared to

single protease inhibitor therapy.

Eur J Med Res. 2003 Feb 21;8(2):56‐60.

36: Lichterfeld M, Nischalke HD, van Lunzen J, Söhne J, Schmeisser N, Woitas R, Sauerbruch

T, Rockstroh JK, Spengler U.

The tandem‐repeat polymorphism of the DC‐SIGNR gene does not affect the susceptibility to

HIV infection and the progression to AIDS.

Clin Immunol. 2003 Apr;107(1):55‐9.

37: Lichterfeld M, Rockstroh JK.

[Antiretroviral treatment of HIV infected patients].

Med Monatsschr Pharm. 2003 Apr;26(4):111‐21; quiz 121‐2.

38: Look MP, Krämer K Rockstroh JK, McCord JM, Packer L.

High dose neutraceuticals in human immunodeficiency virus disease. An under study option?

Current Topics in Neutraceutical Research 2003, 1: 1‐16.

39: Märten A, Renoth S, Heinicke T, Albers P, Pauli A, Mey U, Caspari R, Flieger D, Hanfland

P, Von Ruecker A, Eis‐Hübinger AM, Müller S, Schwaner I, Lohmann U, Heylmann G, Sauer‐

bruch T, Schmidt‐Wolf IG.

98

Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical

phase I/II trial in patients with metastatic renal cell carcinoma.

Hum Gene Ther. 2003 Mar 20;14(5):483‐94.

40: Mey U, Gorschlüter M, Ziske C, Kleinschmidt R, Glasmacher A, Schmidt‐Wolf IG.

Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial.

Anticancer Drugs. 2003 Mar;14(3):233‐8.

41: Mey U, Glasmacher A, Hahn C, Gorschlüter M, Ziske C, Mergelsberg M, Sauerbruch T,

Schmidt‐Wolf IG.

Evaluation of an ultrasound‐guided technique for central venous access via the internal jugu‐

lar vein in 493 patients.

Support Care Cancer. 2003 Mar;11(3):148‐55.

42: Mey U, Strehl J, Gorschlüter M, Ziske C, Glasmacher A, Pralle H, Schmidt‐Wolf I.

Advances in the treatment of hairy‐cell leukaemia.

Lancet Oncol. 2003 Feb;4(2):86‐94.

43: Nattermann J, Nischalke HD, Kupfer B, Rockstroh J, Hess L, Sauerbruch T, Spengler U.

Regulation of CC chemokine receptor 5 in hepatitis G virus infection.

AIDS. 2003 Jul 4;17(10):1457‐62.

44: Neef M, Biecker E, Heller J, Schepke M, Nischalke HD, Wolff M, Spengler U,

Reichen J, Sauerbruch T.

Portal hypertension is associated with increased mRNA levels of vasopressor G‐protein‐

coupled receptors in human hepatic arteries.

Eur J Clin Invest. 2003 Mar;33(3):249‐55.

45: Neef M, Kerekes Z, Fischer HP, Sauerbruch T, Spengler U.

Acenocoumarol is not a safe alternative for anticoagulation in phenprocoumon‐induced he‐

patic failure. Report of two cases.

Digestion. 2003;67(1‐2):100‐4.

46: Overhaus M, Decker P, Zhou H, Textor HJ, Hirner A, Scheurlen C.

The congenital duplication cyst: a rare differential diagnosis of retrosternal pain and dys‐

phagia in a young patient.


47: Pels H, Schmidt‐Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V, Zellner A, Schackert

G, Reichmann H, Kroschinsky F, Vogt‐Schaden M, Egerer G, Bode U, Schaller C, Deckert M,

Fimmers R, Helmstaedter C, Atasoy A, Klockgether T, Schlegel U.

99

Primary central nervous system lymphoma: results of a pilot and phase II study of systemic

and intraventricular chemotherapy with deferred radiotherapy.

J Clin Oncol. 2003 Dec 15;21(24):4489‐95.

48: Pöge U, Stoschus B, Stoffel‐Wagner B, Gerhardt T, Klehr HU, Sauerbruch T, Woitas RP.

Cystatin C as an endogenous marker of glomerular filtration rate in renal transplant patients.

Kidney Blood Press Res. 2003;26(1):55‐60.

49: Qurishi N, Kreuzberg C, Lüchters G, Effenberger W, Kupfer B, Sauerbruch T, Rockstroh

JK, Spengler U.

Effect of antiretroviral therapy on liver‐related mortality in patients with HIV and hepatitis C

virus coinfection.

Lancet. 2003 Nov 22;362(9397):1708‐13.

50: Rabe C, Lenz M, Schmitz V, Pilz T, Fimmers R, Sauerbruch T, Caselmann WH.

An independent evaluation of modern prognostic scores in a central European cohort of 120

patients with hepatocellular carcinoma.

Eur J Gastroenterol Hepatol. 2003 Dec;15(12):1305‐15.

51: Rockstroh JK.

Management of hepatitis B and C in HIV co‐infected patients.

J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S59‐65.

52: Ruhnke M, Böhme A, Buchheidt D, Donhuijsen K, Einsele H, Enzensberger R, Glasmacher

A, Gümbel H, Heussel CP, Karthaus M, Lambrecht E, Südhoff T, Szelényi H; Infectious Dis‐

eases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).

Diagnosis of invasive fungal infections in hematology and oncology‐‐guidelines of the Infec‐

tious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology

(DGHO).

Ann Hematol. 2003 Oct;82 Suppl 2:S141‐8.

53: Schepke M, Roth F, Fimmers R, Brensing KA, Sudhop T, Schild HH, Sauerbruch T.

Comparison of MELD, Child‐Pugh, and Emory model for the prediction of survival in patients

undergoing transjugular intrahepatic portosystemic shunting.

Am J Gastroenterol. 2003 May;98(5):1167‐74.

100

54: Schepke M, Roth F, Koch L, Heller J, Rabe C, Brensing KA, Schiedermaier P, Schild HH,

Sauerbruch T.

Prognostic impact of renal impairment and sodium imbalance in patients undergoing

transjugular intrahepatic portosystemic shunting for the prevention of variceal rebleeding.

Digestion. 2003;67(3):146‐53

55: Scheuring UJ, Seitz HM, Wellmann A, Hartlapp JH, Tappe D, Brehm K, Spengler U, Sauer‐

bruch T, Rockstroh JK.

Long‐term benzimidazole treatment of alveolar echinococcosis with hematogenic subcuta‐

neous and bone dissemination.

Med Microbiol Immunol. 2003 Nov;192(4):193‐5.

56: Schiedermaier P, Koch L, Stoffel‐Wagner B, Layer G, Sauerbruch T.

Effect of propranolol and depot lanreotide SR on postprandial and circadian portal haemody‐

namics in cirrhosis.

Aliment Pharmacol Ther. 2003 Oct 15;18(8):777‐84.

57: Schmidt T, Ziske C, Märten A, Endres S, Tiemann K, Schmitz V, Gorschlüter M, Schneider

C, Sauerbruch T, Schmidt‐Wolf IG.

Intratumoral immunization with tumor RNA‐pulsed dendritic cells confers antitumor immu‐

nity in a C57BL/6 pancreatic murine tumor model.

Cancer Res. 2003 Dec 15;63(24):8962‐7.


Gene therapy for hematological malignancies.

Clin Exp Med. 2003 May;3(1):4‐14.


Non‐viral and hybrid vectors in human gene therapy: an update.

Trends Mol Med. 2003 Feb;9(2):67‐72. Review.

60: Schmidt‐Wolf IG, Rockstroh JK, Schüller H, Hirner A, Grohe C, Müller‐Hermelink HK,

Huhn D.

Malignant thymoma: current status of classification and multimodality treatment.

Ann Hematol. 2003 Feb;82(2):69‐76.

61: Schmidt‐Wolf IG, Rockstroh JK, Schlegel U, Pels H, Mey U, Strehl J, Weiss R, Huhn D.

Treatment options of AIDS‐related lymphoma.

Expert Opin Pharmacother. 2003 Aug;4(8):1331‐43.

101

62: Schwarze C, Terjung B, Lilienweiss P, Beuers U, Herzog V, Sauerbruch T, Spengler U.

IgA class antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and autoim‐

mune hepatitis.

Clin Exp Immunol. 2003 Aug;133(2):283‐9.

63: Steigerwald R, Rabe C, Schmitz V, Schmidt‐Wolf IG, Alt M, Caselmann WH.

Requirements for adeno‐associated virus‐derived non‐viral vectors to achieve stable and site‐

specific integration of plasmid DNA in liver carcinoma cells.

Digestion. 2003;68(1):13‐23.

64: Streetz KL, Tacke F, Leifeld L, Wüstefeld T, Graw A, Klein C, Kamino K, Spengler U, Kreipe

H, Kubicka S, Müller W, Manns MP, Trautwein C.

Interleukin 6/gp130‐dependent pathways are protective during chronic liver diseases.

Hepatology. 2003 Jul;38(1):218‐29.

65: Strehl J, Mey U, Glasmacher A, Djulbegovic B, Mayr C, Gorschlüter M, Ziske C,

Schmidt‐Wolf IG.

High‐dose chemotherapy followed by autologous stem cell transplantation as first‐line ther‐

apy in aggressive non‐Hodgkin's lymphoma: a meta‐analysis.

Haematologica. 2003 Nov;88(11):1304‐15.

66: Strehl J, Schepke M, Wardelmann E, Caselmann WH, Sauerbruch T.

[Chronic diarrhea in a 43‐year‐old patient].

Internist (Berl). 2003 May;44(5):626‐30.

67: Terjung B, Neubrand M, Sauerbruch T.

[Acute biliary colic. Etiology, diagnosis and therapy].

Internist (Berl). 2003 May;44(5):570‐6, 570‐84.

68: Terjung B, Lemnitzer I, Dumoulin FL, Effenberger W, Brackmann HH, Sauerbruch T,

Spengler U.

Bleeding complications after percutaneous liver biopsy. An analysis of risk factors.

Digestion. 2003;67(3):138‐45.

69: Voigt E, Rockstroh J.

Hepatitis C bei HIV‐Infektion.

Med Rev 2003, 4, 5‐8.

102

70: von Unruh GE, Voss S, Sauerbruch T, Hesse A.

Reference range for gastrointestinal oxalate absorption measured with a standardized

[13C2]oxalate absorption test.

J Urol. 2003 Feb;169(2):687‐90.

71: Wardelmann E, Losen I, Hans V, Neidt I, Speidel N, Bierhoff E, Heinicke T,

Pietsch T, Büttner R, Merkelbach‐Bruse S.

Deletion of Trp‐557 and Lys‐558 in the juxtamembrane domain of the c‐kit protooncogene is

associated with metastatic behavior of gastrointestinal stromal tumors.

Int J Cancer. 2003 Oct 10;106(6):887‐95.

72: Wasmuth JC, Hackbarth F, Rockstroh JK, Sauerbruch T, Spengler U.

Changes of lymphocyte apoptosis associated with sequential introduction of highly active

antiretroviral therapy.

HIV Med. 2003 Apr;4(2):111‐9.

73: Woitas R.P., Ahlenstiel G., Sauerbruch T., Spengler U.

Frequency of the 32‐base pair deletion in the chemokine receptor CCR5 gene is not increased

in hepatitis C patients – Reply.

Gastroenterology 2003, 124(5): 1560‐1561

74: Woitas R.P., Ahlenstiel G., Sauerbruch T., Spengler U.

HCV chronic infection and CCR5‐Delta 32/Delta 32 – Reply.

Gastroenterology 2003, 124(3); 869‐870.

75: Ziske C, Schlie C, Gorschlüter M, Glasmacher A, Mey U, Strehl J, Sauerbruch T, Schmidt‐

Wolf IG.

Prognostic value of CA 19‐9 levels in patients with inoperable adenocarcinoma of the pan‐

creas treated with gemcitabine.

Br J Cancer. 2003 Oct 20;89(8):1413‐7.

76: Ziske C, Mezger J, Jiménez C, Kleinschmidt R, Pels H, Schlegel U, Schmidt‐Wolf IG.

High‐dose chemotherapy with autologous peripheral blood stem cell support for recurrent

primary AFP‐producing intracranial germinoma.

Ger Med Sci. 2003 Jul 1;1:Doc03.

103

2004

1: Ahlenstiel G, Woitas RP, Rockstroh J, Spengler U.

CC‐chemokine receptor 5 (CCR5) in hepatitis C‐‐at the crossroads of the antiviral immune re‐

sponse?

J Antimicrob Chemother. 2004 Jun;53(6):895‐8.

2: Allam JP, Paus T, Reichel C, Bieber T, Novak N.

DRESS syndrome associated with carbamazepine and phenytoin.

Eur J Dermatol. 2004 Sep‐Oct;14(5):339‐42.

3: Aretz S, Uhlhaas S, Sun Y, Pagenstecher C, Mangold E, Caspari R, Möslein G, Schulmann K,

Propping P, Friedl W.

Familial adenomatous polyposis: aberrant splicing due to missense or silent mutations in the

APC gene.

Hum Mutat. 2004 Nov;24(5):370‐80.

4: Aretz S, Uhlhaas S, Caspari R, Mangold E, Pagenstecher C, Propping P, Friedl W.

Frequency and parental origin of de novo APC mutations in familial adenomatous polyposis.

Eur J Hum Genet. 2004 Jan;12(1):52‐8.

5: Bartram J, Cotruvo J, Exner M, Fricker C, Glasmacher A.

Heterotrophic plate count measurement in drinking water safety management: report of an

Expert Meeting Geneva, 24‐25 April 2002.

Int J Food Microbiol. 2004 May 1;92(3):241‐7.

6: Breuhahn K, Vreden S, Haddad R, Beckebaum S, Stippel D, Flemming P, Nussbaum, T, Ca‐

selmann WH, Haab BB, Schirmacher P.

Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon

regulation and insulin‐like growth factor II overexpression.

Cancer Res. 2004 Sep 1;64(17):6058‐64.

7: Caspari R, von Falkenhausen M, Krautmacher C, Schild H, Heller J, Sauerbruch T.

Comparison of capsule endoscopy and magnetic resonance imaging for the detection of pol‐

yps of the small intestine in patients with familial adenomatous polyposis or with Peutz‐

jeghers' syndrome.

Endoscopy. 2004 Dec;36(12):1054‐9.

104

8: Clotet B, Raffi F, Cooper D, Delfraissy JF, Lazzarin A, Moyle G, Rockstroh, J, Soriano V,

Schapiro J.

Clinical management of treatment‐experienced, HIV‐infected patients with the fusion inhibi‐

tor enfuvirtide: consensus recommendations.

AIDS. 2004 May 21;18(8):1137‐46.

9: Complex Trait Consortium.

The Collaborative Cross, a community resource for the genetic analysis of complex traits.

Nat Genet. 2004 Nov;36(11):1133‐7.

10: Demant AW, Schmiedel A, Simula SM, Klein B, Klehr HU, Sauerbruch T, Woitas

RP.

High‐risk dialysis: pregnancy in a patient with extended Stanford‐B‐aneurysm of the aorta and

end‐stage renal disease.

Nephrol Dial Transplant. 2004 Jun;19(6):1634‐6.

11: Dietrich CG, Gartung C, Lorenzen J, Geier A, Wasmuth HE, Matern S, Lammert F.

Enlarged cervical lymph nodes and elevated liver chemistry tests: a therapeutic dilemma.

Ann Hepatol. 2004 Jul‐Sep;3(3):118‐20.

12: Dietrich CG, Geier A, Salein N, Lammert F, Roeb E, Oude Elferink RP, Matern S, Gartung C.

Consequences of bile duct obstruction on intestinal expression and function of multidrug

resistance‐associated protein 2.


13: Ebert O, Wilbert D, Buttgereit P, Ziske C, Flieger D, Schmidt‐Wolf IGH.

Effects of recombinant adenovirus‐mediated expression of IL‐2 and IL‐12 in human B lym‐

phoma cells on co‐cultured PBMC.

Genet Vaccines Ther. 2004 Oct 14;2(1):15.

14: Fickert P, Fuchsbichler A, Wagner M, Zollner G, Kaser A, Tilg H, Krause R, Lammert F,

Langner C, Zatloukal K, Marschall HU, Denk H, Trauner M.

Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4)

knockout mice.


15: Figge A, Lammert F, Paigen B, Henkel A, Matern S, Korstanje R, Shneider BL, Chen F, Stol‐

tenberg E, Spatz K, Hoda F, Cohen DE, Green RM.

Hepatic overexpression of murine Abcb11 increases hepatobiliary lipid secretion and reduces

hepatic steatosis.

J Biol Chem. 2004 Jan 23;279(4):2790‐9.

105

16: Gehrke R, Brauchle MA, Reifenberg K, Hildt E, Gruetzner U, Schmitz V, Schlicht HJ, Hof‐

schneider PH, Caselmann WH, Rabe C.

Accumulation of 8‐hydroxy‐2'‐deoxyguanosine adducts in HBx recombinant HepG2 cells and

HBx transgenic mice.

Digestion. 2004;70(2):117‐26.

17: Geier A, Reugels M, Weiskirchen R, Wasmuth HE, Dietrich CG, Siewert E, Gartung C, Lo‐

renzen J, Bosserhoff AK, Brugmann M, Gressner AM, Matern S, Lammert F.

Common heterozygous hemochromatosis gene mutations are risk factors for inflammation

and fibrosis in chronic hepatitis C.

Liver Int. 2004 Aug;24(4):285‐94.

18: Glasmacher A, Goldschmidt H, Mezger J, Haferlach T, Schmidt‐Wolf IG, Gieseler F

Phase II trial. Oral idarubicin, dexamethasone and vincristine in the treatment of multiple

myeloma: final analysis of a phase II trial.

Haematologica. 2004 Mar;89(3):371‐3.

19: Glasmacher A.

Invasive fungal infections in patients with hematologic malignancies: the next steps.

Support Cancer Ther. 2004 Oct 1;2(1):31‐3.

20: Glasmacher A.

Initial high dose chemotherapy plus autologous stem cell support improves survival out‐

comes compared with a standard CHOP regimen in people with higher intermediate risk ag‐

gressive lymphoma.

Cancer Treat Rev. 2004 Oct;30(6):577‐82.

21: Grünhage F, Spengler U, Fischer HP, Sauerbruch T.

Autoimmune hepatitis‐‐sequel of a relapsing hepatitis A in a 75‐year‐old woman.

Digestion. 2004;70(3):187‐91. Epub 2004 Nov 19.

22: Haas S, Rockstroh JK, Spengler U, Fischer HP.

[Nucleoside induced hepatopathy in HIV patients. Diagnostic value of liver

biopsy assessment]

Pathologe. 2004 Sep;25(5):406‐11.

23: Hesse M, Berg T, Wiedenmann B, Spengler U, Woitas RP, Magin TM.

A frequent keratin 8 p.L227L polymorphism, but no point mutations in keratin 8 and 18

genes, in patients with various liver disorders.

J Med Genet. 2004 Apr;41(4):e42.

106

24: Hoffmann C, Chow KU, Wolf E, Faetkenheuer G, Stellbrink HJ, van Lunzen J, Jaeger H,

Stoehr A, Plettenberg A, Wasmuth JC, Rockstroh J, Mosthaf F, Horst HA, Brodt HR.

Strong impact of highly active antiretroviral therapy on survival in patients with human im‐

munodeficiency virus‐associated Hodgkin's disease.

Br J Haematol. 2004 May;125(4):455‐62.

25: Jungck M, Grünhage F, Spengler U, Dernac A, Mathiak M, Caspari R, Friedl W, Sauerbruch

T.

E‐cadherin expression is homogeneously reduced in adenoma from patients with familial

adenomatous polyposis: an immunohistochemical study of E‐cadherin, beta‐catenin and

cyclooxygenase‐2 expression.

Int J Colorectal Dis. 2004 Sep;19(5):438‐45.

26: Jüngst C, Cheng B, Gehrke R, Schmitz V, Nischalke HD, Ramakers J, Schramel P, Schirma‐

cher P, Sauerbruch T, Caselmann WH.

Oxidative damage is increased in human liver tissue adjacent to hepatocellular carcinoma.

Hepatology. 2004 Jun;39(6):1663‐72.

27: Koek GH, Vos R, Flamen P, Sifrim D, Lammert F, Vanbilloen B, Janssens J, Tack J.

Oesophageal clearance of acid and bile: a combined radionuclide, pH, and Bilitec study.

Gut. 2004 Jan;53(1):21‐6.

28: Kribben B, Heller J, Trebicka J, Sauerbruch T, Bruss M, Göthert M, Molderings GJ.

Agmatine (decarboxylated arginine), a modulator of liver cell homeostasis and proliferation.

Naunyn Schmiedebergs Arch Pharmacol. 2004 Feb;369(2):160‐5.

29: Lammert F, Wang DQ, Hillebrandt S, Geier A, Fickert P, Trauner M, Matern S, Paigen B,

Carey MC.

Spontaneous cholecysto‐ and hepatolithiasis in Mdr2‐/‐ mice: a model for low phospholipid‐

associated cholelithiasis.

Hepatology. 2004 Jan;39(1):117‐28.

30: Langhans B, Braunschweiger I, Schweitzer S, Sauerbruch T, Spengler U.

Primary immunisation of hepatitis C virus (HCV)‐specific antibody producing B cells by lipi‐

dated peptides.

Vaccine. 2004 Mar 29;22(11‐12):1441‐7.

107

31: Langhans B, Schweitzer S, Nischalke HD, Braunschweiger I, Sauerbruch T, Spengler U.

Hepatitis C virus‐derived lipopeptides differentially induce epitope‐specific immune responses

in vitro.

J Infect Dis. 2004 Jan 15;189(2):248‐53.

32: Leo E, Scheuer L, Schmidt‐Wolf IGH, Kerowgan M, Schmitt C, Leo A, Baumbach T,

Kraemer A, Mey U, Benner A, Parwaresch R, Ho AD.

Significant thrombocytopenia associated with the addition of rituximab to a combination of

fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma.

Eur J Haematol. 2004 Oct;73(4):251‐7.

33: Linnebank M, Schmidt S, Kolsch H, Linnebank A, Heun R, Schmidt‐Wolf IGH, Glasmacher

A, Fliessbach K, Klockgether T, Schlegel U, Pels H.

The methionine synthase polymorphism D919G alters susceptibility to primary central nerv‐

ous system lymphoma.

Br J Cancer. 2004 May 17;90(10):1969‐71.

34: Lütjohann D, Hahn C, Prange W, Sudhop T, Axelson M, Sauerbruch T, von Bergmann K,

Reichel C.

Influence of rifampin on serum markers of cholesterol and bile acid synthesis in men.

Int J Clin Pharmacol Ther. 2004 Jun;42(6):307‐13.

35: Manns MP, Caselmann WH, Wiedmann KH, Wedemeyer H.

[Standard treatment of chronic hepatitis B]


36: Martin‐Carbonero L, Benhamou Y, Puoti M, Berenguer J, Mallolas J, Quereda C, Arizcor‐

reta A, Gonzalez A, Rockstroh J, Asensi V, Miralles P, Laguno M, Moreno L, Giron JA, Vogel

M, Garcia‐Samaniego J, Nunez M, Romero M, Moreno S, de la Cruz JJ, Soriano V.

Incidence and predictors of severe liver fibrosis in human immunodeficiency virus‐infected

patients with chronic hepatitis C: a European collaborative study.

Clin Infect Dis. 2004 Jan 1;38(1):128‐33. Epub 2003 Dec 08.

37: Mauss S, Scholten S, Wolf E, Berger F, Schmutz G, Jaeger H, Kurowski M, Rockstroh JK;

Klinische Arbeitsgruppe AIDS Deutschland, Germany.

A prospective, controlled study assessing the effect of lopinavir on amprenavir concentra‐

tions boosted by ritonavir.

HIV Med. 2004 Jan;5(1):15‐7.

108

38: Müller T, Mas‐Marques A, Sarrazin C, Wiese M, Halangk J, Witt H, Ahlenstiel G, Spengler

U, Goebel U, Wiedenmann B, Schreier E, Berg T.

Influence of interleukin 12B (IL12B) polymorphisms on spontaneous and treatment‐induced

recovery from hepatitis C virus infection.

J Hepatol. 2004 Oct;41(4):652‐8.

39: Nagaraj S, Ziske C, Schmidt‐Wolf IGH.

Human cytokine‐induced killer cells have enhanced in vitro cytolytic activity via non‐viral inter‐

leukin‐2 gene transfer.

Genet Vaccines Ther. 2004 Aug 25;2(1):12.

40: Nagaraj S, Ziske C, Schmidt‐Wolf IGH.

Dendritic cell, the immunotherapeutic cell for cancer.

Indian J Med Res. 2004 Apr;119(4):133‐8. Review.

41: Nattermann J, Nischalke HD, Feldmann G, Ahlenstiel G, Sauerbruch T, Spengler U.

Binding of HCV E2 to CD81 induces RANTES secretion and internalization of CC chemokine

receptor 5.

J Viral Hepat. 2004 Nov;11(6):519‐26.

42: Neubrand MW, Dominguez‐Munoz JE, Reichel C, Kampmann S, Eschmann K, von Falken‐

hausen M, Bregulla M, Malfertheiner P, Sauerbruch T.

Effect of intraduodenal administration of ursodeoxycholic acid on interdigestive interaction

between gallbladder motility, pancreatic secretion and endocrine activity.

Digestion. 2004;69(3):149‐57.

43: Nischalke HD, Nattermann J, Lichterfeld M, Woitas RP, Rockstroh JK, Sauerbruch T,

Spengler U.

Rapid determination of the Delta32 deletion in the human CC‐chemokine receptor 5 (CCR5)

gene without DNA extraction by lightcycler real‐time polymerase chain reaction.

AIDS Res Hum Retroviruses. 2004 Jul;20(7):750‐4.

44: Nischalke HD, Nattermann J, Fischer HP, Sauerbruch T, Spengler U, Dumoulin FL.

Semiquantitative analysis of intrahepatic CC‐chemokine mRNas in chronic hepatitis C.

Mediators Inflamm. 2004 Dec;13(5‐6):357‐9.

45: Nguyen HN, Domingues GR, Winograd R, Lammert F, Silny J, Matern S.

Impedance characteristics of esophageal motor function in achalasia.

Dis Esophagus. 2004;17(1):44‐50.

46: Oette M, Kaiser R, Daumer M, Akbari D, Fätkenheuer G, Rockstroh JK, Stechel J, Rieke A,

Mauss S, Schmaloer D, Gobels K, Vogt C, Wettstein M, Haussinger D.

109

Primary drug‐resistance in HIV‐positive patients on initiation of first‐line antiretroviral therapy

in Germany.

Eur J Med Res. 2004 May 28;9(5):273‐8.

47: Pauli‐Magnus C, Lang T, Meier Y, Zodan‐Marin T, Jung D, Breymann C, Zimmermann R,

Kenngott S, Beuers U, Reichel C, Kerb R, Penger A, Meier PJ, Kullak‐Ublick GA.

Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p‐glycoprotein

3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy.

Pharmacogenetics. 2004 Feb;14(2):91‐102.

48: Paus TC, Schneider G, Van De Vondel P, Sauerbruch T, Reichel C.

Diagnosis and therapy of intrahepatic cholestasis of pregnancy.

Z Gastroenterol. 2004 Jul;42(7):623‐8. Review.

49: PEGASYS Study NR16071.

Peginterferon Alfa‐2a (40 Kilodaltons) and Ribavirin in Patients With Chronic Hepatitis C and

Normal Aminotransferase Levels.

Gastroenterology 2004 Dec;127(6):1724‐32.

50: Pöge U, Look M, Gerhardt T, Klehr HU, Sauerbruch T, Woitas RP.

Intravenous treatment of hyperhomocysteinemia in patients on chronic hemodialysis‐‐a pilot

study.

Ren Fail. 2004 Nov;26(6):703‐8.

51: Pöge U, Gerhardt T, Bokenkamp A, Stoffel‐Wagner B, Klehr HU, Sauerbruch T, Woitas RP.

Time course of low molecular weight proteins in the early kidney transplantation period‐‐

influence of corticosteroids.

Nephrol Dial Transplant. 2004 Nov;19(11):2858‐63.

52: Rabe C, Schmitz V, Paashaus M, Musch A, Zickermann H, Dumoulin FL, Sauerbruch T, Ca‐

selmann WH.

Does intubation really equal death in cirrhotic patients? Factors influencing outcome in pa‐

tients with liver cirrhosis requiring mechanical ventilation.

Intensive Care Med. 2004 Aug;30(8):1564‐71. Epub 2004 Jun 26.

110

53: Rabe C, Mey U, Paashaus M, Musch A, Tasci S, Glasmacher A, Schmidt‐Wolf IGH, Sauer‐

bruch T, Dumoulin FL.

Outcome of patients with acute myeloid leukemia and pulmonary infiltrates requiring invasive

mechanical ventilation‐a retrospective analysis.

J Crit Care. 2004 Mar;19(1):29‐35.

54: Rockstroh J, Jann O, Wilke O, Noske R, Brodner D, Kalus S, Schneider U, Krocker C, Horn

W.

Investigations of emission behavelour for laser printers and copiers – Development of a test

method.

Materialprüfung. 2004, 46 (9), S. 465‐471.


[HIV‐infection: modern antiretroviral therapy].



HIV and hepatitis C virus co‐infection.

Lancet Infect Dis. 2004 Jul;4(7):437‐44.

57: Rockstroh JK, Vogel M.

Therapy of hepatitis C in HIV‐coinfection.

Eur J Med Res. 2004 Jun 30;9(6):304‐8.

58: Rockstroh JK, Mauss S.

Clinical perspective of fusion inhibitors for treatment of HIV.

J Antimicrob Chemother. 2004 May;53(5):700‐2.

59: Rockstroh JK.

[Interview with Professor Jürgen Rockstroh, director of the Bonn University Clinic. Atazanavir

in general practice].

MMW Fortschr Med. 2004 Apr 26;146 Spec No 1:18‐9.

60: Salzberger B, Marcus U, Vielhaber B, Arasteh K, Golz J, Brockmeyer NH, Rockstroh J.

German‐Austrian recommendations for the antiretroviral therapy of HIV‐infection (status May

2004).

Eur J Med Res. 2004 Nov 29;9(11):491‐504.

61: Sauerbruch T, Schepke M.

[Variceal hemorrhage: primary and secondary prophylaxis].

Dtsch Med Wochenschr. 2004 Sep 3;129 Suppl 2:S68‐70.

62: Schäfer PK, Sauerbruch T.

111

[Rudolf Schindler (1888‐‐1968)‐‐"father" of gastroscopy].


63: Schakowski F, Buttgereit P, Mazur M, Märten A, Schöttker B, Gorschlüter M, Schmidt‐

Wolf IGH.

Novel non‐viral method for transfection of primary leukemia cells and cell lines.

Genet Vaccines Ther. 2004 Jan 12;2(1):1.

64: Schepke M.

Can we predict hepatocellular carcinoma by endoscopy?

Digestion. 2004;70(4):231‐2.

65: Schepke M, Kleber G, Nurnberg D, Willert J, Koch L, Veltzke‐Schlieker W, Hellerbrand C,

Kuth J, Schanz S, Kahl S, Fleig WE, Sauerbruch T; German Study Group for the Primary Pro‐

phylaxis of Variceal Bleeding.

Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis.

Hepatology. 2004 Jul;40(1):65‐72.

66: Schildgen O, Schewe CK, Vogel M, Daumer M, Kaiser R, Weitner L, Matz B, Rockstroh JK.

Successful therapy of hepatitis B with tenofovir in HIV‐infected patients failing previous ade‐

fovir and lamivudine treatment.

AIDS. 2004 Nov 19;18(17):2325‐7.

67: Schlenk RF, Frohling S, Hartmann F, Fischer JT, Glasmacher A, del Valle F, Grimminger W,

Gotze K, Waterhouse C, Schoch R, Pralle H, Mergenthaler HG, Hensel M, Koller E, Kirchen H,

Preiss J, Salwender H, Biedermann HG, Kremers S, Griesinger F, Benner A, Addamo B,

Dohner K, Haas R, Dohner H; AML Study Group Ulm.

Phase III study of all‐trans retinoic acid in previously untreated patients 61 years or older with

acute myeloid leukemia.

Leukemia. 2004 Nov;18(11):1798‐803.

68: Schmiegel W, Pox C, Adler G, Fleig W, Folsch UR, Frühmorgen P, Graeven U, Hohenber‐

ger W, Holstege A, Junginger T, Kuhlbacher T, Porschen R, Propping P, Riemann JF, Sauer R,

Sauerbruch T, Schmoll HJ, Zeitz M, Selbmann HK; DGVS

[S3‐Guidelines Conference "Colorectal Carcinoma" 2004]


112

69: Schmitz V, Wang L, Barajas M, Gomar C, Prieto J, Qian C.

Treatment of colorectal and hepatocellular carcinomas by adenoviral mediated gene transfer

of endostatin and angiostatin‐like molecule in mice.

Gut. 2004 Apr;53(4):561‐7.

70: Schmitz V, Tirado‐Ledo L, Tiemann K, Raskopf E, Heinicke T, Ziske C, Gonzalez‐Carmona

MA, Rabe C, Wernert N, Prieto J, Qian C, Sauerbruch T, Caselmann WH.

Establishment of an orthotopic tumour model for hepatocellular carcinoma and non‐invasive

in vivo tumour imaging by high resolution ultrasound in mice.

J Hepatol. 2004 May;40(5):787‐91.

71: Schneider C, Schmidt T, Ziske C, Tiemann K, Lee KM, Uhlinsky V, Behrens P, Sauerbruch T,

Schmidt‐Wolf IGH, Mühlradt PF, Schmidt J, Märten A.

Tumour suppression induced by the macrophage activating lipopeptide MALP‐2 in an ultra‐

sound guided pancreatic carcinoma mouse model.

Gut. 2004 Mar;53(3):355‐61.

72: Sievers E, Albers P, Schmidt‐Wolf IGH, Märten A.

Telomerase pulsed dendritic cells for immunotherapy for renal cell carcinoma.

J Urol. 2004 Jan;171(1):114‐9.

73: Siewert E, Dietrich CG, Lammert F, Heinrich PC, Matern S, Gartung C, Geier A.

Interleukin‐6 regulates hepatic transporters during acute‐phase response.

Biochem Biophys Res Commun. 2004 Sep 10;322(1):232‐8.

74: Soriano V, Cacoub P, Cargnel A, Mauss S, Sulkowski M, Hatzakis A, Rockstroh J, Puoti M,

Dieterich D.

Reply to Bruno et al.: update to HIV‐hepatitis C virus consensus guidelines.

AIDS. 2004 Oct 21;18(15):2102‐2103.

75: Soriano V, Puoti M, Sulkowski M, Mauss S, Cacoub P, Cargnel A, Dieterich D, Hatzakis A,

Rockstroh J.

Care of patients with hepatitis C and HIV co‐infection.

AIDS. 2004 Jan 2;18(1):1‐12. Review.

76: Spengler U; Qurishi N; Rockstroh J; et al.

HIV/HCV coinfection, HAART, and liver‐related mortality ‐ Reply .

Lancet. 2004 364;( 9436):758

113

77: Terjung B, Bogsch F, Klein R, Sohne J, Reichel C, Wasmuth JC, Beuers U, Sauerbruch T,

Spengler U.

Diagnostic accuracy of atypical p‐ANCA in autoimmune hepatitis using ROC‐ and multivariate

regression analysis.

Eur J Med Res. 2004 Sep 29;9(9):439‐48.

78: Torriani FJ, Rodriguez‐Torres M, Rockstroh JK, Lissen E, Gonzalez‐Garcia J, Lazzarin A,

Carosi G, Sasadeusz J, Katlama C, Montaner J, Sette H Jr, Passe S, De Pamphilis J, Duff F,

Schrenk UM, Dieterich DT; APRICOT Study Group.

Peginterferon Alfa‐2a plus ribavirin for chronic hepatitis C virus infection in HIV‐infected pa‐

tients.

N Engl J Med. 2004 Jul 29;351(5):438‐50.

79: Vogel M, Voigt E, Michaelis HC, Sudhop T, Wolff M, Turler A, Sauerbruch T, Rockstroh JK,

Spengler U.

Management of drug‐to‐drug interactions between cyclosporine A and the protease‐inhibitor

lopinavir/ritonavir in liver‐transplanted HIV‐infected patients.

Liver Transpl. 2004 Jul;10(7):939‐44.

80: Voigt E, Wasmuth JC, Vogel M, Mauss S, Schmutz G, Kaiser R, Rockstroh JK.

Safety, efficacy and development of resistance under the new protease inhibitor lopi‐

navir/ritonavir: 48‐week results.

Infection. 2004 Apr;32(2):82‐8.

81: von Lilienfeld‐Toal M, Dietrich MP, Glasmacher A, Lehmann L, Breig P, Hahn C, Schmidt‐

Wolf IGH, Märklein G, Schroeder S, Stuber F.

Markers of bacteremia in febrile neutropenic patients with hematological malignancies: pro‐

calcitonin and IL‐6 are more reliable than C‐reactive protein.

Eur J Clin Microbiol Infect Dis. 2004 Jul;23(7):539‐44.

82: von Lilienfeld‐Toal M, Merkelbach‐Bruse S, Dumoulin FL.

An unusual presentation of a common disease.

Ann Rheum Dis. 2004 Jul;63(7):887‐8.

83: von Unruh GE, Voss S, Sauerbruch T, Hesse A.

Dependence of oxalate absorption on the daily calcium intake.

J Am Soc Nephrol. 2004 Jun;15(6):1567‐73.

114

84: Voss S, Zimmermann DJ, Hesse A, von Unruh GE.

The effect of oral administration of calcium and magnesium on intestinal oxalate absorption

in humans.

Isotopes Environ Health Stud. 2004 Sep; 40(3):199‐205.

85: Voss S, von Unruh GE.

Oxalatabsorption bei rezidivierender Kalziumoxalat‐Steinbildung.

URO‐NEWS. 2004, 6, 56‐59.

86: Wade JC, Glasmacher A.

Vancomycin does not benefit persistently febrile neutropenic people with cancer.

European View. Cancer Treat Rev. 2004 Feb;30(1):119‐26.

87: Wald O, Pappo O, Ari ZB, Azzaria E, Wiess ID, Gafnovitch I, Wald H, Spengler U, Galun E,

Peled A.

The CCR5Delta32 allele is associated with reduced liver inflammation in hepatitis C virus infec‐

tion.

Eur J Immunogenet. 2004 Dec;31(6):249‐52.

88: Wald O, Pappo O, Safadi R, Dagan‐Berger M, Beider K, Wald H, Franitza S, Weiss I, Avniel

S, Boaz P, Hanna J, Zamir G, Eid A, Mandelboim O, Spengler U, Galun E, Peled A

Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated

with hepatitis C virus or hepatitis B virus.

Eur J Immunol. 2004 Apr;34(4):1164‐74.

89: Wasmuth HE, Werth A, Mueller T, Berg T, Dietrich CG, Geier A, Gartung C, Lorenzen J,

Matern S, Lammert F.

Haplotype‐tagging RANTES gene variants influence response to antiviral therapy

in chronic hepatitis C.

Hepatology. 2004 Aug;40(2):327‐34. Erratum in: Hepatology. 2004 Oct;40(4):1028.

90: Wasmuth HE, Kunz D, Graf J, Stanzel S, Purucker EA, Koch A, Gartung C,

Heintz B, Gressner AM, Matern S, Lammert F.

Hyperglycemia at admission to the intensive care unit is associated with elevated serum con‐

centrations of interleukin‐6 and reduced ex vivo secretion of

tumor necrosis factor‐alpha.

Crit Care Med. 2004 May;32(5):1109‐14.

115

91: Wasmuth HE, Matern S, Lammert F.

From genotypes to haplotypes in hepatobiliary diseases: one plus one equals

(sometimes) more than two.

Hepatology. 2004 Mar;39(3):604‐7. Review.

92: Wasmuth HE, Stolte C, Geier A, Dietrich CG, Gartung C, Lorenzen J, Matern S, Lammert F.

The presence of non‐organ‐specific autoantibodies is associated with a negative response to

combination therapy with interferon and ribavirin for chronic hepatitis C.

BMC Infect Dis. 2004 Feb 13;4(1):4.

93: Wasmuth HE, Werth A, Mueller T, Berg T, Dietrich CG, Geier A, Schirin‐Sokhan R, Gartung

C, Lorenzen J, Matern S, Lammert F.

CC chemokine receptor 5 delta32 polymorphism in two independent cohorts of hepatitis C

virus infected patients without hemophilia.

J Mol Med. 2004 Jan;82(1):64‐9. Epub 2003 Dec 13.

94: Wasmuth JC, Grun B, Terjung B, Homrighausen A, Spengler U.

ROC analysis comparison of three assays for the detection of antibodies against double‐

stranded DNA in serum for the diagnosis of systemic lupus erythematosus.

Clin Chem. 2004 Nov;50(11):2169‐71.

95: Wasmuth JC, la Porte CJ, Schneider K, Burger DM, Rockstroh JK.

Comparison of two reduced‐dose regimens of indinavir (600 mg vs 400 mg twice daily) and

ritonavir (100 mg twice daily) in healthy volunteers (COREDIR).

Antivir Ther. 2004 Apr;9(2):213‐20.

96: Wasmuth JC, Nischalke HD, Jutte A, Fätkenheuer G, Salzberger B, Sauerbruch T,

Spengler U, Rockstroh JK, Dumoulin FL.

Chemokine mRNA levels in mononucleated cells of HIV‐infected patients before and after

initiation of PI‐ versus NNRTI‐containing HAART.

Antiviral Res. 2004 Mar;61(3):207‐12.

97: Winkler P, Ellinger S, Boetzer AM, Arendt BM, Berthold HK, Rockstroh JK, Spengler U,

Goerlich R.

Lymphocyte proliferation and apoptosis in HIV‐seropositive and healthy subjects during long‐

term ingestion of fruit juices or a fruit‐vegetable‐concentrate rich in polyphenols and antioxi‐

dant vitamins.

Eur J Clin Nutr. 2004 Feb;58(2):317‐25.

116

98: Wyen C, Hoffmann C, Schmeier N, Wohrmann A, Qurishi N, Rockstroh J, Esser S, Rieke A,

Ross B, Lorenzen T, Schmitz K, Stenzel W, Salzberger B, Fätkenheuer G.

Progressive Multifocal Leukencephalopathy in Patients on highly Active Antiretroviral Ther‐

apy: Survival and Risk Factors of Death.

J Acquir Immune Defic Syndr. 2004 Oct 1;37(2):1263‐1268.

99: Ziske C, Nagaraj S, Märten A, Gorschlüter M, Strehl J, Sauerbruch T, Abraham NG,

Schmidt‐Wolf IGH.

Retroviral IFN‐alpha gene transfer combined with gemcitabine acts synergistically via cell cy‐

cle alteration in human pancreatic carcinoma cells implanted orthotopically in nude mice.

J Interferon Cytokine Res. 2004 Aug;24(8):490‐6.

117

2005

1: Ahlenstiel G, Iwan A, Nattermann J, Bueren K, Rockstroh JK, Brackmann HH, Kupfer B,

Landt O, Peled A, Sauerbruch T, Spengler U, Woitas RP.

Distribution and effects of polymorphic RANTES gene alleles in HIV/HCV coinfection – A pro‐

spective cross‐sectional study.

World J Gastroenterol. 2005 Dec 28;11(48):7631‐7638.

2: Allen TM, Altfeld M, Geer SC, Kalife ET, Moore C, O'sullivan KM, Desouza I, Feeney ME,

Eldridge RL, Maier EL, Kaufmann DE, Lahaie MP, Reyor L, Tanzi G, Johnston MN, Brander C,

Draenert R, Rockstroh JK, Jessen H, Rosenberg ES, Mallal SA, Walker BD.

Selective escape from CD8+ T‐cell responses represents a major driving force of human im‐

munodeficiency virus type 1 (HIV‐1) sequence diversity and reveals constraints on HIV‐1 evolu‐

tion.

J Virol. 2005 Nov;79(21):13239‐49.

3: Arendt BM, Ellinger S, Kekic K, Geus L, Fimmers R, Spengler U, Müller WU, Goerlich R.

Single and repeated moderate consumption of native or dealcoholized red wine show differ‐

ent effects on antioxidant parameters in blood and DNA strand breaks in peripheral leuko‐

cytes in healthy volunteers: a randomized controlled trial (ISRCTN68505294).

Nutr J. 2005 Nov 14;4:33.

4: Aretz S, Stienen D, Uhlhaas S, Pagenstecher C, Mangold E, Caspari R, Propping P, Friedl W.

Large submicroscopic genomic APC deletions are a common cause of typical familial

adenomatous polyposis.

J Med Genet. 2005 Feb;42(2):185‐92.

5: Balduin M, Sierra S, Daumer MP, Rockstroh JK, Oette M, Fätkenheuer G, Kupfer B, Beer‐

enwinkel N, Hoffmann D, Selbig J, Pfister HJ, Kaiser R.

Evolution of HIV resistance during treatment interruption in experienced patients and after

restarting a new therapy.

J Clin Virol. 2005 Dec;34(4):277‐87.

6: Balta Z, Nattermann J, Flacke S, Sauerbruch T.

[Budd‐Chiari syndrome in a patient with paroxysmal nocturnal haemoglobinuria].

Dtsch Med Wochenschr. 2005 Oct 7;130(40):2257‐60.

118

7: Becker MR, Schneider B, Reber U, Pöge U, Klein B, Klehr HU, Zhou H, Fischer HP, Eis‐

Hubinger AM.

Renal anemia aggravated by long‐term parvovirus b19 and cytomegalovirus infection in a re‐

nal transplant patient: case report and evaluation of b19 seroprevalence in dialysis patients.


8: Beerenwinkel N, Sing T, Lengauer T, Rahnenfuhrer J, Roomp K, Savenkov I, Fischer R,

Hoffmann D, Selbig J, Korn K, Walter H, Berg T, Braun P, Fätkenheuer G, Oette M, Rockstroh

J, Kupfer B, Kaiser R, Daumer M.

Computational methods for the design of effective therapies against drug resistant HIV

strains.

Bioinformatics. 2005 Nov 1;21(21):3943‐50.

9: Biecker E, Schepke M, Sauerbruch T.

The role of endoscopy in portal hypertension.

Dig Dis. 2005;23(1):11‐7.

10: Biecker E, De Gottardi A, Neef M, Unternahrer M, Schneider V, Ledermann M, Sagesser H,

Shaw S, Reichen J.

Long‐term treatment of bile duct‐ligated rats with rapamycin (sirolismus) significantly at‐

tenuates liver fibrosis: analysis of the underlying mechanisms.

J Pharmacol Exp Ther. 2005; 313 (3): 952‐61.

11: Biecker E, Heller J, Appenrodt B, Schepke M, Sauerbruch T.

[Gastrointestinal bleeding in portal hypertension in liver cirrhosis].


12: Bonn O, Schmidt‐Wolf G, Risse F, Glasmacher A, Kleinschmidt R, Schmidt‐Wolf IGH.

Vindesine and etoposide: A practical and well‐tolerated therapy for elderly patients or pa‐

tients in reduced clinical condition with extensive‐stage small‐cell lung cancer (SCLC).

Med Sci Monit. 2005 Feb;11(2):PI19‐21.

13: Brouwers J, Tack J, Lammert F, Augustijns P.

Intraluminal drug and formulation behavior and integration in in vitro permeability estima‐

tion: A case study with amprenavir.

J Pharm Sci 2005; 95 (2): 372‐383

14: Buck C, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, Paar WD.

Pharmacokinetics of piperacillin‐tazobactam: intermittent dosing versus continuous infusion.

Int J Antimicrob Agents. 2005 Jan;25(1):62‐7.

15: Domingues GR, Winograd R, Lemme EM, Lammert F, Silny J, Matern S, Nguyen HN.

119

Characteristics of oesophageal bolus transport in patients with mild oesophagitis.

Eur J Gastroenterol Hepatol. 2005 Mar;17(3):323‐32.

16: Erhardt M, Gorschlüter M, Sager J, Ziske C, Strehl J, Lilienfeld‐Toal MV, Schmidt‐Wolf

IGH.

Transfection of human monocyte‐derived dendritic cells with CpG oligonucleotides.

Immunol Cell Biol. 2005 Jun;83(3):278‐85.

17: Fätkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AI,

Saag MS, Goebel FD, Rockstroh JK, Dezube BJ, Jenkins TM, Medhurst C, Sullivan JF, Ridgway

C, Abel S, James IT, Youle M, van der Ryst E.

Efficacy of short‐term monotherapy with maraviroc, a new CCR5 antagonist, in patients in‐

fected with HIV‐1.

Nat Med. 2005 Nov;11(11):1170‐2.

18: Fliessbach K, Helmstaedter C, Urbach H, Althaus A, Pels H, Linnebank M, Juergens A, Glas‐

macher A, Schmidt‐Wolf IGH, Klockgether T, Schlegel U.

Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective

study.

Neurology. 2005 Apr 12;64(7):1184‐8.

19: Geier A, Dietrich CG, Voigt S, Ananthanarayanan M, Lammert F, Schmitz A, Trauner M,

Wasmuth HE, Boraschi D, Balasubramaniyan N, Suchy FJ, Matern S, Gartung C.

Cytokine‐dependent regulation of hepatic organic anion transporter gene transactivators in

mouse liver.

Am J Physiol Gastrointest Liver Physiol. 2005 Nov;289(5):G831‐41.

20: Geier A, Gartung C, Theurl I, Weiss G, Lammert F, Dietrich CG, Weiskirchen R, Zoller H,

Hermanns B, Matern S.

Occult celiac disease prevents penetrance of hemochromatosis.

World J Gastroenterol. 2005 Jun 7;11(21):3323‐6.

21: Gerhardt T, Wolff M, Fischer HP, Sauerbruch T, Reichel C.

Pitfalls in the diagnosis of intestinal tuberculosis: a case report.

Scand J Gastroenterol. 2005 Feb;40(2):240‐3.

22: Girardi E, Sabin CA, d'Arminio Monforte A, Hogg B, Phillips AN, Gill MJ, Dabis F, Reiss P,

Kirk O, Bernasconi E, Grabar S, Justice A, Staszewski S, Fätkenheuer G, Sterne JA; Antiretro‐

viral Therapy Cohort Collaboration.

Incidence of Tuberculosis among HIV‐infected patients receiving highly active antiretroviral

therapy in Europe and North America.

Clin Infect Dis. 2005 Dec 15;41(12):1772‐82.

120

23: Glantz A, Marschall HU, Lammert F, Mattsson LA.

Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexa‐

methasone and ursodeoxycholic acid.

Hepatology. 2005 Dec;42(6):1399‐405.

24: Glasmacher A, Hahn C, Fleischhack G, Marklein G, Walger P.

Penicillin‐basierte Strategien der Antibiotika‐Therapie: Wirksamkeit und Resistenzenent‐

wicklung.

Chemotherapie‐Journal 2005; 14, S. 198‐206.

25: Glasmacher A, von Lilienfeld‐Toal M, Schulte S, Hahn C, Schmidt‐Wolf IGH, Prentice A.

An evidence‐based evaluation of important aspects of empirical antibiotic therapy in febrile

neutropenic patients.

Clin Microbiol Infect. 2005 Oct;11 Suppl 5:17‐23.

26: Glasmacher A, Prentice A.

Evidence‐based review of antifungal prophylaxis in neutropenic patients with haematological

malignancies.

J Antimicrob Chemother. 2005 Sep;56 Suppl 1:i23‐i32.

27: Glasmacher A, Prentice A, Gorschlüter M, Engelhart S, Hahn C, Djulbegovic, B, Schmidt‐

Wolf I.

Misleading statements in a meta‐analysis – Reply.

Journal of Clinical Oncology 2005, 36: 9429‐32.

28: Glasmacher A, von Lilienfeld‐Toal M.

The current status of thalidomide in the management of multiple myeloma.

Acta Haematol. 2005;114 Suppl 1:3‐7.

29: Gorschlüter M, Mey U, Glasmacher A, Schwerdtfeger R, Schmidt‐Wolf IGH.

Acute myeloid leukemia with near‐triploid karyotype and extramedullary involvement of me‐

diastinum.

Bone Marrow Transplant. 2005 Dec;36(12):1107.

121

30: Gorschlüter M, Mey U, Strehl J, Ziske C, Schepke M, Schmidt‐Wolf IGH, Sauerbruch T,

Glasmacher A.

Neutropenic enterocolitis in adults: systematic analysis of evidence quality.

Eur J Haematol. 2005 Jul;75(1):1‐13.

31: Gressner O, Wasmuth HE, Lammert F.

Gentests zur Einschätzung des Fibroserisikos bei chronischer Hepatitis C – Faktum oder Visi‐

on?

Med Welt 2005; 56 (11): 490‐494.

32: Grünhage F, Sauerbruch T, Spengler U.

[Tuberculosis‐‐current therapeutic concepts].


33: Heinicke T, Wardelmann E, Sauerbruch T, Tschampa HJ, Glasmacher A, Palmedo H.

Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tu‐

mours using 18fluoro‐deoxyglucose‐positron emission tomography.

Anticancer Res. 2005 Nov‐Dec;25(6C):4591‐4.

34: Heller J, Trebicka J, Shiozawa T, Schepke M, Neef M, Hennenberg M, Sauerbruch T.

Vascular, hemodynamic and renal effects of low‐dose losartan in rats with secondary biliary

cirrhosis.

Liver Int. 2005 Jun;25(3):657‐66.

35: Hillebrandt S, Wasmuth HE, Weiskirchen R, Hellerbrand C, Keppeler H, Werth A, Schirin‐

Sokhan R, Wilkens G, Geier A, Lorenzen J, Kohl J, Gressner AM, Matern S, Lammert F.

Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and

humans.

Nat Genet. 2005 Aug;37(8):835‐43.

36: Hoppe B, von Unruh G, Laube N, Hesse A, Sidhu H.

Oxalate degrading bacteria: new treatment option for patients with primary and secondary

hyperoxaluria?

Urol Res. 2005 Nov;33(5):372‐375.

37: Hoppe B, von Unruh GE, Blank G, Rietschel E, Sidhu H, Laube N, Hesse A.

Absorptive hyperoxaluria leads to an increased risk for urolithiasis or nephrocalcinosis in cys‐

tic fibrosis.

Am J Kidney Dis. 2005 Sep;46(3):440‐5.

38: Hornberger J, Green J, Wintfeld N, Cavassini M, Rockstroh J, Giuliani G, De Carli C, Lazza‐

rin A.

122

Cost‐effectiveness of enfuvirtide for treatment‐experienced patients with HIV in Italy.

HIV Clin Trials. 2005 Mar‐Apr;6(2):92‐102.

39: Ingiliz P, Rockstroh JK.

[HIV and hepatitis coinfection].

Dtsch Med Wochenschr. 2005 Dec 16;130 Suppl 5:S216‐8.

40: Katsika D, Grjibovski A, Einarsson C, Lammert F, Lichtenstein P, Marschall HU.

Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of

43141 twin pairs.

Hepatology 2005; 41 (5):1138‐1143.

41: Kuntzen T, Friedrichs N, Fischer HP, Eis‐Hubinger AM, Sauerbruch T, Spengler U.

Postinfantile giant cell hepatitis with autoimmune features following a human herpesvirus 6‐

induced adverse drug reaction.


42: Kupfer B, Ruf T, Matz B, Nattermann J, Spengler U, Rockstroh JK, Brackmann HH, Blumel

J, Tacke M, Kaiser R.

Comparison of GB virus C, HIV, and HCV infection markers in hemophiliacs exposed to non‐

inactivated or inactivated factor concentrates.

J Clin Virol. 2005 Sep;34(1):42‐7.

43: Lamberti C, Sauerbruch T, Glasmacher A.

Adjuvant capecitabine is at least as effective as fluorouracil plus leucovorin for survival in

people with resected stage III colon cancer.

Cancer Treat Rev. 2005 Dec;31(8):648‐52.

44: Lamberti C, Sauerbruch T.

[Early diagnosis of colorectal tumors].


45: Lamberti C, Di Blasi K, Archut D, Fimmers R, Mathiak M, Bollmann M, Vogel J, Kinder‐

mann D, Mezger J, Schmidt‐Wolf IGH, Sauerbruch T.

Population‐based registration of unselected colorectal cancer patients: five‐year survival in

the region of Bonn/Rhine‐Sieg, y.


46: Lamberti C, Schweiger N, Hartschuh W, Schulz T, Becker‐Wegerich P, Kuster W, Rutten

A, Sauerbruch T, Ruzicka T, Kruse R.

Birt‐Hogg‐Dube syndrome: germline mutation in the (C)8 mononucleotide tract of the BHD

gene in a patient.

123

Acta Derm Venereol. 2005;85(2):172‐3.

47: Lammert F.

The current study documents the higher risk of gall stones as a result of hormone substitu‐

tion.

Deutsche Medizinische Wochenschrift 2005;130(14): 865.

48: Lammert F, Sauerbruch T.

Mechanisms of disease: the genetic epidemiology of gallbladder stones.

Nat Clin Pract Gastroenterol Hepatol. 2005 Sep;2(9):423‐33.

49: Lammert F, Wang DQ.

New insights into the genetic regulation of intestinal cholesterol absorption.


50: Lammert F, Matern S.

The genetic background of cholesterol gallstone formation: an inventory of human

lithogenic genes.

Curr Drug Targets Immune Endocr Metabol Disord. 2005 Jun;5(2):163‐70.

51: Lammert F, Wilkens G, Dietrich CG, Geier A, Wasmuth HE, Matern S.

Extrahepatische Manifestationen chronischer Lebererkrankungen

Versicherungsmedizin. 2005 Jun 1;57(2):64‐71.

52: Langhans B, Ahrendt M, Nattermann J, Sauerbruch T, Spengler U.

Comparative study of NK cell‐mediated cytotoxicity using radioactive and flow cytometric

cytotoxicity assays.

J Immunol Methods. 2005 Nov 30;306(1‐2):161‐8.

53: Langhans B, Schweitzer S, Braunschweiger I, Schulz M, Sauerbruch T, Spengler U.

Cytotoxic capacity of hepatitis C virus (HCV)‐‐specific lymphocytes after in vitro immunization

with HCV‐derived lipopeptides.

Cytometry A. 2005 May;65(1):59‐68.

54: Lewandowski S, Rodgers AL, Laube N, von Unruh G, Zimmermann D, Hesse A.

Oxalate and its handling in a low stone risk vs a stone‐prone population group.

World J Urol. 2005 Nov;23(5):330‐3.

55: Lichterfeld M, Qurishi N, Hoffmann C, Hochdorfer B, Brockmeyer NH, Arasteh K, Mauss

S, Rockstroh JK; Clinical AIDS Working Group (KAAD).

Treatment of HIV‐1‐associated Kaposi's sarcoma with pegylated liposomal doxorubicin and

HAART simultaneously induces effective tumor remission and CD4+ T cell recovery.

Infection. 2005 Jun;33(3):140‐7.

124

56: Lichterfeld M, Haas S, Fischer HP, Voigt E, Rockstroh JK, Spengler U.

Liver histopathology in human immunodeficiency virus‐hepatitis C virus co‐infected patients

with fatal liver disease.

J Gastroenterol Hepatol. 2005 May;20(5):739‐45.

57: Lichterfeld M, Schmeisser N, Qurishi N, Vogel M, Brackmann HH, Spengler U, Rockstroh

JK.

Clinical outcomes of HIV‐HCV co‐infection in a large cohort of haemophiliac patients.

J Infect. 2005 Apr;50(3):221‐8.

58: Linnebank M, Pels H, Kleczar N, Farmand S, Fliessbach K, Urbach H, Orlopp K, Klock‐

gether T, Schmidt‐Wolf IGH, Schlegel U.

MTX‐induced white matter changes are associated with polymorphisms of methionine me‐

tabolism.

Neurology. 2005 Mar 8;64(5):912‐3.

59: Maertens J, Glasmacher A, Selleslag D, Ngai A, Ryan D, Layton M, Taylor A, Sable C, Kart‐

sonis N.

Evaluation of serum sandwich enzyme‐linked immunosorbent assay for circulating galacto‐

mannan during caspofungin therapy: results from the caspofungin invasive aspergillosis

study.

Clin Infect Dis. 2005 Jul 1;41(1):e9‐14.

60: Maschmeyer G, Glasmacher A.

Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal,

caspofungin.

Mycoses. 2005 Jul;48(4):227‐34.

61: Mauss S, Rockstroh JK.

HCV/HIV‐coinfection‐‐is there a state of the art after APRICOT and RIBAVIC?

J Antimicrob Chemother. 2005 Oct;56(4):615‐8.

125

62: Mehrle S, Frank S, Schmidt J, Schmidt‐Wolf IGH, Märten A.

SAP and SLAM expression in anti‐CD3 activated lymphocytes correlates with cytotoxic activ‐

ity.

Immunol Cell Biol. 2005 Feb;83(1):33‐9.

63: Meissner A, Lammert F, von Unruh G.

Kalziumoxalat‐Urolithiasis bei Patienten mit Morbus Crohn.

Uro‐News. 2005: 69‐70.

64: Möbius U, Lubach‐Ruitman M, Castro‐Frenzel B, Stoll M, Esser S, Voigt E, Christensen S,

Rump JA, Fätkenheuer G, Behrens GM, Schmidt RE.

Switching to atazanavir improves metabolic disorders in antiretroviral‐experienced patients

with severe hyperlipidemia.

J Acquir Immune Defic Syndr. 2005 Jun 1;39(2):174‐80.

65: Mocroft A, Soriano V, Rockstroh J, Reiss P, Kirk O, de Wit S, Gatell J, Clotet B, Phillips AN,

Lundgren JD; EuroSIDA Study Group.

Is there evidence for an increase in the death rate from liver‐related disease in patients with

HIV?

AIDS. 2005 Dec 2;19(18):2117‐25.

66: Mocroft A, Phillips AN, Soriano V, Rockstroh J, Blaxhult A, Katlama C, Boron‐Kaczmarska

A, Viksna L, Kirk O, Lundgren JD; EuroSIDA Study Group.

Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: in‐

creased incidence of stopping due to toxicity or patient/physician choice in patients with

hepatitis C coinfection.

AIDS Res Hum Retroviruses. 2005 Sep;21(9):743‐52.

67: Mocroft A, Phillips AN, Soriano V, Rockstroh J, Blaxhult A, Katlama C, Boron‐Kaczmarska

A, Viksna L, Kirk O, Lundgren JD; The EuroSIDA Study Group.

Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: in‐

creased incidence of stopping due to toxicity or patient/physician choice in patients with

hepatitis C coinfection.

AIDS Res Hum Retroviruses. 2005 Jun;21(6):527‐36.

68: Mocroft A, Rockstroh J, Soriano V, Ledergerber B, Kirk O, Vinogradova E, Reiss P, Kat‐

lama C, Phillips AN, Lundgren JD; EuroSIDA Study Group.

Are specific antiretrovirals associated with an increased risk of discontinuation due to toxici‐

ties or patient/physician choice in patients with hepatitis C virus coinfection?

Antivir Ther. 2005;10(7):779‐90.

126

69: Musch A, Rabe C, Paik MD, Berna MJ, Schmitz V, Hoffmann P, Nischalke HD, Sauerbruch

T, Caselmann WH.

Altered expression of TGF‐beta receptors in hepatocellular carcinoma—effects of a constitu‐

tively active TGF‐beta type I receptor mutant.

Digestion. 2005;71(2):78‐91.

70: Nattermann J, Schneiders AM, Leifeld L, Langhans B, Schulz M, Inchauspe G, Matz B,

Brackmann HH, Houghton M, Sauerbruch T, Spengler U.

Serum antibodies against the hepatitis C virus E2 protein mediate antibody‐dependent cellu‐

lar cytotoxicity (ADCC).

J Hepatol. 2005 Apr;42(4):499‐504.

71: Nattermann J, Nischalke HD, Hofmeister V, Ahlenstiel G, Zimmermann H, Leifeld L, Weiss

EH, Sauerbruch T, Spengler U.

The HLA‐A2 restricted T cell epitope HCV core 35‐44 stabilizes HLA‐E expression and inhibits

cytolysis mediated by natural killer cells.

Am J Pathol. 2005 Feb;166(2):443‐53.

72: Nattermann J, Nischalke HD, Hofmeister V, Kupfer B, Ahlenstiel G, Feldmann G, Rock‐

stroh J, Weiss EH, Sauerbruch T, Spengler U.

HIV‐1 infection leads to increased HLA‐E expression resulting in impaired function of natural

killer cells.

Antivir Ther. 2005;10(1):95‐107.

73: Nitz UA, Mohrmann S, Fischer J, Lindemann W, Berdel WE, Jackisch C, Werner C, Ziske C,

Kirchner H, Metzner B, Souchon R, Ruffert U, Schutt G, Pollmanns A, Schmoll HJ, Middecke

C, Baltzer J, Schrader I, Wiebringhaus H, Ko Y, Rosel S, Schwenzer T, Wernet P, Hinke A,

Bender HG, Frick M; West Study Group.

Comparison of rapidly cycled tandem high‐dose chemotherapy plus peripheral‐blood stem‐

cell support versus dose‐dense conventional chemotherapy for adjuvant treatment of high‐

risk breast cancer: results of a multicentre phase III trial.

Lancet. 2005 Dec 3;366(9501):1935‐44.

74: Orlopp K, Schmidt‐Wolf IGH, Urbach H, Schlegel U.

[Acute central nervous symptoms in oncologic patients].


75: Pels H, Montesinos‐Rongen M, Schaller C, Schlegel U, Schmidt‐Wolf IGH, Wiestler OD,

Deckert M.

VH gene analysis of primary CNS lymphomas.

J Neurol Sci. 2005 Feb 15;228(2):143‐7.

76: Pöge U, Gerhardt TM, Stoffel‐Wagner B, Palmedo H, Klehr HU, Sauerbruch T,

127

Woitas RP.

Beta‐Trace protein is an alternative marker for glomerular filtration rate in renal transplanta‐

tion patients.

Clin Chem. 2005 Aug;51(8):1531‐3.

77: Pöge U, Gerhardt T, Palmedo H, Klehr HU, Sauerbruch T, Woitas RP.

MDRD equations for estimation of GFR in renal transplant recipients.

Am J Transplant. 2005 Jun;5(6):1306‐11.

78: Pöge U, Gerhardt TM, Woitas RP.

N‐terminal pro‐B‐type natriuretic peptide and mortality in coronary heart disease.

N Engl J Med. 2005 May 12;352(19):2025‐6; author reply 2025‐6.

79: Prentice AG, Glasmacher A.

Making sense of itraconazole pharmacokinetics.

J Antimicrob Chemother. 2005 Sep;56 Suppl 1:i17‐i22.

80: Rabe C, Paar WD, Knopp A, Munch J, Musch A, Rockstroh J, Martin S, Sauerbruch T,

Dumoulin FL.

[Malaria in the emergency room. Results of the emergency treatment of 137 patients with

symptomatic malaria].


81: Rabe C, Musch A, Schirmacher P, Kruis W, Hoffmann R.

Acute hepatitis induced by an Aloe vera preparation: a case report.

World J Gastroenterol. 2005 Jan 14;11(2):303‐4.

82: Raskopf E, Dzienisowicz C, Hilbert T, Rabe C, Leifeld L, Wernert N, Sauerbruch T, Prieto J,

Qian C, Caselmann WH, Schmitz V.

Effective angiostatic treatment in a murine metastatic and orthotopic hepatoma model.

Hepatology. 2005 Jun;41(6):1233‐40.

83: Reinhardt MJ, Strunk H, Gerhardt T, Roedel R, Jaeger U, Bucerius J, Sauerbruch T, Bier‐

sack HJ, Dumoulin FL.

Detection of Klatskin's tumor in extrahepatic bile duct strictures using delayed 18F‐FDG

PET/CT: preliminary results for 22 patient studies.

J Nucl Med. 2005 Jul;46(7):1158‐63.

128

84: Rockstroh JK.

Should HIV/HCV coinfected patients with severe hepatitis be treated for hepatitis C.

Presse Med. 2005 Nov 19;34(20 Pt 2):1585‐8.

85: Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, Kirk O, Phillips A, Led‐

ergerber B, Lundgren J; EuroSIDA Study Group.

Influence of hepatitis C virus infection on HIV‐1 disease progression and response to highly

active antiretroviral therapy.

J Infect Dis. 2005 Sep 15;192(6):992‐1002.

86: Salzer U, Chapel HM, Webster AD, Pan‐Hammarstrom Q, Schmitt‐Graeff A, Schlesier M,

Peter HH, Rockstroh JK, Schneider P, Schaffer AA, Hammarstrom L, Grimbacher B.

Mutations in TNFRSF13B encoding TACI are associated with common variable immunodefi‐

ciency in humans.

Nat Genet. 2005 Aug;37(8):820‐8.

87: Sauerbruch T, Heller J.

[Portal hypertension and gastrointestinal bleeding].

Dtsch Med Wochenschr. 2005 Dec 16;130 Suppl 5:S239‐40.


Is endoscopic variceal band ligation more effective than propranolol for the prevention of

esophageal hemorrhage?

Nat Clin Pract Gastroenterol Hepatol. 2005 Sep;2(9):396‐7.

89: Schlenk RF, Germing U, Hartmann F, Glasmacher A, Fischer JT, del Valle y Fuentes F, Got‐

ze K, Pralle H, Nerl C, Salwender H, Grimminger W, Petzer A, Hensel M, Benner A, Zick L,

Dohner K, Frohling S, Dohner H; AML Study Group (AMLSG).

High‐dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leu‐

kemia.

Leukemia. 2005 Jun;19(6):978‐83.

129

90: Schmiegel W, Pox C, Adler G, Fleig W, Folsch UR, Fruhmorgen P, Graeven U, Hohenber‐

ger W, Holstege A, Kuhlbacher T, Porschen R, Propping P, Riemann JF, Sauer R, Sauerbruch

T, Schmoll HJ, Zeitz M, Selbmann HK; Deutschen Gesellschaft für Verdauungs‐ und Stoff‐

wechselkrankheiten; Deutschen Krebshilfe; Deutschen Krebsgesellschaft; Deutschen Gesell‐

schaft fur Hämatologie und Onkologie; Deutschen Gesellschaft für Innere Medizin; Deut‐

schen Gesellschaft für Koloproctologie; Deutschen Gesellschaft für Pathologie; Deutschen

Gesellschaft für Radioonkologie; Deutschen Gesellschaft fur Viszeralchirurgie; Deutschen

Röntgengesellschaft; Deutschen vereinten Gesellschaft für klinische Chemie und Laborato‐

riumsmedizin e.V.

[S3‐guideline conference "Colorectal Cancer" 2004].

Dtsch Med Wochenschr. 2005 Apr 8;130 Suppl 1:S5‐53.

91: Schmitz V, Tirado‐Ledo L, Raskopf E, Rabe C, Wernert N, Wang L, Prieto J, Qian C, Sauer‐

bruch T, Caselmann WH.

Effective antitumour mono‐ and combination therapy by gene delivery of angiostatin‐like

molecule and interleukin‐12 in a murine hepatoma model.

Int J Colorectal Dis. 2005 Nov;20(6):494‐501.

92: Schmitz V, Kornek M, Hilbert T, Dzienisowicz C, Raskopf E, Rabe C, Sauerbruch T, Qian C,

Caselmann WH.

Treatment of metastatic colorectal carcinomas by systemic inhibition of vascular endothelial

growth factor signaling in mice.

World J Gastroenterol. 2005 Jul 28;11(28):4332‐6.

93: Schulmann K, Brasch FE, Kunstmann E, Engel C, Pagenstecher C, Vogelsang H, Krüger S,

Vogel T, Knaebel HP, Rüschoff J, Hahn SA, Knebel‐Doeberitz MV, Moeslein G, Meltzer SJ,

Schackert HK, Tympner C, Mangold E, Schmiegel W; HNPCC Consortium.

HNPCC‐associated small bowel cancer: clinical and molecular characteristics.


94: Schulte S, Wilhelm K, Glasmacher A.

Behandlung der tumorinduzierten Hyperkalzämie im Nierenversagen – ein Fallbeispiel.

Geburtshilfe und Frauenheilkunde 2005; 65: 694‐97.

95: Sheldon JA, Corral A, Rodes B, Mauss S, Rockstroh J, Berger F, Schwarze‐Zander C, Sori‐

ano V.

Risk of selecting K65R in antiretroviral‐naive HIV‐infected individuals with chronic hepatitis B

treated with adefovir.

AIDS. 2005 Nov 18;19(17):2036‐8.

130

96: Siener R, Schade N, Nicolay C, von Unruh GE, Hesse A.

The efficacy of dietary intervention on urinary risk factors for stone formation in recurrent

calcium oxalate stone patients.

J Urol. 2005 May;173(5):1601‐5.

97: Sing T, Svicher V, Beerenwinkel N, Ceccherini‐Silberstein F, Däumer M, Kaiser R, Walter

H, Korn K, Hoffmann D, Oette M, Rockstroh JK, Fätkenheuer G, Perno CF, Lengauer T

Characterization of Novel HIV Drug Resistance Mutations Using Clustering, Multidimensional

Scaling and SVM‐Based Feature Ranking.

Knowledge Discovery in Databases: PKDD 2005

Lecture Notes in Computer Science, 2005, Volume 3721/2005, 285‐296.

98: Soriano V, Puoti M, Bonacini M, Brook G, Cargnel A, Rockstroh J, Thio C, Benhamou Y.

Care of patients with chronic hepatitis B and HIV co‐infection: recommendations from an HIV‐

HBV International Panel.

AIDS. 2005 Feb 18;19(3):221‐40. No abstract available. Erratum in: AIDS. 2005 Mar 24;19(6):3 p

following 640.

99: Tasci S, Burghard A, Schäfer H, Rabe C, Ewig S, Lüderitz B.

[Long‐term outcome of intrapleural fibrinolytic therapy via small‐bore catheter drainage in

the management of complicated parapneumonic effusion and empyema‐a case series].

Med Klin (Munich). 2005 Apr 15;100(4):181‐5.

100 Terjung B, Spengler U.

Role of auto‐antibodies for the diagnosis of chronic cholestatic liver diseases.

Clin Rev Allergy Immunol. 2005 Apr;28(2):115‐33.

101: Vogel M, Voigt E, Schäfer N, Goldmann G, Schwarz N, Kalff JC, Sauerbruch T, Wolff M,

Rockstroh JK, Spengler U.

Orthotopic liver transplantation in human immunodeficiency virus (HIV)‐positive patients:

outcome of 7 patients from the Bonn cohort.

Liver Transpl. 2005 Dec;11(12):1515‐21.

102: Vogel M, Rockstroh JK.

Safety of lopinavir/ritonavir for the treatment of HIV‐infection.

Expert Opin Drug Saf. 2005 May;4(3):403‐20.


[Therapy of hepatitis B and hepatitis C coinfection in HIV patients].

MMW Fortschr Med. 2005 Apr 25;147 Spec No 1:56‐9.

131

104: Vogel M, Bieniek B, Jessen H, Schewe CK, Hoffmann C, Baumgarten A, Kroidl A, Bogner

JR, Spengler U, Rockstroh JK.

Treatment of acute hepatitis C infection in HIV‐infected patients: a retrospective analysis of

eleven cases.

J Viral Hepat. 2005 Mar;12(2):207‐11.

105: von Lilienfeld‐Toal M, Sievers E, Bodemuller V, Mihailescu C, Märten A, Gorschlüter M,

Schmidt‐Wolf IGH.

Coculture with dendritic cells promotes proliferation but not cytotoxic activity of gam‐

ma/delta T cells.

Immunol Lett. 2005 Jun 15;99(1):103‐8.

106: von Lilienfeld‐Toal M, Glasmacher A.

Risk assessment of patients with hematologic malignancies who develop fever accompanied

by pulmonary infiltrates: a historical cohort study.

Cancer. 2005 Feb 15;103(4):874; discussion 875.

107: von Unruh GE, Ernst FB, Schmidt ME, Steiner G, Hesse A, Muller SC.

Intestinal oxalate absorption in patients with continent urinary diversion.

World J Urol. 2005 Nov;23(5):334‐7.

108: Voss S, Hesse A, von Unruh GE

La absorcion intestinal de oxalato en pacientes con litiasis oxalocalcica.

Rev Urol. 2005; 6 (3): 79‐85.

109: Wang HH, Lammert F, Wang DQ.

Ezetimibe and its inhibitory effects on intestinal cholesterol absorption.

Vasc Dis Prevention 2005; 2 (2): 165‐175.

110: Wang H, Mengsteab S, Tag CG, Gao CF, Hellerbrand C, Lammert F, Gressner AM, Weis‐

kirchen R.

Transforming growth factor‐beta1 gene polymorphisms are associated with progression of

liver fibrosis in Caucasians with chronic hepatitis C infection.

World J Gastroenterol. 2005 Apr 7;11(13):1929‐36.

111: Wasmuth HE, Kunz D, Yagmur E, Timmer‐Stranghoner A, Vidacek D, Siewert E, Bach J,

Geier A, Purucker EA, Gressner AM, Matern S, Lammert F.

Patients with acute on chronic liver failure display "sepsis‐like" immune paralysis.

J Hepatol. 2005 Feb;42(2):195‐201.

132

112: Wasmuth JC, Rockstroh JK.

Spleen infarction in a patient with HIV infection.

Med Klin (Munich). 2005 Oct 15;100(10):683‐5.

113: Wiegand J, Schuler A, Kanzler S, Lohse A, Beuers U, Kreisel W, Spengler U, Koletzko S,

Jansen PL, Hochhaus G, Mollmann HW, Prols M, Manns MP.

Budesonide in previously untreated autoimmune hepatitis.

Liver Int. 2005 Oct;25(5):927‐34.

114: Woitas RP, Stoschus B, Terjung B, Vogel M, Kupfer B, Brackmann HH, Rockstroh JK, Sau‐

erbruch T, Spengler U.

Hepatitis C‐associated autoimmunity in patients coinfected with HIV.

Liver Int. 2005 Dec;25(6):1114‐21.

115: Wolff M, Schaefer N, Rabe C, Spengler U, Hirner A.

Successful transplantation of a liver from a donor with fatal ethylene glycol poisoning.

Liver Transpl. 2005 Aug;11(8):990‐2.

116: Yang XP, Schaper F, Teubner A, Lammert F, Heinrich PC, Matern S, Siewert E.

Interleukin‐6 plays a crucial role in the hepatic expression of SOCS3 during acute inflamma‐

tory processes in vivo.

J Hepatol. 2005 Oct;43(4):704‐10.

117: Zimmermann DJ, Hesse A, von Unruh GE.

Influence of a high‐oxalate diet on intestinal oxalate absorption.

World J Urol. 2005 Nov;23(5):324‐9.

118: Zimmermann DJ, Voss S, von Unruh GE, Hesse A.

Importance of magnesium in absorption and excretion of oxalate.

Urol Int. 2005;74(3):262‐7.

133

2006

1: Acalovschi M, Ciocan A, Mostean O, Tirziu S, Chiorean E, Keppeler H, Schirin‐Sokhan R,

Lammert F.

Are plasma lipid levels related to ABCG5/ABCG8 polymorphisms? A preliminary study in sib‐

lings with gallstones.

Eur J Intern Med. 2006 Nov;17(7):490‐4.

2: Altfeld M, Kalife ET, Qi Y, Streeck H, Lichterfeld M, Johnston MN, Burgett N, Swartz ME,

Yang A, Alter G, Yu XG, Meier A, Rockstroh JK, Allen TM, Jessen H, Rosenberg ES, Carrington

M, Walker BD.

HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to

the Initial CD8(+) T Cell Response against HIV‐1.

PLoS Med. 2006 Oct;3(10):e403.

3: Appenrodt B, Schepke M, Kuntz‐Hehner S, Schmiedel A, Sauerbruch T.

A patient with portal hypertension and blindness after transjugular intrahepatic portosys‐

temic shunt.

Eur J Gastroenterol Hepatol. 2006 Apr;18(4):447‐9.

4: Aretz S, Uhlhaas S, Goergens H, Siberg K, Vogel M, Pagenstecher C, Mangold E, Caspari R,

Propping P, Friedl W.

MUTYH‐associated polyposis: 70 of 71 patients with biallelic mutations present with an at‐

tenuated or atypical phenotype.

Int J Cancer. 2006 Aug 15;119(4):807‐14.

5: Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, Buggisch P, Goeser T,

Rasenack J, Pape GR, Schmidt WE, Kallinowski B, Klinker H, Spengler U, Martus P, Alshuth U,

Zeuzem S.

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of

peginterferon‐alfa‐2a plus ribavirin.


6: Betts R, Glasmacher A, Maertens J, Maschmeyer G, Vazquez JA, Teppler H, Taylor A, Lu‐

pinacci R, Sable C, Kartsonis N.

Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutro‐

penic patients.

Cancer. 2006 Jan 15;106(2):466‐73.

134

7: Biecker E, Sauerbruch T.

Control of infection in gastrointestinal endoscopy.


8: Biecker E, Fischer HP, Lutterbey G, Pütz U, Sauerbruch T, Lammert F.

Recurring, severe upper abdominal pain in a 45 year old patient.


9: Biecker E, Trebicka J, Fischer HP, Sauerbruch T, Lammert F.

Portal hypertension and nodular regenerative hyperplasia in a patient with celiac disease.


10: Brouwers J, Tack J, Lammert F, Augustijns P.

Intraluminal drug and formulation behavior and integration in in vitro permeability estima‐

tion: a case study with amprenavir.

J Pharm Sci. 2006 Feb;95(2):372‐83.

11: Dietrich CG, Gartung C, Siewert E, Lammert F, Matern S, Geier A.

Therapierefraktäre schwere pulmonal‐arterielle Hypertonie nach Lebertransplantation bei

HCV‐Leberzirrhose.


12: Dilger K, Cascorbi I, Grünhage F, Hohenester S, Sauerbruch T, Beuers U.

Multidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrho‐

sis.

Liver Int. 2006 Apr;26(3):285‐90.

13: Ellis E, Wagner M, Lammert F, Nemeth A, Gumhold J, Strassburg CP, Kylander C, Katsika

D, Trauner M, Einarsson C, Marschall HU.

Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by

rifampicin.

J Hepatol 2006; 44 (1): 243‐245

14: Erhardt M, Schmidt‐Wolf IGH, Sievers E, Frank S, Strehl J, von Lilienfeld‐Toal M, Gorschlü‐

ter M.

Anti‐tumoral capabilities of effector cells after IFN‐alpha or CpG‐motif treatment of cocul‐

tured dendritic cells.

Arch Immunol Ther Exp (Warsz). 2006 Nov‐Dec;54(6):403‐9.

135

15: Feldmann G, Nischalke HD, Nattermann J, Banas B, Berg T, Teschendorf C, Schmiegel W,

Duhrsen U, Halangk J, Iwan A, Sauerbruch T, Caselmann WH, Spengler U.

Induction of interleukin‐6 by hepatitis C virus core protein in hepatitis C‐associated mixed

cryoglobulinemia and B‐cell non‐Hodgkin's lymphoma.

Clin Cancer Res. 2006 Aug 1;12(15):4491‐8.

16: Feldmann G, Nattermann J, Nischalke HD, Gorschlüter M, Kuntzen T, Ahlenstiel G, Ger‐

hardt T, Wolff M, Sauerbruch T, Spengler U, Dumoulin FL.

Detection of human aspartyl (asparaginyl) beta‐hydroxylase and homeobox B7 mRNA in

brush cytology specimens from patients with bile duct cancer.

Endoscopy. 2006 Jun;38(6):604‐9.

17: Frank J, Poblete‐Gutiérrez P, Weiskirchen R, Gressner O, Merk HF, Lammert F.

Hemochromatosis gene sequence deviations in German patients with porphyria cutanea

tarda.

Physiol Res 2006; 55 (Suppl. 2): 75‐83.

18: Gerhardt T, Wolff M, Fischer HP, Sauerbruch T, Reichel C.

Diagnostic difficulties with intestinal tuberculosis.

Scand J Gastroenterol. 2006;41(9): 1119‐20.

19: Gerhardt T, Pöge U, Stoffel‐Wagner B, Ahrendt M, Wolff M, Spengler U, Palmedo H, Sau‐

erbruch T, Woitas RP.

Estimation of glomerular filtration rates after orthotopic liver transplantation: Evaluation of

cystatin C‐based equations.

Liver Transpl. 2006 Nov;12(11):1667‐72.

20: Gerhardt T, Milz S, Schepke M, Feldmann G, Wolff M, Sauerbruch T, Dumoulin FL.

C‐reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma.

World J Gastroenterol. 2006 Sep 14;12(34):5495‐500.

21: Glasmacher A, Prentrice A.

An open‐label randomized trial comparing itraconazole oral solution with fluconazole oral

solution for primary prophylaxis of fungal infections in patients with haematological malig‐

nancy and profound neutropenia.

J Antimicrob Chemother. 2006;57(2): 317‐25.

22: Glasmacher A, Prentrice A.

The role of meta‐analysis in the evaluation of antifungal prophylaxis: authors' response


23: Glasmacher A, Prentice A.

136

Current experience with itraconazole in neutropenic patients: a concise overview of pharma‐

cological properties and use in prophylactic and empirical antifungal therapy.

Clin Microbiol Infect. 2006 Dec;12 Suppl 7:84‐90.

24: Glasmacher A, von Lilienfeld‐Toal M.

An evidence based review of the available antibiotic treatment options for neutropaenic pa‐

tients and a recommendation for treatment guidelines.

Int J Infect Dis. 2006 Sep;10 Suppl 2:S9‐S16.

25: Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld‐Toal M,

Orlopp K, Schmidt‐Wolf I, Gorschlüter M.

A systematic review of phase‐II trials of thalidomide monotherapy in patients with relapsed or

refractory multiple myeloma.

Br J Haematol. 2006 Mar;132(5):584‐93.

26: Glasmacher A, Cornely O, Ullmann AJ, Wedding U, Bodenstein H, Wandt H, Boewer C,

Pasold R, Wolf HH, Hanel M, Dolken G, Junghanss C, Andreesen R, Bertz H; Itraconazole Re‐

search Group of Germany.

An open‐label randomized trial comparing itraconazole oral solution with fluconazole oral

solution for primary prophylaxis of fungal infections in patients with haematological malig‐

nancy and profound neutropenia.

J Antimicrob Chemother. 2006 Feb;57(2):317‐25.

27: Glasmacher A, Cornely OA, Orlopp K, Reuter S, Blaschke S, Eichel M, Silling G, Simons B,

Egerer G, Siemann M, Florek M, Schnitzler R, Ebeling P, Ritter J, Reinel H, Schutt P, Fischer

H, Hahn C, Just‐Nuebling G.

Caspofungin treatment in severely ill, immunocompromised patients: a case‐documentation

study of 118 patients.

J Antimicrob Chemother. 2006 Jan;57(1):127‐34.

28: Gonzalez‐Carmona MA, Schussler S, Serwe M, Alt M, Ludwig J, Sproat BS, Steigerwald R,

Hoffmann P, Quasdorff M, Schildgen O, Caselmann WH.

Hammerhead ribozymes with cleavage site specificity for NUH and NCH display significant

anti‐hepatitis C viral effect in vitro and in recombinant HepG2 and CCL13 cells.

J Hepatol. 2006 Jun;44(6):1017‐25

137

29: Gonzalez‐Carmona MA, Märten A, Hoffmann P, Schneider C, Sievers E, Schmidt‐Wolf IGH,

Sauerbruch T, Caselmann WH.

Patient‐derived dendritic cells transduced with an a‐fetoprotein‐encoding adenovirus and co‐

cultured with autologous cytokine‐induced lymphocytes induce a specific and strong immune

response against hepatocellular carcinoma cells.

Liver Int. 2006 Apr;26(3):369‐79.

30: Gorschlüter M, Mey U, Strehl J, Schepke M, Lamberti C, Sauerbruch T, Glasmacher A.

Cholecystitis in neutropenic patients: retrospective study and systematic review.

Leuk Res. 2006 May;30(5):521‐8.

31: Gorschlüter M, Mey U, Strehl J, Schmitz V, Rabe C, Pauls K, Ziske C, Schmidt‐Wolf IG,

Glasmacher A.

Invasive fungal infections in neutropenic enterocolitis: a systematic analysis of pathogens,

incidence, treatment and mortality in adult patients.

BMC Infect Dis. 2006 Feb 26;6:35.

32: Grünhage F, Lammert F.

Gallstone disease. Pathogenesis of gallstones: A genetic perspective.

Best Pract Res Clin Gastroenterol. 2006;20(6):997‐1015.

33: Hellmann MA, Gerhardt TM, Rabe C, Haas S, Sauerbruch T, Woitas RP.

Goodpasture's syndrome with massive pulmonary haemorrhage in the absence of circulating

anti‐GBM antibodies?

Nephrol Dial Transplant. 2006 Feb;21(2):526‐9.

34: Henkel C, Roderfeld M, Weiskirchen R, Berres ML, Hillebrandt S, Lammert F, Meyer HE,

Stuhler K, Graf J, Roeb E.

Changes of the hepatic proteome in murine models for toxically induced fibrogenesis and

sclerosing cholangitis.

Proteomics. 2006 Dec;6(24):6538‐48.

35: Hennenberg M, Biecker E, Trebicka J, Jochem K, Zhou Q, Schmidt M, Jakobs KH, Sauer‐

bruch T, Heller J.

Defective RhoA/Rho‐kinase signaling contributes to vascular hypocontractility and vasodila‐

tion in cirrhotic rats.


138

36: Hentrich M, Maretta L, Chow KU, Bogner JR, Schurmann D, Neuhoff P, Jager H, Reichelt

D, Vogel M, Ruhnke M, Oette M, Weiss R, Rockstroh J, Arasteh K, Mitrou P.

Highly active antiretroviral therapy (HAART) improves survival in HIV‐associated Hodgkin's

disease: results of a multicenter study.

Ann Oncol. 2006 Jun;17(6):914‐9.

37: Homann N, Stickel F, König IR, Jacobs A, Junghanns K, Benesova M, Schuppan D, Himsel

S, Zuber‐Jerger I, Hellerbrand C, Ludwig D, Caselmann WH, Seitz HK.

Alcohol dehydrogenase 1C*1 allele is a genetic marker for alcohol‐associated cancer in heavy

drinkers.

Int J Cancer. 2006 Apr 15;118(8):1998‐2002.

38: Hombach A, Schlimper C, Sievers E, Frank S, Schild HH, Sauerbruch T, Schmidt‐Wolf IGH,

Abken H.

A recombinant anti‐carcinoembryonic antigen immunoreceptor with combined CD3zeta‐CD28

signalling targets T cells from colorectal cancer patients against their tumour cells.

Gut. 2006 Aug;55(8):1156‐64

39: Hoppe B, Beck B, Gatter N, von Unruh G, Tischer A, Hesse A, Laube N, Kaul P, Sidhu H.

Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1.

Kidney Int. 2006 Oct;70(7):1305‐11.

40: Ingiliz P, Appenrodt B, Grünhage F, Vogel M, Tschampa H, Tasci S, Rockstroh JK.

Lymphoid pneumonitis as an immune reconstitution inflammatory syndrome in a patient with

CD4 cell recovery after HAART initiation.

HIV Med. 2006 Sep;7(6):411‐4.

41: Kornek M, Raskopf E, Guetgemann I, Ocker M, Gerceker S, Gonzalez‐Carmona MA, Rabe

C, Sauerbruch T, Schmitz V.

Combination of systemic thioacetamide (TAA) injections and ethanol feeding accelerates he‐

patic fibrosis in C3H/He mice and is associated with intrahepatic up regulation of MMP‐2,

VEGF and ICAM‐1.

J Hepatol. 2006 Sep;45(3):370‐6. Epub 2006 May 3.

42: Lamberti C, Lundin S, Bogdanow M, Gorschlüter M, Schmidt‐Wolf IGH, Sauerbruch T.

[Adjuvant and palliative chemotherapy of colorectal cancer in Germany outside controlled

trials].


43: Lamberti C, Mangold E, Pagenstecher C, Jungck M, Schwering D, Bollmann M, Vogel J,

Kindermann D, Nikorowitsch R, Friedrichs N, Schneider B, Houshdaran F, Schmidt‐Wolf IGH,

Friedl W, Propping P, Sauerbruch T, Büttner R, Mathiak M.

139

Frequency of hereditary non‐polyposis colorectal cancer among unselected patients with

colorectal cancer in Germany.

Digestion. 2006;74(1):58‐67.

44: Langhans B, Braunschweiger I, Nischalke HD, Nattermann J, Sauerbruch T, Spengler U.

Presentation of the HCV‐derived lipopeptide LP20‐44 by dendritic cells enhances function of

in vitro‐generated CD4+ T cells via up‐regulation of TLR2.

Vaccine. 2006 Apr 12;24(16):3066‐75.

45: Leifeld L, Nattermann J, Fielenbach M, Schmitz V, Sauerbruch T, Spengler U.

Intrahepatic activation of caspases in human fulminant hepatic failure.

Liver Int. 2006 Sep;26(7):872‐9.

46: Leifeld L, Fink K, Debska G, Fielenbach M, Schmitz V, Sauerbruch T, Spengler U.

Anti‐apoptotic function of gelsolin in fas antibody‐induced liver failure in vivo.

Am J Pathol. 2006 Mar;168(3):778‐85.

47: Link BC, Ziske CG, Schepke M, Schmidt‐Wolf IGH, Sauerbruch T.

Total ascitic fluid leukocyte count for reliable exclusion of spontaneous bacterial peritonitis in

patients with ascites.


48: Märten A, Sievers E, Albers P, Müller S, Franchy C, von Ruecker A, Strunk H, Schild HH,

Schmiedel A, Sommer T, Sauerbruch T, Schmidt‐Wolf IGH.

Telomerase‐pulsed dendritic cells: preclinical results and outcome of a clinical phase I/II trial in

patients with metastatic renal cell carcinoma.

Ger Med Sci. 2006 Feb 13;4:Doc02.

49: Maertens J, Glasmacher A, Herbrecht R, Thiebaut A, Cordonnier C, Segal BH, Killar J,

Taylor A, Kartsonis N, Patterson TF, Aoun M, Caillot D, Sable C; Caspofungin Combination

Therapy Study Group.

Multicenter, noncomparative study of caspofungin in combination with other antifungals as

salvage therapy in adults with invasive aspergillosis.

Cancer. 2006 Dec 15;107(12):2888‐97.

50: Meier U, Gressner O, Lammert F, Gressner AM.

Gc‐globulin: roles in response to injury.

Clin Chem. 2006 Jul;52(7):1247‐53.

51: Mey UJ, Olivieri A, Orlopp KS, Rabe C, Strehl JW, Gorschlüter M, Hensel M, Flieger D,

Glasmacher AG, Schmidt‐Wolf IGH.

DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with

relapsed or refractory diffuse large B‐cell lymphoma: a matched‐pair analysis.

140

Leuk Lymphoma. 2006 Dec;47(12):2558‐66.

52: Mey UJ, Orlopp KS, Flieger D, Strehl JW, Ho AD, Hensel M, Bopp C, Gorschlüter M,

Wilhelm M, Birkmann J, Kaiser U, Neubauer A, Florschutz A, Rabe C, Hahn C, Glasmacher AG,

Schmidt‐Wolf IGH.

Dexamethasone, high‐dose cytarabine, and cisplatin in combination with rituximab as salvage

treatment for patients with relapsed or refractory aggressive non‐Hodgkin's lymphoma.

Cancer Invest. 2006 Oct;24(6):593‐600.

53: Mocroft A, Rockstroh J, Soriano V, Kirk O, Viard JP, Caplinskas S, Gasiorowski J, Chiesi A,

Phillips AN, Lundgren JD, EuroSIDA Study Group.

Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected

with HIV and hepatitis C.

Scand J Infect Dis. 2006;38(11‐12):1092‐7.

54: Moehler TM, Hillengass J, Glasmacher A, Goldschmidt H.

Thalidomide in multiple myeloma.

Curr Pharm Biotechnol. 2006 Dec;7(6):431‐40.

55: Nagaraj S, Ziske C, Strehl J, Messmer D, Sauerbruch T, Schmidt‐Wolf IGH.

Dendritic cells pulsed with alpha‐galactosylceramide induce anti‐tumor immunity against pan‐

creatic cancer in vivo.

Int Immunol. 2006 Aug;18(8):1279‐83.

56: Nattermann J, Zimmermann H, Iwan A, von Lilienfeld‐Toal M, Leifeld L, Nischalke HD,

Langhans B, Sauerbruch T, Spengler U.

Hepatitis C virus E2 and CD81 interaction may be associated with altered trafficking of den‐

dritic cells in chronic hepatitis C.

Hepatology. 2006 Oct;44(4):945‐54.

57: Nattermann J, Feldmann G, Ahlenstiel G, Langhans B, Sauerbruch T, Spengler U.

Surface expression and cytolytic function of natural killer cell receptors is altered in chronic

hepatitis C.

Gut. 2006 Jun;55(6):869‐77.

141

58: Nattermann J, Ahlenstiel G, Berg T, Feldmann G, Nischalke HD, Muller T, Rockstroh J,

Woitas R, Sauerbruch T, Spengler U.

The tandem‐repeat polymorphism of the DC‐SIGNR gene in HCV infection.

J Viral Hepat. 2006 Jan;13(1):42‐6.

59: Neubrand MW, Lammert F, Sauerbruch T.

Gallensteinerkrankungen.

Gastroenterologie up2date 2006; 2 (1): 33‐53

60: Nguyen HN, Domingues GR, Lammert F.

Technological insights: combined impedance manometry for esophageal motility testing‐

current results and further implications.

World J Gastroenterol. 2006 Oct 21;12(39):6266‐73.

61: Nguyen HN, Winograd R, Domingues GR, Lammert F.

Postprandial transduodenal bolus transport is regulated by complex peristaltic sequence.

World J Gastroenterol. 2006 Oct 7;12(37):6008‐16.

62: Nguyen HN, Domingues GR, Winograd R, Lammert F, Silny J, Matern S.

Relationship between bolus transit and LES‐relaxation studied with concurrent impedance

and manometry.

Hepatogastroenterology. 2006 Mar‐Apr;53(68):218‐23.

63: Oette M, Kaiser R, Daumer M, Petch R, Fätkenheuer G, Carls H, Rockstroh JK, Schmaloer

D, Stechel J, Feldt T, Pfister H, Häussinger D.

Primary HIV drug resistance and efficacy of first‐line antiretroviral therapy guided by resis‐

tance testing.


64 : Palmedo H, Urbach H, Bender H, Schlegel U, Schmidt‐Wolf IGH, Matthies A, Linnebank

M, Joe A, Bucerius J, Biersack HJ, Pels H.

FDG‐PET in immunocompetent patients with primary central nervous system lymphoma: cor‐

relation with MRI and clinical follow‐up.

Eur J Nucl Med Mol Imaging. 2006 Feb;33(2):164‐8.

65: Perez de la Cruz Moreno M, Oth M, Deferme S, Lammert F, Tack J, Dressman J, Au‐

gustijns P.

Characterization of fasted‐state human intestinal fluids collected from duodenum and jeju‐

num.

J Pharm Pharmacol 2006; 58 (8): 1079‐1089.

142

66: Pöge U, Gerhardt T, Woitas RP.

Calculation of glomerular filtration rate using serum cystatin C in kidney transplant recipients.

Kidney Int. 2006 Nov;70(10):1878; author reply 1878‐9.

67: Pöge U, Gerhardt T, Stoffel‐Wagner B, Palmedo H, Klehr HU, Sauerbruch T, Woitas RP.

Cystatin C‐based calculation of glomerular filtration rate in kidney transplant recipients.

Kidney Int. 2006 Jul;70(1):204‐10.


Prediction of glomerular filtration rate in renal transplant recipients: cystatin C or modifica‐

tion of diet in renal disease equation?

Clin Transplant. 2006 Mar‐Apr;20(2):200‐5.

69: Pöge U, Gerhardt T, Stoffel‐Wagner B, Klehr HU, Sauerbruch T, Woitas RP.

Calculation of glomerular filtration rate based on cystatin C in cirrhotic patients.

Nephrol Dial Transplant. 2006 Mar;21(3):660‐4. Epub 2005 Dec 2.

70: Prentice AG, Glasmacher A, Djulbegovic B.

In meta‐analysis itraconazole is superior to fluconazole for prophylaxis of systemic fungal

infection in the treatment of haematological malignancy.

Br J Haematol. 2006 Mar;132(5):656‐8; author reply 658‐9.

71: Puoti M, Cozzi‐Lepri A, Arici C, Moller NF, Lundgren JD, Ledergerber B, Rickenbach M,

Suarez‐Lozano I, Garrido M, Dabis F, Winnock M, Milazzo L, Gervais A, Raffi F, Gill J, Rock‐

stroh J, Ourishi N, Mussini C, Castagna A, De Luca A, Monforte A; HBV‐HIV International In‐

tercohort Study Group.

Impact of lamivudine on the risk of liver‐related death in 2,041 HBsAg‐ and HIV‐positive indi‐

viduals: results from an inter‐cohort analysis.

Antivir Ther. 2006;11(5):567‐74.

72: Rabe C, Balta Z, Wullner U, Heller J, Hammerstingl C, Tiemann K, Sommer T, Schepke M,

Fischer HP, Sauerbruch T.

Biliary metal stents and air embolism: a note of caution.

Endoscopy. 2006 Jun;38(6):648‐50.

73: Rangnekar AS, Lammert F, Igolnikov A, Green RM.

Quantitative trait loci analysis of mice administered the methionine‐choline deficient dietary

model of experimental steatohepatitis.

Liver Int. 2006 Oct;26(8):1000‐5.

143

74: Reichel C, Grünhage F.

[Differential diagnosis of jaundice].

MMW Fortschr Med. 2006 Jan 19;148(3):37‐40; quiz 41‐2.

75: Risse JH, Rabe C, Pauleit D, Reichmann K, Menzel C, Grunwald F, Strunk H, Biersack HJ,

Palmedo H.

Therapy of hepatocellular carcinoma with iodine‐131‐lipiodol. Results in a large German co‐

hort.

Nuklearmedizin. 2006;45(4):185‐92.

76: Rockstroh JK.

Management of hepatitis C/HIV coinfection.

Curr Opin Infect Dis. 2006 Feb;19(1):8‐13.

77: Rockstroh JK, Hardy WD.

Antiretroviral therapy in coinfected patients: viral hepatitis and tuberculosis.

Curr Opin HIV AIDS. 2006 Sep;1(5):442‐8.

78: Rockstroh JK.

Influence of viral hepatitis on HIV infection.

J Hepatol. 2006;44(1 Suppl):S25‐7.

79: Salmon D, Robain M, Rockstroh JK, Benhamou Y.

Therapeutic management of hepatitis and HIV infection in co‐infected patients: results of a

survey performed before the 2005 Consensus Conference.

J Hepatol. 2006;44(1 Suppl):S2‐5. Epub 2005 Dec 5.

80: San Miguel J, Bladé J, Boccadoro M, Cavenagh J, Glasmacher A, Jagannath S, Lonial S,

Orlowski RZ, Sonneveld P, Ludwig H.

A practical update on the use of bortezomib in the management of multiple myeloma.

Oncologist. 2006 Jan;11(1):51‐61.

81: Sauerbruch T.

Increased pneumonia risk through gastric acid reduction.

Internist 2006;47(4):442.

82: Sauerbruch T.

[Visceral medicine: the gastroenterologist's point of view]


144

83: Sauerbruch T.

[Small intestine diagnosis...with capsule endoscopy. Interview by Maren Schenk].

Dtsch Med Wochenschr. 2006 Oct 27;Suppl 1:72.

84: Schafmayer C, Tepel J, Franke A, Buch S, Lieb S, Seeger M, Lammert F, Kremer B, Folsch

UR, Fandrich F, Schreiber S, Hampe J.

Investigation of the Lith1 candidate genes ABCB11 and LXRA in human gallstone disease.

Hepatology. 2006 Sep;44(3):650‐7.

85: Schepke M, Appenrodt B, Heller J, Zielinski J, Sauerbruch T.

Prognostic factors for patients with cirrhosis and kidney dysfunction in the era of MELD: re‐

sults of a prospective study.

Liver Int. 2006 Sep;26(7):834‐9.

86: Schepke M.

Oesophagus varices: Primary bleeding prophylaxis – Response.

Dtsch Med Wochenschr. 2006 Jun 2;131(31‐32):1758.

87: Schepke M.

[Primary prevention of variceal bleeding in cirrhosis].


88: Schiedermaier P, Koch L, Mojon A, Hermida R, Layer G, Sauerbruch T.

Circadian rhythm of fasting and postprandial portal blood flow in cirrhosis.

Scand J Gastroenterol. 2006 Jul;41(7):826‐32.

89: Schildgen O, Sirma H, Funk A, Olotu C, Wend UC, Hartmann H, Helm M, Rockstroh JK,

Willems WR, Will H, Gerlich WH.

Variant of hepatitis B virus with primary resistance to adefovir.

N Engl J Med. 2006 Apr 27;354(17):1807‐12.

90: Schlenk RF, Frohling S, Hartmann F, Fischer JT, Glasmacher A, Del Valle F, Gotze K, Nerl C,

Schoch R, Pralle H, Mergenthaler HG, Hensel M, Koller E, Kirchen H, Matzdorff A, Salwender

H, Biedermann HG, Kremers S, Haase D, Benner A, Dohner K, Dohner H.

Intensive consolidation versus oral maintenance therapy in patients 61 years or older with

acute myeloid leukemia in first remission: results of second randomization of the AML HD98‐

B treatment Trial.

Leukemia. 2006 Apr;20(4):748‐50.

145

91: Schmidt J, Ryschich E, Sievers E, Schmidt‐Wolf IGH, Buchler MW, Märten A.

Telomerase‐specific T‐cells kill pancreatic tumor cells in vitro and in vivo.

Cancer. 2006 Feb 15;106(4):759‐64.

92: Schmidt‐Wolf IGH, Glasmacher A, Hahn‐Ast C, Juttner A, Schnurr T, Cremer F, Moehler T,

Goldschmidt H, Busert B, Schubert R, Schwanitz G.

Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH:

diagnostic and prognostic relevance.

Cancer Genet Cytogenet. 2006 May;167(1):20‐5.

93: Schmitz V, Dombrowski F, Prieto J, Qian C, Diehl L, Knolle P, Sauerbruch T, Caselmann

WH, Spengler U, Leifeld L.

Induction of murine liver damage by overexpression of CD40 ligand provides an experimental

model to study fulminant hepatic failure.

Hepatology. 2006 Aug;44(2):430‐9.

94: Schmitz V, Vilanueva H, Raskopf E, Hilbert T, Barajas M, Dzienisowicz C, Gorschlüter M,

Strehl J, Rabe C, Sauerbruch T, Prieto J, Caselmann WH, Qian C.

Increased VEGF levels induced by anti‐VEGF treatment are independent of tumor burden in

colorectal carcinomas in mice.

Gene Ther. 2006 Aug;13(16):1198‐205.

95: Schmutz G, Nelson M, Lutz T, Sheldon J, Bruno R, von Boemmel F, Hoffmann C,

Rockstroh J, Stoehr A, Wolf E, Soriano V, Berger F, Berg T, Carlebach A,

Schwarze‐Zander C, Schurmann D, Jaeger H, Mauss S.

Combination of tenofovir and lamivudine versus tenofovir after lamivudine

failure for therapy of hepatitis B in HIV‐coinfection.

AIDS. 2006 Oct 3;20(15):1951‐4.

96: Schulte S, Ackermann T, Bertram N, Sauerbruch T, Paar WD.

Determination of the newer quinolones levofloxacin and moxifloxacin in plasma by high‐

performance liquid chromatography with fluorescence detection.

J Chromatogr Sci. 2006 Apr;44(4):205‐8.

97: Siewert E, Lammert F, Koppitz P, Schmidt T, Matern S.

Eosinophilic gastroenteritis with severe protein‐losing enteropathy: successful treatment

with budesonide.

Dig Liver Dis. 2006 Jan;38(1):55‐9. Epub 2005 Dec 1.

146

98: Streeck H, Rockstroh JK.

Challenges in the treatment of HIV and HCV coinfection.

Expert Rev Clin Immunol. 2006 Sep;2(5):811‐22.

99: Streeck H, Jessen H, Alter G, Teigen N, Waring MT, Jessen A, Stahmer I, van Lunzen J,

Lichterfeld M, Gao X, Allen TM, Carrington M, Walker BD, Rockstroh JK, Altfeld M.

Immunological and virological impact of highly active antiretroviral therapy initiated during

acute HIV‐1 infection.

J Infect Dis. 2006 Sep 15;194(6):734‐9.

100: Tasci S, Glasmacher A, Lentini S, Tschubel K, Ewig S, Molitor E, Sauerbruch T, Lüderitz B,

Rabe C.

Pseudomembranous and obstructive Aspergillus tracheobronchitis – optimal diagnostic

strategy and outcome.

Mycoses. 2006 Jan;49(1):37‐42.

101: Telusma G, Datta S, Mihajlov I, Ma W, Li J, Yang H, Newman W, Messmer BT, Minev B,

Schmidt‐Wolf IGH, Tracey KJ, Chiorazzi N, Messmer D.

Dendritic cell activating peptides induce distinct cytokine profiles.

Int Immunol. 2006 Nov;18(11):1563‐73.

102: Tillmann HL, Hadem J, Leifeld L, Zachou K, Canbay A, Eisenbach C, Graziadei I, Encke J,

Schmidt H, Vogel W, Schneider A, Spengler U, Gerken G, Dalekos GN, Wedemeyer H, Manns

MP.

Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a

multicenter experience.

J Viral Hepat. 2006 Apr;13(4):256‐63.

103: Vaidyanathan S, von Unruh GE, Watson ID, Laube N, Willets S, Soni BL.

Hyperoxaluria, hypocitraturia, hypomagnesiuria, and lack of intestinal colonization by Oxalo‐

bacter formigenes in a cervical spinal cord injury patient with suprapubic cystostomy, short

bowel, and nephrolithiasis.

ScientificWorldJournal. 2006 Apr 6;6:2403‐10.

104: van Bommel F, Zollner B, Sarrazin C, Spengler U, Huppe D, Moller B, Feucht HH, Wie‐

denmann B, Berg T.

Tenofovir for patients with lamivudine‐resistant hepatitis B virus (HBV) infection and high

HBV DNA level during adefovir therapy.

Hepatology. 2006 Aug;44(2):318‐25.

105: Verheyen J, Litau E, Sing T, Daumer M, Balduin M, Oette M, Fätkenheuer G, Rockstroh

JK, Schuldenzucker U, Hoffmann D, Pfister H, Kaiser R.

147

Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6‐gag in therapy‐naive and

therapy‐experienced patients.

Antivir Ther. 2006;11(7):879‐87.

106: Vogel M, Lichterfeld M, Kaufmann DE, Mui SK, Altfeld M, Voigt E, Ahlenstiel G, Kupfer B,

Walker B, Spengler U, Rockstroh JK.

Structured treatment interruptions following immediate initiation of HAART in eight patients

with acute HIV‐1 seroconversion.

Eur J Med Res. 2006 Jul 31;11(7):273‐8.

107: Vogel M, Nattermann J, Baumgarten A, Klausen G, Bieniek B, Schewe K, Jessen H,

Boeseckeg C, Rausch M, Lutz T, Fenske S, Schranzo D, Kummerle T, Schuler C,Theisen A,

Mayr C, Seidel T, Rockstroh JK.

Pegylated interferon‐alpha for the treatment of sexually transmitted acute hepatitis C in HIV‐

infected individuals.

Antivir Ther. 2006;11(8):1097‐101.

108: Voigt E, Schulz C, Klausen G, Goelz J, Mauss S, Schmutz G, Jessen H, Weitner L, Mutz A,

Schranz D, Rockstroh JK, Kaad Study Group.

Pegylated interferon alpha‐2b plus ribavirin for the treatment of chronic hepatitis C in HIV‐

coinfected patients.

J Infect. 2006 Jul;53(1):36‐42.

109: von Lilienfeld‐Toal M, Schneider A, Orlopp K, Hahn‐Ast C, Glasmacher A, Stuber F.

Change of procalcitonin predicts clinical outcome of febrile episodes in patients with hemato‐

logical malignancies.

Support Care Cancer. 2006 Dec;14(12):1241‐5. Epub 2006 May 30.

110: von Lilienfeld‐Toal M, Nattermann J, Feldmann G, Sievers E, Frank S, Strehl J, Schmidt‐

Wolf IGH.

Activated gammadelta T cells express the natural cytotoxicity receptor natural killer p 44 and

show cytotoxic activity against myeloma cells.

Clin Exp Immunol. 2006 Jun;144(3):528‐33.

111: von Unruh GE, Bell AE, Hesse A.

Effect of oxalate test dose size on absolute and percent oxalate absorption.

Isotopes Environ Health Stud. 2006 Mar;42(1):107‐12.

148

112: Voss S, Hesse A, Zimmermann DJ, Sauerbruch T, von Unruh GE.

Intestinal oxalate absorption is higher in idiopathic calcium oxalate stone formers than in

healthy controls: measurements with the [(13)C2]oxalate absorption test.

J Urol. 2006 May;175(5):1711‐5.

113: Wang A, Zhang Y, He L, Shen Z, Liao W, Han M, Li R, Liang D, Wu S, Hahn‐Ast C, Glas‐

macher A, Liekwok WA.

Clinical study on the efficacy and safety of intravenous itraconazole infusion for the treat‐

ment of invasive fungal infection in china.

Jpn J Infect Dis. 2006 Dec;59(6):370‐6.

114: Willinek WA, Hadizadeh D, von Falkenhausen M, Koscielny A, Wolff M, Schepke M,

Schild HH, Strunk H.

Magnetic resonance (MR) imaging and MR angiography for evaluation and follow‐up of he‐

patic artery banding in patients with hepatic involvement of hereditary hemorrhagic te‐

langiectasia.

Abdom Imaging. 2006 Nov‐Dec;31(6):694‐700.

115: Yildiz Y, Matern H, Thompson B, Allegood JC, Warren RL, Ramirez DM, Hammer RE,

Hamra FK, Matern S, Russell DW

Mutation of beta‐glucosidase 2 causes glycolipid storage disease and impaired male fertility.

J Clin Invest 2006, 116 (11): 2985‐2994.

116: Zhou Q, Hennenberg M, Trebicka J, Jochem K, Leifeld L, Biecker E, Sauerbruch T, Heller

J.

Intrahepatic upregulation of RhoA and Rho‐kinase signalling contributes to increased hepatic

vascular resistance in rats with secondary biliary cirrhosis.

Gut. 2006 Sep;55(9):1296‐305.

149

2007

1: Ahlenstiel G, Roomp K, Däumer M, Nattermann J, Vogel M, Rockstroh JK, Beerenwinkel N,

Kaiser R, Nischalke HD, Sauerbruch T, Lengauer T, Spengler U; Kompetenznetz HIV/AIDS.

Selective pressures of HLA genotypes and antiviral therapy on human immunodeficiency virus

type 1 sequence mutation at a population level.

Clin Vaccine Immunol. 2007 Oct;14(10):1266‐73.

2: Ahlenstiel G, Nischalke HD, Bueren K, Berg T, Vogel M, Biermer M, Grünhage F, Sauer‐

bruch T, Rockstroh J, Spengler U, Nattermann J.

The GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in

HCV/HIV co‐infected but not in HCV mono‐infected patients.

J Hepatol. 2007 Sep;47(3):348‐55.

3: Appenrodt B, Sauerbruch T.

Antibiotic therapy and prophylaxis in liver cirrhosis and infection .


4: Biecker E, Roth F, Heller J, Schild HH, Sauerbruch T, Schepke M.

Prognostic role of the initial portal pressure gradient reduction after TIPS in patients with

cirrhosis.


5: Boor P, Konieczny A, Villa L, Schult AL, Bücher E, Rong S, Kunter U, van Roeyen CR, Pola‐

kowski T, Hawlisch H, Hillebrandt S, Lammert F, Eitner F, Floege J, Ostendorf T.

Complement C5 mediates experimental tubulointerstitial fibrosis.

J Am Soc Nephrol. 2007 May;18(5):1508‐15.

6: Breitkreutz I, Lokhorst HM, Raab MS, Holt B, Cremer FW, Herrmann D, Glasmacher A,

Schmidt‐Wolf IGH, Blau IW, Martin H, Salwender H, Haenel A, Sonneveld P, Goldschmidt H.

Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on

peripheral blood stem cell collection yield.

Leukemia. 2007 Jun;21(6):1294‐9.

150

7: Buch S, Schafmayer C, Völzke H, Becker C, Franke A, von Eller‐Eberstein H, Kluck C, Bäss‐

mann I, Brosch M, Lammert F, Miquel JF, Nervi F, Wittig M, Rosskopf D, Timm B, Höll C, See‐

ger M, ElSharawy A, Lu T, Egberts J, Fändrich F, Fölsch UR, Krawczak M, Schreiber S, Nürn‐

berg P, Tepel J, Hampe J.

A genome‐wide association scan identifies the hepatic cholesterol transporter ABCG8 as a

susceptibility factor for human gallstone disease.

Nat Genet. 2007 Aug;39(8):995‐9.

8: Burmeister T, Schwartz S, Taubald A, Jost E, Lipp T, Schneller F, Diedrich H, Thomssen H,

Mey UJ, Eucker J, Rieder H, Gökbuget N, Hoelzer D, Thiel E.

Atypical BCR‐ABL mRNA transcripts in adult acute lymphoblastic leukemia.

Haematologica. 2007;92(12): 1699‐702.

9: Caspari R, Lamberti C.

The impact of molecular genetics on screening of hereditary non‐polyposis colorectal cancer.

Acta Endoscopica. 2007;37(2): 165‐179.

10: Courts C, Montesinos‐Rongen M, Martin‐Subero JI, Brunn A, Siemer D, Zühlke‐Jenisch R,

Pels H, Jürgens A, Schlegel U, Schmidt‐Wolf IGH, Schaller C, Reifenberger G, Sabel M,

Warnecke‐Eberz U, Wiestler OD, Küppers R, Siebert R, Deckert M.

Transcriptional profiling of the nuclear factor‐kappaB pathway identifies a subgroup of pri‐

mary lymphoma of the central nervous system with low BCL10 expression.

J Neuropathol Exp Neurol. 2007 Mar;66(3):230‐7.

11: Demant AW, Schmiedel A, Büttner R, Lewalter T, Reichel C.

Heart failure and malignant ventricular tachyarrhythmias due to hereditary hemochromatosis

with iron overload cardiomyopathy.

Clin Res Cardiol. 2007 Dec;96(12):900‐903.

12: Dumoulin FL, Horst E, Sauerbruch T, Gerhardt T.

[Palliative locoregional therapy for hilar cholangiocarcinoma: photodynamictherapy and

brachytherapy].

Zentralbl Chir. 2007 Aug;132(4):336‐41.

13 : Emmelkamp JM, Rockstroh JK.

CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions‐

review of the literature.

Eur J Med Res. 2007 Oct 15;12(9):409‐17.

151

14: Engelhart S, Glasmacher A, Simon A, Exner M.

Air sampling of Aspergillus fumigatus and other thermotolerant fungi: comparative perform‐

ance of the Sartorius MD8 airport and the Merck MAS‐100 portable bioaerosol sampler.

Int J Hyg Environ Health. 2007 Dec;210(6):733‐9.

15: Feldmann G, Nattermann J, Gerhardt T, Nähle CP, Spengler U, Woitas R.

Partial remission of a newly diagnosed diffuse large B‐cell Non‐Hodgkin's lymphoma in a

hemodialysis patient after administration of immuno‐chemotherapy with rituximab‐CHOP.

Int J Lab Hematol. 2007 Dec;29(6):469‐73.

16: Flieger D, Varvenne M, Kleinschmidt R, Schmidt‐Wolf IGH.

Influence of immunomodulatory drugs on the cytotoxicity induced by monoclonal antibody

17‐1A and interleukin‐2.

Cell Immunol. 2007 Mar;246(1):26‐33.

17: Geiser F, Hahn C, Conrad R, Liedtke R, Sauerbruch T, Schmidt‐Wolf IGH, Glasmacher A.

Interaction of psychological factors and the effect of epoetin‐alfa treatment in cancer pa‐

tients on hemoglobin and fatigue.

Support Care Cancer. 2007 Mar;15(3):273‐8.

18: Glas M, Hennemann B, Hirschmann B, Marienhagen J, Schmidt‐Wolf IGH, Herrlinger U,

Bogdahn U, Hau P.

Complete response after treatment with a somatostatin analogue in an adult patient with

recurrent medulloblastoma.

Acta Oncol. 2007 Oct 12;:1‐2.

19: Gorschlüter M, Glasmacher A, Sarazin S, Hackbarth F, Hoebert E, Orlopp K, Schmidt‐Wolf

IGH, Mey U.

CD4+ T lymphocyte counts after autologous transplantation in multiple myeloma: a retro‐

spective study.

Leuk Lymphoma. 2007 Mar;48(3):506‐12.

20: Gressner O, Sauerbruch T.

Secondary small cell neuroendocrine carcinoma of the cervix after radiotherapy for cervical

squamous cell carcinoma.

Int J Gynaecol Obstet. 2007 Nov;99(2):138.

152

21: Gressner O, Meier U, Hillebrandt S, Wasmuth HE, Köhl J, Sauerbruch T, Lammert F.

Gc‐globulin concentrations and C5 haplotype‐tagging polymorphisms contribute to variations

in serum activity of complement factor C5.

Clin Biochem. 2007 Jul;40(11):771‐5.

22: Grünhage F, Heller J, Appenrodt B, Schmitz V, Sauerbruch T.

[Medical therapy of complications in liver cirrhosis.]

Internist (Berl). 2007 Dec;48(12):1349‐1357.

23: Grünhage F, Acalovschi M, Tirziu S, Walier M, Wienker TF, Ciocan A, Mosteanu O, Sauer‐

bruch T, Lammert F.

Increased gallstone risk in humans conferred by common variant of hepatic ATP‐binding cas‐

sette transporter for cholesterol.

Hepatology. 2007 Sep;46(3):793‐801.

24: Grünhage F, Lammert F.

Pathogenesis of gallstones: a genetic perspective (vol 20, pg 997, 2006)

Best Pract Res Clin Gastroenterol. 2007;21(4): 749‐751.

25: Gülberg V, Gerbes AL, Sauerbruch T, Appenrodt B.

Insufficient sensitivity of reagent strips for spontaneous bacterial peritonitis.

Hepatology. 2007 Nov;46(5):1669; author reply 1669‐70.

26: Hedde JP, Neuhaus T, Schüller H, Metzler U, Schmidt‐Wolf IGH, Kleinschmidt R, Losem C,

Lange O, Grohe C, Stier S, Ko YD.

A phase I/II trial of topotecan and radiation therapy for brain metastases in patients with solid

tumors.

Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):839‐44.

27: Heller J, Sauerbruch T.

Prevention of recurrent haemorrhage.

Best Pract Res Clin Gastroenterol. 2007;21(1):43‐53. Review.

28: Helmberger T, Dogan S, Straub G, Schrader A, Jüngst C, Reiser M, Waggershauser T, Ja‐

kobs T, Hoffmann RT, Löhe F, Graeb C, Rau HG, Schauer R, Jauch KW, Caselmann WH, Göke

B, Jüngst D.

Liver resection or combined chemoembolization and radiofrequency ablation improve sur‐

vival in patients with hepatocellular carcinoma.

Digestion. 2007;75(2‐3):104‐12.

153

29: Hennenberg M, Trebicka J, Biecker E, Schepke M, Sauerbruch T, Heller J.

Vascular dysfunction in human and rat cirrhosis: role of receptor‐desensitizing and calcium‐

sensitizing proteins.

Hepatology. 2007 Feb;45(2):495‐506.

30: Herold M, Haas A, Srock S, Neser S, Al‐Ali KH, Neubauer A, Dölken G, Naumann R, Knauf

W, Freund M, Rohrberg R, Höffken K, Franke A, Ittel T, Kettner E, Haak U, Mey U, Klinken‐

stein C, Assmann M, von Grünhagen U, East German Study Group Hematology and Oncology

Study

Rituximab added to first‐line mitoxantrone, chlorambucil, and prednisolone chemotherapy

followed by interferon maintenance prolongs survival in patients with advanced follicular

lymphoma: an East German Study Group Hematology and Oncology Study.

J Clin Oncol. 2007;25(15): 1986‐92.

31: Hofmann WP, Fernandez B, Herrmann E, Welsch C, Mihm U, Kronenberger B, Feldmann

G, Spengler U, Zeuzem S, Sarrazin C.

Somatic hypermutation and mRNA expression levels of the BCL‐6 gene in patients with hepa‐

titis C virus‐associated lymphoproliferative diseases.

J Viral Hepat. 2007 Jul;14(7):484‐91.

32: Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J,

McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt‐Wolf IGH, Barbarash O, Gokmen E,

O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial.

Temsirolimus, interferon alfa, or both for advanced renal‐cell carcinoma.

N Engl J Med. 2007 May 31;356(22):2271‐81.

33: Jüngst C, Sreejayan N, Eder MI, von Stillfried N, Zündt B, Spelsberg FW, Kullak‐Ublick GA,

Jüngst D, von Ritter C.

Lipid peroxidation and mucin secretagogue activity in bile of gallstone patients.

Eur J Clin Invest. 2007;37(9): 731‐6.

34: Katlama C, Esposito R, Gatell JM, Goffard JC, Grinsztejn B, Pozniak A, Rockstroh J, Stoehr

A, Vetter N, Yeni P, Parys W, Vangeneugden T; the POWER 1 study group.

Efficacy and safety of TMC114/ritonavir in treatment‐experienced HIV patients: 24‐week re‐

sults of POWER 1.

AIDS. 2007 Feb 19;21(4):395‐402.

154

35: Koch A, Hrychyk A, Hartmann W, Waha A, Mikeska T, Waha A, Schüller U, Sörensen N,

Berthold F, Goodyer CG, Wiestler OD, Birchmeier W, Behrens J, Pietsch T

Mutations of the Wnt antagonist AXIN2 (Conductin) result in TCF‐dependent transcription in

medulloblastomas.

Int J Cancer. 2007;121(2): 284‐91.

36: Kronenberger B, Berg T, Herrmann E, Hinrichsen H, Gerlach T, Buggisch P, Spengler U,

Goeser T, Nasser S, Wursthorn K, Pape GR, Hopf U, Zeuzem S.

Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with inter‐

feron‐alpha and ribavirin: results from a randomized, placebo‐controlled, double‐blind trial.

Eur J Gastroenterol Hepatol. 2007 Aug;19(8):639‐46.

37: Kupfer B, Sing T, Schüffler P, Hall R, Kurz R, McKeown A, Schneweis KE, Eberl W,

Oldenburg J, Brackmann HH, Rockstroh JK, Spengler U, Däumer MP, Kaiser R, Lengauer T,

Matz B.

Fifteen years of env C2V3C3 evolution in six individuals infected clonally with human immuno‐

deficiency virus type 1.

J Med Virol. 2007 Nov;79(11):1629‐39.

38: Kupfer B, Matz B, Däumer MP, Roden F, Rockstroh JK, Qurishi N, Spengler U, Kaiser R.

Frequent detection of cell‐associated HIV‐1 RNA in patients with plasma viral load <50 cop‐

ies/ml.

J Med Virol. 2007 Oct;79(10):1440‐5.

39: Lamberti C, Lundin S, Bogdanow M, Pagenstecher C, Friedrichs N, Büttner R, Sauerbruch

T.

Microsatellite instability did not predict individual survival of unselected patients with colo‐

rectal cancer.

Int J Colorectal Dis. 2007 Feb;22(2):145‐52.

40: Lammert F, Reichel C.

[Intrahepatic cholestasis of pregnancy: new molecular mechanisms and clinical pathways].

Dtsch Med Wochenschr. 2007 Nov;132(45):2378‐82.

155

41: Lammert F, Neubrand MW, Bittner R, Feussner H, Greiner L, Hagenmüller F, Kiehne KH,

Ludwig K, Neuhaus H, Paumgartner G, Riemann JF, Sauerbruch T;.

Deutschen Gesellschaft für Verdauungs‐und Stoffwechselkrankheiten; Deutschen Gesell‐

schaft für Viszeralchirurgie zur Diagnostik und Behandlung von Gallensteinen.

S3‐guidelines for diagnosis and treatment of gallstones. German Society for Digestive and

Metabolic Diseases and German Society for Surgery of the Alimentary Tract].

Z Gastroenterol. 2007 Sep;45(9):971‐1001.

42: Langhans B, Ahrendt M, Spengler U

Response to: Flow cytometric cellediated cytotoxicity assay.

J Immunol Methods. 2007;318(1‐2): 160‐161.

43: Lorch A, Kollmannsberger C, Hartmann JT, Metzner B, Schmidt‐Wolf IGH, Berdel WE,

Weissinger F, Schleicher J, Egerer G, Haas A, Schirren R, Beyer J, Bokemeyer C, Rick O; Ger‐

man Testicular Cancer Study Group.

Single versus sequential high‐dose chemotherapy in patients with relapsed or refractory

germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer

Study Group.

J Clin Oncol. 2007 Jul 1;25(19):2778‐84.

44: Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M.

The way forward in HCV treatment‐‐finding the right path.

Nat Rev Drug Discov. 2007 Dec;6(12):991‐1000. Review. Erratum in: Nat Rev Drug Discov. 2008

Jan;7(1):102.

45: Märten A, Lilienfeld‐Toal M, Büchler MW, Schmidt J.

Zoledronic acid has direct antiproliferative and antimetastatic effect on pancreatic carcinoma

cells and acts as an antigen for delta2 gamma/delta T cells.

J Immunother. 2007;30(4): 370‐7.

46: Mella JG, Schirin‐Sokhan R, Rigotti A, Pimentel F, Villarroel L, Wasmuth HE, Sauerbruch

T, Nervi F, Lammert F, Miquel JF.

Genetic evidence that apolipoprotein E4 is not a relevant susceptibility factor for cholelithi‐

asis in two high‐risk populations.

J Lipid Res. 2007 Jun;48(6):1378‐85.

156

47: Mey UJ, Maier A, Schmidt‐Wolf IGH, Ziske C, Forstbauer H, Banat GA, Reber M, Strehl

JW, Gorschlüter M.

Pegfilgrastim as hematopoietic support for dose‐dense chemoimmunotherapy with R‐

CHOP14 as first‐line therapy in elderly patients with diffuse large B cell lymphoma.

Support Care Cancer. 2007 Jul;15(7):877‐84.

48: Mocroft A, Staszewski S, Weber R, Gatell J, Rockstroh J, Gasiorowski J, Panos G, Mon‐

forte A, Rakhmanova A, Phillips AN, Lundgren JD; EuroSIDA study group.

Risk of discontinuation of nevirapine due to toxicities in antiretroviral‐naive and ‐experienced

HIV‐infected patients with high and low CD4+ T‐cell counts.

Antivir Ther. 2007;12(3):325‐33.

49: Nattermann J, Vogel M, Berg T, Danta M, Axel B, Mayr C, Bruno R, Tural C, Klausen G,

Clotet B, Lutz T, Grünhage F, Rausch M, Nischalke HD, Schewe K, Bienek B, Haerter G, Sauer‐

bruch T, Rockstroh JK, Spengler U; Kompetenznetz HIV/AIDS.

Effect of the interleukin‐6 C174G gene polymorphism on treatment of acute and chronic

hepatitis C in human immunodeficiency virus coinfected patients.

Hepatology. 2007 Oct;46(4):1016‐25.

50: Oette M, Kaiser R, Däumer M, Fätkenheuer G, Rockstroh JK, Knechten H, Mitrenga D,

Beerenwinkel N, Sagir A, Pfister H, Häussinger D.

[Epidemiology of primary drug resistance in chronically HIV‐infected patients in Nordrhein‐

Westfalen, Germany, 2001‐2005].


51: Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J,

Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang‐Koehler K, Bechstein

WO, Niedergethmann M, Schmidt‐Wolf IGH, Roll L, Doerken B, Riess H.

Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curativein‐

tent resection of pancreatic cancer: a randomized controlled trial.

JAMA. 2007 Jan 17;297(3):267‐77.


Can modifications of the MDRD formula improve the estimation of glomerular filtration rate

in renal allograft recipients?

Nephrol Dial Transplant. 2007 Dec;22(12):3610‐3615.


Renal handling of cystatin C.

Nephrol Dial Transplant. 2007 Apr;22(4):1267‐8.

157

54: Rodríguez‐Torres M, Gonzalez‐Garcia J, Bräu N, Solá R, Moreno S, Rockstroh J, Smaill F,

Mendes‐Correa MC, DePamphilis J, Torriani FJ, APRICOT Investigators .

Occult hepatitis B virus infection in the setting of hepatitis C virus (HCV) and human immuno‐

deficiency virus (HIV) co‐infection: clinically relevant or a diagnostic problem?

J Med Virol. 2007;79(6): 694‐700.

55: Rockstroh J.

HIV/hepatitis co‐infection.

J HIV Ther 2007; 12 (1): 1.

56: Sagir A, Oette M, Kaiser R, Däumer M, Fätkenheuer G, Rockstroh JK, Knechten H,

Schmutz G, Hower M, Emmelkamp J, Pfister H, Häussinger D; RESINA Study Team.

Trends of prevalence of primary HIV drug resistance in Germany.

J Antimicrob Chemother. 2007 Oct;60(4):843‐8.

57: Salzberger B, Däumer M, Gute P, Jaeger H, Knechten H, van Lunzen J, Mauss S, Mayr C,

Moll A, Plettenberg A, Rockstroh J, Staszewski S, Stellbrink HJ, Stoll M, Sturmer M.

Consensus recommendation from a group of German experts for the use of enfuvirtide in

heavily pretreated HIV patients.

Eur J Med Res. 2007;12(3): 93‐102.

58: Schafmayer C, Völzke H, Buch S, Egberts J, Spille A, von Eberstein H, Franke A, Seeger M,

Hinz S, Elsharawy A, Rosskopf D, Brosch M, Krawczak M, Foelsch UR, Schafmayer A, Lam‐

mert F, Schreiber S, Faendrich F, Hampe J, Tepel J.

Investigation of the Lith6 candidate genes APOBEC1 and PPARG in human gallstone disease.

Liver Int. 2007 Sep;27(7):910‐9.

59: Schakowski F, Gorschlüter M, Buttgereit P, Märten A, Lilienfeld‐Toal MV, Junghans C,

Schroff M, König‐Merediz SA, Ziske C, Strehl J, Sauerbruch T, Wittig B, Schmidt‐Wolf IGH.

Minimal size MIDGE vectors improve transgene expression in vivo.

In Vivo. 2007 Jan‐Feb;21(1):17‐23.

60: Schepke M.

Hepatorenal syndrome: current diagnostic and therapeutic concepts.

Nephrol Dial Transplant. 2007 Sep;22 Suppl 8:viii2‐viii4.

61: Schmitz V, Raskopf E, Gonzalez‐Carmona MA, Vogt A, Rabe C, Leifeld L, Kornek M, Sauer‐

bruch T, Caselmann WH.

Plasminogen fragment K1‐5 improves survival in a murine hepatocellular carcinoma model.

Gut. 2007 Feb;56(2):271‐8. Epub 2006 Jun 29.

158

62: Schneider G, Paus TC, Kullak‐Ublick GA, Meier PJ, Wienker TF, Lang T, van de Vondel P,

Sauerbruch T, Reichel C.

Linkage between a new splicing site mutation in the MDR3 alias ABCB4 gene and intrahepatic

cholestasis of pregnancy.

Hepatology. 2007 Jan;45(1):150‐8.

63: Schuler U, Bammer S, Aulitzky WE, Binder C, Böhme A, Egerer G, Sandherr M, Schwerdt‐

feger R, Silling G, Wandt H, Glasmacher A, Ehninger G.

Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal ther‐

apy for neutropenic fever in patients with haematological malignancy.

Onkologie. 2007 Apr;30(4):185‐91.

64: Sievers E, Dreimuller P, Haferkamp A, Schmidt‐Wolf IGH, Buchler MW, Schmidt J, Märten

A.

Characterization of primary renal carcinoma cultures.

Urol Int. 2007;79(3):235‐43.

65: Simon A, Besuden M, Vezmar S, Hasan C, Lampe D, Kreutzberg S, Glasmacher A, Bode U,

Fleischhack G.

Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or

autologous stem cell transplants.

Support Care Cancer. 2007 Feb;15(2):213‐20.

66: Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M, Mauss S, Bräu N,

Hatzakis A, Pol S, Rockstroh J.

Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations

from the HCV‐HIV International Panel .

AIDS. 2007;21(9):1073‐89.

67: Spengler U, Nattermann J.

Immunopathogenesis in hepatitis C virus cirrhosis.

Clin Sci (Lond). 2007 Feb;112(3):141‐55.

68: Stickel F, Lammert F.

NASH, Insulinresistenz und Diabetes mellitus.

Med Welt 2007; 58 (5): 231‐239.

69: Streeck H, Rockstroh JK.

Review of tipranavir in the treatment of drug‐resistant HIV.

Ther Clin Risk Manag. 2007 Aug;3(4):641‐51.

70: Terjung B, Lammert F.

159

[Lactose intolerance: new aspects of an old problem].

Dtsch Med Wochenschr. 2007 Feb 9;132(6):271‐5. .Erratum in: Dtsch Med Wochenschr. 2007

Mar 23;132(12):634.

71: Tischendorf JJ, Yagmur E, Scholten D, Vidacek D, Koch A, Winograd R, Gressner AM,

Trautwein C, Wasmuth HE, Lammert F.

The interleukin‐6 (IL6)‐174 G/C promoter genotype is associated with the presence of septic

shock and the ex vivo secretion of IL6.

Int J Immunogenet. 2007 Dec;34(6):413‐8.

72: Trebicka J, Hennenberg M, Laleman W, Shelest N, Biecker E, Schepke M, Nevens F, Sau‐

erbruch T, Heller J.

Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho‐kinase and ac‐

tivation of endothelial nitric oxide synthase.

Hepatology. 2007 Jul;46(1):242‐53.

73 Trebicka J, Sauerbruch T, Heller J.

Atorvastatin and portal pressure –Reply.

Hepatology. 2007;46(4): 1310‐1310 .

74: van der Lee M, Sankatsing R, Schippers E, Vogel M, Fätkenheuer G, van der Ven A, Kroon

F, Rockstroh J, Wyen C, Bäumer A, de Groot E, Koopmans P, Stroes E, Reiss P, Burger D.

Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvas‐

tatin in HIV‐infected patients.

Antivir Ther. 2007;12(7):1127‐32.

75: Van Mil SW, Milona A, Dixon PH, Mullenbach R, Geenes VL, Chambers J, Shevchuk V,

Moore GE, Lammert F, Glantz AG, Mattsson LA, Whittaker J, Parker MG, White R, Williamson

C.

Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of

pregnancy.



[Chronic HIV infection. Current therapeutic aspects].

Internist (Berl). 2007 May;48(5):519‐24; quiz 525. German.

77: Vogel M, Rockstroh J.

Highlights of the third international workshop on HIV and hepatitis coinfection.

Expert Rev Anti Infect Ther. 2007 Oct;5(5):769‐71.

78: Vogel M, Wasmuth JC, Rockstroh JK, Holm S, Kuhlmann B.

Repeated HCV‐clearance in an HIV‐infected patient.

160

Infection. 2007 Apr;35(2):120‐1.

79: von Lilienfeld‐Toal M, Hahn‐Ast C, Kirchner H, Flieger D, Dölken G, Glasmacher A.

A randomized comparison of immediate versus delayed application of G‐CSF in induction

therapy for patients with acute myeloid leukemia unfit for intensive chemotherapy.

Haematologica. 2007 Dec;92(12):1719‐20.

80: von Lilienfeld‐Toal M, Midgley K, Lieberbach S, Barnard L, Glasmacher A, Gilleece M,

Cook G.

Observation‐based early warning scores to detect impending critical illness predict in‐hospital

and overall survival in patients undergoing allogeneic stem cell transplantation.

Biol Blood Marrow Transplant. 2007 May;13(5):568‐76.

81: von Lilienfeld‐Toal M, Gilleece M, Cook G.

Systemic toxoplasmosis post allogeneic stem cell transplantation (Allo‐SCT): lessons learned

from HIV?

Biol Blood Marrow Transplant. 2007;13(7): 871‐2.

82: Walden CM, Sandhoff R, Chuang CC, Yildiz Y, Butters TD, Dwek RA, Platt FM, van der

Spoel AC.

Accumulation of glucosylceramide in murine testis, caused by inhibition of beta‐glucosidase 2:

implications for spermatogenesis.

J Biol Chem. 2007;282(45): 32655‐64.

83: Wasmuth HE, Glantz A, Keppeler H, Simon E, Bartz C, Rath W, Mattsson LA, Marschall

HU, Lammert F.

Intrahepatic cholestasis of pregnancy: the severe form is associated with common variants of

the hepatobiliary phospholipid transporter ABCB4 gene.

Gut. 2007 Feb;56(2):265‐70.

84: Wasmuth JC, Lambertz I, Voigt E, Vogel M, Hoffmann C, Burger D, Rockstroh JK.

Maintenance of indinavir by dose adjustment in HIV‐1‐infected patients with indinavir‐related

toxicity.

Eur J Clin Pharmacol. 2007 Oct;63(10):901‐8.

161

85: Wasmuth JC, Rodermann E, Voigt E, Vogel M, Lauenroth‐Mai E, Jessen A, Burger D, Rock‐

stroh JK.

Comparison of indinavir + ritonavir 600 + 100 mg vs. 400 + 100 mg BID combinations in HIV1‐

infected patients guided by therapeutic drug monitoring.

Eur J Med Res. 2007 Jul 26;12(7):289‐94.

86: Wasmuth JC, Rockstroh JK.

[HIV‐infection]

Dtsch Med Wochenschr. 2007 Mar 30;132(13):673‐83; quiz 685‐6.

87: Weinberger F, Lammert F.

[Splenectomy in splenic artery thrombosis in the context of chronic pancreatitis].

Dtsch Med Wochenschr. 2007 Nov;132(44):2323‐4. German. No abstract available.

88: Wittenburg H, Lammert F.

Genetic predisposition to gallbladder stones.

Semin Liver Dis. 2007 Feb;27(1):109‐21.

89: Wojcik K, Vogel M, Voigt E, Speidel N, Kalff JC, Goldmann G, Oldenburg J, Sauerbruch T,

Rockstroh JK, Spengler U.

Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV‐infected

patients: outcome in the Bonn cohort.

AIDS. 2007 Jun 19;21(10):1363‐5.

90: Yagmur E, Rizk M, Stanzel S, Hellerbrand C, Lammert F, Trautwein C, Wasmuth HE,

Gressner AM.

Elevation of endoglin (CD105) concentrations in serum of patients with liver cirrhosis and car‐

cinoma.

Eur J Gastroenterol Hepatol. 2007 Sep;19(9):755‐61.

162

2008

1: Antiretroviral Therapy Cohort Collaboration

Life expectancy of individuals on combination antiretroviral therapy in high‐income countries:

a collaborative analysis of 14 cohort studies.

Lancet 2008;372(9635): 293‐99.

2: Appenrodt B, Wolf A, Grünhage F, Trebicka J, Schepke M, Rabe C, Lammert F, Sauerbruch

T, Heller J.

Prevention of paracentesis‐induced circulatory dysfunction: midodrine vs albumin. A random‐

ized pilot study.

Liver Int. 2008 Aug;28(7):1019‐25.

3: Balta Z, Sauerbruch T, Hirner A, Büttner R, Fischer HP.

[Primary neuroendocrine carcinoma of the liver. From carcinoid tumor to small‐cell hepatic

carcinoma: case reports and review of the literature].

Pathologe. 2008 Feb;29(1):53‐60.

4: Baulmann J, Schillings U, Rickert S, Uen S, Düsing R, Illyes M, Cziraki A, Nickenig G, Meng‐

den T.

A new oscillometric method for assessment of arterial stiffness: comparison with tonometric

and piezo‐electronic methods.

J Hypertens. 2008 Mar;26(3):523‐8.

5: Beier I, Düsing R, Vetter H, Schmitz U.

Epidermal growth factor stimulates Rac1 and p21‐activated kinase in vascular smooth muscle

cells.

Atherosclerosis. 2008 Jan;196(1):92‐7.

6: Biecker E, Trebicka J, Kang A, Hennenberg M, Sauerbruch T, Heller J.

Treatment of bile duct‐ligated rats with the nitric oxide synthase transcription enhancer AVE

9488 ameliorates portal hypertension.

Liver Int. 2008 Mar;28(3):331‐8.

7: Biecker E, Heller J, Schmitz V, Lammert F, Sauerbruch T.

Effiziente Diagnostik und Therapie gastrointestinaler Blutungen.

Dt. Ärzteblatt 2008; 105(5):85‐94.

163

8: Bihari P, Vippola M, Schultes S, Praetner M, Khandoga AG, Reichel CA, Coester C, Tuomi T,

Rehberg M, Krombach F.

Optimized dispersion of nanoparticles for biological in vitro and in vivo studies

Part Fibre Toxicol. 2008 Nov 6;5:14.

9: Blass SC, Ellinger S, Vogel M, Ingiliz P, Spengler U, Stehle P, von Ruecker A, Rockstroh JK.

Overweight HIV patients with abdominal fat distribution treated with protease inhibitors are

at high risk for abnormalities in glucose metabolism a reason for glycemic control.

Eur J Med Res. 2008 May 26;13(5):209‐14.

10: Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B,

Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan

DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ,

Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen BY; BENCHMRK Study Teams.

Subgroup and resistance analyses of raltegravir for resistant HIV‐1 infection.

N Engl J Med. 2008 Jul 24;359(4):355‐65.

11: Düsing R, Nitschmann S.

[Therapy of patients at high risk for vascular events: telmisartan, ramipril or a combination?].

Internist (Berl). 2008 Sep;49(9):1137‐40.

12: Düsing R.

[Hypertensive patient with metabolic syndrome: would you prescribe

a diuretic as the initial treatment? (interview by Thomas Meissner)].

MMW Fortschr Med. 2008 Mar 20;150(12):17.

13: Ellinger S, Arendt BM, Fimmers R, Stehle P, Spengler U, Goerlich R.

Bolus ingestion but not regular consumption of native or dealcoholized red wine modulates

selected immunological functions of leukocytes in healthy volunteers.

Ann Nutr Metab. 2008;52(4):288‐95.

14: Emmelkamp JM, Rockstroh JK.

Maraviroc, risks and benefits: a review of the clinical literature.

Expert Opin Drug Saf. 2008 Sep;7(5):559‐69.

15: German‐Austrian recommendations for HIV postexposure prophylaxis.

Eur J Med Res. 2008 Dec 3;13(12):539‐45.

164

16: Glantz A, Reilly SJ, Benthin L, Lammert F, Mattsson LA, Marschall HU.

Intrahepatic cholestasis of pregnancy: Amelioration of pruritus by UDCA is associated with

decreased progesterone disulphates in urine.

Hepatology. 2008 Feb;47(2):544‐51.

17 : Gonzalez‐Carmona MA, Lukacs‐Kornek V, Timmerman A, Shabani S, Kornek M, Vogt A,

Yildiz Y, Sievers E, Schmidt‐Wolf IG, Caselmann WH, Sauerbruch T, Schmitz V.

CD40ligand‐expressing dendritic cells induce regression of hepatocellular carcinoma by acti‐

vating innate and acquired immunity in vivo.

Hepatology. 2008 Jul;48(1):157‐68.

18: Gorschlüter M, Schmitz V, Mey U, Hahn‐Ast C, Schmidt‐Wolf IG, Sauerbruch T.

Endoscopy in patients with acute leukaemia after intensive chemotherapy.

Leuk Res. 2008 Oct;32(10):1510‐7.

19: Gressner O, Popp H, Mey U, Friedrichs N, Strehl J, Sauerbruch T, Schmidt‐Wolf IG,

Gorschlüter M.

Long‐term survival of a patient with small cell lung cancer after nine lines of chemotherapy

and radiation.

Onkologie. 2008 Sep;31(8‐9):469‐72.

20: Grünhage F, Rezori B, Neef M, Lammert F, Sauerbruch T, Spengler U, Reichel C.

Elevated soluble tumor necrosis factor receptor 75 concentrations identify patients with liver

cirrhosis at risk of death.

Clin Gastroenterol Hepatol. 2008 Nov;6(11):1255‐62.

21: Grünhage F, Jungck M, Lamberti C, Berg C, Becker U, Schulte‐Witte H, Plassmann D, Rah‐

ner N, Aretz S, Friedrichs N, Buettner R, Sauerbruch T, Lammert F.

Association of familial colorectal cancer with variants in the E‐cadherin (CDH1) and cyclin D1

(CCND1) genes.

Int J Colorectal Dis. 2008 Feb;23(2):147‐54.

22: Grünhage F, Jungck M, Lamberti C, Keppeler H, Becker U, Schulte‐Witte H, Plassmann D,

Friedrichs N, Buettner R, Aretz S, Sauerbruch T, Lammert F.

Effects of common haplotypes of the ileal sodium dependent bile acid transporter gene on

the development of sporadic and familial colorectal cancer: a case control study.

BMC Med Genet. 2008 Jul 21;9:70.

23: Grünhage F, Heller J, Appenrodt B, Schmitz V, Sauerbruch T.

[Complications of liver cirrhosis, medical management].

Med Klin (Munich). 2008 Jul 15;103(7):482‐90.

165

24: Grünhage F, Jungck M, Lamberti C, Schulte‐Witte H, Plassmann D, Becker U, Rahner N,

Aretz S, Friedrichs N, Buettner R, Sauerbruch T, Lammert F.

Contribution of common monoallelic MUTYH gene variants in German patients with familial

colorectal cancer.

Cancer Biomark. 2008;4(2):55‐61.

25: Haenisch B, von Kügelgen I, Bönisch H, Göthert M, Sauerbruch T, Schepke M, Marklein G,

Höfling K, Schröder D, Molderings GJ.

Regulatory mechanisms underlying agmatine homeostasis in humans.

Am J Physiol Gastrointest Liver Physiol. 2008 Nov;295(5):G1104‐10.

26: Harris RJ, Sterne JA, Abgrall S, Dabis F, Reiss P, Saag M, Phillips AN, Chêne G, Gill JM,

Justice AC, Rockstroh J, Sabin CA, Mocroft A, Bucher HC, Hogg RS, Monforte AD, May M,

Egger M; Antiretroviral Therapy Cohort Collaboration.

Prognostic importance of anaemia in HIV type‐1‐infected patients starting antiretroviral ther‐

apy: collaborative analysis of prospective cohort studies.

Antivir Ther. 2008;13(8):959‐67.

27: Hausen A, Sauerbruch T.

26‐year‐old patient with nausea and pressure pain in the upper abdomen].


28: Hennenberg M, Trebicka J, Sauerbruch T, Heller J.

Mechanisms of extrahepatic vasodilation in portal hypertension.

Gut. 2008 Sep;57(9):1300‐14.

29: Höblinger A, Tiemann K, Nickenig G, Sauerbruch T, Lammert F.

Resolution of refractory ascites after transcoronary septal ablation for hypertrophic obstruc‐

tive cardiomyopathy in a cirrhotic patient.


30: Höblinger A, Lammert F.

Genetics of biliary tract diseases: new insights into gallstone disease and biliary tract cancers.

Curr Opin Gastroenterol. 2008 May;24(3):363‐71.

31: Kaskel P, Tuschy S, Wagner A, Bannert C, Cornely OA, Glasmacher A, Lipp HP, Ullmann AJ.

Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of

suspected systemic fungal infection in the German hospital setting.

Ann Hematol. 2008 Apr;87(4):311‐9.

32: Kornek M, Lukacs‐Kornek V, Limmer A, Raskopf E, Becker U, Klöckner M, Sauerbruch T,

Schmitz V.

166

1,2‐dioleoyl‐3‐trimethylammonium‐propane (DOTAP)‐formulated, immune‐stimulatory vascu‐

lar endothelial growth factor a small interfering RNA (siRNA) increases antitumoral efficacy in

murine orthotopic hepatocellular carcinoma with liver fibrosis.

Mol Med. 2008 Jul‐Aug;14(7‐8):365‐73.

33: Kornek M, Raskopf E, Tolba R, Becker U, Klöckner M, Sauerbruch T, Schmitz V.

Accelerated orthotopic hepatocellular carcinomas growth is linked to increased expression of

pro‐angiogenic and prometastatic factors in murine liver fibrosis.

Liver Int. 2008 Apr;28(4):509‐18.

34: Krawczyk M, Wolska M, Schwartz S, Grünhage F, Terjung B, Portincasa P, Sauerbruch T,

Lammert F.

Concordance of genetic and breath tests for lactose intolerance in a tertiary referral centre.

J Gastrointestin Liver Dis. 2008 Jun;17(2):135‐9.

35: Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, Lee B, Heckerman D, Carl‐

son J, Reyor LL, Kleyman M, McMahon CM, Birch C, Schulze Zur Wiesch J, Ledlie T, Koehrsen

M, Kodira C, Roberts AD, Lauer GM, Rosen HR, Bihl F, Cerny A, Spengler U, Liu Z, Kim AY,

Xing Y, Schneidewind A, Madey MA, Fleckenstein JF, Park VM, Galagan JE, Nusbaum C,

Walker BD, Lake‐Bakaar GV, Daar ES, Jacobson IM, Gomperts ED, Edlin BR, Donfield SM,

Chung RT, Talal AH, Marion T, Birren BW, Henn MR, Allen TM.

Naturally occurring dominant resistance mutations to hepatitis C virus protease and poly‐

merase inhibitors in treatment‐naïve patients.

Hepatology. 2008 Dec;48(6):1769‐78.

36: Lammert F, Neubrand MW, Bittner R, Feussner H, Greiner L, Hagenmüller F, Kiehne KH,

Ludwig K, Neuhaus H, Paumgartner G, Riemann JF, Sauerbruch T; Deutsche Gesellschaft für

Verdauungs‐ und Stoffwechselkrankheiten (DGVS); Deutsche Gesellschaft für Viszeralchi‐

rurgie (DGVC).

[Short version of the updated S3 (level 3) guidelines for diagnosis and treatment of gallstones

of the German Society for Digestive and Metabolic Diseases and the German Society for the

Surgery of the Alimentary Tract].

Dtsch Med Wochenschr. 2008 Feb;133(7):311‐6.

37: Leifeld L, Merk Ph, Schmitz V, Nattermann J, Kalff JC, Hirner A, Sauerbruch T, Spengler U.

Course and therapy of acute liver failure.

Eur J Med Res 2008;13:87‐91.

167

38: Low E, Vogel M, Rockstroh J, Nelson M.

Acute hepatitis C in HIV‐positive individuals.

AIDS Rev. 2008 Oct‐Dec;10(4):245‐53.

39: Mehendale S, van Lunzen J, Clumeck N, Rockstroh J, Vets E, Johnson PR, Anklesaria P,

Barin B, Boaz M, Kochhar S, Lehrman J, Schmidt C, Peeters M, Schwarze‐Zander C, Kabamba

K, Glaunsinger T, Sahay S, Thakar M, Paranjape R, Gilmour J, Excler JL, Fast P, Heald AE.

A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 sub‐

type C adeno‐associated virus vaccine.

AIDS Res Hum Retroviruses. 2008 Jun;24(6):873‐80.

40: Muehlenberg K, Wiedmann K, Keppeler H, Sauerbruch T, Lammert F.

Recurrent intrahepatic cholestasis of pregnancy and chain‐like choledocholithiasis in a female

patient with stop codon in the ABDC4‐gene of the hepatobiliary phospholipid transporter].


41: Nattermann J, Sherzada R, Iwan A, Bogen D, Niederle IM, Schulte D, Mertens E, Nischalke

HD, Krämer B, Sauerbruch T, Leifeld L, Spengler U.

Hepatitis C virus‐induced secretion of inflammatory chemokines preferentially recruits

NKG2A+CD8+ T cells.

J Infect Dis. 2008 Jul 15;198(2):213‐7.

42: Nattermann J, Vogel M, Nischalke HD, Danta M, Ahlenstiel G, Michalk M, Sauerbruch T,

Rockstroh JK, Spengler U; Kompetenznetz HIV/AIDS.

The transforming growth factor‐beta high‐producer genotype is associated with response to

hepatitis C virus‐specific therapy in HIV‐positive patients with acute hepatitis C.

AIDS. 2008 Jul 11;22(11):1287‐92.

43: Nellessen CM, Pöge U, Brensing KA, Sauerbruch T, Klehr HU, Rabe C.

Diffuse alveolar haemorrhage in a systemic lupus erythematosus patient successfully treated

with rituximab: a case report.

Nephrol Dial Transplant. 2008 Jan;23(1):385‐6.

44: Okamoto K, Neureiter D, Alinger B, Sass G, Schmitz V, DiFazio P, Kaufmann B, Schlösser

A, Haus U, Hahn EG, Herold C, Ocker M.

The dual EGF/VEGF receptor tyrosine kinase inhibitor AEE788 inhibits growth of human hepa‐

tocellular carcinoma xenografts in nude mice.

Int J Oncol 2008;33:733‐742.

168

45: Pavlova A, Diaz‐Lacava A, Zeitler H, Satoguina J, Niemann B, Krause M, Scharrer I,

Hoerauf A, Wienker T, Oldenburg J.

Increased frequency of the CTLA‐4 49 A/G polymorphism in patients with acquired haemo‐

philia A compared to healthy controls.

Haemophilia. 2008 Mar;14(2):355‐60.

46: Potthoff A, Wedemeyer H, Boecher WO, Berg T, Zeuzem S, Arnold J, Spengler U, Gruen‐

greiff K, Kaeser T, Schuchmann M, Bergk A, Forestier N, Deterding K, Manns MP, Trautwein

C; Hep‐Net B/C Co‐infection Study Group.

The HEP‐NET B/C co‐infection trial: A prospective multicenter study to investigate the efficacy

of pegylated interferon‐alpha2b and ribavirin in patients with HBV/HCV co‐infection.

J Hepatol. 2008 Nov;49(5):688‐94


Estimation of glomerular filtration rate by use of beta‐trace protein.

Clin Chem. 2008 Aug;54(8):1403‐5.


Equations to estimate GFR using serum cystatin C in kidney transplant recipients.

Am J Kidney Dis. 2008 Aug;52(2):383‐4.

49: Pöge U, Gerhardt TM, Stoffel‐Wagner B, Woitas RP.

Need of standardization for creatinine and cystatin C‐based GFR equations in renal transplan‐

tation.

Nephrol Dial Transplant. 2008 May;23(5):1763; author reply 1763‐4.


Beta‐trace protein‐based equations for calculation of GFR in renal transplant recipients.

Am J Transplant. 2008 Mar;8(3):608‐15.

51: Raskopf E, Vogt A, Sauerbruch T, Schmitz V.

siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in

vivo.

J Hepatol. 2008 Dec;49(6):977‐84.

52: Rockstroh J, Dejesus E, Donatacci L, Wat C, Bertasso A, Labriola‐Tompkins E, Shikhman A,

Atkins B, Guimaraes D, Wilkinson M, Thommes J, Rowell L, Demasi R, Salgo M.

Adherence to enfuvirtide and its impact on treatment efficacy.

AIDS Res Hum Retroviruses. 2008 Feb;24(2):141‐8.

169

53: Rockstroh JK, Vogel M.

Metabolic changes under HIV therapy.

Diabetes Stoffwech Herz 2008; 17(4): 289‐97.

54: Rockstroh JK, Wasmuth JC.

[Rational use of modern substances for the treatment of HIV‐infection].

Internist (Berl). 2008 Dec;49(12):1463‐4, 1466‐9.

55: Rockstroh JK, Bhagani S, Benhamou Y, Bruno R, Mauss S, Peters L, Puoti M, Soriano V,

Tural C; EACS Executive Committee.

European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment

of chronic hepatitis B and C coinfection in HIV‐infected adults.

HIV Med. 2008 Feb;9(2):82‐8

56: Sagir A, Adams O, Oette M, Vogel M, Kupfer B, Emmelkamp J, Rockstroh J, Häussinger D.

SEN Virus infection in HIV/HCV coinfected patients.

Eur J Med Res. 2008 Nov 24;13(11):495‐9.

57: Salloum S, Oniangue‐Ndza C, Neumann‐Haefelin C, Hudson L, Giugliano S, aus dem

Siepen M, Nattermann J, Spengler U, Lauer GM, Wiese M, Klenerman P, Bright H,

Scherbaum N, Thimme R, Roggendorf M, Viazov S, Timm J.

Escape from HLA‐B*08‐restricted CD8 T cells by hepatitis C virus is associated with fitness

costs.

J Virol. 2008 Dec;82(23):11803‐12.

58: Sanyal AJ, Boyer T, Garcia‐Tsao G, Regenstein F, Rossaro L, Appenrodt B, Blei A, Gülberg

V, Sigal S, Teuber P; Terlipressin Study Group.

A randomized, prospective, double‐blind, placebo‐controlled trial of terlipressin for type 1

hepatorenal syndrome.


59: Sass G, Leukel P, Schmitz V, Raskopf E, Ocker M, Neureiter D, Meissnitzer M, Tasika E,

Tannapfel A, Tiegs G.

Inhibition of heme oxygenase 1 expression by small interfering RNA decreases orthotopic

tumor growth in livers of mice.

Int J Cancer. 2008 Sep 15;123(6):1269‐77.

170

60: Schepke M, Wiest R, Flacke S, Heller J, Stoffel‐Wagner B, Herold T, Ghauri M, Sauerbruch

T.

Irbesartan plus low‐dose propranolol versus low‐dose propranolol alone in cirrhosis: a pla‐

cebo‐controlled, double‐blind study.

Am J Gastroenterol.2008 May;103(5):1152‐8.

61: Schmitz V, Raskopf E, Gonzalez‐Carmona MA, Vogt A, Kornek M, Sauerbruch T, Casel‐

mann WH.

Plasminogen derivatives encoding kringles 1‐4 and kringles 1‐5 exert indirect antiangiogenic

and direct antitumoral effects in experimental lung cancer.

Cancer Invest. 2008 Jun;26(5):464‐70.

62: Seidel MF, Fiebich BL, Ulrich‐Merzenich G, Candelario‐Jalil E, Koch FW, Vetter H.

Serotonin mediates PGE2 overexpression through 5‐HT2A and 5‐HT3 receptor subtypes in

serum‐free tissue culture of macrophage‐like synovial cells.

Rheumatol Int. 2008 Aug;28(10):1017‐22.

63: Sikora P, von Unruh GE, Beck B, Feldkötter M, Zajaczkowska M, Hesse A, Hoppe B.

[13C2]oxalate absorption in children with idiopathic calcium oxalate urolithiasis or primary

hyperoxaluria.

Kidney Int. 2008 May;73(10):1181‐6.

64: Soriano V, Geretti AM, Perno CF, Fätkenheuer G, Pillay D, Reynes J, Tambussi G, Calvez V,

Alcamí J, Rockstroh J.

Optimal use of maraviroc in clinical practice.

AIDS. 2008 Nov 12;22(17):2231‐40.

65: Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S, Peters L,

Karlsson A, Katlama C, Toro C, Kupfer B, Vogel M, Lundgren J; EuroSIDA Study Group.

Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in

HIV‐infected patients with anti‐HCV antibodies in Europe.

J Infect Dis. 2008 Nov 1;198(9):1337‐44.

66: Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, Zoulim F, Mauss S, Rockstroh J.

Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV‐

Hepatitis B Virus International Panel.

AIDS. 2008 Jul 31;22(12):1399‐410.

67: Spengler U.

[Eosinophilic esophagitis].

Dtsch Med Wochenschr. 2008 Sep;133(36):1783‐4.

68: Spengler U, Fischer HP.

171

[Liver biopsy at the intersection of clinical and pathological diagnosis].

Pathologe. 2008 Feb;29(1):6‐14.

69: Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR,

Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Zhao J, Chen J,

Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda

DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen BY, Teppler H. BENCHMRK Study Teams. Ral‐

tegravir with optimized background therapy for resistant HIV‐1 infection.

N Engl J Med. 2008 Jul 24;359(4):339‐54.

70: Tedaldi E, Peters L, Neuhaus J, Puoti M, Rockstroh J, Klein MB, Dore GJ, Mocroft A, Sori‐

ano V, Clotet B, Lundgren JD; SMART Study Group and International Network for Strategic

Initiatives in Global HIV Trials (INSIGHT).

Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the

strategic management of antiretroviral therapy (SMART) study.

Clin Infect Dis. 2008 Dec 1;47(11):1468‐75.

71: Thomas E, von Unruh GE, Hesse A.

Influence of a low‐ and a high‐oxalate vegetarian diet on intestinal oxalate absorption and

urinary excretion.

Eur J Clin Nutr. 2008 Sep;62(9):1090‐7.

72: Trebicka J, Biecker E, Gruenhage F, Stolte M, Meier‐Ruge WA, Sauerbruch T, Lammert F.

Diagnosis of megacystis‐microcolon intestinal hypoperistalsis syndrome with aplastic desmo‐

sis in adulthood: a case report.

Eur J Gastroenterol Hepatol. 2008 Apr;20(4):353‐5.

73: Trebicka J, Leifeld L, Hennenberg M, Biecker E, Eckhardt A, Fischer N, Pröbsting AS,

Clemens C, Lammert F, Sauerbruch T, Heller J.

Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cir‐

rhotic rats.

Hepatology. 2008 Apr;47(4):1264‐76.

74: Voigt E, Tillmann RL, Schewe JC, Molitor E, Schildgen O.

ARDS in an HIV‐positive patient associated to respiratory syncytial virus.

Eur J Med Res. 2008 Mar 31;13(3):131‐2.

172

75: von Wagner M, Hofmann WP, Teuber G, Berg T, Goeser T, Spengler U, Hinrichsen H,

Weidenbach H, Gerken G, Manns M, Buggisch P, Herrmann E, Zeuzem S.

Placebo‐controlled trial of 400 mg amantadine combined with peginterferon alfa‐2a and ri‐

bavirin for 48 weeks in chronic hepatitis C virus‐1 infection.

Hepatology. 2008 Nov;48(5):1404‐11.

76: Wasmuth JC, Fischer HP, Sauerbruch T, Dumoulin FL.

Fatal acute liver failure due to reactivation of hepatitis B following treatment with fludara‐

bine/cyclophosphamide/rituximab for low grade non‐Hodgkin's lymphoma.

Eur J Med Res. 2008 Oct 27;13(10):483‐6.

77: Wyen C, Hendra H, Vogel M, Hoffmann C, Knechten H, Brockmeyer NH, Bogner JR,

Rockstroh J, Esser S, Jaeger H, Harrer T, Mauss S, van Lunzen J, Skoetz N, Jetter A, Groneuer

C, Fätkenheuer G, Khoo SH, Egan D, Back DJ, Owen A. German Competence Network for

HIV/AIDS.

Impact of CYP2B6 983T>C polymorphism on non‐nucleoside reverse transcriptase inhibitor

plasma concentrations in HIV‐infected patients.

J Antimicrob Chemother. 2008 Apr;61(4):914‐8.

78: Zeitler H, Ulrich‐Merzenich G, Richter DF, Vetter H, Walger P.

Multiple benign symmetric lipomatosis‐‐a differential diagnosis of obesity. Is there a rationale

for fibrate treatment?.

Obes Surg. 2008 Oct;18(10):1354‐6.

79: Ziske C, Tiemann K, Schmidt T, Nagaraj S, Märten A, Schmitz V, Clarenbach R, Sauerbruch

T, Schmidt‐Wolf IG.

Real‐time high‐resolution compound imaging allows percutaneous initiation and surveillance

in an orthotopic murine pancreatic cancer model.

Pancreas. 2008 Mar;36(2):146‐52.

173

2009

1: Ahlenstiel G, Woitas RP, Iwan A, Nattermann J, Feldmann G, Rockstroh JK, Oldenburg J,

Kupfer B, Sauerbruch T, Spengler U.

Effects of the CCR5‐Delta32 mutation on hepatitis C virus‐specific immune responses in pa‐

tients with haemophilia.

Immunol Invest. 2009;38(3‐4):284‐96.

2: Ahlenstiel G, Woitas RP, Iwan A, Nattermann J, Feldmann G, Rockstroh JK, Oldenburg J,

Kupfer B, Sauerbruch T, Spengler U.

Effects of the CCR5‐Delta32 mutation on hepatitis C virus‐specific immune responses in pa‐

tients with haemophilia.

Immunol Invest. 2009;38(1):1‐13.

3: Appenrodt B, Zielinski J, Brensing KA, Heller J, Sauerbruch T, Schepke M.

Degree of hepatic dysfunction and improvement of renal function predict survival in patients

with HRS type I: a retrospective analysis.


4: Berg T, Weich V, Teuber G, Klinker H, Möller B, Rasenack J, Hinrichsen H, Gerlach T,

Spengler U, Buggisch P, Balk H, Zankel M, Neumann K, Sarrazin C, Zeuzem S.

Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1‐

infected patients.

Hepatology. 2009 Aug;50(2):369‐77.

5: Berthold HK, Schober P, Scheurlen C, Marklein G, Horré R, Gouni‐Berthold I, Sauerbruch T.

Use of the lactose‐[13C]ureide breath test for diagnosis of small bowel bacterial overgrowth:

comparison to the glucose hydrogen breath test.

J Gastroenterol. 2009;44(9):944‐51.

6: Biecker E, Classen L, Sauerbruch T, Schepke M.

Does therapy of oesophageal varices influences the progression of varices?

Eur J Gastroenterol Hepatol. 2009 Jul;21(7):751‐5.

174

7: Darwish Murad S, Plessier A, Hernandez‐Guerra M, Fabris F, Eapen CE, Bahr MJ, Trebicka J,

Morard I, Lasser L, Heller J, Hadengue A, Langlet P, Miranda H, Primignani M, Elias E, Lee‐

beek FW, Rosendaal FR, Garcia‐Pagan JC, Valla DC, Janssen HL; EN‐Vie (European Network

for Vascular Disorders of the Liver).

Etiology, management, and outcome of the Budd‐Chiari syndrome.

Ann Intern Med. 2009 Aug 4;151(3):167‐75.

8: Dolan G, Hermans C, Klamroth R, Schutgens RE, Spengler U.

Challenges and controversies in haemophilia care in adulthood.

Haemophilia. 2009; 15 Suppl 1: 20‐7.

9: Düsing R, Sellers F.

ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a

review of their role after the ONTARGET trial.

Curr Med Res Opin. 2009 Sep;25(9):2287‐301.

10: Düsing R, Handrock R, Klebs S, Tousset E, Vrijens B

Impact of supportive measures on drug adherence in patients with essential hypertension

treated with valsartan: the randomized, open‐label, parallel group study VALIDATE.

J Hypertens. 2009 Apr;27(4):894‐901.

11: Gerhardt T, Terjung B, Knipper P, Palmedo H, Woitas RP, Kalff J, Sauerbruch T, Spengler

U.

Renal impairment after liver transplantation ‐ a pilot trial of calcineurin inhibitor‐free vs. cal‐

cineurin inhibitor sparing immunosuppression in patients with mildly impaired renal function

after liver transplantation.

Eur J Med Res. 2009 May 14;14(5):210‐5.

12: Hennenberg M, Trebicka J, Kohistani AZ, Heller J, Sauerbruch T.

Vascular hyporesponsiveness to angiotensin II in rats with CCl(4)‐induced liver cirrhosis.

Eur J Clin Invest. 2009 Oct;39(10):906‐13.

13: Hennenberg M, Trebicka J, Buecher D, Heller J, Sauerbruch T.

Lack of effect of norfloxacin on hyperdynamic circulation in bile duct‐ligated rats despite re‐

duction of endothelial nitric oxide synthase function: result of unchanged vascular Rho‐

kinase?

Liver Int. 2009 Jul;29(6):933‐41.

175

14: Hennenberg M, Trebicka J, Stark C, Kohistani AZ, Heller J, Sauerbruch T.

Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with

secondary biliary cirrhosis.

Br J Pharmacol. 2009 May;157(2):258‐70.

15: Höblinger A, Grünhage F, Sauerbruch T, Lammert F.

Association of the c.3972C>T variant of the multidrug resistance‐associated protein 2 Gene

(MRP2/ABCC2) with susceptibility to bile duct cancer.

Digestion. 2009;80(1):36‐9.

16: Höblinger A, Erdmann C, Strassburg CP, Sauerbruch T, Lammert F.

Coinheritance of hereditary spherocytosis and reversibility of cirrhosis in a young female pa‐

tient with hereditary hemochromatosis.

Eur J Med Res. 2009 Apr 16;14(4):182‐4.

17: Hüneburg R, Lammert F, Rabe C, Rahner N, Kahl P, Büttner R, Propping P, Sauerbruch T,

Lamberti C.

Chromocolonoscopy detects more adenomas than white light colonoscopy or narrow band

imaging colonoscopy in hereditary nonpolyposis colorectal cancer screening.

Endoscopy. 2009 Apr;41(4):316‐22.

18: Klotz L, Burgdorf S, Dani I, Saijo K, Flossdorf J, Hucke S, Alferink J, Nowak N, Beyer M,

Mayer G, Langhans B, Klockgether T, Waisman A, Eberl G, Schultze J, Famulok M, Kolanus W,

Glass C, Kurts C, Knolle PA.

The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell‐intrinsic

fashion and suppresses CNS autoimmunity.

J Exp Med. 2009 Sep 28;206(10):2079‐89.

Erratum in: J Exp Med. 2009 Dec 21;206(13):3159. Novak, Natalija [corrected to Nowak, Nina].

19: Krämer B, Schulte D, Körner C, Zwank C, Hartmann A, Michalk M, Söhne J, Langhans B,

Nischalke HD, Coenen M, Möhl C, Vogt A, Hennenberg M, Sauerbruch T, Spengler U, Nat‐

termann J.

Regulation of NK cell trafficking by CD81.

Eur J Immunol. 2009 Dec;39(12):3447‐58.

20: Körner C, Krämer B, Schulte D, Coenen M, Mauss S, Fätkenheuer G, Oldenburg J, Nat‐

termann J, Rockstroh JK, Spengler U.

Effects of HCV co‐infection on apoptosis of CD4+ T‐cells in HIV‐positive patients.

Clin Sci (Lond).2009 May 14;116(12):861‐70.

176

21: Kuhli R, Grünhage F, Reuss HP, Franke W, Reichel C.

Disease Activity and Work‐Related Behavior and Experience Patterns in Patients with Crohn's

Disease.

Physik Med Rehabilitationsmed Kurort. 2009; 19 (3): 169‐74.

22: Lang SA, Moser C, Fichnter‐Feigl S, Schachtschneider P, Hellerbrand C, Schmitz V, Schlitt

HJ, Geissler EK, Stoeltzing O.

Targeting heat‐shock protein 90 improves efficacy of rapamycin in a model of hepatocellular

carcinoma in mice.

Hepatology. 2009 Feb;49(2):523‐32.

23: Lankisch TO, Behrens G, Ehmer U, Möbius U, Rockstroh J, Wehmeier M, Kalthoff S, Frei‐

berg N, Manns MP, Schmidt RE, Strassburg CP.

Gilbert's syndrome and hyperbilirubinemia in protease inhibitor therapy‐‐an extended haplo‐

type of genetic variants increases risk in indinavir treatment.

J Hepatol. 2009 May;50(5):1010‐8.

24: Lanoy E, May M, Mocroft A, Phillip A, Justice A, Chêne G, Furrer H, Sterling T, Monforte

AD, Force L, Gill J, Harris R, Hogg RS, Rockstroh J, Saag M, Khaykin P, de Wolf F, Sterne JA,

Costagliola D. antiretroviral therapy cohort collaboration (ART‐CC)

Prognosis of patients treated with cART from 36 months after initiation, according to current

and previous CD4 cell count and plasma HIV‐1 RNA measurements.

AIDS. 2009 Oct 23;23(16):2199‐208.

25: Leifeld L, Kothe S, Söhl G, Hesse M, Sauerbruch T, Magin TM, Spengler U.

Keratin 18 provides resistance to Fas‐mediated liver failure in mice.

Eur J Clin Invest. 2009 Jun;39(6):481‐8.

26 : Linke A, Brossart P, Schmidt‐Wolf IG, Gonzalez‐Carmona MA, Ziske C, Messmer D,

Schmitz V, Sauerbruch T.

Enhanced inhibition of tumor growth with depletion of CD25 regulatory cells and intratu‐

moral immunization with tumor RNA‐pulsed dendritic cells in a C57BL/6 pancreatic tumor

model.

Pancreas. 2009 Jul;38(5):602‐4.

27: Mas Marques A, Mueller T, Welke J, Taube S, Sarrazin C, Wiese M, Halangk J, Witt H, Ah‐

lenstiel G, Spengler U, Goebel U, Schott E, Weich V, Schlosser B, Wasmuth HE, Lammert F,

Berg T, Schreier E.

Low‐density lipoprotein receptor variants are associated with spontaneous and treatment‐

induced recovery from hepatitis C virus infection.

Infect Genet Evol. 2009 Sep;9(5):847‐52.

177

28: Mikl J, Sulkowski MS, Benhamou Y, Dieterich D, Pol S, Rockstroh J, Robinson PA, Ranga

M, Stern JO.

Hepatic profile analyses of tipranavir in Phase II and III clinical trials.

BMC Infect Dis. 2009 Dec 14;9:203.

29: Nattermann J, Tacke F.

The structure behind diversity: covariance networks in hepatitis C virus sequences are associ‐

ated with treatment response.

Hepatology.2009 May;49(5):1767‐9.

30: Peters L, Mocroft A, Soriano V, Rockstroh JK, Losso M, Valerio L, Aldins P, Reiss P, Leder‐

gerber B, Lundgren JD; EuroSIDA Study Group

Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV‐1‐infected pa‐

tients with maximum virologic suppression.


31: Quante M, Raskopf E, Stahl S, Vogt A, Sauerbruch T, Schmitz V.

No functional and transductional significance of specific neuropilin 1 siRNA inhibition in colon

carcinoma cell lines lacking VEGF receptor 2.

Oncol Rep. 2009 May;21(5):1161‐8.

32: Quante M, Zhou H, Sauerbruch T.

Reply to the comment on "atypical retroperitoneal fibrosis associated with biliary stricture:

IgG4‐ related sclerosing disease?" by Matsushita et al.

Scand J Gastroenterol. 2009;44(9):1152.

33: Quante M, Appenrodt B, Randerath S, Wolff M, Fischer HP, Sauerbruch T.

Atypical Ormond's disease associated with bile duct stricture mimicking cholangiocarcinoma.

Scand J Gastroenterol. 2009;44(1):116‐20.

34: Raskopf E, Gerceker S, Vogt A, Standop J, Sauerbruch T, Schmitz V.

Plasminogen fragment K1‐3 inhibits expression of adhesion molecules and experimental HCC

recurrence in the liver.

Int J Colorectal Dis. 2009 Jul;24(7):837‐44.

35: Reuter S, Meyer D, Knechten H, Oette M, Mitrenga D, Rockstroh J, Fätkenheuer G, Häus‐

singer D.

[Pre‐exposure prophylaxis in HIV‐‐a vision or soon a reality?].

Dtsch Med Wochenschr. 2009 Dec;134(50):2582‐4.

178

36: Risse JH, Pauleit D, Bender H, Rabe C, Fischer HP, Biersack HJ, Bucerius J.

18F‐FDG‐PET and histopathology in 131I‐lipiodol treatment for primary liver cancer.

Cancer Biother Radiopharm. 2009 Aug;24(4):445‐52.

37: Rockstroh J.

HIV and the liver.

J HIV Ther. 2009 Mar;14(1):2‐3.

38: Rockstroh JK.

Hot topics in HIV and hepatitis coinfection: non‐invasive diagnosis of liver disease, liver trans‐

plantation, and new drugs for treatment of hepatitis coinfection.

HIV Clin Trials. 2009 Mar‐Apr;10(2):110‐5.

39: Sankatsing RR, Wit FW, Vogel M, de Groot E, Brinkman K, Rockstroh JK, Kastelein JJ,

Stroes ES, Reiss P.

Increased carotid intima‐media thickness in HIV patients treated with protease inhibitors as

compared to non‐nucleoside reverse transcriptase inhibitors.

Atherosclerosis. 2009 Feb;202(2):589‐95.

40: Sauerbruch T, Gonzalez‐Carmona AM, Nitschmann S.

[Sorafenib in advanced hepatocellular carcinoma].

Internist (Berl). 2009 Nov;50(11):1290‐2.

41: Schepke M, Biecker E, Appenrodt B, Heller J, Sauerbruch T.

Coexisting gastric varices should not preclude prophylactic ligation of large esophageal

varices in cirrhosis.

Digestion. 2009;80(3):165‐9.

42: Schrickel JW, Lewalter T, Lüderitz B, Nickenig G, Klehr HU, Rabe C.

Recovery from ultra‐high dose organophosphate poisoning after "in‐the‐field" antidote

treatment: potential lessons for civil defense.

J Emerg Med. 2009 Oct;37(3):279‐82.

43: Schulte D, Vogel M, Langhans B, Krämer B, Körner C, Nischalke HD, Steinberg V, Michalk

M, Berg T, Rockstroh JK, Sauerbruch T, Spengler U, Nattermann J.

The HLA‐E(R)/HLA‐E(R) genotype affects the natural course of hepatitis C virus (HCV) infec‐

tion and is associated with HLA‐E‐restricted recognition of an HCV‐derived peptide by inter‐

ferongamma‐ secreting human CD8(+) T cells.

J Infect Dis. 2009 Nov 1;200(9):1397‐401.

179

44: Soriano V, Perno CF, Kaiser R, Calvez V, Gatell JM, di Perri G, Pillay D, Rockstroh J, Geretti

AM.

When and how to use maraviroc in HIV‐infected patients.

AIDS. 2009 Nov 27;23(18):2377‐85.

45: Soriano V, Peters M, Rockstroh J

Fourth HIV & Hepatitis Coinfection Workshop; June 19‐21, 2008; Madrid, Spain.

HIV Clin Trials. 2009 Jan‐Feb;10(1):52‐62.

46: Spengler U.

Hepatic microcirculation: a critical but neglected factor for the outcome of viral hepatitis.

J Hepatol. 2009 Mar;50(3):631‐3.

47: Standop J, Schäfer N, Overhaus M, Schmitz V, Ladwein L, Hirner A, Kalff JC.

Endoscopic management of anastomotic hemorrhage from pancreatogastrostomy.

Surg Endosc. 2009 Sep;23(9):2005‐10.

48: Standop J, Glowka T, Schmitz V, Schäfer N, Overhaus M, Hirner A, Kalff JC.

Operative re‐intervention following pancreatic head resection: indications and outcome.

J Gastrointest Surg. 2009 Aug;13(8):1503‐9.

49: Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M,

Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bah‐

lo M, Stewart GJ, Booth DR, George J.

IL28B is associated with response to chronic hepatitis C interferon‐alpha and ribavirin ther‐

apy.

Nat Genet. 2009 Oct;41(10):1100‐4.

50: Terjung B, Spengler U.

Atypical p‐ANCA in PSC and AIH: a hint toward a "leaky gut"?

Clin Rev Allergy Immunol. 2009 Feb;36(1):40‐51.

51: Trebicka J, Hennenberg M, Schulze Pröbsting A, Laleman W, Klein S, Granzow M, Nevens

F, Zaagsma J, Heller J, Sauerbruch T.

Role of beta3‐adrenoceptors for intrahepatic resistance and portal hypertension in liver cir‐

rhosis.

Hepatology.2009 Dec;50(6):1924‐35.

52: Ulrich‐Merzenich G, Panek D, Zeitler H, Wagner H, Vetter H.

New perspectives for synergy research with the "omic"‐technologies.

Phytomedicine. 2009 Jun;16(6‐7):495‐508.

53: Ulrich‐Merzenich G, Zeitler H, Vetter H, Kraft K.

180

Synergy research: vitamins and secondary plant components in the maintenance of the re‐

doxhomeostasis and in cell signaling.

Phytomedicine. 2009 Jan;16(1):2‐16.

54: van de Laar T, Pybus O, Bruisten S, Brown D, Nelson M, Bhagani S, Vogel M, Baumgarten

A, Chaix ML, Fisher M, Gotz H, Matthews GV, Neifer S, White P, Rawlinson W, Pol S, Rock‐

stroh J, Coutinho R, Dore GJ, Dusheiko GM, Danta M.

Evidence of a large, international network of HCV transmission in HIV‐positive men who have

sex with men.


55: van der Lugt J, Colbers A, Molto J, Hawkins D, van der Ende M, Vogel M, Wyen C, Schutz

M, Koopmans P, Ruxrungtham K, Richter C, Burger D; SARA study team.

The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type‐1‐infected

pregnant women.

Antivir Ther. 2009;14(3):443‐50.

56: Vogel M, Rockstroh J.

The Treatment of Chronic Hepatitis C Virus Infection in HIV Co‐infection.

Eur J Med Res. 2009 Dec 14;14(12):507‐15.

57: Vogel M, Deterding K, Wiegand J, Grüner NH, Baumgarten A, Jung MC, Manns MP, We‐

demeyer H, Rockstroh JK; German Hepatitis Group; Hep‐Net.

Initial presentation of acute hepatitis C virus (HCV) infection among HIV‐negative and

HIVpositive individuals‐experience from 2 large German networks on the study of acute HCV

infection.

Clin Infect Dis. 2009 Jul 15;49(2):317‐9; author reply 319.


Liver disease: the effects of HIV and antiretroviral therapy and the implications for early anti‐

retroviral therapy initiation.

Curr Opin HIV AIDS. 2009 May;4(3):171‐5.

59: Vogel M, Bertram N, Wasmuth JC, Wyen C, Voigt E, Schwarze‐Zander C, Sudhop T, Fät‐

kenheuer G, Rockstroh JK, Reichel C.

Nevirapine pharmacokinetics in HIV‐infected and HIV/HCV‐coinfected individuals.

J Antimicrob Chemother. 2009 May;63(5):988‐91.

181

60: Vogel M, Page E, Nelson M, Rockstroh JK.

Treatment of acute hepatitis C in HIV‐positive individuals: what are the challenges?

J HIV Ther. 2009 Mar;14(1):8‐12.

61: Zeitler H, Ulrich‐Merzenich G, Panek D, Goldmann G, Vidovic N, Brackmann HH, Olden‐

burg J.

Immunoadsorption in the treatment of Acquired Haemophilia.

Atheroscler Suppl. 2009 Dec 29;10(5):122‐125.

62: Ziske C, Etzrodt PE, Eliu AS, Gorschlüter M, Strehl J, Flieger D, Messmer D, Schmitz V,

Gonzalez‐Carmona MA, Sievers E, Brossart P, Sauerbruch T, Schmidt‐Wolf IG.

Increase of in vivo antitumoral activity by CD40L (CD154) gene transfer into pancreatic tumor

cell‐dendritic cell hybrids.

Pancreas. 2009 Oct; 38(7):758‐65.

182

2010

1: Anadol E, Kaiser R, Verheyen J, Schülter E, Emmelkamp J, Schwarze‐Zander C, Kupfer B,

Wasmuth JC, Rockstroh JK.

Transmission of human immunodeficiency virus I drug resistance ‐ a case report. What are the

clinical implications?

Eur J Med Res. 2010 May 18;15(5):225‐30.

2: Appenrodt B, Grünhage F, Gentemann MG, Thyssen L, Sauerbruch T, Lammert F.

Nucleotide‐binding oligomerization domain containing 2 (NOD2) variants are genetic risk fac‐

tors for death and spontaneous bacterial peritonitis in liver cirrhosis.

Hepatology. 2010 Apr;51(4):1327‐33.

3: Appenrodt B, Lehmann LE, Thyssen L, Gentemann M, Rabe C, Molitor E, Trebicka J, Stüber

F, Sauerbruch T.

Is detection of bacterial DNA in ascitic fluid of clinical relevance?


4: Avouac J, Walker U, Tyndall A, Kahan A, Matucci‐Cerinic M, Allanore Y; EUSTAR, Miniati I,

Muller A, Iannone F, Distler O, Becvar R, Sierakowsky S, Kowal‐Bielecka O, Coelho P, Cabane

J, Cutolo M, Shoenfeld Y, Valentini G, Rovensky J, Riemekasten G, Vlachoyiannopoulos P,

Caporali R, Jiri S, Inanc M, Zimmermann Gorska I, Carreira P, Novak S, Czirjak L, Oliveira

Ramos F, Jendro M, Chizzolini C, Kucharz EJ, Richter J, Cozzi F, Rozman B, Mallia CM, Gabri‐

elli A, Farge D, Kiener HP, Schöffel D, Airo P, Wollheim F, Martinovic D, Trotta F, Jablonska S,

Reich K, Bombardieri S, Siakka P, Pellerito R, Bambara LM, Morovic‐Vergles J, Denton C,

Hinrichs R, Van den Hoogen F, Damjanov N, Kötter I, Ortiz V, Heitmann S, Krasowska D,

Seidel M, Hasler P, Van Laar JM, Kaltwasser JP, Foeldvari I, Juan Mas A, Bajocchi G, Wis‐

lowska M, Pereira Da Silva JA, Jacobsen S, Worm M, Graniger W, Kuhn A, Stankovic A, Cos‐

sutta R, Majdan M, Damjanovska Rajcevska L, Tikly M, Nasonov EL, Steinbrink K, Herrick A,

Müller‐Ladner U, Dinc A, Scorza R, Sondergaard K, Indiveri F, Nielsen H, Szekanecz Z, Silver

RM, Antivalle M, Espinosa IB, García de la Pena Lefebvre P, Midtvedt O, Launay D, Valesini F,

Tuvik P, Ionescu RM, Del Papa N, Pinto S, Wigley F, Mihai C, Sinziana Capranu M, Sunderköt‐

ter C, Jun JB, Alhasani S, Distler JH, Ton E, Soukup T, Seibold J, Zeni S, Nash P, Mouthon L, De

Keyser F, Duruöz MT, Cantatore FP, Strauss G, von Mülhen CA, Pozzi MR, Eyerich K, Szechin‐

ski J, Keiserman M, Houssiau FA, Román‐Ivorra JA, Krummel‐Lorenz B, Aringer M, West‐

hovens R, Bellisai F, Mayer M, Stoeckl F, Uprus M, Volpe A, Buslau M, Yavuz S, Granel B, Val‐

derílio Feijó A, Del Galdo F, Popa S, Zenone T, Ricardo Machado X, Pileckyte M, Stebbings S,

Mathieu A, Tulli A, Tourinho T, Souza R, Acayaba de Toledo R, Stamp L, Solanki K, Veale D,

Francisco Marques Neto J, Bagnato GF, Loyo E, Toloza S, Li M, Ahmed Abdel Atty Mohamed

183

W, Cobankara V, Olas J, Salsano F, Oksel F, Tanaseanu CM, Foti R, Ancuta C, Vonk M,

Caramashi P, Beretta L, Balbir A, Chiàla A, Pasalic Simic K, Ghio M, Stamenkovic B, Rednic S,

Host N, Pellerito R, Hachulla E, Furst DE.

Characteristics of joint involvement and relationships with systemic inflammation in systemic

sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database.

J Rheumatol. 2010 Jul;37(7):1488‐501.

5: Bickel M, Anadol E, Vogel M, Hofmann WP, von Hentig N, Kuetscher J, Kurowski M,

Moench C, Lennemann T, Lutz T, Bechstein WO, Brodt HR, Rockstroh J.

Daily dosing of tacrolimus in patients treated with HIV‐1 therapy containing a ritonavir‐

boosted protease inhibitor or raltegravir.


6: Boesecke C, Rockstroh JK.

Current therapy of HBV/HIV coinfection.

Hot Topics in Viral Hepatitis 2010;6(17): 25‐31.


Älter werden mit Hämophilie, HIV und Hepatitis C.

Mitteilungen der Deutschen Hämophiliegesellschaft Sonderdruck 1/10:33‐37.

8: Carrera F, Lok CE, de Francisco A, Locatelli F, Mann JF, Canaud B, Kerr PG, Macdougall IC,

Besarab A, Villa G, Kazes I, Van Vlem B, Jolly S, Beyer U,

Dougherty FC; PATRONUS Investigators.

Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethyl‐

ene glycol‐epoetin beta versus darbepoetin alfa administered monthly: a randomized com‐

parative trial.


9: Coenen M, Nattermann J.

The role of CCR5 in HCV infection.

Eur J Med Res. 2010 Mar 30;15(3):97‐101.

10: Daskalow K, Rohwer N, Raskopf E, Dupuy E, Kühl A, Loddenkemper C, Wiedenmann B,

Schmitz V, Cramer T.

Role of hypoxia‐inducible transcription factor 1alpha for progression and chemosensitivity of

murine hepatocellular carcinoma.

J Mol Med. 2010;88(8): 817‐27.

184

11: Düsing R.

Optimizing blood pressure control through the use of fixed combinations.

Vasc Health Risk Manag. 2010 May 25;6:321‐5.

12: Dore GJ, Soriano V, Rockstroh J, Kupfer B, Tedaldi E, Peters L, Neuhaus J, Puoti M, Klein

MB, Mocroft A, Clotet B, Lundgren JD, SMART INSIGHT study group

Frequent hepatitis B virus rebound among HIV‐hepatitis B virus‐coinfected patients following

antiretroviral therapy interruption.

AIDS. 2010;24(6): 857‐65.

13: Ehren K, Marx A, Wasmuth JC.

[Unexplained chronic hypokalaemia in a young woman].

Dtsch Med Wochenschr. 2010 Oct;135(41):2021‐3.

14: García‐Pagán JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, Abraldes JG, Nevens

F, Vinel JP, Mössner J, Bosch J; Early TIPS (Transjugular Intrahepatic Portosystemic Shunt)

Cooperative Study Group.

Early use of TIPS in patients with cirrhosis and variceal bleeding.

N Engl J Med. 2010 Jun 24;362(25):2370‐9.

15: Gerhardt T, Rings D, Höblinger A, Heller J, Sauerbruch T, Schepke M.

Combination of bilateral metal stenting and trans‐stent photodynamic therapy for

palliative treatment of hilar cholangiocarcinoma.

Z Gastroenterol. 2010, Jan;48(1):28‐32.

16: Grünhage F, Wasmuth JC, Herkenrath S, Vidovic N, Goldmann G, Rockstroh J, Lammert F,

Oldenburg J, Sauerbruch T, Spengler U.

Transient elastography discloses identical distribution of liver fibrosis in chronic hepatitis C

between HIV‐negative and HIV‐positive patients on HAART.

Eur J Med Res. 2010 Apr 8;15(4):139‐44.

17: Grünhage F, Nattermann J.

Viral hepatitis: human genes that limit infection.

Best Pract Res Clin Gastroenterol. 2010;24(5): 709‐23.

18: Grünhage F, Nattermann J, Gressner OA, Wasmuth HE, Hellerbrand C, Sauerbruch

T, Spengler U, Lammert F.

Lower copy numbers of the chemokine CCL3L1 gene in patients with chronic hepatitis C.

J Hepatol. 2010;52(2): 153‐9.

185

19: Hoekstra J, Guimarães AH, Leebeek FW, Darwish Murad S, Malfliet JJ, Plessier A, Her‐

nandez‐Guerra M, Langlet P, Elias E, Trebicka J, Primignani M, Garcia‐Pagan JC, Valla DC, Ri‐

jken DC, Janssen HL; European Network for Vascular Disorders of the Liver (EN‐Vie).

Impaired fibrinolysis as a risk factor for Budd‐Chiari syndrome.

Blood. 2010 Jan 14;115(2):388‐95.

20: Hippe V, Strehl JW, Fieke J, Sauerbruch T.

[62‐year‐old patient with abdominal pain and ascites. Angioneurotic edema (C1 esterase inhi‐

bitor deficiency)].

Dtsch Med Wochenschr. 2010 Aug;135(31‐32):1547‐8.

21: Lange CM, Roomp K, Dragan A, Nattermann J, Michalk M, Spengler U, Weich V, Lengauer

T, Zeuzem S, Berg T, Sarrazin C.

HLA class I allele associations with HCV genetic variants in patients with chronic HCV geno‐

types 1a or 1b infection.

J Hepatol. 2010;53(6): 1022‐8.

22: Langhans B, Braunschweiger I, Arndt S, Schulte W, Satoguina J, Layland LE, Vidovic N,

Hoerauf A, Oldenburg J, Sauerbruch T, Spengler U.

Core‐specific adaptive regulatory T‐cells in different outcomes of hepatitis C.

Clin Sci (Lond). 2010 Apr 20;119(2):97‐109.

23: Leifeld L, Clemens C, Heller J, Trebicka J, Sauerbruch T, Spengler U.

Expression of urotensin II and its receptor in human liver cirrhosis and fulminant hepatic fail‐

ure.

Dig Dis Sci. 2010;55(5): 1458‐64.

24: Lenz JC, Rockstroh JK.

Vicriviroc, a new CC‐chemokine receptor 5 inhibitor for treatment of HIV: properties, promises

and challenges.

Expert Opin Drug Metab Toxicol. 2010 Sep;6(9):1139‐50.

25: Lutz P, Maring D, Tschampa HJ, Sauerbruch T.

[A 25‐year‐old patient with colonic pseudo‐obstruction, hyponatremia, hypertension, and dif‐

fuse pain].

Med Klin (Munich). 2010 Apr;105(4):267‐72.

26: Lutz P, Sauerbruch T.

[A patient with striking skull and stomach].

Dtsch Med Wochenschr. 2010 Apr;135(15):757‐8.

27: Manekeller S, Sauerbruch T, Fischer HP, Propping P, Hirner A.

186

[Heterozygous alpha‐1‐antitrypsin deficiency (PiMZ): risk factor in the development of

primary liver carcinoma in non‐cirrhotic liver?].


28: Manns MP, Woynarowski M, Kreisel W, Lurie Y, Rust C, Zuckerman E, Bahr MJ, Günther

R, Hultcrantz RW, Spengler U, Lohse AW, Szalay F, Färkkilä M, Pröls M, Strassburg CP, Euro‐

pean AIH‐BUC‐Study Group

Budesonide induces remission more effectively than prednisone in a controlled trial of

patients with autoimmune hepatitis.

Gastroenterology. 2010;139(4): 1198‐206.

29: Marcus U, Rockstroh J, Schmidt RE, Expertenworkshop GWB und DAIG.

[Recommendations to improve the current situation of HIV testing].

Dtsch Med Wochenschr. 2010;135(23): 1201‐2.

30: Nischalke HD, Vogel M, Mauss S, Baumgarten A, Lutz T, Danta M, Naumann U, Coenen M,

Sauerbruch T, Rockstroh JK, Spengler U, Nattermann J.

The cytotoxic lymphocyte antigen 4 polymorphisms affect response to hepatitis C virusspeci‐

fic therapy in HIV(+) patients with acute and chronic hepatitis C virus co‐infection.

AIDS. 2010 Aug 24;24(13):2001‐7.

31: Oldenburg J, Zeitler H, Pavlova A.

Genetic markers in acquired haemophilia.

Haemophilia. 2010 May;16 Suppl 3:41‐5.

32: Opravil M, Klimkait T, Louvel S, Wolf E, Battegay M, Fux CA, Bernasconi E, Vogel M,

Speck R, Weber R; and the Swiss HIV Cohort Study.

Prior Therapy Influences the Efficacy of Lamivudine Monotherapy in Patients with Lami‐

vudine‐resistant HIV‐1 Infection.

J Acquir Immune Defic Syndr. 2010;54(1),:51‐58.

33: Pavlova A, Zeitler H, Scharrer I, Brackmann HH, Oldenburg J.

HLA genotype in patients with acquired haemophilia A.

Haemophilia. 2010 May;16(102):107‐12.

187

34: Plessier A, Darwish‐Murad S, Hernandez‐Guerra M, Consigny Y, Fabris F, Trebicka J,

Heller J, Morard I, Lasser L, Langlet P, Denninger MH, Vidaud D, Condat B, Hadengue A,

Primignani M, Garcia‐Pagan JC, Janssen HL, Valla D, European Network for Vascular Disor‐

ders of the Liver (EN‐Vie)

Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow‐up

study.

Hepatology. 2010;51(1): 210‐8.

35: Rabe C, Appenrodt B, Hoff C, Ewig S, Klehr HU, Sauerbruch T, Nickenig G,Tasci S.

Severe respiratory failure due to diffuse alveolar hemorrhage: clinical characteristics and out‐

come of intensive care.

J Crit Care. 2010 Jun;25(2):230‐5.

36: Raskopf E, Vogt A, Standop J, Sauerbruch T, Schmitz V.

Inhibition of neuropilin‐1 by RNA‐interference and its angiostatic potential in the treatment of

hepatocellular carcinoma.


37: Reichel C, Streit J, Ott K, Wunsch S.

Appropriateness of Crohn's disease therapy in gastroenterological rehabilitation.

Digestion. 2010;82(4): 239‐45.

38: Reichel C, Streit J, Wunsch S.

Linking Crohn's disease health status measurements with International Classification of Func‐

tioning, Disability and Health and vocational rehabilitation outcomes.

J Rehabil Med. 2010;42(1): 74‐80.

39: Rockstroh J, Guaraldi G, Deray G.

HIV and the body: a review of multidisciplinary management.

HIV Med. 2010 Sep;11 Suppl 2:1‐8.

40: Rockstroh JK, Gatell J, Landman R, Antinori A.

Management of late‐presenting patients with HIV infection.

Antivir Ther. 2010;15 Suppl 1:25‐30.

41: Schewe K, Noah C, Sirma H, Schmiedel S, van Lunzen J, Rockstroh JK, Schildgen O.

Is there Emergence of Clinical HBV Resistance Under Long‐Term HBV Combination Therapy? A

Challenging Case Report

Viruses. 2010;2(8): 1564‐1570.

188

42: Schildgen O, Olotu C, Funk A, Zöllner B, Helm M, Rockstroh JK, Sirma H.

Selection and counterselection of the rtI233V adefovir resistance mutation during antiviral

therapy.

J Clin Microbiol. 2010;48(2): 631‐4.

43: Schwarze‐Zander C, Becker S, Wenzel J, Rockstroh JK, Spengler U, Yassin AF.

Bacteremia caused by a novel helicobacter species in a 28‐year‐old man with X‐linked agam‐

maglobulinemia.

J Clin Microbiol. 2010 Dec;48(12):4672‐6.

44: Schwarze‐Zander C, Neibecker M, Othman S, Tural C, Clotet B, Blackard JT, Kupfer B,

Luechters G, Chung RT, Rockstroh JK, Spengler U.

GB virus C coinfection in advanced HIV type‐1 disease is associated with low CCR5 and CXCR4

surface expression on CD4(+) T‐cells.

Antivir Ther. 2010;15(5):745‐52.

45: Seidel MF, Herguijuela M, Forkert R, Otten U.

Nerve growth factor in rheumatic diseases.

Semin Arthritis Rheum. 2010 Oct;40(2):109‐26.

46: Spengler U.

[Non adherence ‐ non response in transplantation medicine].

Ther Umsch. 2010 Jun;67(6):317‐22.

47: Standop J, Glowka T, Schmitz V, Schaefer N, Hirner A, Kalff JC.

Emergency Kausch‐Whipple procedure: indications and experiences.

Pancreas. 2010 Mar;39(2):156‐9.

48: Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, Rockstroh JK,

Schechter M, Katlama C, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Clotet B,

Zhao J, Wan H, Rhodes RR, Strohmaier KM, Barnard RJ, Isaacs RD, Nguyen BY, BENCHMRK

Study Teams.

Long‐term efficacy and safety of Raltegravir combined with optimized background therapy in

treatment‐experienced patients with drug‐resistant HIV infection: week 96

results of the BENCHMRK 1 and 2 Phase III trials.

Clin Infect Dis. 2010;50(4): 605‐12.

189

49: Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients, Lodwick

RK, Sabin CA, Porter K, Ledergerber B, van Sighem A, Cozzi‐Lepri A, Khaykin P, Mocroft A,

Jacobson L, De Wit S, Obel N, Castagna A, Wasmuth JC, Gill J, Klein MB, Gange S, Riera M,

Mussini C, Gutiérrez F, Touloumi G, Carrieri P, Guest JL, Brockmeyer NH, Phillips AN.

Death rates in HIV‐positive antiretroviral‐naive patients with CD4 count greater than 350 cells

per microL in Europe and North America: a pooled cohort observational study.

Lancet. 2010 Jul 31;376(9738):340‐5.

50: Terjung B, Söhne J, Lechtenberg B, Gottwein J, Muennich M, Herzog V, Mähler M, Sauer‐


p‐ANCAs in autoimmune liver disorders recognise human beta‐tubulin isotype 5 and cross‐

react with microbial protein FtsZ.

Gut. 2010 Jun;59(6):808‐16.

51: Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, Lokhnygina Y,

Kullig U, Göbel U, Capka E, Wiegand J, Schiefke I, Güthoff W, Grüngreiff K, König I, Spengler

U, McCarthy J, Shianna KV, Goldstein DB, McHutchison JG, Timm J, Nattermann J, German

Anti‐D Study Group.

A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C

virus and jaundice.

Gastroenterology. 2010;139(5): 1586‐92, 1592.e1.

52: Trebicka J, Hennenberg M, Odenthal M, Shir K, Klein S, Granzow M, Vogt A, Dienes HP,

Lammert F, Reichen J, Heller J, Sauerbruch T.

Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover

of hepatic stellate cells.

J Hepatol. 2010 Oct;53(4):702‐12.

53: van Bömmel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, Erhardt

A, Hüppe D, Stein K, Trojan J, Sarrazin C, Böcher WO, Spengler U, Wasmuth HE, Reinders JG,

Möller B, Rhode P, Feucht HH, Wiedenmann B, Berg T.

Long‐term efficacy of tenofovir monotherapy for hepatitis B virus‐monoinfected patients

after failure of nucleoside/nucleotide analogues.

Hepatology. 2010;51(1): 73‐80.

54: Ulrich‐Merzenich G, Panek D, Zeitler H, Vetter H, Wagner H.

Drug development from natural products: exploiting synergistic effects.

Indian J Exp Biol. 2010 Mar;48(3):208‐19.

190

55: Vidovic N, Lochowsky RS, Goldmann G, Rockstroh J, Wasmuth JC, Spengler U, Sauer‐

bruch T, Lammert F, Oldenburg J, Grünhage F.

Correlation of transient elastography with APRI and FIB‐4 in a cohort of patients with con‐

genital bleeding disorders and HCV or HIV/HCV coinfection.

Haemophilia. 2010 Sep 1;16(5):778‐85.

56: Vogel M, Bertram N, Wasmuth JC, Emmelkamp J, Rockstroh JK, Reichel C.

Determination of nevirapine in plasma by GC‐MS.

J Chromatogr Sci. 2010 Feb;48(2):91‐4.

57: Vogel M, Bösecke C, Wasmuth JC, Rockstroh JK.

[HIV and hepatitis C co‐infection].

Dtsch Med Wochenschr. 2010 Jun;135(23):1186‐91.

58: Vogel M, Dominguez S, Bhagani S, Azwa A, Page E, Guiguet M, Valantin MA,Katlama C,

Rockstroh JK, Nelson M.

Treatment of acute HCV infection in HIV‐positive patients: experience from a multicentre

European cohort.

AntivirTher. 2010;15(2):267‐79.

59: Vogel M, Schwarze‐Zander C, Wasmuth JC, Spengler U, Sauerbruch T, Rockstroh JK.

The treatment of patients with HIV.

Dtsch Arztebl Int. 2010 Jul;107(28‐29):507‐15; quiz 516.

60: Vogel M, Strach K, Ehren K, Woitas R, Wasmuth JC.

[Avascular necrosis of the bone after organ transplantation].

Internist (Berl). 2010 May;51(5):662, 664‐6.

61: Vogel M, van de Laar T, Kupfer B, Stellbrink HJ, Kümmerle T, Mauss S, Knecht G, Berger

A, Bruisten S, Rockstroh JK.

Phylogenetic analysis of acute hepatitis C virus genotype 4 infections among human immu‐

nodeficiency virus‐positive men who have sex with men in Germany.

Liver Int. 2010 Sep;30(8):1169‐72


Treatment of acute hepatitis C in HIV infection.

J Antimicrob Chemother. 2010 Jan;65(1):4‐9.

191

63: Vogel M, Ahlenstiel G, Hintsche B, Fenske S, Trein A, Lutz T, Schürmann D, Stephan C,

Khaykin P, Bickel M, Mayr C, Baumgarten A, Buggisch P, Klinker H, John C, Gölz J, Staszewski

S, Rockstroh JK.

The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin ther‐

apy for the treatment of chronic HCV infection in HIV‐positive Individuals.

Eur J Med Res. 2010 Mar 30;15(3):102‐11.

64: Woitas R.

[Assessment of renal function with cystatin C].

Dtsch Med Wochenschr. 2010 Jun;135(24):1252‐4.

65: Zeitler H, Ulrich‐Merzenich G, Goldmann G, Vidovic N, Brackmann HH, Oldenburg J.

The relevance of the bleeding severity in the treatment of acquired haemophilia – an update

of a single‐centre experience with 67 patients.

Haemophilia. 2010 May;16(102):95‐101.

66: Zimmermann HW, Seidler S, Nattermann J, Gassler N, Hellerbrand C, Zernecke A, Ti‐

schendorf JJ, Luedde T, Weiskirchen R, Trautwein C, Tacke F.

Functional contribution of elevated circulating and hepatic non‐classical CD14CD16 monocytes

to inflammation and human liver fibrosis.

PLoS ONE. 2010;5(6): e11049.

192

2011

1: Albert M, Benito J, Bhagani S, Boesecke C, Deterding K, Dominguez S, Fisher M, Fontanet

A, Garcia D, Gilson R, Guiguet M, Hoepelman AI, Horban A, Katlama C, Mallolas J, Page E,

Peters L, Pozniak A, Prins M, Puoti M, Rauch A, Rodger A, Rockstroh JK, Soriano V, Stephan

C, Thibault V, Tural C, Valantin MA, van de Laar T, van der Meer J, Vella S, Vogel M, de Wit S,

Autran B, Clotet B, Danta M, Journiac M, Matthews G, Meyer‐Olson D, Nelson M, Schmidt R,

Wedemeyer H.

Acute hepatitis C in HIV‐infected individuals: recommendations from the European AIDS

Treatment Network (NEAT) consensus conference.

AIDS. 2011 Feb 20;25(4):399‐409.

2: Antinori A, Coenen T, Costagiola D, Dedes N, Ellefson M, Gatell J, Girardi E, Johnson M,

Kirk O, Lundgren J, Mocroft A, D'Arminio Monforte A, Phillips A, Raben D, Rockstroh JK,

Sabin C, Sönnerborg A, De Wolf F; European Late Presenter Consensus Working Group.

Late presentation of HIV infection: a consensus definition.

HIV Med. 2011 Jan;12(1):61‐4.

3: Appenrodt B, Trebicka J, Sauerbruch T.

[Complications of liver cirrhosis].


4: Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman

ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R; HCV RESPOND‐2

Investigators.

Boceprevir for previously treated chronic H CV genotype 1 infection.

N Engl J Med. 2011 Mar 31;364(13):1207‐17.

5: Bätzing‐Feigenbaum J, Kollan C, Kühne A, Matysiak‐Klose D, Gunsenheimer‐Bartmeyer B,

Hamouda O; ClinSurv HIV Study Group.

Cohort profile: the German ClinSurv HIV project‐‐a multicentre open clinical cohort study sup‐

plementing national HIV surveillance.

HIV Med. 2011 May;12(5):269‐78.

6: Bannister WP, Cozzi‐Lepri A, Kjær J, Clotet B, Lazzarin A, Viard JP, Kronborg G, Duiculescu

D, Beniowski M, Machala L, Phillips A; EuroSIDA group.

Estimating prevalence of accumulated HIV‐1 drug resistance in a cohort of patients on antiret‐

roviral therapy.

J Antimicrob Chemother. 2011 Apr;66(4):901‐11.

193

7: Biecker E, Hausdörfer I, Grünhage F, Strunk H, Sauerbruch T.

Critical flicker frequency as a marker of hepatic encephalopathy in patients before and after

transjugular intrahepatic portosystemic shunt.

Digestion. 2011;83(1‐2):24‐31.


Treatment of acute hepatitis C infection in HIV‐infected patients.

Curr Opin HIV AIDS. 2011 Jul;6(4):278‐84.

9: Boesecke C, Vogel M.

HIV and hepatitis C co‐infection: acute HCV therapy.

Curr Opin HIV AIDS. 2011 Nov;6(6):459‐64.

10: Boyer TD, Sanyal AJ, Garcia‐Tsao G, Blei A, Carl D, Bexon AS, Teuber P; Terlipressin Study

Group.

Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1:

relationship of serum creatinine to hemodynamics.

J Hepatol. 2011 Aug;55(2):315‐21.

11: Boyer TD, Sanyal AJ, Garcia‐Tsao G, Regenstein F, Rossaro L, Appenrodt B, Gülberg V,

Sigal S, Bexon AS, Teuber P; Terlipressin Study Group.

Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome

type 1.

Liver Transpl. 2011 Nov;17(11):1328‐32.

12: Coenen M, Nischalke HD, Krämer B, Langhans B, Glässner A, Schulte D, Körner C, Sauer‐

bruch T, Nattermann J, Spengler U.

Hepatitis C virus core protein induces fibrogenic actions of hepatic stellate cells via toll‐like

receptor 2.

LabInvest. 2011 Sep;91(9):1375‐82.

13: Cornberg M, Protzer U, Petersen J, Wedemeyer H, Berg T, Jilg W, Erhardt A, Wirth S,

Sarrazin C, Dollinger MM, Schirmacher P, Dathe K, Kopp IB, Zeuzem S, Gerlich WH, Manns

MP; AWMF.

[Prophylaxis, diagnosis and therapy of hepatitis B virus infection ‐ the German guideline].


194

14: Distler JH, Jordan S, Airo P, Alegre‐Sancho JJ, Allanore Y, Balbir Gurman A, Caporali R,

Caramaschi P, Carreira PE, Chizzolini C, Cutolo M, Tuncay Duruöz M, Farge‐Bancel D, Hessel‐

strand R, Iannone F, De Keyser F, Kucharz EJ, Launay D, García de la Peña Lefebvre P, Lu‐

kacova O, Marasini B, Martinovic D, Marques Neto JF, Radic M, Rednic S, Riemekasten G,

Rovensky J, Seidel MF, Senel S, Smith V, Sunderkötter C, Ton E, van Laar JM, Matucci‐Cerinic

M, Müller Ladner U, Distler O.

Is there a role for TNFα antagonists in the treatment of SSc? EUSTAR expert consensus de‐

velopment using the Delphi technique.

Clin Exp Rheumatol. 2011 Mar‐Apr;29(2 Suppl 65):S40‐5.

15: Dore GJ, Matthews GV, Rockstroh J.

Future of hepatitis C therapy: development of direct‐acting antivirals.


16: Düsing R.

[On the value of diuretics for hypertension treatment].


17: Düsing R.

[In Process Citation].

MMW Fortschr Med. 2011 Dec 15;153(51‐52):21.

18: Düsing R.

[Diuretics in the treatment of hypertension : Efficacy, safety and tolerability].

Internist (Berl). 2011 Dec;52(12):1484‐91.

19: Eron JJ Jr, Rockstroh JK, Reynes J, Andrade‐Villanueva J, Ramalho‐Madruga JV, Bekker

LG, Young B, Katlama C, Gatell‐Artigas JM, Arribas JR, Nelson M, Campbell H, Zhao J, Rod‐

gers AJ, Rizk ML, Wenning L, Miller MD, Hazuda D, DiNubile MJ, Leavitt R, Isaacs R, Robert‐

son MN, Sklar P, Nguyen BY; QDMRK Investigators.

Raltegravir once daily or twice daily in previously untreated patients with HIV‐1: a randomised,

active‐controlled, phase 3 non‐inferiority trial.

Lancet Infect Dis. 2011 Dec;11(12):907‐15. Epub 2011 Sep 18. Erratum in: Lancet Infect

Dis. 2011 Dec;11(12):895. Dosage error in article text.

20: European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel.

Acute hepatitis C in HIV‐infected individuals: recommendations from the European AIDS

Treatment Network (NEAT) consensus conference.

AIDS. 2011 Feb 20;25(4):399‐409.

21: Fernandez‐Ruiz V, Kawa M, Berasain C, Iñiguez M, Schmitz V, Martinez‐Ansó E, Iñar‐

rairaegui M, Herrero I, Sangro B, D'Avola D, Quiroga J, Qian C, Prieto J.

195

Treatment of murine fulminant hepatitis with genetically engineered endothelial progenitor

cells.

J Hepatol. 2011 Oct;55(4):828‐37

22: Gerbes AL, Sauerbruch T, Dathe K.

[Method report: German S3‐guideline "ascites, spontaneous bacterial peritonitis, hepatorenal

syndrome"].


23: Gerbes AL, Gülberg V, Sauerbruch T, Wiest R, Appenrodt B, Bahr MJ, Dollinger MM, Röss‐

le M, Schepke M.

[German S 3‐guideline "ascites, spontaneous bacterial peritonitis, hepatorenal syndrome"].


24: Gerhardt T, Pöge U, Stoffel‐Wagner B, Palmedo H, Sauerbruch T, Woitas RP.

Is beta‐trace protein an alternative marker of glomerular filtration rate in liver transplant re‐

cipients?

Liver Int. 2011 Oct;31(9):1345‐51.

25: Gerhardt T, Pöge U, Stoffel‐Wagner B, Palmedo H, Sauerbruch T, Woitas RP.

Creatinine‐based glomerular filtration rate estimation in patients with liver disease: the new

Chronic Kidney Disease Epidemiology Collaboration equation is not better.


26: González‐Carmona MA, Vogt A, Heinicke T, Quasdorff M, Hoffmann P, Yildiz Y, Schneider

C, Serwe M, Bartenschlager R, Sauerbruch T, Caselmann WH.

Inhibition of hepatitis C virus gene expression by adenoviral vectors encoding antisense RNA

in vitro and in vivo.

J Hepatol. 2011 Jul;55(1):19‐28.

27: Hennenberg M, Trebicka J, Kohistani Z, Stark C, Nischalke HD, Krämer B, Körner C, Klein

S, Granzow M, Fischer HP, Heller J, Sauerbruch T.

Hepatic and HSC‐specific sorafenib effects in rats with established secondary biliary cirrhosis.

Lab Invest. 2011 Feb;91(2):241‐51.

28: Hensel M, Goetzenich A, Lutz T, Stoehr A, Moll A, Rockstroh J, Hanhoff N, Jäger H,

Mosthaf F.

HIV and cancer in Germany.

Dtsch Arztebl Int. 2011 Feb;108(8):117‐22.

29: Höblinger A, Gerhardt T, Gonzalez‐Carmona MA, Hüneburg R, Sauerbruch T, Schmitz V.

Feasibility and safety of long‐term photodynamic therapy (PDT) in the palliative treatment of

patients with hilar cholangiocarcinoma.

196

Eur J Med Res. 2011 Sep 12;16(9):391‐5.

30: Hoffmann C, Schmid H, Müller M, Teutsch C, van Lunzen J, Esser S, Wolf T, Wyen C,

Sabranski M, Horst HA, Reuter S, Vogel M, Jäger H, Bogner J, Arasteh K.

Improved outcome with rituximab in patients with HIV‐associated multicentric Castleman

disease.

Blood. 2011 Sep 29;118(13):3499‐503.

31: Jung N, Fischer J, Lehmann C, Rockstroh JK, Fätkenheuer G.

[HIV infection: a chronic disease with new challenges].


32: Koelsch KK, Boesecke C, McBride K, Gelgor L, Fahey P, Natarajan V, Baker D, Bloch M,

Murray JM, Zaunders J, Emery S, Cooper DA, Kelleher AD; PINT study team.

Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay

characteristics and the HIV viral reservoir.

AIDS. 2011 Nov13;25(17):2069‐78.

33: Körner C, Tolksdorf F, Riesner K, Krämer B, Schulte D, Nattermann J, Rockstroh JK,

Spengler U.

Hepatitis C coinfection enhances sensitization of CD4(+) T‐cells towards Fas‐induced apop‐

tosis in viraemic and HAART‐controlled HIV‐1‐positive patients.

Antivir Ther. 2011;16(7):1047‐55.

34: Krawczyk M, Mihalache F, Höblinger A, Acalovschi M, Lammert F, Zimmer V.

Pancreatic cancer risk variant ABO rs505922 in patients with cholangiocarcinoma.

World J Gastroenterol. 2011 Nov 7;17(41):4640‐2.

35: Krämer B, Eisenhardt M, Glässner A, Körner C, Sauerbruch T, Spengler U, Nattermann J.

Do lambda‐IFNs IL28A and IL28B act on human natural killer cells?

Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):E519‐20; author reply E521‐2. Epub

2011 Aug 8.

36: Kwiecinski M, Noetel A, Elfimova N, Trebicka J, Schievenbusch S, Strack I, Molnar L, von

Brandenstein M, Töx U, Nischt R, Coutelle O, Dienes HP, Odenthal M.

Hepatocyte growth factor (HGF) inhibits collagen I and IV synthesis in hepatic stellate cells by

miRNA‐29 induction.

PLoS One. 2011;6(9):e24568.

37: Langhans B, Kupfer B, Braunschweiger I, Arndt S, Schulte W, Nischalke HD, Nattermann

J, Oldenburg J, Sauerbruch T, Spengler U.

Interferon‐lambda serum levels in hepatitis C.

J Hepatol. 2011 May;54(5):859‐65.

197

38: Lenz JC, Rockstroh JK.

S/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challenges.

Expert Opin Investig Drugs. 2011 Apr;20(4):537‐48.

39: Lutz P, Wasmuth JC, Nischalke HD, Vidovic N, Grünhage F, Lammert F, Oldenburg J,

Rockstroh JK, Sauerbruch T, Spengler U.

Progression of liver fibrosis in HIV/HCV genotype 1 co‐infected patients is related to the T al‐

lele of the rs12979860 polymorphism of the IL28B gene.

Eur J Med Res. 2011 Aug 8;16(8):335‐41.

40: Matthews GV, Rockstroh J.

HIV and hepatitis C coinfection.


41: Mihalache F, Höblinger A, Grünhage F, Krawczyk M, Gärtner BC, Acalovschi M, Sauer‐

bruch T, Lammert F, Zimmer V.

Heterozygosity for the alpha1‐antitrypsin Z allele may confer genetic risk of cholangiocarci‐

noma.

Aliment Pharmacol Ther. 2011;33(3):389‐94.

42: Moleda L, Trebicka J, Dietrich P, Gäbele E, Hellerbrand C, Straub RH, Sauerbruch T,

Schoelmerich J, Wiest R.

Amelioration of portal hypertension and the hyperdynamic circulatory syndrome in cirrhotic

rats by neuropeptide Y via pronounced splanchnic vasoaction.

Gut. 2011 Aug;60(8):1122‐32.

43: Nattermann J, Nitschmann S.

[Therapy of hepatitis delta. The Hep‐Net International Delta Hepatitis Intervention Trial].

Internist (Berl). 2011 Nov;52(11):1365‐6.

44: Nattermann J, Vogel M, Nischalke HD, Danta M, Mauss S, Stellbrink HJ, Baumgarten A,

Mayr C, Bruno R, Tural C, Klausen G, Clotet B, Naumann U, Lutz T, Rausch M, Schewe K, Bie‐

nek B, Haerter G, Sauerbruch T, Rockstroh JK, Spengler U.

Genetic variation in IL28B and treatment‐induced clearance of hepatitis C virus in HIV‐positive

patients with acute and chronic hepatitis C.

J Infect Dis. 2011 Mar 1;203(5):595‐601

45: Nattermann J, Timm J, Nischalke HD, Olbrich A, Michalk M, Tillmann HL, Berg T, Wede‐

meyer H, Tenckhoff H, Wiese M, Kullig U, Göbel U, Capka E, Schiefke I, Güthof W, Grüngreiff

K, König I, Roggendorf M, Sauerbruch T, Spengler U; East German HCV Study Group.

198

The predictive value of IL28B gene polymorphism for spontaneous clearance in a single

source outbreak cohort is limited in patients carrying the CCR5Δ32 mutation.

J Hepatol. 2011 Dec;55(6):1201‐6.

46: Nattermann J.

NK cells in acute hepatitis C.

J Hepatol. 2011 Aug;55(2):265‐7.

47: Neibecker M, Schwarze‐Zander C, Rockstroh JK, Spengler U, Blackard JT.

Evidence for extensive genotypic diversity and recombination of GB virus C (GBV‐C) in Ger‐

many.

J Med Virol. 2011 Apr;83(4):685‐94.

48: Neukam K, Nattermann J, Rallón N, Rivero A, Caruz A, Macías J, Vogel M, Benito J,

Camacho A, Mira J, Schwarze‐Zander C, Barreiro P, Martínez A, Rockstroh J, Soriano V,

Pineda J.

Different distributions of hepatitis C virus genotypes among HIV‐infected patients with acute

and chronic hepatitis C according to interleukin‐28B genotype.

HIV Med. 2011 Sep;12(8):487‐93.

49: Neukam K, Camacho A, Caruz A, Rallón N, Torres‐Cornejo A, Rockstroh JK, Macías J,

Rivero A, Benito JM, López‐Cortés LF, Nattermann J, Gómez‐Mateos J, Soriano V, Pineda

JA.

Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)‐

coinfected patients using HCV genotype, IL28B variations, and HCV‐RNA load.

J Hepatol. 2011 Dec 13. [Epub ahead of print]

50: Nischalke HD, Berger C, Luda C, Müller T, Berg T, Coenen M, Krämer B, Körner C, Tre‐

bicka J, Grünhage F, Lammert F, Nattermann J, Sauerbruch T, Spengler U.

The CXCL1 rs4074 A allele is associated with enhanced CXCL1 responses to TLR2 ligands

and predisposes to cirrhosis in HCV genotype 1‐infected Caucasian patients.

J Hepatol. 2011 Dec 13. [Epub ahead of print].

199

51: Nischalke HD, Berger C, Aldenhoff K, Thyssen L, Gentemann M, Grünhage F, Lammert F,

Nattermann J, Sauerbruch T, Spengler U, Appenrodt B.

Toll‐like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased

risk for spontaneous bacterial peritonitis in liver cirrhosis.

J Hepatol. 2011 Nov;55(5):1010‐6.

52: Nischalke HD, Berger C, Luda C, Berg T, Müller T, Grünhage F, Lammert F, Coenen M,

Krämer B, Körner C, Vidovic N, Oldenburg J, Nattermann J, Sauerbruch T, Spengler U.

The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis

but shows no or weak association in hepatitis C cirrhosis.

PLoS One. 2011;6(11):e27087.

53: Pabst S, Hammerstingl C, Hundt F, Gerhardt T, Nickenig G, Woitas R, Skowasch D.

[Pulmonary hypertension in end‐stage renal disease: three case reports].

Dtsch Med Wochenschr. 2011 May;136(18):944‐7.

54: Paredes R, Puertas MC, Bannister W, Kisic M, Cozzi‐Lepri A, Pou C, Bellido R, Betancor G,

Bogner J, Gargalianos P, Bánhegyi D, Clotet B, Lundgren J, Menéndez‐Arias L, Martinez‐

Picado J; EuroSIDA Study Group.

A376S in the connection subdomain of HIV‐1 reverse transcriptase confers increased risk of

virological failure to nevirapine therapy.

J Infect Dis. 2011 Sep 1;204(5):741‐52.

55: Peters L, Neuhaus J, Mocroft A, Soriano V, Rockstroh J, Dore G, Puoti M, Tedaldi E, Clotet

B, Kupfer B, Lundgren JD, Klein MB. SMART Study Group.

Hyaluronic acid levels predict increased risk of non‐AIDS death in hepatitis‐coinfected persons

interrupting antiretroviral therapy in the SMART Study.

Antivir Ther. 2011;16(5):667‐75.

56: Podzamczer D, Andrade‐Villanueva J, Clotet B, Taylor S, Rockstroh JK, Reiss P, Domingo

P, Gellermann HJ, de Rossi L, Cairns V, Soriano V.

Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil

fumarate and emtricitabine over 48 weeks, in treatment‐naïve HIV‐1‐infected patients (the

ARTEN study).

HIV Med. 2011 Jul;12(6):374‐82.

57: Pöge U, Gerhardt T, Stoffel‐Wagner B, Sauerbruch T, Woitas RP.

Validation of the CKD‐EPI formula in patients after renal transplantation.


200

58: Raskopf E, Sauerbruch T, Schmitz V.

Apoptotic Potency of Angiostatic Compounds in the Treatment of Cancer.

Curr Pharm Biotechnol. 2011 May 24. [Epub ahead of print].

59: Raskopf E, Vogt A, Decker G, Hirt S, Daskalow K, Cramer T, Standop J, Gonzalez‐Carmona

MA, Sauerbruch T, Schmitz V.

Combination of Hypoxia and RNA‐Interference Targeting VEGF Induces Apoptosis in Hepa‐

toma Cells via Autocrine Mechanisms.

Curr Pharm Biotechnol. 2011 May 24. [Epub ahead of print].

60: Reekie J, Reiss P, Ledergerber B, Sedlacek D, Parczewski M, Gatell J, Katlama C,

Fätkenheuer G, Lundgren JD, Mocroft A; EuroSIDA study group.

A comparison of the long‐term durability of nevirapine, efavirenz and lopinavir in routine

clinical practice in Europe: a EuroSIDA study.

HIV Med. 2011 May;12(5):259‐68.

61: Reekie J, Gatell JM, Yust I, Bakowska E, Rakhmanova A, Losso M, Krasnov M, Francioli P,

Kowalska JD, Mocroft A; EuroSIDA in EuroCoord.

Fatal and nonfatal AIDS and non‐AIDS events in HIV‐1‐positive individuals with high CD4 cell

counts according to viral load strata.

AIDS. 2011 Nov 28;25(18):2259‐68.

62: Riemann JF, Maar C, Betzler M, Brenner H, Sauerbruch T.

[Early detection of colonic cancer in the National Cancer Program‐‐present status and rec‐

ommendations].


63: Riemann J, Moeslein G, Büttner R, Fürst A, Post S, Ebert M, Goecke T, Sauerbruch T.

Hereditary tumors of the Gastrointestinal tract.

Viszeralmedizin. 2011;27(4): 329‐335

64: Rockstroh JK, Lennox JL, Dejesus E, Saag MS, Lazzarin A, Wan H, Walker ML, Xu X, Zhao

J, Teppler H, Dinubile MJ, Rodgers AJ, Nguyen BY, Leavitt R, Sklar P; STARTMRK Investiga‐

tors.

Long‐term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for

treatment‐naive human immunodeficiency virus‐1‐infected patients: 156‐week results from

STARTMRK.

Clin Infect Dis. 2011 Oct;53(8):807‐16.

201

65: Rockstroh JK, Teppler H, Zhao J, Sklar P, Miller MD, Harvey CM, Strohmaier KM, Leavitt

RY, Nguyen BY.

Clinical efficacy of raltegravir against B and non‐B subtype HIV‐1 in phase III clinical studies.

AIDS. 2011 Jul 17;25(11):1365‐9.

66: Rockstroh JK, Peters L, Wedemeyer H.

Is there a need for liver disease monitoring in HIV patients in Africa?

Antivir Ther. 2011;16(3):287‐9.

67: Roger SD, Locatelli F, Woitas RP, Laville M, Tobe SW, Provenzano R, Golper TA, Ruang‐

kanchanasetr P, Lee HY, Wu KD, Nowicki M, Ladanyi A, Martínez‐Castelao A, Beyer U,

Dougherty FC.

C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with

chronic kidney disease not on dialysis.


68: Ruhl M, Knuschke T, Schewior K, Glavinic L, Neumann‐Haefelin C, Chang DI, Klein M,

Heinemann FM, Tenckhoff H, Wiese M, Horn PA, Viazov S, Spengler U, Roggendorf M,

Scherbaum N, Nattermann J, Hoffmann D, Timm J; East German HCV Study Group..

CD8+ T‐cell response promotes evolution of hepatitis C virus nonstructural proteins.


69: Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, Fiore

F, Van Buskirk M, Bilbao JI, Ettorre GM, Salvatori R, Giampalma E, Geatti O, Wilhelm K,

Hoffmann RT, Izzo F, Iñarrairaegui M, Maini CL, Urigo C, Cappelli A, Vit A, Ahmadzadehfar H,

Jakobs TF, Lastoria S; European Network on Radioembolization with Yttrium‐90 Resin Mi‐

crospheres (ENRY).

Survival after yttrium‐90 resin microsphere radioembolization of hepatocellular carcinoma

across Barcelona clinic liver cancer stages: a European evaluation.

Hepatology. 2011 Sep 2;54(3):868‐78.

70: Scharl M, Leucht K, Frey‐Wagner I, Zeitz J, Hausmann M, Fischbeck A, Liebisch G, Keller‐

meier S, Pesch T, Arikkat J, Schmitz G, Fried M, Yildiz Y, Rogler G.

Knock‐out of β‐glucosidase 2 has no influence on dextran sulfate sodium‐induced colitis.

Digestion. 2011;84(2):156‐67.

71: Scheel TK, Gottwein JM, Carlsen TH, Li YP, Jensen TB, Spengler U, Weis N,

Bukh J.

Efficient culture adaptation of hepatitis C virus recombinants with genotype‐specific core‐NS2

by using previously identified mutations.

J Virol. 2011 Mar;85(6):2891‐906.

202

72: Schipani A, Wyen C, Mahungu T, Hendra H, Egan D, Siccardi M, Davies G, Khoo S, Fätken‐

heuer G, Youle M, Rockstroh J, Brockmeyer NH, Johnson MA, Owen A, Back DJ; German

Competence Network for HIV/AIDS.

Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirap‐

ine dose selection in HIV‐infected individuals.

J Antimicrob Chemother. 2011 Jun;66(6):1332‐9.

73: Schmidt AJ, Rockstroh JK, Vogel M, An der Heiden M, Baillot A, Krznaric I, Radun D.

Trouble with bleeding: risk factors for acute hepatitis C among HIV‐positive gay men from

Germany‐‐a case‐control study.

PLoS One. 2011 Mar 8;6(3):e17781.

74: Schramm C, Gotthardt D, Spengler U, Schirmacher P, Weismüller T.

[Primary sclerosing cholangitis ‐ challenges for all. The German Study Group PSC].


75: Schulze Zur Wiesch J, Thomssen A, Hartjen P, Tóth I, Lehmann C, Meyer‐Olson D, Colberg

K, Frerk S, Babikir D, Schmiedel S, Degen O, Mauss S, Rockstroh J, Staszewski S, Khaykin P,

Strasak A, Lohse AW, Fätkenheuer G, Hauber J, van Lunzen J.

Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection:

CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease.

J Virol. 2011 Feb;85(3):1287‐97.

76: Schülter E, Oette M, Balduin M, Reuter S, Rockstroh J, Fätkenheuer G, Esser S, Lengauer

T, Agacfidan A, Pfister H, Kaiser R, Akgül B.

HIV prevalence and route of transmission in Turkish immigrants living in North‐Rhine West‐

phalia, Germany.

Med Microbiol Immunol. 2011 Nov;200(4):219‐23.

77: Seidel MF, Müller W.

Differential pharmacotherapy for subgroups of fibromyalgia patients with specific considera‐

tion of 5‐HT3 receptor antagonists.

Expert Opin Pharmacother. 2011 Jun;12(9):1381‐91.

78: Sibbing B, Nattermann J.

Hepatitis C virus infection and genetic susceptibility to therapy.

J Gastrointestin Liver Dis. 2011 Dec;20(4):397‐406.

203

79: Sivritas D, Becher MU, Ebrahimian T, Arfa O, Rapp S, Bohner A, Mueller CF, Umemura T,

Wassmann S, Nickenig G, Wassmann K.

Antiproliferative effect of estrogen in vascular smooth muscle cells is mediated by Kruppel‐

like factor‐4 and manganese superoxide dismutase.

Basic Res Cardiol. 2011 Jun;106(4):563‐75.

80: Smalberg JH, Koehler E, Darwish Murad S, Plessier A, Seijo S, Trebicka J, Primignani M,

de Maat MP, Garcia‐Pagan JC, Valla DC, Janssen HL, Leebeek FW; European Network for Vas‐

cular Disorders of the Liver (EN‐Vie).

The JAK2 46/1 haplotype in Budd‐Chiari syndrome and portal vein thrombosis.

Blood. 2011 Apr 14;117(15):3968‐73.

81: Smith KR, Suppiah V, O'Connor K, Berg T, Weltman M, Abate ML, Spengler U, Bassendine

M, Matthews G, Irving WL, Powell E, Riordan S, Ahlenstiel G, Stewart GJ, Bahlo M, George J,

Booth DR; the International Hepatitis C Genetics Consortium (IHCGC).

Identification of improved IL28B SNPs and haplotypes for prediction of drug response in

treatment of hepatitis C using massively parallel sequencing in a cross‐sectional European

cohort.

Genome Med. 2011 Aug 31;3(8):57.

82: Soliman EZ, Prineas RJ, Roediger MP, Duprez DA, Boccara F, Boesecke C, Stephan C,

Hodder S, Stein JH, Lundgren JD, Neaton JD.

Prevalence and prognostic significance of ECG abnormalities in HIV‐infected patients: results

from the Strategies for Management of Antiretroviral Therapy study.

J Electrocardiol. 2011 Nov‐Dec;44(6):779‐85.

83: Soriano V, Grint D, d'Arminio Monforte A, Horban A, Leen C, Poveda E, Antunes F, de Wit

S, Lundgren J, Rockstroh J, Peters L.

Hepatitis delta in HIV‐infected individuals in Europe.

AIDS. 2011 Oct 23;25(16):1987‐92.

84: Soriano V, Sherman KE, Rockstroh J, Dieterich D, Back D, Sulkowski M, Peters M.

Challenges and opportunities for hepatitis C drug development in HIV‐hepatitis C virus‐co‐

infected patients.

AIDS. 2011 Nov 28;25(18):2197‐208.

85: Spengler U.

Management of end‐stage liver disease in HIV/hepatitis C virus co‐infection.


86: Steffens B, Kümmerle T, Koch S, Birtel A, Schwarze‐Zander C, Emmelkamp J, Kern WV,

Hertenstein C, Wyen C, Lehmann C, Cornely OA, Rockstroh J, Fätkenheuer G.

204

Acceptance and tolerability of an adjuvanted nH1N1 vaccine in HIV‐infected patients in the

Cologne‐Bonn cohort.

Eur J Med Res. 2011 Jul 25;16(7):289‐94.

87: Stoll M, Kollan C, Bergmann F, Bogner J, Faetkenheuer G, Fritzsche C, Hoeper K, Horst

HA, van Lunzen J, Plettenberg A, Reuter S, Rockstroh J, Stellbrink HJ, Hamouda O, Bart‐

meyer B; ClinSurv Study Group.

Calculation of direct antiretroviral treatment costs and potential cost savings by using gener‐

ics in the German HIV ClinSurv cohort.

PLoS One. 2011;6(9):e23946. Epub 2011 Sep 9.

88: Suppiah V, Gaudieri S, Armstrong NJ, O'Connor KS, Berg T, Weltman M, Abate ML,

Spengler U, Bassendine M, Dore GJ, Irving WL, Powell E, Hellard M, Riordan S, Matthews G,

Sheridan D, Nattermann J, Smedile A, Müller T, Hammond E, Dunn D, Negro F, Bochud PY,

Mallal S, Ahlenstiel G, Stewart GJ, George J, Booth DR; International Hepatitis C Genetics

Consortium (IHCGC).

IL28B, HLA‐C, and KIR variants additively predict response to therapy in chronic hepatitis C

virus infection in a European Cohort: a cross‐sectional study.

PLoS Med. 2011 Sep;8(9):e1001092.

89: Talens S, Hoekstra J, Dirkx SP, Darwish Murad S, Trebicka J, Elias E, Primignani M, García‐

Pagán JC, Valla DC, Janssen HL, Leebeek FW, Rijken DC;

EN‐Vie Study Group. Proteomic analysis reveals that apolipoprotein A1 levels are decreased in

patients with Budd‐Chiari syndrome.

J Hepatol. 2011 May;54(5):908‐14.

90: Trebicka J, Krag A, Gansweid S, Appenrodt B, Schiedermaier P, Sauerbruch T, Spengler

U.

Endotoxin and tumor necrosis factor‐receptor levels in portal and hepatic vein of patients

with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt.


91: Trebicka J, Racz I, Siegmund SV, Cara E, Granzow M, Schierwagen R, Klein S, Wojtalla A,

Hennenberg M, Huss S, Fischer HP, Heller J, Zimmer A, Sauerbruch T.

Role of cannabinoid receptors in alcoholic hepatic injury: steatosis and fibrogenesis are in‐

creased in CB2 receptor‐deficient mice and decreased in CB1 receptor knockouts.

Liver Int. 2011 Jul;31(6):860‐70..

205

92: Viard JP, Souberbielle JC, Kirk O, Reekie J, Knysz B, Losso M, Gatell J, Pedersen C, Bogner

JR, Lundgren JD, Mocroft A; EuroSIDA Study Group.

Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study.

AIDS. 2011 Jun 19;25(10):1305‐15.

93: Vogel M, Boesecke C, Rockstroh JK.

Acute hepatitis C infection in HIV‐positive patients.

Curr Opin Infect Dis. 2011 Feb;24(1):1‐6.

94: Vogel M, Friedrich O, Lüchters G, Holleczek B, Wasmuth JC, Anadol E, Schwarze‐Zander

C, Nattermann J, Oldenburg J, Sauerbruch T, Rockstroh JK, Spengler U.

Cancer risk in HIV‐infected individuals on HAART is largely attributed to oncogenic infections

and state of immunocompetence.

Eur J Med Res. 2011 Mar 28;16(3):101‐7.

95: Vogel M, Page E, Boesecke C, Reiberger T, Schwarze‐Zander C, Mauss S, Baumgarten A,

Wasmuth JC, Nelson M, Rockstroh JK; the European AIDS Treatment Network (NEAT) Study

Group.

Liver Fibrosis Progression After Acute Hepatitis C Virus Infection in HIV‐Positive Individuals.

Clin Infect Dis. 2011 Dec 7. [Epub ahead of print].

96: Weich V, Herrmann E, Chung TL, Sarrazin C, Hinrichsen H, Buggisch P, Gerlach T, Klinker

H, Spengler U, Bergk A, Zeuzem S, Berg T.

The determination of GGT is the most reliable predictor of nonresponsiveness to interferon‐

alpha based therapy in HCV type‐1 infection.

J Gastroenterol. 2011 Dec;46(12):1427‐36.

97: Wiegand J, Neumann K, Böhm S, Weich V, Teuber G, Klinker H, Möller B, Rasenack J, Hin‐

richsen H, Gerlach T, Spengler U, Buggisch P, Sarrazin C, Berg T.

Importance of minimal residual viremia for relapse prediction in patients with chronic hepati‐

tis C genotype 1 infection.

Clin Infect Dis. 2011 Dec;53(11):1111‐4.

98: Wyen C, Hendra H, Siccardi M, Platten M, Jaeger H, Harrer T, Esser S, Bogner JR, Brock‐

meyer NH, Bieniek B, Rockstroh J, Hoffmann C, Stoehr A, Michalik C, Dlugay V, Jetter A,

Knechten H, Klinker H, Skaletz‐Rorowski A, Fätkenheuer G, Egan D, Back DJ, Owen A; Ger‐

man Competence Network for HIV/AIDS Coordinators.

Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms

are associated with early discontinuation of efavirenz‐containing regimens.

J Antimicrob Chemother. 2011 Sep;66(9):2092‐8.

99: Zimmermann HW, Seidler S, Gassler N, Nattermann J, Luedde T, Trautwein C, Tacke F.

206

Interleukin‐8 is activated in patients with chronic liver diseases and associated with hepatic

macrophage accumulation in human liver fibrosis.

PLoS One. 2011;6(6):e21381.

100: Zoufaly A, an der Heiden M, Kollan C, Bogner JR, Fätkenheuer G, Wasmuth JC, Stoll M,

Hamouda O, van Lunzen J; ClinSurv Study Group.

Clinical outcome of HIV‐infected patients with discordant virological and immunological re‐

sponse to antiretroviral therapy.

J Infect Dis. 2011 Feb 1;203(3):364‐71.

207

2012

1: Anadol E, Beckebaum S, Radecke K, Paul A, Zoufaly A, Bickel M, Hitzenbichler F, Ganten T,

Kittner J, Stoll M, Berg C, Manekeller S, Kalff JC, Sauerbruch T, Rockstroh JK, Spengler U.

Orthotopic liver transplantation in human‐immunodeficiency‐virus‐positive patients in Ger‐

many.

AIDS Res Treat.2012; Epub 2012 Jul 30.

2: Appenrodt B, Sauerbruch T.

Susceptibility to spontaneous bacterial peritonitis‐‐are genetics the future?

Liver Int. 2012 Feb;32(2):177‐8.

3: Arendt E, Jaroszewicz J, Rockstroh J, Meyer‐Olson D, Zacher BJ, Mederacke I, Manns MP,

Wedemeyer H, Cornberg M, Wursthorn K.

Improved immune status corresponds with long‐term decline of quantitative serum hepatitis

B surface antigen in HBV/HIV co‐infected patients.

Viral Immunol. 2012 Dec;25(6):442‐7.

4: Battegay M, Rockstroh JK.

[Advances in management of HIV infections].


5: Boesecke C, Pett SL.

Clinical studies with chemokine receptor‐5 (CCR5)‐inhibitors.

Curr Opin HIV AIDS. 2012 Sep;7(5):456‐62.


[Treatment of chronic hepatitis C in HIV coinfection].

MMW Fortschr Med. 2012 May 16;154 Suppl 1:42‐4.


Acute hepatitis C in patients with HIV.

Semin Liver Dis. 2012 May;32(2):130‐7.

8: Boesecke C, Wedemeyer H, Rockstroh JK.

Diagnosis and treatment of acute hepatitis C virus infection.

Infect Dis Clin North Am. 2012 Dec;26(4):995‐1010.

208

9: Clajus C, Hanke N, Gottlieb J, Stadler M, Weismüller TJ, Strassburg CP, Bröcker V, Bara C,

Lehner F, Drube J, Kielstein JT, Schwarz A, Gueler F, Haller H, Schiffer M.

Renal comorbidity after solid organ and stem cell transplantation.

Am J Transplant. 2012 Jul;12(7):1691‐9.

10: DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Yale K,

Szwarcberg J, White K, Cheng AK, Kearney BP; GS‐236‐0103 Study Team.

Co‐formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus

ritonavir‐boosted atazanavir plus co‐formulated emtricitabine and tenofovir disoproxil fu‐

marate for initial treatment of HIV‐1 infection: a randomised, double‐blind, phase 3, non‐

inferiority trial.

Lancet. 2012 Jun 30;379(9835):2429‐38.

11: DeJesus E, Rockstroh JK, Lennox JL, Saag MS, Lazzarin A, Zhao J, Wan H, Rodgers AJ,

Walker ML, Miller M, DiNubile MJ, Nguyen BY, Teppler H, Leavitt R, Sklar P; STARTMRK In‐

vestigators.

Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treat‐

ment‐naïve HIV‐1‐infected patients: week‐192 overall and subgroup analyses from STARTMRK.

HIV Clin Trials. 2012 Jul‐Aug;13(4):228‐32. doi: 10.1310/hct1304‐228. Erratum in: HIV Clin Trials.

2012 Sep‐Oct;13(5):preceding 233.

12: Düsing R, Brunel P, Baek I, Baschiera F.

Sustained blood pressure‐lowering effect of aliskiren compared with telmisartan after a sin‐

gle missed dose.

J Hypertens. 2012 May;30(5):1029‐40.

13: Ehmer U, Kalthoff S, Fakundiny B, Pabst B, Freiberg N, Naumann R, Manns MP, Strass‐

burg CP.

Gilbert syndrome redefined: a complex genetic haplotype influences the regulation of glu‐

curonidation.

Hepatology. 2012 Jun;55(6):1912‐21.

14: Eisenhardt M, Glässner A, Krämer B, Körner C, Sibbing B, Kokordelis P, Nischalke HD,

Sauerbruch T, Spengler U, Nattermann J.

The CXCR3(+)CD56Bright phenotype characterizes a distinct NK cell subset with anti‐fibrotic

potential that shows dys‐regulated activity in hepatitis C.

PLoS One. 2012;7(7):e38846.

15: Genovese D, Boesecke C, Coppola N, Vella S.

Virus Variability and Its Impact on HIV and Hepatitis Therapy.

Adv Virol. 2012;2012:607527.

209

16: Glässner A, Eisenhardt M, Krämer B, Körner C, Coenen M, Sauerbruch T, Spengler U, Nat‐

termann J.

NK cells from HCV‐infected patients effectively induce apoptosis of activated primary human

hepatic stellate cells in a TRAIL‐, FasL‐ and NKG2D‐dependent manner.

Lab Invest. 2012 Jul;92(7):967‐77.

17: Gonzalez‐Carmona MA, Sandhoff R, Tacke F, Vogt A, Weber S, Canbay AE, Rogler G, Sau‐

erbruch T, Lammert F, Yildiz Y.

Beta‐glucosidase 2 knockout mice with increased glucosylceramide show impaired liver re‐

generation.

Liver Int. 2012 Oct;32(9):1354‐62.

18: Grünhage F, Hochrath K, Krawczyk M, Höblinger A, Obermayer‐Pietsch B, Geisel J, Trau‐

ner M, Sauerbruch T, Lammert F.

Common genetic variation in vitamin D metabolism is associated with liver stiffness.

Hepatology. 2012 Nov;56(5):1883‐91.

19: Hadem J, Strassburg CP, Manns MP.

Prediction of outcome and selection of the liver transplantat candidate in acute liver failure.

Front Physiol. 2012;3:340.

20: Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK, Müller M, Fätkenheuer G, Seidel E,

Nickelsen M, Wolf T, Rieke A, Schürmann D, Schmidmaier R, Planker M, Alt J, Mosthaf F,

Engert A, Arasteh K, Hoffmann C.

Stage‐adapted treatment of HIV‐associated Hodgkin lymphoma: results of a prospective mul‐

ticenter study.

J Clin Oncol. 2012 Nov 20;30(33):4117‐23.

21: Hesse M, Raulf A, Pilz GA, Haberlandt C, Klein AM, Jabs R, Zaehres H, Fügemann CJ,

Zimmermann K, Trebicka J, Welz A, Pfeifer A, Röll W, Kotlikoff MI, Steinhäuser C, Götz M,

Schöler HR, Fleischmann BK.

Direct visualization of cell division using high‐resolution imaging of M‐phase of the cell cycle.

Nat Commun. 2012;3:1076.

22: Hundt F, Pabst S, Hammerstingl C, Skowasch D, Woitas R.

PRECAPILLARY PULMONARY HYPERTENSION IN PATIENTS WITH CHRONIC KIDNEY DISEASE

ON DIALYSIS AND WITHOUT DIALYSIS: RESULTS OF THE PEPPER‐STUDY.

Nephrol Dial Transplant. 2012;27:2(2):390.

210

23: Ingiliz P, Rockstroh JK.

HIV‐HCV co‐infection facing HCV protease inhibitor licensing: implications for clinicians.

Liver Int. 2012 Sep;32(8):1194‐9.

24: Jalali Z, Rockstroh JK.

Antiviral drugs and the treatment of hepatitis C.

Curr HIV/AIDS Rep. 2012 Jun;9(2):132‐8.

25: Jaroszewicz J, Reiberger T, Meyer‐Olson D, Mauss S, Vogel M, Ingiliz P, Payer BA, Stoll M,

Manns MP, Schmidt RE, Flisiak R, Wedemeyer H, Peck‐Radosavljevic M, Rockstroh J, Corn‐

berg M.

Hepatitis B surface antigen concentrations in patients with HIV/HBV co‐infection.

PLoS One. 2012;7(8):e43143.

26: Klein S, Klösel J, Schierwagen R, Körner C, Granzow M, Huss S, Mazar IG,Weber S, van

den Ven PF, Pieper‐Fürst U, Fürst DO, Nattermann J, Lammert F, Sauerbruch T, Trebicka J.

Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofi‐

broblasts and thereby attenuates hepatic fibrosis in rats.

Lab Invest. 2012 Oct; 92(10):1440‐50.

27: Klein S, Van Beuge MM, Granzow M, Beljaars L, Schierwagen R, Kilic S, Heidari I, Huss S,

Sauerbruch T, Poelstra K, Trebicka J.

HSC‐specific inhibition of Rho‐kinase reduces portal pressure in cirrhotic rats without major

systemic effects.

J Hepatol. 2012 Dec;57(6):1220‐7.

28: Koelsch KK, Boesecke C, McBride K, Gelgor L, Fahey P, Natarajan V, Baker D, Bloch M,

Murray JM, Zaunders J, Emery S, Cooper DA, Kelleher AD; PINT study team.

Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay

characteristics and the HIV viral reservoir.

AIDS. 2011 Nov 13;25(17):2069‐78.

29: Konieczny N, Schwarze‐Zander C, Hausen A, Beissel A, Meyer C, Rockstroh J, Kalff JC,

Pantelis D.

[HPV‐Related Squamous Cell Carcinoma of the Rectum in an HIV‐Positive Patient ‐ A Rare Dif‐

ferential Diagnosis.].

Zentralbl Chir. 2012 Dec 13. [Epub ahead of print]

30: Koppitz H, Rockstroh JK, Schüller H, Standop J, Skowasch D, Müller‐Hermelink HK,

Schmidt‐Wolf IG.

State‐of‐the‐art classification and multimodality treatment of malignant thymoma.

Cancer Treat Rev. 2012 Aug;38(5):540‐8.

211

31: Krämer B, Körner C, Kebschull M, Glässner A, Eisenhardt M, Nischalke HD, Alexander M,

Sauerbruch T, Spengler U, Nattermann J.

Natural killer p46High expression defines a natural killer cell subset that is potentially in‐

volved in control of hepatitis C virus replication and modulation of liver fibrosis.

Hepatology. 2012 Oct;56(4):1201‐13.

32: Körner C, Riesner K, Krämer B, Eisenhardt M, Glässner A, Wolter F, Berg T, Müller T, Sau‐

erbruch T, Nattermann J, Spengler U, Nischalke HD.

TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased

risk for hepatocellular carcinoma (HCC) in HCV‐infected patients.

BMC Cancer. 2012 Mar 8;12:85.

33: Lacombe K, Rockstroh J.

HIV and viral hepatitis coinfections: advances and challenges.

Gut. 2012 May;61 Suppl 1:i47‐58.

34: Langhans B, Nischalke HD, Arndt S, Braunschweiger I, Nattermann J, Sauerbruch T,

Spengler U.

Ribavirin exerts differential effects on functions of Cd4+ Th1, Th2, and regulatory T cell clones

in hepatitis C.

PLoS One. 2012;7(7):e42094.

35: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in Euro‐

Coord, Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, Wasmuth JC, van Sighem A,

Kirk O, Obel N, Panos G, Ghosn J, Dabis F, Mary‐Krause M, Leport C, Perez‐Hoyos S, Sobrino‐

Vegas P, Stephan C, Castagna A, Antinori A, d'Arminio Monforte A, Torti C, Mussini C, Isern

V, Calmy A, Teira R, Egger M, Grarup J, Chêne G.

All‐cause mortality in treated HIV‐infected adults with CD4 ≥500/mm3 compared with the

general population: evidence from a large European observational cohort collaboration.

Int J Epidemiol. 2012 Apr;41(2):433‐45.

36: Mauss S, Berger F, Vogel M, Pfeiffer‐Vornkahl H, Alshuth U, Rockstroh JK, Niederau C,

Hüppe D.

Treatment results of chronic hepatitis C genotype 5 and 6 infections in Germany.


37: May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, Thiébaut R, Gill

MJ, Kirk O, van Sighem A, Saag MS, Navarro G, Sobrino‐Vegas P, Lampe F, Ingle S, Guest JL,

Crane HM, D'Arminio Monforte A, Vehreschild JJ, Sterne JA; Antiretroviral Therapy Cohort

Collaboration (ART‐CC).

Heterogeneity in outcomes of treated HIV‐positive patients in Europe and North America:

212

relation with patient and cohort characteristics.

Int J Epidemiol. 2012 Dec;41(6):1807‐20.

38: Mederacke I, Helfritz F, Puls F, Ringe KI, Klempnauer J, Manns MP, Strassburg CP.

Budd‐Chiari syndrome after treatment with budesonide in a cirrhotic patient with autoim‐

mune hepatitis.

Ann Hepatol. 2012 Jan‐Feb;11(1):143‐4.

39: Mederacke I, Filmann N, Yurdaydin C, Bremer B, Puls F, Zacher BJ, Heidrich B, Tillmann

HL, Rosenau J, Bock CT, Savas B, Helfritz F, Lehner F, Strassburg CP, Klempnauer J, Wurst‐

horn K, Lehmann U, Manns MP, Herrmann E, Wedemeyer H.

Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis

delta antigen persistence after liver transplantation.

J Hepatol. 2012 Jan;56(1):115‐22.

40: Mihalache F, Höblinger A, Acalovschi M, Sauerbruch T, Lammert F, Zimmer V.

A common variant in the precursor miR‐146a sequence does not predispose to cholangiocar‐

cinoma in a large European cohort.

Hepatobiliary Pancreat Dis Int.2012 Aug 15;11(4):412‐7.

41: Murray M, Hogg RS, Lima VD, May MT, Moore DM, Abgrall S, Bruyand M, D'Arminio

Monforte A, Tural C, Gill MJ, Harris RJ, Reiss P, Justice A, Kirk O, Saag M, Smith CJ, Weber R,

Rockstroh J, Khaykin P, Sterne JA; Antiretroviral Therapy Cohort Collaboration (ART‐CC).

The effect of injecting drug use history on disease progression and death among HIV‐positive

individuals initiating combination antiretroviral therapy: collaborative cohort analysis.

HIV Med. 2012 Feb;13(2):89‐97.

42: Murray JM, McBride K, Boesecke C, Bailey M, Amin J, Suzuki K, Baker D, Zaunders JJ,

Emery S, Cooper DA, Koelsch KK, Kelleher AD; PINT STUDY TEAM.

Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing

transmission afterwards.

AIDS. 2012 Mar 13;26(5):543‐50.

43: Nachega JB, Morroni C, Zuniga JM, Sherer R, Beyrer C, Solomon S, Schechter M, Rock‐

stroh J.

HIV‐Related Stigma, Isolation, Discrimination, and Serostatus Disclosure: A Global Survey of

2035 HIV‐Infected Adults.

J Int Assoc Physicians AIDS Care (Chic). 2012 May‐Jun;11(3):172‐8.

213

44: Nachega JB, Morroni C, Zuniga JM, Schechter M, Rockstroh J, Solomon S, Sherer R.

HIV Treatment Adherence, Patient Health Literacy, and Health Care Provider‐Patient Commu‐

nication: Results from the 2010 AIDS Treatment for Life International Survey.

J Int Assoc Physicians AIDS Care (Chic). 2012 Mar‐Apr;11(2):128‐33.

45: Neukam K, Camacho A, Caruz A, Rallón N, Torres‐Cornejo A, Rockstroh JK, Macías J,

Rivero A, Benito JM, López‐Cortés LF, Nattermann J, Gómez‐Mateos J, Soriano V, Pineda JA.

Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)‐

coinfected patients using HCV genotype, IL28B variations, and HCV‐RNA load.

J Hepatol. 2012 Apr;56(4):788‐94.

46: Nischalke HD, Coenen M, Berger C, Aldenhoff K, Müller T, Berg T, Krämer B, Körner C,

Odenthal M, Schulze F, Grünhage F, Nattermann J, Sauerbruch T, Spengler U.

The toll‐like receptor 2 (TLR2) ‐196 to ‐174 del/ins polymorphism affects viral loads and suscep‐

tibility to hepatocellular carcinoma in chronic hepatitis C.

Int J Cancer. 2012 Mar 15;130(6):1470‐5.

47: Nischalke HD, Berger C, Luda C, Müller T, Berg T, Coenen M, Krämer B, Körner C, Trebi‐

cka J, Grünhage F, Lammert F, Nattermann J, Sauerbruch T, Spengler U.

The CXCL1 rs4074 A allele is associated with enhanced CXCL1 responses to TLR2 ligands and

predisposes to cirrhosis in HCV genotype 1‐infected Caucasian patients.

J Hepatol. 2012 Apr;56(4):758‐64.

48: Nischalke HD, Schmitz V, Luda C, Aldenhoff K, Berger C, Feldmann G, Sauerbruch T,

Spengler U, Nattermann J.

Detection of IGF2BP3, HOXB7, and NEK2 mRNA expression in brush cytology specimens as a

new diagnostic tool in patients with biliary strictures.

PLoS One. 2012;7(8):e42141.

49: Pabst S, Hammerstingl C, Grau N, Kreuz J, Grohe C, Juergens UR, Nickenig G, Skowasch

D.

Pulmonary arterial hypertension in patients with sarcoidosis: the Pulsar single center experi‐

ence.

Adv Exp Med Biol. 2013;755:299‐305.

50: Peters L, Grint D, Lundgren JD, Rockstroh JK, Soriano V, Reiss P, Grzeszczuk A, Sambata‐

kou H, Mocroft A, Kirk O; EuroSIDA in EuroCoord.

Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV‐infected pa‐

tients.

AIDS. 2012 Sep 24;26(15):1917‐26.

214

51: Pischke S, Gösling J, Engelmann I, Schlue J, Wölk B, Jäckel E, Meyer‐Heithuis C, Lehmann

U, Strassburg CP, Barg‐Hock H, Becker T, Manns MP, Schulz T, Wedemeyer H, Heim A.

High intrahepatic HHV‐6 virus loads but neither CMV nor EBV are associated with decreased

graft survival after diagnosis of graft hepatitis.

J Hepatol. 2012 May;56(5):1063‐9.

52: Raskopf E, Sauerbruch T, Schmitz V.

Apoptotic potency of angiostatic compounds in the treatment of cancer.

Curr Pharm Biotechnol. 2012 Sep 1;13(11):2283‐9.

53: Raskopf E, Vogt A, Decker G, Hirt S, Daskalow K, Cramer T, Standop J, Gonzalez‐Carmona

MA, Sauerbruch T, Schmitz V.

Combination of hypoxia and RNA‐interference targeting VEGF induces apoptosis in hepatoma

cells via autocrine mechanisms.

Curr Pharm Biotechnol. 2012 Sep 1;13(11):2290‐8.

54: Reekie J, Kowalska JD, Karpov I, Rockstroh J, Karlsson A, Rakhmanova A, Horban A, Kirk

O, Lundgren JD, Mocroft A; EuroSIDA in EuroCoord.

Regional differences in AIDS and non‐AIDS related mortality in HIV‐positive individuals across

Europe and Argentina: the EuroSIDA study.

PLoS One. 2012;7(7):e41673.

55: Reuter S, Oette M, Kaiser R, Lengauer T, Fätkenheuer G, Rockstroh JK,

Knechten H, Häussinger D. Risk factors associated with older age in treatment‐naive HIV‐

positive patients. I

Intervirology. 2012;55(2):147‐53.

56: Rifai K, Hadem J, Wiegand J, Potthoff A, Pischke S, Klempnauer J, Strassburg C, Wede‐

meyer H, Manns MP, Tillmann HL.

Gender differences in patient receiving liver transplantation for viral hepatitis.


57: Rockstroh J, Teppler H, Zhao J, Sklar P, Harvey C, Strohmaier K, Leavitt R, Nguyen BY.

Safety and efficacy of raltegravir in patients with HIV‐1 and hepatitis B and/or C virus coinfec‐

tion.

HIV Med. 2012 Feb;13(2):127‐31.

58: Rockstroh JK.

How important is HIV therapy for preventing liver fibrosis progression in HIV‐HCV‐coinfected

individuals?

Antivir Ther. 2012;17(7):1223‐5.

215

59: Sarrazin C, Berg T, Cornberg M, Dollinger M, Ferenci P, Hinrichsen H, Klinker H, Kraus M,

Manns M, Mauss S, Peck‐Radosavljevic M, Schmidt H, Spengler U, Wedemeyer H, Wirth S,

Zeuzem S.

[Expert opinion on boceprevir‐ and telaprevir‐based triple therapies of chronic hepatitis C].

Z Gastroenterol. 2012 Jan;50(1):57‐72..

60: Schaefer M, Sarkar R, Knop V, Effenberger S, Friebe A, Heinze L, Spengler U, Schlaepfer

T, Reimer J, Buggisch P, Ockenga J, Link R, Rentrop M, Weidenbach H, Fromm G, Lieb K,

Baumert TF, Heinz A, Discher T, Neumann K, Zeuzem S, Berg T.

Escitalopram for the prevention of peginterferon‐α2a‐associated depression in hepatitis C

virus‐infected patients without previous psychiatric disease: a randomized trial.

Ann Intern Med. 2012 Jul 17;157(2):94‐103.

61: Schmidt C, Smith C, Barin B, Bakhtyari A, Bart PA, Bekker LG, Chomba E, Clumeck N, Ho D,

Hoosen A, Jaoko W, Kaleebu P, Karita E, Keefer MC, van Lunzen J, McMichael A, Mehendale

S, Peters B, Ramanathan VD, Robinson A, Rockstroh J, Vardas E, Vets E, Weber J, Graham BS,

Than S, Excler JL, Kochhar S, Ho M, Heald A, Fast PE.

Background morbidity in HIV vaccine trial participants from various geographic regions as

assessed by unsolicited adverse events.

Hum Vaccin Immunother. 2012 May;8(5):630‐8.

62: Schmitz V, Sauerbruch T, Raskopf E.

Anti‐tumoural effects of PlgK1‐5 are directly linked to reduced ICAM expression, resulting in

hepatoma cell apoptosis.

Int J Colorectal Dis. 2012 Aug;27(8):1029‐38.

63: Schrem H, Reichert M, Reichert B, Becker T, Lehner F, Kleine M, Bektas H, Johanning K,

Strassburg CP, Klempnauer

J. Value of the SOFA score as a predictive model for short‐term survival in high‐risk liver

transplant recipients with a pre‐transplant labMELD score ≥ 30.

Langenbecks Arch Surg. 2012 Jun;397(5):717‐26.

64: Schwarze‐Zander C, Rockstroh JK.

HIV protease inhibitors in combination with boceprevir: are drug‐drug interactions the same

for all patients?

AIDS. 2012 Sep 10;26(14):1845‐6.

65: Schwarze‐Zander C, Blackard JT, Rockstroh JK.

Role of GB virus C in modulating HIV disease.

Expert Rev Anti Infect Ther. 2012 May;10(5):563‐72.

216

66: Smit PJ, Brady M, Carter M, Fernandes R, Lamore L, Meulbroek M, Ohayon M, Platteau T,

Rehberg P, Rockstroh JK, Thompson M.

HIV‐related stigma within communities of gay men: a literature review.

AIDS Care. 2012;24(4):405‐12.

67: Standop J, Kuhn Y, Glowka TR, Schaefer N, Overhaus M, Schmitz V, Hirner A, Kalff JC.

Association of socio‐economic status and stage of pancreatic cancer at time of surgery in a

German setting.

Hepatogastroenterology. 2012 Nov‐Dec;59(120):2614‐7.

68: Strassburg CP.

Autoimmune hepatitis: new guidelines, new therapies.

Dig Dis. 2012;30 Suppl 1:11‐9.

69: Stöckle M, Elzi L, Rockstroh JK, Battegay M.

[Morbidity and mortality in HIV infection].


70: Tryc AB, Goldbecker A, Berding G, Rümke S, Afshar K, Shahrezaei GH, Pflugrad H, Barg‐

Hock H, Strassburg CP, Hecker H, Weissenborn K.

Cirrhosis‐related Parkinsonism: Prevalence, mechanisms and response to treatments.

J Hepatol. 2012 Dec 5.

71: Ulrich‐Merzenich G, Kelber O, Koptina A, Freischmidt A, Heilmann J, Müller J, Zeitler H,

Seidel MF, Ludwig M, Heinrich EU, Winterhoff H.

Novel neurological and immunological targets for salicylate‐based phytopharmaceuticals and

for the anti‐depressant imipramine.

Phytomedicine. 2012 Jul 15;19(10):930‐9.

72: Ulrich‐Merzenich G, Koptina A, Kelber O, Freischmidt A, Heilmann J, Müller J, Sadeghlar

F, Zeitler H, Wagner H.

Prediction of adverse events by in vivo gene expression profiling exemplified for phytophar‐

maceuticals containing salicylates and the antidepressant imipramine.

Phytomedicine. 2012 Feb 15;19(3‐4):322‐9.

73: van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, Rockstroh JK, Al‐

mond S, Song I, Brothers C, Min S.

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral‐naive adults

with HIV: planned interim 48 week results from SPRING‐1, a dose‐ranging, randomised, phase

2b trial.

Lancet Infect Dis. 2012 Feb;12(2):111‐8.

217

74: Vogel M, Page E, Boesecke C, Reiberger T, Schwarze‐Zander C, Mauss S, Baumgarten A,

Wasmuth JC, Nelson M, Rockstroh JK; European AIDS Treatment Network (NEAT) Study

Group.

Liver fibrosis progression after acute hepatitis C virus infection in HIV‐positive individuals.

Clin Infect Dis. 2012 Feb 15;54(4):556‐9.

75: Vogel M, Page E, Boesecke C, berit AP, Schwarze‐Zander C, Mauss S, Baumgarten A,

Wasmuth JC, Nelson M, Rockstroh JK; European AIDS Treatment Network (NEAT) Study

Group.

Early‐onset liver fibrosis due to primary hepatitis C virus infection is higher over time in HIV‐

infected men. Reply to Fierer et. al.

Clin Infect. Dis. 2012; 55(6): 888‐889.

76: Voigtländer T, Vogel M, Page E, Boesecke C, Reiberger T, Schwarze‐Zander C, Mauss S,

Baumgarten A, Wasmuth JC, Nelson M, Rockstroh JK; European AIDS Treatment Network

(NEAT) Study Group.

AA, Schneider AS, Strassburg CP, Manns MP, Wedemeyer J, Lankisch TO.

Secondary sclerosing cholangitis in critically ill patients: model of end‐stage liver disease score

and renal function predict outcome.

Endoscopy. 2012 Nov;44(11):1055‐8.

77: von Hahn T, Schiene‐Fischer C, Van ND, Pfaender S, Karavul B, Steinmann E, Potthoff A,

Strassburg C, Hamdi N, Abdelaziz AI, Sarrazin C, Müller T, Berg T, Trépo E, Wedemeyer H,

Manns MP, Pietschmann T, Ciesek S.

Hepatocytes that express variants of cyclophilin A are resistant to HCV infection and replica‐

tion.

Gastroenterology. 2012 Aug;143(2):439‐47.e1.

78: Wasmuth JC, Rockstroh JK, Hardy WD.

Drug safety evaluation of maraviroc for the treatment of HIV infection.

Expert Opin Drug Saf. 2012 Jan;11(1):161‐74.

79: Wibral M, Dohmen T, Klingmüller D, Weber B, Falk A.

Testosterone administration reduces lying in men.

PLoS One. 2012;7(10):e46774.

80: Woitas R.

Cystatin C: an endogenous GFR marker and prognosis factor.

J Lab Clin Med. 2012; 36(4):211‐16.

218

81: Wojtalla A, Herweck F, Granzow M, Klein S, Trebicka J, Huss S, Lerner R, Lutz B,

Schildberg FA, Knolle PA, Sauerbruch T, Singer MV, Zimmer A, Siegmund SV.

The endocannabinoid N‐arachidonoyl dopamine (NADA) selectively induces oxidative stress‐

mediated cell death in hepatic stellate cells but not in hepatocytes.

Am J Physiol Gastrointest Liver Physiol. 2012 Apr 15;302(8):G873‐87

82: Wyen C, Jensen B, Hentrich M, Siehl J, Sabranski M, Esser S, Gillor D, Müller M, Van Lun‐

zen J, Wolf T, Bogner JR, Wasmuth JC, Christ H, Fätkenheuer G, Hoffmann C.

Treatment of AIDS‐related lymphomas: rituximab is beneficial even in severely immunosup‐

pressed patients.

AIDS. 2012 Feb 20;26(4):457‐64.

83: Zeitler H, Ulrich‐Merzenich G, Panek D, Goldmann G, Vidovic N, Brackmann HH, Olden‐

burg J.

Extracorporeal Treatment for the Acute und Long‐Term Outcome of Patients with Life‐

Threatening Acquired Hemophilia.

Transfus Med Hemother. 2012 Aug;39(4):264‐270.

Redaktion Gestaltung: Medizinische Klinik Poliklinik · Publikationen der Medizinischen Klinik und...

Documents

Transcript of Redaktion Gestaltung: Medizinische Klinik Poliklinik · Publikationen der Medizinischen Klinik und...